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Biotechnology is one of the five key enabling technologies of the EU’s Horizon 2020 framework, 
a massive funding program for research and innovation to create economic growth, a 
sustainable environment and to increase social wellbeing. 35% of its budget is allocated to 
tackle climate change, to reduce greenhouse gas emission and our dependence on fossil fuels 
and to accelerate the transition towards a bio-based circular economy (1). Investments to boost 
this transition are of utmost importance as the worldwide production of crude oil keeps on rising 
peaking at 4.5 billion metric tons in 2018 (2). The majority thereof is converted into combustible 
fuels releasing carbon in the atmosphere that has been stored for millions of years and 
accelerating global warming. The remaining part is used as feedstocks for chemical products 
which are often used once and incinerated or disposed of, polluting oceans and precious land 
area.  
In order to deliver on the post-Paris (COP1) climate commitments, in which the net emissions of 
greenhouse gasses should be reduced to zero by 2050, a bio-based economy is needed 
powered by industrial biotechnology (3). The latter can deliver sustainable products based on 
renewable resources and enables replacement of energy-intensive chemical processes by more 
biological and environmentally friendly ones. Moreover, in industrial biotechnology based 
processes carbon is recycled at the end of the product’s life, which is the essence of a bio-
based circular economy (4). In addition, bio-organic waste streams or side streams such as CO2 
can be used as feedstocks in industrial biotechnology and they can be transformed to value-
added products (5, 6).  
A key factor in industrial biotechnology is the choice of the appropriate production host, which 
will largely depend on the type of the desired product, and the process conditions and substrate. 
Today many cell factories are used to produce bulk chemicals. Examples are Corynebacterium 
glutamicum, (4 million tons of amino acids annually) (7), Aspergillus niger (2 million tons of citric 
acid) (8), Saccharomyces cerevisiae and Zymomonas mobilis (78 million tons of bioethanol) (9). 
Also for more complex molecules microbial production hosts are used such as Bacillus subtilis 
for vitamin B2 and vitamin B5 (10) and Streptomyces sp. for antibiotics (11).  
Another interesting host is Escherichia coli which is known as a metabolic generalist and can 
produce many compounds such as amino acids (L-lysine, L-threonine, L-methionine) (12–14), 
organic acids (lactic acid, succinic acid) (15–17) and alcohols (ethanol) (18). E. coli is also used 
as an industrial host for recombinant protein therapeutics (19) or if natural producers are absent 
or produce insufficiently. An early success story in that respect is the non-natural production of 
1,3-propanediol (PDO), an important chemical building block in the synthesis of many polymers. 
Using a heterologous pathway with genes originating from Clostridia sp. and Klebsiella sp. titers 
reached up to 130 g/L (20). More recently, E. coli is also being used as a production host in the 
commercialization of complex sugars like human milk oligosaccharides, to which the many 
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beneficial properties of mother’s milk are attribute. Sugars like 2’-fucosyllactose supplemented 
to infant formula have become recently available on the market (21). 
It is not surprising that E. coli has been developed as a production host for such a variety of 
compounds. Indeed, E. coli grows quickly and is a facultative anaerobe meaning it grows with 
and without oxygen. Moreover, a wide variety of genetic toolboxes including CRISPR (22–25) 
are available as well as ready-to-use promoter and terminator databases (26–29). Also, its 
genome is almost completely function-annotated (30, 31) and global regulation (32), stress-
response (33) and protein synthesis (34) are well documented 
Yet, despite the large track record in metabolic engineering of E. coli, there is still room for 
improvement to exploit its full potential as a production host. For example, laboratory 
optimization of heterologous pathways is done on plasmids which is convenient from a cloning 
perspective but less preferred in an industrial setting. Plasmids require antibiotics supplemented 
to the medium and are known to cause extra burden to the cell. In addition, plasmids suffer from 
structural and segregational instability (35, 36) which may affect production leading to batch-to-
batch variations. Chromosomal integration of the biosynthetic pathway alleviates the need for 
expression plasmids, but then two questions arise: (1) How do you efficiently incorporate the 
pathway into the genome and (2) where do you incorporate it? 
The first part of this dissertation deals with these questions (See Figure 1-1). In Chapter 2 a 
new genetic toolbox is developed enabling easy incorporation of large biosynthetic pathways 
into E. coli’s genome, which is with the current techniques, employing homologous 
recombination, highly inefficient (37–39). The toolbox relies on the serine integrase PhiC31, a 
bacteriophage derived recombinase that recognizes small so-called att or attachment sites. 
Depending on their orientation the surrounded DNA is either excised, inverted or replaced (40). 
Exploiting the latter properties, a new knock-out and knock-in toolbox was created. Chapter 3 
subsequently makes use of the developed technique to create a library of strains harboring a 
fluorescent protein on different locations spread over the genome to investigate the relation 
between location and expression. In extension, also the influence of medium composition on 
expression is investigated, as well as the susceptibility of the locations to induced burden. 
Finally, a list is compiled of stable, well-characterized locations with varying expression 
strengths that can be used for incorporating a heterologous pathway.   
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Figure 1-1: Overview. This PhD dissertation consists of three parts. (1) Toolbox development; Here a new 
genetic toolbox is developed to easily incorporate biosynthetic pathways onto the genome (Chapter 2) and 
a location study is performed to evaluate the location-expression relation (Chapter 3). (2) Platform design; 
In this part, new E. coli strains were created totally devoid of nonessential glycosyltransferases to eliminate 
by-product formation and novel strategies were applied to eliminate endotoxin formation. (3) HMO 
production; In the last part, production strains based on the developed platform are created to synthesize 
fucosyllacto-N-neotetraose III, a human milk oligosaccharide, using the techniques from Chapter 2 and 3. 
This molecule is used to compare production metrics and side-product formation between the platform 
strain and its wildtype counterpart.  
From a process engineering perspective on the other hand, E. coli is not an ideal host. Its 
susceptibility to bacteriophage infections (41) and its optimal pH of 7, make E. coli more difficult 
to ferment on industrial scale. Moreover because of its Gram-negative state, the outer 
membrane of E. coli contains endotoxins which are recognized by the mammalian innate 
immune system. In large amounts they may trigger a severe sceptic shock, damaging small 
blood vessels with fatal consequences for the host (42). In a high cell density biotechnological 
production process, these endotoxins can rise to alarming levels and must be monitored and 
eventually be removed to obtain a pure and safe product (43). This imposes extra downstream 
processing as well as regulatory costs. Moreover, these hexa-acylated lipopolysaccharide 
endotoxins are decorated with many sugar molecules (42) and the endogenous 
glycosyltransferases responsible for their synthesis may interfere with an intended heterologous 
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glycan synthesis, e.g. in the production of complex human milk oligosaccharides. As such, 
unwanted side products hampering easy downstream processing can be formed.  
To tackle these problems, the second part of this dissertation focuses on developing new 
Escherichia coli platform strains (See Figure 1-1). In Chapter 4, a new base-strain is created in 
which all nonessential glycosyltransferases are deleted in order to minimize interference of the 
natural metabolism. As these glycosyltransferases are responsible for the synthesis of the 
extracellular polysaccharide matrix and the lipopolysaccharide outer membrane, deletion 
thereof may lead to reduced fitness. Therefore, the new base-strain is also assessed on its 
growth characteristics and antibiotic and osmotic sensitivity. In Chapter 5, novel strategies were 
evaluated to eliminate endotoxin, which is otherwise an essential part of the outer membrane. In 
contrast to the previous chapter, essential glycosyltransferases are thus targeted. The 
elimination strategies used are based on Neisseria meningitidis and Acinetobacter baumannii 
mutants, both Gram-negative bacteria that were found to uniquely survive endotoxin elimination 
(44, 45). Their compensation mechanisms are transferred to E. coli to create an endotoxin free 
production host.  
Finally, in the last part of this dissertation (Chapter 6) the platform strain created in Chapter 4 is 
evaluated by implementing a production pathway towards fucosyllacto-N-neotetraose III 
(FLNT III), an interesting complex human milk oligosaccharide with potential application in 
pharmacological vaccine development against norovirus (46). Using techniques developed in 
Chapter 2 and 3, the pathway is integrated not only in the created platform strain from Chapter 
4, but also in its wildtype counterpart, to compare production metrics on a bio-reactor scale. At 
last also the differences in side-product formation are examined  
In the concluding chapter, Chapter 7, the different strategies used during this PhD dissertation 
are critically analyzed. Perspectives to further improve Escherichia coli as a production platform 
for the synthesis of HMOs are given and discussed.  
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Abstract  
Chromosomal integration of biosynthetic pathways for the biotechnological production of high-
value chemicals is a necessity to develop industrial strains with a high long-term stability and a 
low production variability. However, the introduction of multiple transcription units into the 
microbial genome remains a difficult task. Despite recent advances, current methodologies are 
either laborious or efficiencies highly fluctuate depending on the length and the type of the 
construct. Here we present SIRE, Serine Integrase Recombinational Engineering, a novel 
methodology which combines the ease of recombinase mediated cassette exchange (RMCE) 
with the selectivity of orthogonal att sites of the PhiC31 integrase. As a proof of concept this 
toolbox is developed for Escherichia coli. Using SIRE we were able to introduce a 10.3 kb 
biosynthetic gene cluster on different locations throughout the genome with an efficiency of 
100% for the integrating step and without the need for selection markers on the knock-in 
cassette. Next to integrating large fragments, the option for multitargeting, for deleting operons, 
as well as for performing in vivo assemblies further expand and proof the versatility of the SIRE 
toolbox for E. coli.  
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2.1 Introduction 
Escherichia coli is one of the first bacterial species that had its genome sequenced in 1997 by 
Blattner et al. (31). It has become the synthetic biologist’s favorite workhorse because of its fast 
growth and the availability of a vast amount of engineering tools and knowledge resulting from 
decades of research. E. coli has also proven to be a versatile microbial cell factory. Metabolic 
engineering has led to several industrial processes synthesizing a wide variety of bio-based 
molecules such as L-amino acids (13, 47, 48), diolic monomers  and protein therapeutics (49, 
50). However, many more biotechnological processes have been reported by the scientific 
community, but often they did not meet the production metrics for commercialization such as 
titer, yield and productivity (51). One of the problems here is the plasmid based optimization of 
production pathways, which is convenient from a cloning efficiency perspective; however less 
preferred in an industrial setting, as plasmids require antibiotics for their maintenance and 
cause structural and segregational instability, and metabolic burden (35, 36). On the other hand, 
integrating plasmid-based optimized pathways in the chromosome leads to production loss due 
to copy number differences. There is therefore a need for a fast and reliable method to integrate 
pathways in the chromosome, as this will enable flexible and efficient genome based pathway 
optimization.  
Tools for genome editing can be largely divided into three groups: (1) homologous 
recombination-based methods, (2) nuclease aided methods and (3) recombinase mediated 
engineering tools.   
Endogenous homologous recombination in Escherichia coli only requires endogenous recA 
activity and either the recBCD or the recF recombination pathway to exchange DNA. However, 
recombination is inefficient and requires long homology arms to generate few recombination 
events (52, 53). Fortunately, chromosomal integration using the Red system from 
bacteriophage 𝜆 results in a higher efficiency. It relies on DNA fragments with short (<50 bp) 
homology arms and the 𝜆-phage proteins Exo, Bet and Gam. Gam protects the linear DNA 
fragments from the host’s nucleases while Exo resects the 5’ ends of the fragments, generating 
single stranded 3’ overhangs. Finally Bet promotes annealing to the homologous regions (52). 
Despite an enhanced recombineering efficiency, selection markers are still inevitable when 
using this system. Moreover, efficiency further decreases with larger fragments making 
integration of >2.5 kb DNA fragments profoundly difficult (54). Considering selection markers 
already cover almost 1 kb, multiple gene introduction becomes impossible.  
The nuclease aided methods make use of DNA cleaving enzymes such as the meganuclease I-
SceI (38) or the endonuclease Cas9 in CRISPR set-ups (22–25), which both induce a lethal 
double stranded break at the place of recognition. Repair is done by recombination with an 
introduced DNA fragment using the same 𝜆-Red genes. Non-recombined cells will die as a 
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consequence of the double stranded break. Recent CRISPR set-ups only require one plasmid 
and are able to edit the genome in a one step procedure generating mutants fast and with high 
efficiency (22, 24). However, these methods apply homologous recombination for DNA repair 
and hence suffer from the same size limitations for introducing DNA fragments as stated above. 
Nonetheless, insertion of large fragments was reported successful. Li et al. (2015) stated a 14% 
efficiency for the insertion of an 8 kb fragment while others achieved a 50% efficiency for the 
insertion of a 10 kb construct (37). Operon deletions of 10 kb were reported with an efficiency of 
25% (39). All reported efficiencies dropped significantly when fragment size was increased and 
varied greatly between the different methods. 
Integrase mediated engineering on the other hand does not rely on homologous recombination 
but uses site-specific tyrosine or serine recombinases instead. These recombinases are 
classified depending on their active amino acid within the catalytic domain (Tyr or Ser). They 
bind to specific recognition sites and catalyze cleavage. Depending on the subfamily either 
identical recognition sites, such as a loxP site for the Cre recombinase (55), or non-identical 
recognition sites, such as the attachment sites (att sites) in case of the serine integrase PhiC31, 
are used (56). For the latter, recognition sites attB (bacterium) and attP (phage) recombine to 
attL or attR sites which cannot recombine again except in the presence of the Recombination 
Directionality Factor (RDF). Reunion of the cleaved sites can mediate large DNA deletions, 
insertions or inversions. Most of the adopted systems for knock-ins use a single integration site, 
in which the whole helper plasmid is inserted into the genome. Selectable marker excision is 
afterwards done using a different recombinase, making this technique cumbersome hampering 
broad applicability (57–59). 
The techniques described above either are inefficient, use selection markers, are laborious or 
are unreliable when altering the location of the introduced DNA fragment. Moreover, inserting 
DNA fragments of considerable length remains difficult. In Supplementary Table A.1-1, a 
comparison is made between the different genome editing techniques described above. In 
response, we present Serine Integrase Recombinational Engineering (SIRE), combining 
Recombinase Mediated Cassette Exchange (RMCE) with the orthogonal att sites adopted from 
Colloms et al. (2014) (60) as a toolbox for genome editing. Using SIRE, we were able to 
introduce a variety of large fragments across the E. coli genome with an efficiency of 100% for 
the integrating step and without the need for selection markers on the knock-in cassette. Next to 
creating knock-ins, we also explored and proved effective the options for multitargeting (2.3.4), 
as well as for performing in vivo assemblies (2.3.5).  
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2.2 Material and methods 
2.2.1 Chemicals 
Tryptone and yeast extract were procured from Becton Dickinson. Glucose were procured from 
Riedel-De Haan. All other chemicals were purchased from Sigma-Aldrich, unless stated 
otherwise.  
2.2.2 Oligonucleotides and molecular reagents 
Oligonucleotides were purchased from Integrated DNA Technologies (Leuven, Belgium). 
Sequencing services were conducted by Macrogen (Amsterdam, The Netherlands). 
Deoxynucleotides, agarose and ethidium bromide were purchased from Thermo Fisher 
Scientific. QIAprep Spin Miniprep kit was used for plasmid isolation (QIAgen, USA). Analytik 
Jena kits were used for PCR purification (Jena, Germany). 
2.2.3 Strains 
E. coli K-12 MG1655 ΔendA ΔrecA (DE3) (sNS2.01) was used for all experiments and was a 
gift from Kristala Prather (Addgene bacterial strain #37854) (61). E. coli One Shot Top10 
ElectrocompTM cells (Life Technologies) were solely used for cloning purposes. Landing pads 
were introduced according to Datsenko & Wanner (2000) (54). An overview of all strains is 
given in Supplementary Table A.1-2. 
2.2.4 Media and culture conditions 
The culture medium lysogeny broth (LB) consisting of 1% tryptone, 0.5% yeast extract and 
0.5% sodium chloride was used throughout the work. Lysogeny broth agar (LBA) is similarly 
composed with the addition of 12 g/L agar. If required, media were supplemented with the 
antibiotics ampicillin (100 μg/mL), spectinomycin (100 µg/µL), kanamycin (50 μg/mL), 
gentamycin (30 µg/mL), chloramphenicol (34 μg/ mL) or tetracycline (10 µg/mL). 
For growth experiments measuring fluorescence a defined medium was used containing 2 g/L 
NH4Cl, 5 g/L (NH4)2SO4, 3 g/L KH2PO4, 7.3 g/L K2HPO4, 8.4 g/L MOPS, 0.5 g/L NaCl, 0.5 g/L 
MgSO4 ·7H2O, and 16.5 g/L glucose·H2O, 1 ml/L trace element solution and 100 μL/L of a 0.967 
g/L Na2MoO4·2H2O molybdate solution. The trace element solution contained 3.6 g/L 
FeCl2·4H2O, 5 g/L CaCl2·2H2O, 1.3 g/L MnCl2·2H2O, 0.38 g/L CuCl2·2H2O, 0.5 g/L CoCl2·6H2O, 
0.94 g/L ZnCl2, 0.0311 g/L H3BO4, 0.4 g/L Na2EDTA·2H2O, 1.01 g/L thiamine·HCl. The defined 
medium was sterilized with a bottle top filter (Corning PTFE filter, 0.22 μm). 
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2.2.5 Plasmids 
The plasmid list is found in Supplementary Table A.1-3. For the donor plasmids (pDonorX) the 
ColA ori together with the kanamycin resistance gene originates from pCOLADuet™-1 Vector 
(Novagen). Donor fragment Dasher was purchased from DNA2.0 under their IP‐Free Protein 
Paintbox reagents agreement (ATUM, USA). As a promoter the strong constitutive promoter 
proD from Davis et al. (2011) (62) was chosen and as a terminator E. coli’s rnpB_T1 was used. 
Genes from the violacein biosynthetic gene clusters were isolated from pETM6-E12-vioABECD 
which was a gift from Mattheos Koffas (63) and obtained from Addgene (Addgene plasmid 
#73440). Plasmids were constructed using CPEC according to Tian & Quan (2009) (64). Serine 
integrase attachment sites were integrated in the oligonucleotides. The annotated sequence 
map of pDonor1 is found in Supplementary Table A.1-4. 
pLP1 was constructed using CloneJET PCR Cloning Kit (ThermoFisher, USA) and the 
chloramphenicol resistance gene flanked with the serine integrase attachment sites. The latter 
were included in the oligonucleotides. The landing pad vector pLP2 was constructed using 
CPEC according to Tian & Quan (2009) (64) with pLP1 as template and with the serine 
integrase attachment sites and PCR tag regions in the oligonucleotides. Subsequent pLP 
vectors originate from pLP2 and were also constructed using CPEC according to Tian & Quan 
(2009) (64). The annotated sequence map of pLP2 is found in Supplementary Table A.1-5. 
The vector pInt1 comprises of a temperature sensitive pSC101 ori and an ampicillin resistance 
gene. The serine integrase PhiC31 originated from pET-phiC31 which was a gift from dr. Maria 
R. Foulquié-Moreno and the pLac promoter is the endogenous promoter from Escherichia coli 
K-12 MG1655. The vector was constructed using CPEC according to Tian & Quan (2009) (64). 
The annotated sequence map of pInt1 is found in Supplementary Table A.1-6. 
2.2.6 SIRE general protocol 
A landing pad with a selectable marker e.g. chloramphenicol flanked with att sites is first 
introduced (500 ng) in sNS2.01 using homologous recombination according to Datsenko & 
Wanner (2000) (54). Obtained colonies varied between 10 and 30 per strain. In case of a knock-
in, pDonorX carrying the donor DNA flanked with complementary att sites is transformed (200 
ng) according to Datsenko & Wanner (2000) (54). Colonies are selected on kanamycin 
containing LBA plates and subsequently prepared for another round of transformation. Next, 
pInt1 containing the PhiC31 integrase is introduced (200 ng). Cells containing pInt1 are selected 
on spectinomycin while simultaneously expressing the integrase overnight with 0.4 mM IPTG  
(isopropyl-β-D-thiogalactopyranoside) induction on LBA plates. Colonies were checked by PCR 
to evaluate the removal of the landing pad in case of a knock-out or the length of the integrated 
cassette in case of a knock-in. For the latter flanking primers were used when the insert was 
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smaller than 2.5 kB. For larger fragments two primer pairs were used: a forward flanking primer 
was combined with a reverse primer inside the integrated region and vice versa. Finally, the 
strain is fully devoid of any remaining plasmids after overnight curing at 42°C. 
2.2.7 Fluorescence measurements  
Fluorescence and OD measurements were performed in a Tecan M200 Pro microplate reader 
(for Dasher: excitation 488 nm and emission 520 nm) using a Greiner bio-one (Vilvoorde, 
Belgium) black μclear 96 well plate. Cells were cultured in the defined medium described above 
and inoculated 1% from precultures which were grown in a carbon limiting 2.2 g/L glucose·H2O 
defined medium variant. Fluorescence values were corrected for background fluorescence and 
optical density measured at 600 nm and compared between strains at the start of the stationary 
phase. This point was calculated by the specific moment in the growth curve where the 
log(OD600) deviates 25% from the linear fit of the maximum specific growth rate. The latter was 
calculated according to Kahm et al. (2010) (65). 
2.2.8 In vivo assembly 
E. coli One Shot Top10 ElectrocompTM cells (Life Technologies, Belgium) were transformed with 
pInt1 and selected for their spectinomycin resistance. Obtained colonies were subsequently 
made electrocompetent according to Datsenko & Wanner (2000) (54) after induction with 0.4 
mM IPTG. 500 ng of each linearized fragment flanked with orthogonal att sites were mixed with 
50 µL competent cells and electroporated in 0.2 cm-gap cuvettes at 2.0 kV, 25 µF, 200 Ω in a 
Gene Pulser electroporation apparatus (BioRad, USA). The yellow fluorescent protein yPET 
originates from YPet-pBAD which was a gift from Patrick Daugherty & Michael Davidson and 
obtained from Addgene (Addgene plasmid #54860). 
2.2.9 Violacein measurements 
Strains were cultured at 30°C in LB and induced with 1 mM IPTG. 500 µL sample was extracted 
with an equal amount of ethanol and vortexed. Next, the samples were spun down to remove 
cell debris. The optical density of the supernatant was measured at 585 nm using a Jasco V630 
Bio spectrophotometer and compared to a standard dilution series made from violacein from 
Janthinobacterium lividum purchased at Sigma-Aldrich containing >85% violacein.  
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2.3 Results and discussion 
SIRE combines RMCE technology with PhiC31’s orthogonal att sites to create a versatile 
genome engineering toolbox for the insertion or deletion of (large) biosynthetic pathways in 
Escherichia coli (Figure 2-1). Both the creation of a knock-out and knock-in start with the 
introduction of a ‘landing pad’ at the site of interest on the genome using homologous 
recombination. Such a ‘landing pad’ typically consists of a selectable marker flanked with att 
sites and PCR tag regions for easy cassette pick-up from the plasmid backbone. Once a 
landing pad strain is created, the PhiC31 integrase can be used to perform the desired genomic 
modification(s). 
 
Figure 2-1: (a) To create a knock-out, a landing pad flanked with complementary att sites is introduced into 
the genome using conventional techniques (1). Next the vector containing the PhiC31 integrase (pInt1) is 
introduced into the E. coli strain (2). Expressing the integrase by inducing the pLac promoter results in 
excision of the landing pad leaving an attL or attR scar (3).(b) A knock-in on the other hand requires a 
landing pad flanked with orthogonal att sites (1). Next the vector pDonor1 carrying the donor DNA (2) and 
finally the vector containing the PhiC31 integrase (pInt1) (3) are consecutively transformed in the E. coli 
strain. Expressing the integrase by inducing the pLac promoter results in the recombination of the 
orthogonal attB and attP pairs replacing the landing pad with the donor DNA on the genome (4). 
2.3.1 Creating a knock-out 
In the case of a knock-out, the landing pad is flanked with a complementary attB and attP site. 
In our case, we used a chloramphenicol selection marker flanked with attBTT and attPTT sites 
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(See Supplementary Table A.1-7) which can recombine after expression of the PhiC31 serine 
integrase (Figure 2-1a). The introduction of a selectable antibiotic marker and its subsequent 
excision is done analogous to previously described methodologies (38, 54). These techniques 
for creating knock-outs are not hampered by the size-limitation of 2.5 kB for introducing DNA 
fragments, for only one selectable marker is used. Our method only differs in the excision step 
by the use of a serine integrase. In brief, the helper plasmid pKD46 (54) is introduced carrying 
the 𝜆-RED machinery to enable homologous recombination of the landing pad cassette. Next, 
plasmid pInt1 is transformed expressing the serine integrase PhiC31 upon IPTG induction (See 
2.2.6). As a consequence the complementary attB and attP sites recombine, excising the 
landing pad and leaving an attL scar. The resulting strains are cured from remaining plasmids in 
nonselective medium at the nonpermissive temperature of 42°C due to the temperature 
sensitive variant of the pSC101 ori (66).  
We introduced these knock-out landing pads at five randomly chosen intergenic locations 
across the E. coli genome (Figure 2-2b), distributed between the different macrodomains. The 
exact positions are: yahK-yahL, 26.7°; dadX_cvrA, 96.0°; yffL_yffM, 198.7°, sibD_siBE, 247.9°, 
yjhB_fecE, 349.9°. In addition, we also chose to delete three endogenous biosynthetic gene 
clusters of different lengths: otsAB (2.2 kB), pgaABCD (6 kB), waaDQ (14 kb). After introducing 
pInt1 and expressing the PhiC31 integrase, eight colonies of each experiment were checked by 
PCR and Sanger sequencing. All colonies tested displayed the envisaged knock-out with 
excision of the landing pad, leaving an attL scar and indicating a 100% efficiency for the marker 
excision  step. The attL scar incorporates one half of the attB and attP site, altering its sequence 
and rendering it inactive in the absence of the RDF factor. The advantage of the att scar over 
the scars of other recombineering techniques such as the Flp-FRT or the Cre-loxP 
recombination systems (67) is the inactivity of the att scar. Multiple att scars in the genome do 
not recombine in follow-up engineering rounds, as we were able to introduce up to 15 attL sites 
in one strain (See Chapter 4). This is in contrast to FRT or loxP scars, negating the risk of 
chromosomal instability due to unwanted deletions or inversions in the genome. Though it was 
recently reported that attL and attR of the PhiC31 integrase without its RDF recombine very 
weakly in E. coli (68), our flanking sites only result in attL sites which do not recombine when 
the integrase is expressed.  
2.3.2 Creating a knock-in 
To create a knock-in using only one integrase requires the use of 2 orthogonal att pairs, without 
any crosstalk between each other. Colloms et al. (2014) (60) developed such orthogonal att 
sites for the serine integrase PhiC31, in which the central two base pair core of the attachment 
site is crucial and must match perfectly for efficient recombination. There are only six orthogonal 
attB and attP pairs (See Supplementary Table A.1-7) with a distinct dinucleotide which only 
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recombine in a defined orientation and not with each other. Applying those recombinational 
sites with the principle of cassette exchange, it is possible to switch a landing pad by your gene 
of interest (GOI) in a predictable orientation (Figure 2-1b).  
 
Figure 2-2: (a) Simplified representation of the different donor DNA constructs. Their lengths vary from: 
bla, 1.1 kb; Dasher-bla, 2.2 kb; lacI-vioAB-bla, 7.5 kb; lacI-vioABE-bla, 8.2 kb; lacI-vioABEC-bla, 10.0 kb to 
lacI-vioABECD, 10.3 kb. (b) Circular representation of the E. coli genome in which the chosen intergenic 
locations are displayed by gray dots. Image was constructed using CiVi (69). The origin (oriC) and 
terminus (ter) of replication are also indicated. 
To assess knock-in efficiency, strain sNS2.02 was used which contains a chloramphenicol 
resistance landing pad flanked with attBCC and attBTT sites on the mntH locus, a high expression 
location according to Bryant et al. (2014) (70). Next, the donor vector pDonor1 carrying a 2.2 kb 
cassette comprising of the reporter gene Dasher (Atum, USA), a green fluorescent protein with 
a proD promoter (62), together with an ampicillin marker bla flanked with orthogonal attPCC and 
attPTT sites, is introduced and subsequently selected for on kanamycin containing plates of 
which the resistance gene lies on the pDonor1 backbone. After transformation of the vector 
pDonor1 in strain sNS2.02, plasmid pInt1 with the PhiC31 integrase under the endogenous 
pLac promoter is introduced and selected for on spectinomycin of which the resistance gene 
lies on the pInt1 backbone. Exchange between the landing pad and the donor DNA is achieved 
by inducing the expression of the integrase. All eight colonies tested acquired the Dasher-bla 
knock-in in the expected orientation, which was confirmed by PCR and Sanger sequencing. 
Importantly, these colonies were obtained without selection for the ampicillin marker bla. Vector 
backbone markers were selected for after introduction of pDonor1 and pInt1. It should be noted 
that alteration of the protocol in which first pInt1 and then the donor DNA vector is introduced, 
failed to provide correct integrants. One possibility is that cassette exchange occurs rapidly after 
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transformation of the pDonor construct even at low copy numbers and that the integrase cannot 
alter all copies of the chromosome present in the cell during exponential growth. Consequently, 
replication of the donor plasmid would only produce daughter cell without the integrating vector 
and the desired chromosomal knock-in may be lost through the subsequent growth cycles.  
2.3.3 Length-efficiency relation 
To validate the knock-in workflow, the length-efficiency relation of the methodology was tested. 
To that end we made several new knock-in cassettes, using pDonor1 as a template, with 
varying lengths of the biosynthetic gene cluster for the synthesis of the indole derivative 
violacein (71). To create intermediate lengths of donor DNA the violacein pathway was split to 
obtain intermediate products such as protodeoxyviolaceinic acid (vioABE) and 
deoxychromoviridans (vioABEC). The ampicillin resistance gene bla was added to the cassettes 
in case selective pressure would be necessary for larger constructs. The complete vioABECD 
gene cluster by Cress et al. (2016) (63) was used as the final construct. Expression of the 
cluster genes is controlled by optimized T7-lacO promoters and hence the lacI gene was also 
introduced between the flanking att sites. The lengths of the different donor DNA constructs 
varies from 1.1 to 10.3 kb. An overview is given in Figure 2-2a. Next to varying the knock-in 
length, the same five distinct intergenic locations were evaluated to validate the knock-in 
methodology across the different macrodomains of the E. coli genome (Figure 2-2b). 
Using the workflow as described above each of the six donor carrier vectors was introduced in 
the five landing pad strains. These 30 strains were then transformed with pInt1 and induced to 
express the PhiC31 integrase. Without applying selective pressure for the bla marker, all 
landing pad location - donor DNA combinations yielded only correct integrants in the expected 
orientation (8 colonies per combination checked with PCR). To quantify genomic violacein 
production from the vioABECD cassette introduced at the five locations, we had to remove 
remaining pDonor plasmids in the final strains for remaining donor vector would bias the results. 
After transferring them up to 8 times in an overnight growth cycle at 42°C, all strains were 
devoid of remaining donor or pInt1 plasmids. The violacein producing strains were then cultured 
at 30°C and violacein was extracted using ethanol. Production was measured at 585 nm (72) 
and quantified using a violacein standard from Janthinobacterium lividum (Sigma-Aldrich, USA). 
The production details are depicted in Figure 2-3. As expected, the production varied with 
varying genome locations (73).  
This validation of knock-in size independency demonstrates the versatility of the SIRE 
methodology and proves it allows to easily introduce biosynthetic gene clusters up to 10.3 kb 
throughout the E. coli genome without the need to co-integrate selection markers or use 
multiple recombinases in contrast to other recombinase aided techniques (57–59). SIRE’s 
100% integrating efficiency makes it a reliable tool for genome editing. In addition, the 
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methodology is fully plasmid-based, rendering it easy to be adopted or altered for user-specific 
requirements. Nevertheless, the laborious curing efforts to remove remaining (donor) plasmids 
hampered a convenient workflow. To that end, the ColA ori of the donor vector pDonor1 was 
switched with the temperature sensitive variant of the pSC101 ori (66) (pDonor7), the same ori 
as the pInt1 integrase expression plasmid, which enables curing at 42°C. By repeating the 
Dasher-bla knock-in experiments in sNS2.02 using the temperature sensitive variant of the 
donor vector, we confirmed the same efficiency for the optimized SIRE methodology (PCR and 
Sanger sequencing of eight colonies). After an overnight curing at 42°C, all plasmids were 
eliminated. 
 
Figure 2-3: Left: Overview of the violacein production of the five strains in which the vioABECD cluster has 
been incorporated, after curation from all remaining plasmids. Values are corrected for wild type 
background and error bars represent standard deviation of three replicates. Right: Streak plate of the 
corresponding strains: at the top sNS2.01 (wild type) and then clockwise strains sNS2.08-12. 
2.3.4 Multitargeting 
With the optimized variant of the pDonor1 construct, we explored the possibility to 
simultaneously target multiple loci for integration on the genome. This would provide the user 
with an extra tool within the same system to e.g. create a higher copy number of a transcription 
unit of interest without having to use plasmid based optimization. To this end we created strains 
carrying double and triple landing pads with the same att sites, but with different selectable 
markers, such as tetracycline and gentamicin. All double and the triple combinations of the loci 
dadX_cvrA, yffL_yffM and sibD_sibE were foreseen of the necessary landing pads. Repeating 
SIRE with the Dasher-bla donor DNA, we found that simultaneous integration on multiple 
locations can be achieved. All eight colonies tested for all double landing pad strains had 
integrated the Dasher-bla knock-in cassette on both locations without selection for the genomic 
integrants and thus without loss of efficiency. Also the triple landing pad strain showed the 
knock-ins on all three locations without the need for selective pressure albeit at a lower 
efficiency of 75%. The latter may be enhanced by increasing the copy number of the donor 
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plasmid which is for the pSC101 ori only <8 copies per chromosome (74). The more copies in 
the cell the higher the chance of integrating the donor DNA on different locations throughout the 
genome. From the normalized fluorescence data obtained with these strains with one to three 
Dasher GFP copy numbers (Figure 2-4) it is clear that the addition of an extra copy of the 
fluorescent protein compared to the single knock-in enhanced fluorescence twofold. The 
addition of two copies increased fluorescence nearly threefold. The growth curve of each strain 
as well as their fluorescence output in function of time is displayed in Supplementary Figure 
A.1-1 and Supplementary Figure A.1-2 which show that knock-ins affect growth rates. It is 
remarkable that the fluorescent  cassette at dadX_cvrA  has a similar impact on growth rates as 
on the other locations, but in combination with the others significantly reduces the growth rate. 
The difference in fluorescence within the single knock-in and double knock-in groups is 
explained by local effects which influence expression (See also Chapter 3) (70, 73, 75). 
 
Figure 2-4: The fluorescence signal of the wild type (sNS2.01), single (sNS2.09-sNS2.11), double 
(sNS2.13-sNS2.15) and triple knock-ins (sNS2.16) at the beginning of the stationary phase. Fluorescence 
is displayed in arbitrary units (a.u) and corrected for background fluorescence and growth. Error bars 
represent the standard deviation of three replicates. Each strain differs significantly from the others (CI 
95%), except strains sNS2.13 and sNS2.14, as indicated. 
Providing now the availability of a library of strains with landing pads in combination with for 
example a MoClo design (76) for the assembly of the donor constructs, a rapid design-build-test 
cycle is possible. The fast and reliable methodology would enable the researcher to directly 
convey newly designed biochemical pathways towards the genome. This allows an extensive 
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screening of transcription unit libraries directly on the genome after which e.g. the effect of 
location can be assessed in function of production and long-term stability (70, 73, 75). The 
methodology also limits copy number bias for it alleviates the need of plasmids in production 
hosts. 
In this study, we limited the use of orthogonal att sites to their TT- and CC-dinucleotide variants. 
However, other combinations should be possible and the methodology should also work using 
other integrases, as long as there is no cross-over between the different att sites. It is possible 
that other integrases have a larger variety of orthogonal att sites which could extend the 
functionality of the SIRE toolbox. Multiple integrases could also achieve the same chromosomal 
insertion when expressed simultaneously, to allow higher copy numbers. Nonetheless, it is our 
opinion that the use of multiple att sites from the same well-characterized PhiC31 serine 
integrase, which employs relatively small sites and requires no auxiliary host factors (77), is part 
of the elegance of the system. Although pseudo att sites for PhiC31 are known to other 
organisms (78–82), no genomic pseudo att sites in Escherichia coli were found in our study or 
in previous work (79, 83).  
2.3.5 In vivo assembly 
To further expand the SIRE toolbox, an in vivo assembly methodology was explored as an 
alternative to Invitrogen’s Gateway Cloning (84). To that end we created a cassette with a bright 
yellow fluorescent protein yPET (85), with a coding sequence completely different of the one of 
Dasher, under the control of a proD promoter (62) and flanked with orthogonal attP sites. The 
cassette was linearized by PCR. To perform the in vivo assembly test the backbone from pLP1 
was also linearized to obtain the pMB1 ori and the bla marker flanked with orthogonal attB sites. 
500 ng of both linear fragments were then transformed into electrocompetent OneShot Top10 
cells containing pInt1 which were induced with 0.4 mM IPTG. About 25 colonies were obtained 
of which 75% showed a visible bright yellow color indicating a correct assembly. All fluorescent 
colonies were checked by PCR, and eight of them by Sanger sequencing, confirming the 
correct assembly of the plasmid, containing yPET flanked with recombined attL and attR sites. 
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2.4 Conclusions and perspectives 
Valorization of many bio-active molecules synthesized by newly created bio-engineered strains 
with rerouted metabolism often fail during scale-up. One of the problems is the plasmid based 
optimization of production pathways, which is convenient from a cloning efficiency perspective 
but less preferred in an industrial setting, as plasmids require antibiotics for their maintenance 
and cause structural and segregational instability, and metabolic burden (35, 36). On the other 
hand incorporation of multiple-gene pathways onto the genome of Escherichia coli using 
classical techniques as homologous recombination suffer from very low efficiencies (38). Even 
the efficiencies of the latest CRISPR techniques decrease with increasing lengths (22–25). 
However, using the PhiC31 integrase and its orthogonal att sites we have created the SIRE 
toolbox in which we were able to introduce up to 10.3 kb with 100% efficiency and without the 
need for selections markers on the knock-in cassette. Providing now the availability of a library 
of strains with well-characterized landing pads (See also Chapter 3) in combination with for 
example a MoClo design (76) for the assembly of the donor constructs, a rapid design-build-test 
cycle on the genome is now possible. 
The use of the SIRE toolbox in other species was also published in Snoeck et al. (2018) (86) in 
which the knock-out part of SIRE was confirmed in S. cerevisiae. Unfortunately, the knock-in 
protocol failed to provide viable colonies and an expression-toxicity relation may be the cause of 
this problem. Nevertheless, the portability proves the versatility of the toolbox, which may be 
expanded towards other species lacking high homologous recombination efficiency.  
Altogether, the characteristics of the SIRE toolbox provide an easy, efficient and scalable 
genome engineering strategy for deleting genes and introducing large constructs on the 
genome, expanding the metabolic engineering toolbox of E. coli with potential in other 
organisms as well.  
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Abstract  
As a biorefinery platform host, Escherichia coli has been used extensively for the production of 
metabolites of commercial interest. Despite the development of numerous tools and genome 
editing technologies, the question of where to incorporate a synthetic pathway remains 
unanswered. To address this issue, we performed a comprehensive study of E. coli genomic 
expression and linked it not only to 26 rationally selected genomic locations, but also to the 
gene direction in relation to the DNA replication fork, to the carbon and nitrogen source, to DNA 
folding and supercoiling, and to metabolic burden. To enable these experiments, we have 
designed a fluorescent expression cassette to eliminate specific local effects on gene 
expression. Overall it can be concluded that although the expression range obtained by 
changing the genomic location of a pathway is small compared to the range typically seen in 
promoter-RBS libraries, the effect of culture medium, environmental stress and metabolic 
burden can be substantial. The characterization of multiple effects on genomic expression, as 
accomplished in this study, and the associated libraries of well-characterized strains will only 
augment the possibilities for the development of new and better biotechnological production 
hosts.  
 
 
 
  
Chapter 3: Comprehensive study on the expression location of E. coli: does position really matter? 
45 
3.1 Introduction 
The microbial host Escherichia coli has been used extensively for the production of metabolites 
of commercial interest (13, 17, 48, 87–89). Promoter and terminator databases (26–29) are 
readily available as well as various assembly methods (60, 90–92), a large amount of 
expression vectors (34), and numerous gene editing technologies (24, 38, 54, 93, 94). 
Combined with the ever-reducing cost of synthetic DNA, the possibilities for engineering are 
countless. Recent advances have secured the possibility of integrating whole synthetic 
pathways with ease and high efficiency onto the bacterial genome (22, 86), thereby overcoming 
the need for plasmid expression and its associated instability (36). However, the question of 
where to incorporate a synthetic pathway remains unanswered. 
The genome of E. coli MG1655 contains more than 4000 genes or 4.64 Mbp (31) and thus 
numerous positions for the integration of a biosynthetic pathway. Yet, gene expression is 
location-dependent (95) as transcriptional activity of genes located close to each other is 
correlated and influenced by the negative supercoiling state of the genome (73). The latter is 
also affected by growth conditions and stress, which in turn also affect transcription (96–99). 
Furthermore, it was found that some extensive protein occupancy domains (EPODs) are 
localized close to highly expressed genes while others are present in more ‘silent’ regions (100). 
Hence, expression also depends on the proximity of several histone-like nucleoid-associated 
proteins (NAPs) which influence the organization of the chromosome (99, 101, 102). 
Despite this knowledge, few studies have investigated the effect of chromosome position on 
gene expression. In general, a gene dosage effect is observed, i.e. a gene is higher expressed 
when located closer to the origin of replication (oriC) due to the higher copy number of genes 
closer to oriC during replication (95, 103). One study indicates a two-to-three fold variation for a 
lacZ reporter (95) depending on the integration locus, whereas others measured a four-to-
twenty fold difference using a fluorescent protein (104–106). Other research states a 300-fold 
expression difference of a fluorescent reporter and indicates that only 1.4-fold is attributed to the 
gene dosage effect (70). Recently, a high resolution mapping with randomly integrated 
cassettes was created, indicating a more sinusoidal effect of gene expression in function of 
chromosome position and an average four-fold range of expression strength (107). Many of the 
locations of this study may however not be relevant for pathway integration as they were 
obtained by transposon mediated integration, which is generally unstable, can disrupt genes, or 
can interfere with endogenous metabolism. 
Current location related data on expression is thus diverse and non-consistent, due to the 
different locations studied and the different reporter cassettes used. In addition, the fact that 
applying different fermentative conditions affects expression was often not considered, nor was 
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the fact that introducing heterologous genes causes metabolic burden, affects cellular 
resources, and hence influences gene expression. To facilitate use of a specific chromosomal 
position to express or even fine-tune a biosynthetic pathway and to reduce locus-dependent 
variability, a catalogue of specific, uniformly compared locations, which do not interfere with the 
natural metabolism, is essential.  
To address this issue, we have investigated the influence of the chromosome position on 
expression in Escherichia coli. Intergenic locations were rationally selected to minimize 
interaction effects and a fluorescent expression cassette was designed to be isolated from local 
effects originating from the surrounding genes, transcriptional readthrough and transcription 
factors. This cassette was incorporated at the selected locations spread over the genome and 
relative expression levels were determined. DNA strand effects as well as DNA supercoiling 
effects were assessed to further characterize the loci. Also, the influence of medium 
composition on expression was investigated, as well as the susceptibility of the locations to 
induced burden.  
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3.2 Material and methods 
3.2.1 Chemicals 
Tryptone and yeast extract were procured from Becton Dickinson. Glucose were procured from 
Riedel-De Haan. All other chemicals were purchased from Sigma-Aldrich, unless stated 
otherwise.  
3.2.2 Oligonucleotides and molecular reagents 
Oligonucleotides were purchased from Integrated DNA Technologies (Leuven, Belgium). 
Sequencing services were conducted by Macrogen Europe (Amsterdam, The Netherlands) for 
plasmids and LGC genomics (Berlin, Germany) for linear DNA fragments. Deoxynucleotides, 
agarose and ethidium bromide were purchased from Thermo Fisher Scientific. QIAprep Spin 
Miniprep kit was used for plasmid isolation (QIAgen, USA). Analytik Jena kits were used for 
PCR purification (Jena, Germany). 
3.2.3 Strains 
E. coli K-12 MG1655 was used as a base strain for all future modifications. E. coli One Shot 
Top10 ElectrocompTM cells (Life Technologies) were solely used for cloning purposes. Landing 
pads were introduced according to Datsenko & Wanner (2000) (54). An overview of all strains is 
given in Supplementary Table A.2-1. The genomic homologies used to integrate the landing pad 
onto the genome are listed in Supplementary Table A.2-5. 
3.2.4 Media and culture conditions 
The culture medium lysogeny broth (LB) consisting of 1% tryptone, 0.5% yeast extract and 
0.5% sodium chloride was used throughout the work. Lysogeny broth agar (LBA) is similarly 
composed with the addition of 12 g/L agar. If required, media were supplemented with the 
antibiotics ampicillin (100 μg/mL), spectinomycin (100 µg/µL), kanamycin (50 μg/mL), 
gentamycin (30 µg/mL), chloramphenicol (34 μg/ mL) or tetracycline (10 µg/mL). 
For growth experiments measuring fluorescence a defined medium was used containing 2 g/L 
NH4Cl, 5 g/L (NH4)2SO4, 3 g/L KH2PO4, 7.3 g/L K2HPO4, 8.4 g/L MOPS, 0.5 g/L NaCl, 0.5 g/L 
MgSO4 ·7H2O, and 16.5 g/L glucose·H2O, 1 ml/L trace element solution and 100 μL/L of a 0.967 
g/L Na2MoO4·2H2O molybdate solution. The trace element solution contained 3.6 g/L 
FeCl2·4H2O, 5 g/L CaCl2·2H2O, 1.3 g/L MnCl2·2H2O, 0.38 g/L CuCl2·2H2O, 0.5 g/L CoCl2·6H2O, 
0.94 g/L ZnCl2, 0.0311 g/L H3BO4, 0.4 g/L Na2EDTA·2H2O, 1.01 g/L thiamine·HCl. The defined 
medium was sterilized with a bottle top filter (Corning PTFE filter, 0.22 μm). 
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3.2.5 Plasmids  
The landing pad plasmid pLP5 consists of the temperature sensitive pSC101 ori, a kanamycin 
resistance gene, and the tetA resistance cassette flanked with attP sites with a CC and TT 
dinucleotide core respectively (60). The full sequence of landing pad plasmid pLP5 can be 
found in Supplementary Table A.2-3 
The donor plasmids in this chapter contain a pSC101 ori, a kanamycin resistance gene and 
serine integrase attachment (attB) sites with a CC and TT dinucleotide core respectively (60), 
flanking the gene of interest. Different fluorescent proteins were used: mKate2 (108), mCherry 
(109), and several Paintbox proteins (ATUM, USA). Expression was driven by the proD 
promoter (44) with RBS Bba_B0034 (110) and rnpB_T1 was chosen as the terminator (111). 
Donor plasmids were constructed using Golden Gate (91). The full sequence of donor plasmid 
pDonor8 harboring the green fluorescent protein Dasher, can be found in Supplementary Table 
A.2-4. Donor plasmids pDonor9 and pDonor10 are identical to pDonor8, with exception of the 
coding sequence of mCherry (109) and mKate2 (108) respectively. The sequence of pDonor11 
is identical to pDonor8, except for the part from 4349 bp to 1069 bp which was reversed. 
The vector pInt1 is the same as previously described in Chapter 2. The plasmid pLys-M1 
(Addgene plasmid # 109382) was a gift from Tom Ellis (112). All constructs were verified by 
DNA sequencing before use (Macrogen Europe, the Netherlands). Bacterial plasmids are listed 
in Supplementary Table A.2-2.  
3.2.6 SIRE general protocol 
Chromosomal integration of the fluorescent cassettes was done with Serine Integrase 
Recombinational Engineering (SIRE) (86). In brief, a landing pad with selectable marker tetA 
flanked with attPTT and attPCC was introduced in E. coli K-12 MG1655 using homologous 
recombination with the λ Red recombinase system (54). Second, a plasmid carrying the donor 
DNA flanked with complementary attBTT and attBCC sites was introduced and selected for. Next, 
vector pInt1 containing the PhiC31 integrase was introduced and selected for on spectinomycin 
while simultaneously expressing the integrase overnight with 0.4 mM IPTG (isopropyl-β-D-
thiogalactopyranoside) induction on LBA plates. The genomically integrated donor DNA was 
checked with by colony-PCR (Dasher, mCherry or mKate2 cassette) and verified by Sanger 
sequencing for 10% of the strains (LGC Genomics, Germany).  
3.2.7 Selection of the locations 
The genome of E. coli was scanned for intergenic regions that met the predetermined criteria. 
The Python script is given in Supplementary Script A.2-1. 
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3.2.8 Fluorescence assays in plate reader 
Bacterial cultures were inoculated 1% from an LB preculture started from single colony and 
incubated in Greiner Bio-One clear 96 well plates at 37°C and 800 rpm. They were grown 
overnight in the defined medium described above, containing 2.2 g/L glucose·H2O, which led to 
equal outgrowth due to carbon-limitation. Cultures were diluted 100-fold in fresh defined 
medium containing 16.5 g/L glucose·H2O in Greiner Bio-One µClear black 96 well plates. Plates 
were grown in an incubation room of 37°C containing two microplate-shakers (800 rpm), a 
robotic arm and a Tecan Spark 10M microplate reader, performing measurements of 
Dasher (excitation (ex.), 486 nm; emission (em.), 532 nm), mCherry (ex., 575 nm; em., 625 nm), 
mKate2 (ex., 588 nm; em., 633 nm) and optical density (OD, 600 nm) every 30 min. Each 
experiment consisted of a minimum of three biological replicates. We corrected fluorescence 
values by subtracting the fluorescence of the wildtype (E. coli K-12 MG1655) and dividing this 
value by OD600 measurements. The obtained fluorescent output (A.U.) was compared between 
strains at the start of the stationary phase. This point was calculated by the specific moment in 
the growth curve where the log(OD600) deviates 20% from the linear fit of the maximum specific 
growth rate (65). 
3.2.9 Determination of maturation time 
Different candidate fluorescent proteins were tested on plasmid level with the fluorescence 
assay conducted as described above. Fourteen originate from the Protein Paintbox (ATUM, 
USA) and are under the control of the T5 promoter, with the pUC ori and an ampicillin 
resistance gene as selection marker. Other fluorescent proteins are yPET and eBFP2, on 
plasmids yPET-His and pPAB-eBFP2 originating from Addgene (#14031 and #14891 
respectively). The ‘time until fluorescent signal’ was calculated as the time where the 
fluorescence reached 10% of its maximum value subtracted by the time of induction, which was 
after 4h of growth. For determination of the ‘maturation time’ chloramphenicol was added during 
exponential phase, since this antibiotic blocks translation, meaning that additional fluorescence 
can only result from maturated proteins that were already translated. The ‘maturation time’ was 
then calculated by the time where the fluorescence reached 90% of its maximum value, 
subtracted by the time where chloramphenicol was added, which was after 4h, 6.5h or 9.5h 
depending on the growth rate of the strains. 
3.2.10 Carbon and nitrogen source assay 
Different growth media were tested to investigate the influence of carbon and nitrogen source 
on expression profiles of Dasher. To that end, glucose in the defined medium was replaced by 
glycerol in an equimolar carbon concentration (15.35 g/L) (Defined glycerol). To test the 
influence of the nitrogen source, the ammonia salts were replaced by equimolar concentrations 
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of KCl, Na2SO4, and glutamine (respectively 2.79 g/L, 5.37 g/L, and 8.26 g/L) in the defined 
glucose medium (Defined glutamine suppl.). Lastly, the expression was evaluated on LB 
medium (see above). Fluorescence assays were performed as described above. The C-period 
was determined according to the Helmstetter and Cooper (113) model y = A*exp(-C*µmax*x) in 
which the fluorescence output (y) in function of the net distance from oriC (x) is exponentially 
correlated. In order to correlate the given C-period to the available literature, the growth rates 
calculated from plate reader data were scaled to the growth rate of shake flasks with the same 
background and medium (114, 115). 
3.2.11 DNA folding assay 
Strains containing a genomic Dasher cassette were grown with and without novobiocin (500 
µg/mL). Fluorescence assays and analyses were conducted as described above. 
3.2.12 Flow cytometry 
The plasmid pLys-M1 was transformed in strains containing the Dasher reporter cassette using 
heat shock (116). Bacterial cultures were inoculated 1% from an LB preculture started from 
cryovial and incubated in Greiner Bio-One clear 96 well plates at 37°C and 800 rpm. They were 
grown overnight in the defined medium described above containing 2.2 g/L glucose·H2O, which 
led to equal outgrowth due to carbon-limitation. Cultures were diluted 100-fold in fresh defined 
medium containing 2.2 g/L glucose·H2O, with and without induction of 0.2% L-arabinose to 
express the VioB-mCherry reporter. Plates were grown at 37°C and 800 rpm for 16h after which 
cultures were diluted 1000x in phosphate-buffered saline (PBS) (117). 
Cultures were analyzed on a BD LSRFortessaTM Cell analyzer with BD FACSDiva software. 
Calibration was done with BDTM Cytometer Setup and Tracking Beads. The blue (B530, 488 nm, 
filter 533/30) and yellow-green (Y610, 561 nm, filter 610/20) lasers were used for 
measurements of Dasher and VioB-mCherry respectively. Used parameters and PMT voltages 
were forward scatter (FSC: 334), side scatter (SSC: 370 V, with threshold value 500), blue laser 
(B530: 481 V) and yellow-green laser (V610: 670 V). FlowJo_V10 software was used to filter 
out cell debris and select for single cells. Without induction, the considered cells were the total 
amount of green fluorescent cells whereas with induction calculations were done on cells which 
were red as well as green fluorescent.  
  
Chapter 3: Comprehensive study on the expression location of E. coli: does position really matter? 
51 
3.2.13 Statistical analyses 
Statistical analyses of fluorescent assays in the plate reader were performed with a linear 
regression model of the package StatsModel for Python. Each strain or condition was tested in 
at least threefold. Replicates originated from single colonies (n=3).  
Statistical analyses of flow cytometry experiments were performed using the package SciPy for 
Python. Each strain or condition was grown in threefold in defined medium. Replicates 
originated from the same LB preculture (n=3). To determine if induction of the VioB-mCherry 
reporter resulted in lower genomic expression of the Dasher reporter, a paired one-sided t-test 
was performed with a 95% confidence interval. One-sided t-tests were chosen to comply with 
the hypothesis that VioB-mCherry expression results in higher burden and thus can only result 
in lower genomic expression. Strains that were significantly lower in Dasher fluorescence 
because of VioB-mCherry induction (p<0.05), were compared to each other with ANOVA (Tukey 
correction) using SPSS software to determine if these strains were equally influenced by the 
imposed burden. Normality was assumed in all statistical tests. 
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3.3 Results 
3.3.1 Selection of the locations 
To investigate the influence of the chromosome position on expression, we selected several 
intergenic regions spread over the genome to prevent all effects on cellular or metabolic 
processes. To avoid interactions with E. coli regulatory sequences, promoter, 5’-UTR, 3’-UTR 
and terminator regions were excluded, as well as binding sites of sigma factors, enhancers or 
silencers (27, 29, 118, 119). Intergenic regions with substantial transcripts compared to their 
flanking sequences were omitted, since these can hold unknown regulatory sequences (118). 
Genomic parts containing sRNAs and repetitive elements were also excluded (118, 120). As an 
additional constraint, only intergenic regions of at least 200 bp in length were chosen, again to 
avoid an effect on regulation. Based on all these aspects, 74 intergenic locations were selected. 
Of these, 38 were chosen based on their spread over the macrodomains and non-structured 
regions of the E. coli genome (121) and on the orientation of the surrounding genes of the 
intergenic region. Some of the locations are also found within extended protein occupancy 
domains (EPODs), which are regions with peaks in DNA-protein interaction. Six of the chosen 
intergenic regions are within a so-called highly expressed EPOD (heEPOD), which are dense in 
RNA polymerase binding and coincide with highly expressed genes and 12 are within a 
transcriptionally silent EPOD (tsEPOD) with 
relative low levels of RNA polymerase 
binding (100). To enable comparison of the 
data with existing literature on E. coli 
genomic expression, 9 extra locations were 
included in our study i.e. intergenic locations 
lacZ_lacI, ycbW_ycbX, nupG_speC, 
aslB_aslA, atpI_gidB, yieN_trkD, ybbD_ylbG, 
essQ_cspB, and nth_ydgR (70, 105, 106). 
Last, two regions were added because of the 
importance of the (surrounding) genes in E. 
coli research, being fucI_fucK (122), and 
xylB_xylA (123). The locations were named 
based on their neighboring genes. The 49 
selected locations and their position on the 
E. coli genome are shown in Figure 3-1, 
detailed information is included in 
Supplementary Table A.2-6. The 11 
additional locations meet most of the 
Figure 3-1: Genomic map of the E. coli str. K-12 
MG1655 genome, with 49 intergenic regions shown 
as dots. The 26 regions indicated in blue are studied 
more in detail. The four macrodomains and the two 
non-structured regions are indicated in grey areas 
(121). The chromosome positions of the terminus 
(dif; 1,604 kb) and origin of replication (oriC; 3,924 
kb) are also labelled. The map was created with CiVi 
(69). 
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premised criteria, deviations are shown in the last column of Supplementary Table A.2-6. 
3.3.2 Effect of genomic location on expression 
3.3.2.1 Selection and validation of reporter cassette 
To avoid a low signal-to-noise ratio, long maturation time or fast saturation of measurements, 
different candidate fluorescent proteins such as mCherry (109), mKate2 (108), eBFP2 (124) and 
yPET (85) and several Paintbox proteins (ATUM, USA) were tested on plasmid level. The ‘time 
until fluorescent signal’ and the ‘maturation time’ of these fluorescent proteins are given in 
Supplementary Table A.2-7. Based on these data a green fluorescent protein (Dasher) and two 
red fluorescent proteins (mCherry and mKate2) were chosen. Holly GFP, despite having the 
same characteristics as Dasher, was excluded for it has a secondary excitation maximum at 
400 nm potentially interfering with future applications. 
To create expression cassettes insulated from genomic context (62, 125, 126), the selected 
fluorescent proteins were flanked with the insulated strong promoter proD (62) with the strong 
ribosome binding site Bba_B0034 (110) and the high efficient terminator rnpB T1 (111). 
Additionally, biologically neutral 60 bp spacers designed according to Casini et al. (127) and 
~50 bp att sites are surrounding the construct. Davis et al. (62) showed that transcription from 
proD and three other insulated promoters was not upregulated by an upstream promoter-
stimulating sequence, while transcription from four non-insulated promoters was increased in a 
highly variable manner. Additionally, a downstream promoter-repressing sequence had almost 
no effect on the insulated promoters, but had variable effects on the uninsulated promoters, 
meaning that proD can be considered insulated from genomic context (62). The translation 
initiation rate of Bba_B0034 with proD is 751.86 A.U. according to the Salis RBS Calculator 
(128).To validate their suitability for genome-based expression, the expression cassettes were 
inserted on nine different locations. Their fluorescent output is given in Supplementary Figure 
A.2-1. It can be deduced that the output is comparable for the three fluorescent proteins, 
regarding fluctuations between the locations, meaning that the three fluorescent proteins are 
suitable as a marker for this study. Despite Dasher and mKate2 having a similar higher signal-
to-noise ratio compared to mCherry, Dasher was chosen as the reporter fluorescent protein 
because it has a maturation time of around five minutes.  
3.3.2.2 Evaluation of genomic expression.  
The Dasher reporter cassette was integrated at the 49 selected locations and fluorescence 
assays were performed on 96 well-plates. In Figure 3-2A, the fluorescence of the reporter 
cassette in function of the genomic position is shown. A 2.22-fold difference in expression was 
observed between the highest expressing strain (dinD_yicG) and the lowest expressing 
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strain (rseX_yedS). A trend is seen where fluorescence decreases towards 1600 kb and rises 
again towards 4000 kb, which coincides with the locations of dif and oriC respectively. When 
calculating the net distance from oriC, this trend is clearly confirmed (Figure 3-2B) and is in 
accordance to literature where the gene dosage effect was also seen (70, 104). The gene 
expression correlates with the net distance from oriC in an exponentially decreasing manner 
according to the Helmstetter and Cooper model (113) (See Supplementary Table A.2-8). In 
Supplementary Figure A.2-2 the expression strength in function of each location is also given. 
The growth rates of each strain are given in Supplementary Figure A.2-3 and none are 
significantly different from another (95%, with an F-statistic of 1.01 and a p=0.46).  
For the locations within extended protein occupancy domains (EPODs) (100), the gene dosage 
effect also seems to apply as highly expressed EPODs (heEPODs) and transcriptionally silent 
EPODs (tsEPODs) near dif result in a lower fluorescence than near oriC. The output of regions 
within heEPODs is however not higher than for the other locations (see Figure 3-2), but the 
regions within tsEPODs do have a diminished fluorescent output as the intercept of the log-
linear regression is significantly lower (See Supplementary Table A.2-8). Six non-EPOD 
locations also appear to coincide with the tsEPOD group and of these regions ygcE_queE, 
ybfK_kdpE and frvA_rhaM are indeed located close to (<10 kb) tsEPODs. However, the same is 
true for many other locations, so that their lower expression cannot only be attributed to their 
proximity near a tsEPOD region. When looking at the orientation of the surrounding genes, no 
correlation was found with the fluorescent output. 
 
Figure 3-2: Fluorescence of the Dasher reporter cassette corrected for wildtype fluorescence and OD600 
(A.U.) and measured at the start of the stationary phase in function of (A) the spread over the genome (kb) 
and (B) the net distance from oriC (kb). Purple dots represent regions within a heEPOD and red dots 
represent regions within a tsEPOD. The exponential regression line of non-EPOD regions is shown in blue 
while the red regression line only includes the regions within a tsEPOD. The chromosome positions of the 
terminus (dif; 1,604 kb) and origin of replication (oriC; 3,924 kb) are also labelled. Error bars represent 
standard deviation of at least four replicates. Experiment conducted in defined glucose medium. 
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3.3.3  DNA strand effect 
Even though the designed reporter cassette is assumed to be isolated from genomic context, it 
is not possible to completely insulate any biological component (62). To check the possible 
influence of 5’-upstream sequences or readthrough of upstream promoters, the reporter 
cassette was also inserted in the inverted orientation. To simplify analysis, we designed our 
experiment to focus on 26 intergenic locations spread over the macrodomains and non-
structured regions from the initial criteria-based selection, as shown in Supplementary Table 
A.2-6. A scatter plot showing the correlation 
between the two directions is given in Figure 
3-3. For some of the locations, the 
expression of the inverted reporter cassette 
is somewhat higher than the original 
orientation, or vice versa. Yet, the correlation 
between the two directions is close to 1, the 
linear regression is significant (95% with an 
F-statistic of 116.9 and a p-value of 1.05e-
10, see Supplementary Table A.2-9) and all 
data points lay within the 95% prediction 
interval, indicating that insertion of our 
reporter cassette on the leading or lagging 
DNA strand generally has no influence on 
expression. In addition, growth rate 
differences between both orientations for a 
location are negligible (See Supplementary 
Figure A.2-3), so that local differences could 
be attributed to minor influences of surrounding DNA sequences. 
3.3.4 Effect of carbon/nitrogen source 
To evaluate the effect of the carbon source on the expression strength obtained at the different 
locations, we altered the glucose carbon source to glycerol. In addition, we also changed the 
defined medium to lysogeny broth (LB). To see the effect of the nitrogen source we 
supplemented our defined glucose medium with glutamine instead of using ammonium salts. In 
Supplementary Figure A.2-4 the fluorescence output of 26 locations in function of the net 
distance from oriC is given for the 4 media used. Despite a large effect on growth rate (LB = 
0.233 ± 0.008 h-1; defined glucose = 0.178 ± 0.005 h-1, defined glutamine = 0.179 ± 0.007 h-1; 
defined glycerol = 0.154 ± 0.007 h-1), it is clear that changing the medium does not alter the 
gene dosage effect. Also, when calculating the time needed to replicate the chromosome (C-
Figure 3-3: Scatter plot showing the correlation 
between the fluorescence of the reporter cassette 
corrected for OD600 measurements and background 
fluorescence in inverted orientation and in original 
orientation for the 26 tested locations. The linear 
regression line is shown in blue and has a slope of 
0.98 with an R² of 0.83. The 95% prediction interval is 
shown in grey shade. The dashed orange line 
represents a slope equal to one. Error bars represent 
the standard deviation of six replicates. Experiment 
conducted in defined glucose medium. 
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period), being 44.5’, 45.4’, 46.2’ and 51.5’, respectively, these values are in accordance with 
literature, where a constant C-period was found of around 40 minutes, with higher values when 
doubling times are below a certain threshold (113). The measured range of growth rates thus 
does not alter the gene dosage effect as the expression range only varies slightly amid a 1.9-
fold change between locations when glucose is used as the carbon source and a 2.2-fold for 
glycerol and LB. If the growth rate would be much slower, increasing the C-period substantially, 
then a lower dosage might be found.  
 
Figure 3-4: (Top) Scatterplot indicating the fold difference of the different locations relative to the lowest 
fluorescence location for each medium. (Bottom) Overview of the fluorescence of the reporter cassette 
inserted on the 26 chosen intergenic locations, corrected for background fluorescence and OD600 (A.U.). 
Error bars represent the standard deviation of three replicates. 
Nevertheless, differences in medium composition do change the overall fluorescence output, as 
can be seen from Figure 3-4. Despite having a higher growth rate, output on LB is the lowest, 
while the fluorescent output on the defined glutamine medium is the highest. When comparing 
both media, an overall 50% increase is noticed for each location meaning that medium 
composition has a substantial influence on the gene expression, and hence medium 
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optimization significantly influences production performance. In the top part of Figure 3-4, also 
some local effects are noticed in which some locations have a much higher relative expression 
in one medium compared to another, e.g. location ypjC_ileY and thrW_yfkN have a relative 
higher expression when cells are grown on complex or glycerol medium compared to glucose 
as the C-source.  
3.3.5 DNA folding effect 
The transcriptional activity of an expression cassette at a given location is also linked to the 
distribution of DNA gyrase on the genome (73). DNA gyrase is responsible for maintaining the 
negative supercoiling steady state by introducing negative supercoils at the expense of ATP. 
The extent of supercoiling is seen as a global regulator for gene expression and reacts upon 
environmental changes such as osmotic stress, nutritional shifts and temperature changes (99, 
129, 130). Previous studies have revealed more than 300 genes of which the expression is 
positively or negatively correlated to the level of supercoiling (96). In order to investigate the 
sensitivity of our chosen intergenic locations to relaxation of the chromosome, we added 
novobiocin, an aminocoumarin antibiotic which inhibits the ATPase activity of DNA gyrase, to 
the cultures. In Figure 3-5 the relative difference in fluorescence output is given for the 26 
strains grown with and without novobiocin addition. In Supplementary Figure A.2-3, the 
differences in growth rates are also displayed. A general increase in fluorescence is noticed 
upon addition of novobiocin, in spite of some locations where almost no difference is noted, 
while the growth rate is slightly diminished over all strains. This general augmentation of the 
fluorescence at our intergenic locations is remarkable, as others have also shown a decrease in 
expression when novobiocin is added (70, 96). Looking at the macrodomains, the lowest and 
the highest increase in fluorescence appears at the locations found in the non-structured 
domains. However, the average between structured and non-structured domains is not 
significantly different (T = 1.55 and p = 0.16), while the variance is (F = 25.71 and p = 7.45e-8), 
indicating a higher susceptibility for local supercoiling effects e.g. caused by environmental 
changes for locations in these non-structured regions. In this respect, location djlA_yabP found 
in the right non-structured domain stands out with the highest increase of 125%. Interestingly, 
the latter location is the only one having a strongly diminished growth rate in contrast to the 
others, indicating again the sensitivity of this location.  
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Figure 3-5: Difference between the fluorescence with and without addition of 500 µg/mL novobiocin of the 
reporter cassette corrected for OD600 measurements and background fluorescence (left) and the 
corresponding histogram (right). Bars in purple represent locations in non-structured regions. Error bars 
represent the standard deviation of at least three replicates. Experiment conducted in defined glucose 
medium. 
3.3.6 Burden effect 
Heterologous gene expression can be a significant burden for cells. Often this burden is not 
caused by the specific heterologous sequences, but by a general resource depletion in the 
cells. To enable assessment of the effect of this burden, Ceroni et al. developed a fluorescence-
based assay to measure the gene expression capacity of bacterial cells in real time (112). They 
developed several plasmids, including pLys-M1, a medium copy number plasmid with a strong 
promoter-RBS controlling expression of a fusion protein of VioB and mCherry which imposes a 
significant burden upon the cell. By using a ‘capacity monitor’, a fluorescent protein expression 
cassette inserted on a fixed position on the genome, they were able to quantify burden by 
measuring red and green fluorescence.  
To check whether expression at some of our locations is influenced by imposed burden, we 
transformed pLys-M1 in our 26 strains expressing the Dasher reporter cassette on different 
locations spread over the genome. As Ceroni et al. (112) reported ‘escape mutants’, cells not 
able to express the fluorescent protein VioB-mCherry because of mutations in the plasmid 
during the growth cycle, we changed our experimental set-up from plate readers assays to flow 
cytometry experiments to look at single-cell level. Cultures were grown with and without 
induction of the VioB-mCherry cassette (on the burden plasmid pLys-M1) and the genomic 
green fluorescence of both cases was compared (see material and methods). Prior to the 
experiment, the growth rate of all strains with and without imposed burden was determined and 
their differences are displayed in Supplementary Figure A.2-3. The average growth rate 
diminished about 50%, indicating the severity of the imposed burden.  
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In Figure 3-6, the outcome of the flow cytometry experiment is summarized. Genomic locations 
ypjC_ileY, yjip_yjiR, ykgH_betA, thrW_ykfN, ykgA_ykgQ, dadX_cvrA, ileY_ygaQ, ybfC_ybfQ, 
yeeJ_yeeL, ymgF_ycgH and cspF_quuQ are not significantly influenced by imposed burden 
(paired one-sided t-test, p-values in Supplementary Table A.2-10). From the locations 
significantly influenced, djlA_yabP and frwA_frwC are most strongly diminished in genomic 
expression due to the imposed burden. All strains influenced by burden were compared to 
determine significant differences between them (ANOVA analysis with Tukey correction, 
Supplementary Table A.2-11). Not only fluorescence and the growth rate are affected, also the 
coefficient of variation (CV), which is a measure for the spread of distribution, is clearly 
increased (See Supplementary Figure A.2-5) and remains more or less constant for each 
location. Thus, differences in mean fluorescence are solely attributed to the position of the 
fluorescent reporter. Moreover, the change in fluorescence upon induction of the burden 
plasmid and the net distance from oriC for the significantly affected locations is also moderately 
correlated (R² = 0.579 and p = 0.00098, Supplementary Figure A.2-6 and Supplementary Table 
A.2-12), so that if burden has a substantial effect, this effect will be more pronounced near oriC.  
It has to be noted that prior to flow cytometry analysis, the OD600 of the cultures was measured 
(after 16h of incubation at 37°C and 800 rpm). All values were approximately 0.62, except for 
the strain containing djlA_yabP::Dasher which had an OD600 of 0.262 ± 0.022 for three 
replicates. It can be seen on Figure 3-6 that the VioB-mCherry value for this strain is 
significantly lower, while the others do not significantly differ from each other (ANOVA with 
Tukey correction, p-values in Supplementary Table A.2-13) and this strain is more diminished in 
Dasher fluorescence than any other. It is important to realize that flow cytometry shows the 
fluorescence of single cells, meaning that the lower mCherry values cannot be assigned to the 
lower OD values. A more likely hypothesis is that this strain suffers from high burden producing 
less fluorescent proteins. Either way, certainly taking into account the data of the experiment 
with novobiocin, it can be said with certainty that location djlA_yabP is strongly influenced by 
metabolic burden environmental changes. 
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Figure 3-6: Flow cytometry analysis of our 26 strains containing the Dasher sequence on the genome and 
the burden plasmid pLys-M1. The top barplot shows the fluorescent output of Dasher with (green) and 
without (grey) induction of the burden cassette. Strains indicated with an * have a significantly diminished 
(p<0.05) fluorescent output of the reporter cassette due to the imposed burden. The middle barplot shows 
the relative fluorescence of Dasher of induction over control. Strains indicated in dark blue, the significant 
strains from the top barplot, were compared with each other with ANOVA (Tukey correction) to check if 
they were equally influenced by the imposed burden, statistically significant difference is indicated with 
an * (statistical output in Supplementary Table A.2-11). The bottom barplot shows the fluorescence of the 
VioB-mCherry cassette with (orange) and without (grey) induction. Error bars represent the standard 
deviation of three replicates. Experiment conducted in defined glucose medium. 
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3.4 Discussion 
The genome of Escherichia coli MG1655 contains more than 4000 genes or 4.64 Mbp and thus 
numerous positions for the incorporation of a biosynthetic pathway. Few studies have already 
noted a difference in expression at different locations throughout the genome. They all made 
use of fluorescent reporters, either inducible or constitutively expressed, but not every cassette 
was insulated from surrounding genomic context. Also the selection of the locations was not 
consistent, since some used knock-outs, some used intergenic locations and some did random 
integration. Most studies also looked only at a small amount of locations and none of the 
reported studies considered metabolic burden caused by introducing heterologous genes, or 
variations in expression caused by altered environmental conditions. Recently, an extensive 
study made use of transposon mediated integration to insert a fluorescent reporter gene (107). 
By doing so, a high-resolution mapping of the E. coli transcriptional propensity was created. 
However, these locations were randomly obtained and there was an intrinsic selection for 
transposon sensitive locations. The latter is not interesting for pathway engineering as 
introducing heterologous genes causes metabolic burden or stress during culturing conditions, 
which may then lead to unwanted mutations or even pathway elimination. In order to use a 
specific location to express heterologous genes during metabolic engineering, such a location 
should ideally not interfere with the host’s natural metabolism and should be well characterized 
to reduce unpredictability and variability downstream.  
Hence, we conducted our comprehensive study on the effect of genomic location on expression 
in E. coli with a highly insulated expression cassette, taking into account chromosomal 
differences for 49 intergenic locations, and focused for the further characterization of the loci, 
concerning factors like gene orientation, medium composition and metabolic burden, on 26 
locations. We included 11 intergenic locations to compare with previous research (70, 103–106, 
122, 123) and we confirmed the gene dosage effect as the most important factor in gene 
expression variation in E. coli. Most previous studies on genomic locations found a 2-to-40-fold 
difference between the highest and lowest expression location (37, 103–107). For example,  
Scholz et al. reported that 99% of locations are within a 4.2-fold range, with outliers of high 
expression on ribosomal RNA operons and outliers of low expression in tsEPODs (107). As an 
exception, Bryant et al. reported a maximum 300-fold difference (70). In our study we only found 
2.2-fold expression change. This, compared to other studies, small fold change compared to 
other studies is possibly due to the high level of insulation of our expression cassette and the 
stringent selection criteria used to select the loci of interest, so that variations and outliers are 
limited. This might explain the discrepancies with the article of Bryant et al (70). For example, 
locations lacZ_lacI, nupG_specC, aslB_aslA were also tested in our study and were confirmed 
as medium and strong expression locations respectively, yet with a smaller fold difference. We 
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also included the six locations investigated by Urtecho et al. being atpI_gidB and yieN_trkD 
near oriC, nth_ydgR and ygcE_ygcF in the middle of the genome on opposite sides, and 
ybbD_ylbG and essQ-cspB near dif (106). In our study the results for these six locations are 
comparable, with exception of atpI_gidB, which had the lowest expression for Urtecho et al., 
even lower than locations near the terminus of replication, and 4.3 times lower than yieN_trkD, 
which in our study is in the same range as atpI_gidB. A few other studies however reported the 
highest expression for atpI-gidB (103, 105) as it is in our study, indicating again the importance 
of insulation. Also, our strains are compared at the start of the stationary phase rather than at 
the same time point, to make sure all strains are at the same point in their growth cycle. The 
other studies may have looked at other stages of growth, resulting in larger differences (131).  
After determining the effect of loci on expression, we also changed the orientation of our 
reporter cassette for a subset of the locations, in order to investigate the influence of expressing 
from the leading or lagging DNA strand and to evaluate the influence from neighboring 
sequences on genomic expression. We saw no significant difference in expression for the 
inverted orientation. This is in accordance with previous studies (104, 106, 107) and is again a 
confirmation of the isolation of our cassette from genomic context. Next, we investigated the 
effect of changing the culture medium on expression, as medium optimization is often done 
after strains have been completely developed. We found only little difference in fold expression 
change for the four media tested. However, the absolute expression between complex and 
defined glutamine medium differed greatly with an increase of 50%, indicating the importance of 
integrated process design strategies (132). 
Finally, we also investigated the effect of imposed burden on the expression of our reporter 
cassette, spread over the genome. Genomic locations ypjC_ileY, yjip_yjiR, ykgH_betA, 
thrW_ykfN, ykgA_ykgQ, dadX_cvrA, ileY_ygaQ, ybfC_ybfQ, yeeJ_yeeL, ymgF_ycgH and 
cspF_quuQ are not significantly influenced by imposed burden making them excellent choices 
to insert pathway genes that require stable expression. Expression can even be tuned, since 
they all result in a distinct expression. Still, using the genomic location as a tool for expression 
optimization is limited as we only found a 2.2-fold expression range, especially in comparison 
with the fold increase typically seen in promoter-RBS libraries (28). From the locations 
significantly influenced, djlA_yabP and frwA_frwC are most strongly diminished in genomic 
expression due to the imposed burden. Although generally stable genomic expression is 
preferred, this can be interesting for the integration of pathway genes since the expression can 
be adjusted to the burden that is imposed on the cell. The amount of fluorescence and the 
change in fluorescence upon induction of the burden plasmid are moderately negatively 
correlated, which means that the higher the expression at a location, the more likely it is to be 
influenced by burden. Interestingly, the same location showed the highest increase in GFP 
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output when novobiocin was added while other locations seemed unaffected. Novobiocin 
inhibits the ATPase activity of DNA gyrase which is responsible for maintaining the supercoiling 
state. The latter is influenced by the environment. It is clear that various locations react 
differently to culture conditions and environmental changes, with djlA_yabP being the most 
susceptible to changes.  
In conclusion, the output of a biosynthetic pathway is influenced by its chromosomal position. 
Where the effect on expression increase might be small, the effect of culture conditions, 
environmental stress or metabolic burden is substantial. Characterizing multiple effects on 
genomic expression and thus creating libraries of well-characterized strains will only stimulate 
and improve the creation of new and better biotechnological production hosts. 
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Abstract  
The cell wall of Escherichia coli consists of many lipo- and exopolysaccharide molecules. The 
glycosyltransferases responsible for their biosynthesis may interfere with an intended 
production of glycans as they may create unwanted side products resulting in economic losses 
due to the waste of energy by the cell, decreased titers and increased downstream processing 
costs. In order to create a production host unhampered by its inherent metabolism, a new 
platform strain was created in which all nonessential glycosyltransferases are eliminated, 
following a top-down approach. Next, the impact on general cell viability was assessed by 
comparing the growth rate and antibiotic and osmotic sensitivity to its wildtype counterpart. The 
newly created strain retained 90% of its original growth rate and the effect of antibiotic and 
osmotic stress was negligible rendering it suitable as a platform strain.  
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4.1 Introduction 
In nature, E. coli originates from animal intestines spending parts of its life cycle anaerobically 
and aerobically in the environment (31). By gene loss and horizontal gene transfer the ancestral 
E. coli genome was shaped to survive in these very different conditions (133). The genome of 
various natural isolates of E. coli adapted to their specific niche range from 4.5 to 5.5 Mbp 
containing four to five thousand genes of which many are functionally redundant and only 
expressed in a condition-dependent context. These ‘back-up’ genes increase the species’ 
capacity to adapt to a changing environment (134). It is possible that many of these genes are 
unnecessary from an industrial point of view and may even be counterproductive. For example 
the laboratory MG1655 strain contains 44 transposable elements and 8 prophages or phage 
remnants which may lead to genetic instability in stressful environments (133).  
In this respect genome reduction to develop reduced or even minimal cells is being investigated 
to create robust and improved production hosts for industrial biotechnology. It was found that 
reduced cells grow to higher cell densities and thus if reduced genomes and parental strains 
produce the same amount of product per cell, production per biomass will be increased. 
Moreover the lack of unnecessary genes will conserve cellular energy otherwise wasted to 
transcription and translation which may now be used for production instead (134). Deletion of 
the aforementioned insertion sequence (IS) elements may also increase genomic stability and 
predictability of cellular behavior during fermentations (135).  
Genome reduction is however not new but an evolutionary pattern seen in many symbiotic 
bacteria leading to genomes of less than 250 kbp. Buchnera spp. for example are obligate 
endosymbionts that live in symbiosis with aphids (136). Buchnera spp. have lost many of their 
ancestral genes but preserved genes for synthesis and transport of amino acids to compensate 
the aphid’s diet of plant phloem sap which is deficient in many essential amino acids (137). In 
return Buchnera is offered a stable environment in specialized host cells called bacteriocytes. 
This mutualistic relationship has shaped both genomes over time resulting in genome reduction. 
The construction of an artificial reduced genome can thus be regarded as an acceleration of 
evolution (134).  
In the laboratory, genome reduction of the MG1655 E. coli strain led to varying degrees of 
success. In 2005, Hashimoto et al. were able to reduce the genome by 29.7% but at the cost of 
severely impaired growth and genome segregation (138) while others reduced the genome by 
7% and grew normally. The best known case of genome reduction in E. coli is the MDS (multi-
deletion series) strains developed by the Pósfai lab and commercially available through Scarab 
Genomics LLC. The MDS42 strain lacks 14.3% of its parental genome with over 700 genes 
deleted. The MDS42 has a growth rate comparable to the wildtype and grows to higher cell 
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densities. It has a higher electroporation efficiency and is able to maintain plasmids which were 
found unstable in K-12 strains. It was hypothesized that the removal of genes coding for 
membrane-associated proteins, fimbrial and flagellar structure influenced the membrane 
composition and thus the sensitivity to depolarization. In addition the removal of transposable 
elements and insertion sequences contribute to a better physiological and genetic stability 
creating a better host for expressing heterologous pathways (133, 139). The latter was shown 
by an increased L-threonine production in an MDS42 background containing the same 
production-modification as an MG1655 control (140). The MDS42 strain has a more efficient 
cellular metabolism spending less energy on genome replication and unnecessary proteins and 
is thus able to spend more resources on recombinant protein synthesis.  
Next to this top-down approach of elucidating nonessential parts of the genome and subsequent 
deletion thereof, there is also a bottom-up approach to create (minimal) synthetic cells. To 
perform such large-scale genome engineering, there are mainly two strategies. Either an 
existing genome scaffold is divided into a manageable number of parts and modified separately 
before re-assembling into the final construct or the genome of interest is created completely 
synthetically. The latter is probably the most efficient way to incorporate many changes and 
enables the scientist with full control of the desired DNA sequence.  
Using the latter strategy, the Church lab created a fully synthetic Escherichia coli based on the 
MDS42 reduced genome strain in which they replaced 7 codons by their synonymous 
alternatives. The resulting strain is called rE. coli-57 for it uses only 57 out of the common 64 
codons. To do so, 5.4% of all E. coli codons or 62,214 instances were replaced and validated 
(141). The advantage of eliminating a codon is that it’s respective cognate tRNA can be deleted 
as well and that the codon can be reassigned to incorporate non-standard amino acids (nsAA) 
creating new proteins with novel applications. In addition the use of nsAA can be exploited for 
biocontainment strategies (142).  
However a synthetic cell such as the rE. coli-57 does not necessarily mean a reduced or 
minimal cell which only contains essential genes. To create such a synthetic minimal cell, the J. 
Craig Venter Institute based its model on the smallest genome of an autonomously replicating 
cell, Mycoplasma genitalium. Its genome consists only of 580 kbp (525 genes) (143) and just as 
the Buchnera sp. it has undergone substantial genome reduction for it lives in the nutrient-rich 
environment of animal hosts. The result of their work is JCVI-syn3.0, with a genome of 531 kbp 
(473 genes) which is smaller than that of any autonomously replicating cell found in nature. One 
major step on their quest to a minimal cell was the discovery of so called lethal synthetic pairs. 
Such pairs code for an essential function but are paralogs and thus originally classified as 
nonessential for either gene can be deleted without loss of viability. In addition, also quasi-
essential genes were found critical to its success. Albeit these genes are not strictly required for 
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viability, they are required for robust growth. As such a minimal cell is thus not a set of only 
essential genes, it is the smallest possible group of genes that sustain functional cellular life 
(136). The JCVI-syn3.0 minimal synthetic strain primarily retained cell functions related to 
expression and preservation of genome information and membrane-transport functions. As it 
lacks biosynthesis of amino acids, nucleotides and vitamins amongst others, the numerous 
transport systems are key to its survival (143).    
The creation of minimal cells is a leap forward in synthetic biology and it holds the promise of a 
higher predictability and easier engineerability to improve current platform organisms. However 
minimal cells are yet far from true microbial cell factories. From the evolutional genome 
reduction of endosymbionts, it is clear that the smaller the genome the more the organism 
depends on its environment and thus the creation of a minimal genome is also environmental 
condition dependent. The JCVI-syn3.0 for example requires a very rich medium supplying 
almost all necessary small molecules and no environmental stress making it unsuitable for 
industrial conditions found in many biotechnological processes. Creating other strains of 
minimal cells in less-permissive conditions other minimal gene sets will be found. There must be 
a contemplation between reducing the genome of platform organisms and thereby eliminating 
interfering features whilst retaining their performance and robustness in the desired industrial 
setting (144) (See  Figure 4-1).  
 
Figure 4-1: A wild type strain has an abundance of genes of which many have unknown functions and are 
often unnecessary. Genome reduction trims the genome streamlining it for better performance but 
consequently makes the strain also more dependent on nutrients from its environment. Minimal cells 
therefore require very rich medium and containing only the minimum set of genes to sustain life. It is 
important to find a balance between the native and minimal set of genes to create a true chassis for 
industrial biotechnology retaining the robustness and growth rate of its wildtype strain while removing 
irrelevant genes that interfere in the production processes. Figure adopted from Unthan et al. (2015) (144). 
The creation of such a chassis, be it either from a top-down or a bottom-up approach, would 
then acquire the benefits of a trimmed genome wasting less energy to unnecessary genes and 
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being genetically more stable while remaining the growth rate and robustness of its wildtype 
parental strain. The knowledge gained from genome reductions and in extension the creation of 
(minimal) synthetic cells has improved the pursuit for chassis organisms for industrial 
biotechnology, yet at this point such genome-scale engineering requires a tremendous amount 
of work and is still cost inefficient.  
Therefore, to create a chassis to produce complex glycans such as human milk 
oligosaccharides (HMO), we focused only on the glycosyltransferases, which make up 1% to 
2% of the total gene products from bacteria (145). Many of these enzymes are involved in the 
synthesis of the extracellular polysaccharide matrix including, poly-N-acetylglucosamine (146), 
colanic acid (147), the enterobacterial common antigen (148) and in the O-antigen and core 
oligosaccharides (149) of the lipopolysaccharide outer membrane, which are all dispensable for 
the cell and thus a waste of energy. Moreover, glycosyltransferases often do not have a 
stringent specificity and because HMOs resemble the outer cell wall structures, the host’s 
endogenous glycosyltransferases may take part in the production pathway. The latter will 
interfere with the intended product formation causing unwanted by-product and eventually 
creates a product loss.  
As fermentation technology is indispensable for the synthesis of these complex 
oligosaccharides because micro-organisms recycle the expensive nucleotide sugars necessary 
for their production, we chose to do a ‘glycominimisation’ effort on the model organism of 
Escherichia coli, which is already used for the production of 2’-fucosyllactose, the most 
abundant human milk oligosaccharides (150). The glycominimisation is a top-down approach to 
eliminate all nonessential glycosyltransferases of Escherichia coli, creating a chassis strain in 
which heterologous oligosaccharide synthesis is unhampered by the endogenous metabolism. 
To create such a strain, a list of these glycosyltransferases was made and subsequently deleted 
(4.3.1). As their deletion may have led to reduced fitness, its growth rate (4.3.2), antibiotic 
(4.3.3) and osmotic (4.3.4) sensitivity were also evaluated. 
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4.2 Material and methods 
4.2.1 Chemicals 
Tryptone and yeast extract were procured from Becton Dickinson. Glucose was procured from 
Riedel-De Haan. All other chemicals were purchased from Sigma-Aldrich, unless stated 
otherwise.  
4.2.2 Oligonucleotides and molecular reagents 
Oligonucleotides were purchased from Integrated DNA Technologies (Leuven, Belgium). 
Sequencing services were conducted by LGC genomics (Berlin, Germany). Deoxynucleotides, 
agarose and ethidium bromide were purchased from Thermo Fisher Scientific. QIAprep Spin 
Miniprep kit was used for plasmid isolation (QIAgen, USA). Analytik Jena kits were used for 
PCR purification (Jena, Germany). 
4.2.3 Strains 
E. coli K-12 MG1655 was used as a base strain for all future modifications. E. coli One Shot 
Top10 ElectrocompTM cells (Life Technologies) were solely used for cloning purposes. An 
overview of the strains used in this chapter is listed in Supplementary Table A.3-1 
4.2.4 Media and culture conditions 
The culture medium lysogeny broth (LB) consisting of 1% tryptone, 0.5% yeast extract and 
0.5% sodium chloride was used throughout the work. Lysogeny broth agar (LBA) is similarly 
composed with the addition of 12 g/L agar. If required, media were supplemented with the 
antibiotics ampicillin (100 μg/mL), spectinomycin (100 µg/µL), kanamycin (50 μg/mL), 
gentamycin (30 µg/mL), chloramphenicol (34 μg/ mL) or tetracycline (10 µg/mL). 
For growth experiments measuring optical density a defined medium was used containing 2 g/L 
NH4Cl, 5 g/L (NH4)2SO4, 3 g/L KH2PO4, 7.3 g/L K2HPO4, 8.4 g/L MOPS, 0.5 g/L NaCl, 0.5 g/L 
MgSO4 ·7H2O, and 16.5 g/L glucose·H2O, 1 ml/L trace element solution and 100 μL/L of a 0.967 
g/L Na2MoO4·2H2O molybdate solution. The trace element solution contained 3.6 g/L 
FeCl2·4H2O, 5 g/L CaCl2·2H2O, 1.3 g/L MnCl2·2H2O, 0.38 g/L CuCl2·2H2O, 0.5 g/L CoCl2·6H2O, 
0.94 g/L ZnCl2, 0.0311 g/L H3BO4, 0.4 g/L Na2EDTA·2H2O, 1.01 g/L thiamine·HCl.  
4.2.5 Plasmids 
The landing pad plasmid pLP6 was constructed  using CPEC according to Tian & Quan (2009) 
(64) and originates from pLP1 (86) (See 2.2.5) where the chloramphenicol marker was replaced 
with a kanamycin marker and the ‘TT’ core dinucleotide of the att sites with ‘CA’. pInt1 was used 
Chapter 4: A glycominimisation effort 
74 
according to Snoeck et al. (2018) (86) and pTKRED was a gift from Edward Cox & Thomas 
Kuhlman (Addgene plasmid # 41062) (38). 
4.2.6 SIRE protocol 
The SIRE knock-out protocol as described by Snoeck et al. (2018) (86) (Chapter 2) was slightly 
adapted to create all modification in Chapter 4. In brief, the landing pad with the selectable 
marker chloramphenicol flanked with att sites is first introduced using homologous 
recombination according to Kuhlman & Cox (2010) (38). Selected colonies were subsequently 
prepared for another round of transformation where homologous recombination is performed 
using a kanamycin selectable marker flanked with att sites. Next, selected colonies are 
prepared for the final transformation round in which pInt1 containing the PhiC31 integrase is 
introduced. Cells containing pInt1 are selected for on spectinomycin while simultaneously 
expressing the integrase overnight with 0.4 mM IPTG (isopropyl-β-D-thiogalactopyranoside) 
induction on LBA plates. Colonies were checked by PCR to evaluate the removal of both 
landing pads which is then confirmed using Sanger sequencing (LCG Genomics, Germany). 
Finally, the strain is cured of any remaining plasmids after overnight culturing at 42°C 
4.2.7 Growth trials in microtiter plates  
Optical density (OD) measurements were performed in a Tecan M200 Pro microplate reader 
using a Greiner bio-one (Vilvoorde, Belgium) polystyrene F-bottom 96 well plates. Cells were 
cultured in the defined medium described above and inoculated 1% from precultures which 
were grown in a carbon limiting 2.2 g/L glucose·H2O defined medium variant. The maximum 
specific growth rate was calculated according to Kahm et al. (2010) (65). For the antibiotic and 
osmotic sensitivity experiments, the displayed concentrations were supplemented to the 
medium in a 100 mL volumetric flask and subsequently filter sterilized using a 0,22 µm Corning 
filter system.  
4.2.8 NGS sequencing 
The genome of the glycominimised strain was extracted according to the manufacturing 
protocol (Qiagen DNeasy Blood and Tissue Kit). NGS was performed by Fasteris (Geneva, 
Swiss) using paired reads of 150 bp with an average coverage of 860. Using FastqC 
(Babraham Informatics), the average per base PHRED quality scores for forward and reverse 
reads were calculated. Trimmomatic v0.36 was used to clip illumina adapters and to remove low 
quality bases (151). Finally, the trimmed data was analyzed using Breseq (152) 
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4.2.9 MIC determination 
The minimum inhibitory concentration was determined as the lowest concentration of an 
antibiotic where the growth rate was less or equal than 10% of the growth rate when no 
antibiotic was added.  
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4.3 Results and discussion 
4.3.1 Creation of the glycominimised strain 
To create a strain devoid of all nonessential glycosyltransferases, all 38 genes listed in Table 
4-1 need to be deleted. Many of these genes are involved in the formation of the extracellular 
matrix which consists of many carbohydrate polymers such as cellulose, poly-𝛽-1,6-N-
acetylglucosamine (PNAG) and colanic acid (153) (See Figure 4-2). For a recent review about 
lipopolyssacharides the reader is redirected to Bertani & Ruiz (2018) (154). Another important 
group of glycosyltransferases is involved in the synthesis of core oligosaccharides attached to 
lipidA which is the major constituent of the outer layer of the outer cell membrane (42). To 
simplify the knock-out strategy and because many of these glycosyltransferases are clustered in 
operons, we chose to delete the entire operon. In this way instead of 38, only 15 knock-outs 
need to be achieved. The essential glycosyltransferases involved in LPS, lpxB and waaA were 
untouched for obvious reasons. Also, glycosyltransferases involved in the formation of 
peptidoglycan were spared (pbpC, mtgA, murG, mrcA and mrcB) because e.g. the double 
knockout of the isoenzymes coded by mrcA and mrcB (155), 2 peptidoglycan 
glycosyltransferases, is lethal and to create robust strains retaining their Gram-negative state.  
Table 4-1: Overview of all deleted glycosyltransferases and their corresponding functions.  
Function Gene name glycosyltransferases 
Synthesis of PNAG pgaC, pgaD 
Synthesis of ECA rfe, rffT, rffM 
Synthesis of cellulose bcsA, bcsB 
Synthesis of colonic acid wcaA, wcaC, wcaE, wcaI, wcaJ, wcaL 
Synthesis of core oligosaccharides  
waaU, waaJ, waaO, waaB, waaS, waaG, waaQ, waaH, waaF, 
waaC, wbbI 
Synthesis of OPGs opgG, opgH 
Glycan synthesis glgA, glgB, malQ 
Trehalose synthesis otsA, otsB 
Other hexosyltransferases arnT, arnC 
Predicted glycosyltransferases ycjM, yaiP, yfdH, wbbK, yibD 
The knock-out procedure was adapted from Snoeck et al. (2018) (86) (See 4.2.6) and 
extensively described in Chapter 2. To decrease the total amount of transformation steps for 
the successive knock-out of the 15 operons, a new knock-out cassette was created in line with 
the original pLP1 (See 2.2.5) cassette. Instead of a chloramphenicol marker, a kanamycin 
resistance gene is used flanked with attB and attP sites but with a ‘CA’ core dinucleotide in 
contrast to the original ‘TT‘ sequence. Consequently, these 2 knock-out cassettes are flanked 
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with different att sites which are orthogonal and do not interfere with each other. The advantage 
of this system is that it’s possible to do 2 knock-outs successively because of the 2 different 
selection markers. In addition, both markers can be recovered during one integration step 
because of the orthogonal att sites. By doing 2 knock-outs in the same round, 2 transformation 
and 1 curation step are eliminated, saving up to 1 week of labour per 2 knockouts.  
 
Figure 4-2: Simplified schematic overview of the most important glycocalyx molecules. Glc: D-glucose; 
GlcA: D-glucuronic acid; GlcNAc: N-acetyl-glucosamine; Pyr: pyruvate; Gal: D-galactose; Fuc: L-fucose; 
Hep: L-glycero-D-manno-heptose; Kdo: 3-deoxy-D-manno-oct-2-ulosonic acid.  
The resulting strain, the glycominimised strain (GM-strain), has a reduced genome in which a 
total of 68 genes have been deleted which accounts for almost 100 kb or more than 2% of the 
entire genome. All knockouts were successively checked with Sanger sequencing, but to 
confirm the final strain next-generation sequencing was performed. Using Breseq (152), the 
output of the NGS was analyzed and the results are displayed in Table 4-2. All the created 
knock-outs were confirmed and display the created 53 bp attL scar. Next to these intended 
modifications, 7 mutations were uncovered of which 5 are found inside coding sequences. 
There are 2 deletions found in fhuA and nfrA, which act as a phage receptor and one silent 
point mutations in a putative gene. 2 actual point mutations may affect the ethanolamine 
ammonia lyase and the protoporphydrin oxidase. Luckily none of them hamper the envisaged 
glycan synthesis.  
In addition, also 5 IS-mediated modifications were found. One of them, deleted 10 kb ranging 
from uspC to yecR including the intended knock-out of otsAB and the araHGF cluster which 
eliminates the GM-strain of arabinose transport. Interestingly, another IS-mediated modification 
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caused the deletion of rcsA, a transcriptional regulator of colanic acid and thus interfering with 
the GDP-fucose synthesis, an important building block of HMOs. However, the complete colanic 
acid operon is knocked-out in the GM-strain making this deletion redundant. Next, to these 
modifications, Breseq also detected 2 clusters which are completely deleted as ‘unassigned 
missing coverage evidence’ but deletion was confirmed using Sanger sequencing. As a 
consequence, the GM-strain lacks glycolate degradation and malate synthesis. Finally, also a 
new junction was found in which pseudogenes of the E14 prophage are disappeared.  
In total 30 modifications were found compared to the reference sequence of Escherichia coli K-
12 MG1655 (NC_000913.3) of which only 15 were intended. After comparing these results with 
the sequencing of the wildtype strain, we found that 3 modifications were already present, 
probably due to several years of cultivation at the lab. The GC intergenic insertion at gltP_ycjC, 
the IS-mediated disruption of yeaJ and also the modification at fhuA. The remaining unintended 
modifications are thus the result of successive rounds of engineering while introducing and 
expressing the 𝜆-RED genes for homologous recombination. From ALE experiments, a 
spontaneous mutation rate ranging from 0.3-3*10-3 mutations per generations was found (156–
159). Estimating that ~2500 generations were needed to obtain the glycominimised strain, 
cultivation would account for 1 to 7 mutations. As 𝜆-RED genes were repeatedly introduced, the 
mutation rate was probably higher explaining the 12 unintended ones. Overall, the genotype of 
the GM-strain is confirmed lacking the envisaged nonessential glycosyltransferases.  
4.3.2 Growth rate determination 
In creation of the GM-strain, 15 single knock-out strains were also created as well as 13 
intermediate strains ranging from 2 to 14 knock-outs. To determine the maximum specific 
growth rate, described by the Monod equation as:  
 
𝜇 =
𝜇𝑚𝑎𝑥𝑆
𝐾𝑆 + 𝑆
 
(1) 
where 𝜇 is the specific growth rate (h-1), 𝜇𝑚𝑎𝑥 is the maximum specific growth rate (h-1) for the 
culture, 𝑆 is the substrate concentration (mass/volume), and 𝐾𝑆 is the half-saturation constant 
(mass/volume), a growth experiment was set-up on microtiter scale with the 29 created strains 
and the wildtype as a control. 
The results are depicted in Figure 4-3 in function of the amount of modifications. The maximum 
specific growth rate was calculated according to the R package grofit (65) using the model free 
spline method for fitting growth curves of which the maximal slope is the 𝜇𝑚𝑎𝑥-parameter. 
According to Kahm et al. (2010) (65), the spline fit produces a more accurate estimate for the 
maximum specific growth parameter than other parametric fits such as Gompertz or the logistic 
law.  
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Table 4-2: Output from NGS analysis. Each modification or mutation relative to the wildtype is listed in 
function of their genomic position, corresponding genetic region and function. Modifications in bold were 
intended.  
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Table 4-2: Output from NGS analysis. Each modification or mutation relative to the wildtype is listed in 
function of their genomic position, corresponding genetic region and function. Modifications in bold were 
intended. (Continued) 
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Figure 4-3: Comparison of the maximum specific growth rate for the GM-strain (sNS4.29) and the wildtype 
(sNS3.01) and all intermediate strains. Error bars represent standard deviation of at least three replicates.  
From the figure it is clear that the more knock-outs were performed the lower the growth rate. 
From the single knock-outs the wecG-rfe deletion showed the lowest growth rate, but this 
decline was not seen when this modification was added in the preparation of the GM-strain 
(sNS4.17). In contrast, the largest decline in the intermediate strains is attributed to the yibD 
deletion, which showed only little difference in growth rate compared to the wildtype as a single 
knock-out (sNS4.07). The growth rate of a combinatorial knock-out strain is thus difficult to 
predict according to their single knock-out counterparts and interactive effects are in play. The 
growth rate of the final GM-strain (sNS4.29) is about 90% of the wildtype’s which is slightly 
higher than that of the closest intermediate strains. The explanation of the differences in growth 
rates for these strains is probably not only the combination of the created knock-outs but also 
due to the multiple engineering rounds. Each engineering round may have introduced other 
modifications as seen in 4.3.1 influencing the growth rate in turn. Also the successive culturing 
in the preparation of the GM-strain may have replicated the phenomenon of laboratory adaptive 
evolution (ALE) selecting for the faster growing strain indicated by the small increase in growth 
rate towards the final strains. 
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4.3.3 Antibiotic sensitivity relation  
From section 4.3.1, it is clear that cell wall of the glycominimised strain has undergone a major 
transformation. Not only the loss of the O-antigen and core-oligosaccharides but also the 
removal of several exopolysaccharides have changed the outer cell surface and thus the 
permeability of the membrane. To investigate this effect, we have compared the sensitivity of 10 
commonly used antibiotics from several classes and mode of actions to the growth rate of the 
glycominimised strain and the wildtype. In Table 4-3 an overview is given of the chosen 
antibiotics.  
Table 4-3: List of the tested antibiotics and their corresponding class and working mechanism.  
Antibiotic Type antibiotic Mechanism Molar mass (g/mol) 
Ampicillin (Amp) Aminopenicillin  Cell wall interference 349.4 
Chloramphenicol (Chlor) Other  Inhibiting protein synthesis 323.1 
Erythromycin (Ery) Macrolides Inhibiting protein synthesis 733.9 
Rifampin (Rif) Other Inhibiting RNA synthesis 822.9 
Fosfomycin (Fos) Other Cell wall interference 138.1 
Kanamycin (Kan) Aminoglycoside  Inhibiting protein synthesis 484.5 
Lincomycin (Linc) Lincosamides Inhibiting protein synthesis 406.5 
Streptomycin (Strep) Aminoglycoside Inhibiting protein synthesis 581.6 
Tetracycline (Tetr) Tetracyclines Inhibiting protein synthesis 444.4 
Trimethoprim (Tri) Other DNA synthesis interference 290.3 
 
In Figure 4-4, a heatmap is given in which the growth rate relative to the growth rate when no 
antibiotics are supplied is displayed in function of an increasing antibiotic concentration. The 
𝜇𝑚𝑎𝑥 at concentration 0 is normalized at 100% for each strain so that both strains can be easily 
compared independent from their absolute 𝜇𝑚𝑎𝑥 which is slightly different from each other (See 
Figure 4-3). From the figure, a diminished sensitivity to ampicillin, fosfomycin and lincomycin of 
the glycominimised strain can be seen. In contrast the sensitivity to streptomycin, 
chloramphenicol and trimethoprim has increased. For all other antibiotics the relative growth 
rate remains more or less the same.  
In Figure 4-5 each case is displayed in more detail and in Table 4-4 the MIC-values are 
calculated. From the figure the higher resistance to fosfomycin stands out. At a concentration of 
1.32 µg/mL the glycominimised strain still retains 90% of its original growth rate whereas the 
wildtype is unable to grow. An explanation for this result may be found in the mode of action of 
the antibiotic and the genotype of the GM strain. Fosfomycin interferes with cell wall biogenesis 
and inhibits UDP-N-acetylglucosamine-3-enolpyruvyltransferase, coded by murA. It catalyzes 
the ligation of PEP to UDP-GlcNAc, as the committed step in peptidoglycan synthesis. As 
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previously described, the GM strains lacks several exo- and lipopolysaccharides which are rich 
in N-acetylglucosamine and thus may have an increased pool in UDP-GlcNAc. Therefore, the 
GM strain may require a higher concentration of fosfomycin for murA inhibition.  
 
Figure 4-4: Heat map of the relative specific growth rate as a percentage of the maximum specific growth 
rate when no antibiotics are added (Concentration range = 0) for the wildtype (WT) and the GM-strain. 
Table 4-4: Overview of the MICs: minimum inhibitory concentration. All concentrations are in µg/mL. 
Strain Amp Chl Ery Rif Fos Kan Linc Strep Tetr Tri 
WT 12.75 8 300 16 1.32 32 2000 65.2 1.35 1.25 
GM >25.5 4 150 16 5.28 16 2000 16.3 2.7 1.25 
 
A lower sensitivity is also found for ampicillin and lincomycin which just like fosfomycin are small 
molecules that use membrane porins like OmpC and OmpF to enter the cell (160). It is possible 
that the GM strain has less outer membrane proteins as also seen in deep rough mutants (42) 
that lack the inner core sugars of LPS (161). Less porins through which these molecules enter 
may account for the decrease in sensitivity. On the other hand deep rough mutants are also 
known for their increased sensitivity towards hydrophobic antibiotics such as erythromycin and 
rifampin where a >32-fold increase was noticed (162–164). However, the effect on the GM 
strain, which also lacks the inner core oligosaccharides, is less pronounced for erythromycin 
and almost completely absent for rifampin. The little differences seen in tetracycline and 
streptomycin on the other hand are in accordance with the effect on deep rough mutants in 
literature (164).  
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Figure 4-5: The relative specific growth rate is displayed in function of the applied concentration for the WT 
strain (darker colored bars) and the GM-strain (lighter colored bars). Error bars represent standard 
deviations of at least 3 replicates.  
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4.3.4 Osmotic stress sensitivity 
Osmosis is defined as the process that takes place in which solvent molecules pass through a 
semi-permeable membrane from a less concentrated solution to a higher concentrated solution 
until an equilibrium occurs. Osmotic pressure is then the minimum pressure needed to apply to 
the solution to prevent the solvent from flowing. In bacteria the semi-permeable membrane is 
the cell wall and Escherichia coli will maintain its homeostasis by osmoregulation. E. coli will 
therefore import ions or synthesize compatible solutes like e.g. glycine betaine or trehalose to 
maintain its equilibrium. As the semi-permeable membrane of the GM-strain is severely altered, 
the osmotic sensitivity is also verified in analogy with the antibiotic sensitivity test.  
For dilute concentrations, the Van ’t Hoff equation for osmotic pressure 𝜋 states:  
 𝜋 = 𝑖𝐶𝑅𝑇 (2) 
In which, 𝑖, is the dimensionless Van ’t Hoff index, 𝐶 the concentration of the solute (mol.L-1), 𝑅 
the ideal gas constant and 𝑇 the temperature (K). The Van ’t Hoff index 𝑖 is the ratio between 
the actual concentration of particles (e.g. ions) and the molarity of the solute. For example, for 
salts which dissociate in water the Van ’t Hoff index is the sum of all ions originating from one 
molecule.  
To test the osmotic sensitivity a concentration array of KCl, NaCl and sucrose was applied to 
the GM strain and the wildtype. In Figure 4-6, the relative growth rate is plotted in function of the 
concentration of each solute as well as the osmotic pressure. There seems to be an inverse 
logarithmic correlation between the growth rate and the arcsinh of the osmotic pressure. From 
an osmotic pressure of 2 arcsinh(atm), the difference in relative specific growth rate between 
the GM- and the wildtype strain also enlarges. This means that at higher concentrations of the 
solute the GM-strain is indeed more sensitive while differences are small at lower 
concentrations. Between sucrose and the salts with respectively a Van ‘t Hoff factor of 1 and 2 
little difference exists between the growth rate and the osmotic pressure for the wildtype strain. 
In contrast, the GM-strain suffers more when the Van ‘t Hoff factor is increased.  
An explanation of the increased sensitivity of the GM-strain can be explained by the knock-out 
of otsAB, which is responsible for the synthesis of trehalose. E. coli can accumulate trehalose 
as an osmoprotectans when exposed to osmotic stress or low temperatures (165). The inability 
of trehalose production in the synthetic defined medium may account for the higher sensitivity.  
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Figure 4-6: The barplots depict the relative specific growth rate in function of the concentration of the 
osmolyte. The darker shaded bars represent the wildtype while the lighter bars represent the GM strain. In 
the top right figure the growth rate is plotted in function of the osmotic strength. The dashed lines picture 
the GM strain. Error bars are standard deviations calculated from at least 3 replicates. 
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4.4 Conclusion and perspective  
In order to create a platform host for the synthesis of specialty oligosaccharides, we deleted all 
nonessential glycosyltransferases in Escherichia coli K-12 MG1655, called the glycominimised 
strain. Deletion of their coding genes will ensure that no by-products are made coming from the 
endogenous metabolism that in case of HMOs which resemble the outer cell wall structures, is a 
potential problem. By-products would then create product loss and increased down-stream 
processing costs.  
Next-generation sequencing confirmed the presence of all envisaged knock-outs of the 
glycominimised strain as well as some other unintended modifications. Luckily none of them 
interfere with the synthesis of activated sugars or the central metabolism necessary for HMO 
production. However, one should be aware that successively engineering your production host 
using homologous engineering, may lead to unwanted modifications and undesired results. 
Other targeted and rational engineering strategies, already discussed in the introduction of 
Chapter 2, do not provide any outcome. Methods using either serine integrases or CRISPR all 
rely on homologous recombination to either insert the landing pad sequence or to escape the 
mutant from a lethal double stranded break respectively. In addition CRISPR utilizing methods 
are susceptible to off-target effects increasing undesired mutations. The best way of creating a 
highly modified strain is by using a bottom-up approach to create a (semi-) synthetic cell.  
By deleting more than 2% of the glycominimised genome, severely altering its cell wall and 
because all activated sugars necessary for HMO production shunt from the central metabolism, 
the growth rate of the newly created strain is of major concern. When comparing the GM-strain 
and all intermediate strains, we found that still 90% of its parental growth rate was retained, 
making it still usable as a production host. To further evaluate its viability, we also evaluated its 
antibiotic and osmotic sensitivity and did not find any major concern.  
In Chapter 7, this strain will be further evaluated and tested by implementing an actual pathway 
for the production of FLNT III (fucosyllacto-N-neotetraose III), a pentasaccharide human milk 
oligosaccharide.  
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Abstract  
Endotoxin is a major constituent of the outer membrane of Gram-negative bacteria and induces 
the mammalian innate immune system triggering a severe sceptic shock. It was long thought 
that endotoxin was an essential part of the cell wall, but since the discovery of endotoxin-free 
isolates in Neisseria sp. and Acinetobacter sp., this view is challenged. Using the compensation 
mechanisms that allow these mutants to survive an LPS-free existence, we attempted to create 
an endotoxin-free Escherichia coli strain. Elimination of endotoxin would then alleviate the need 
to measure, control and finally remove these endotoxins in a biotechnological production 
process. Using these compensation mechanisms, we succeeded in deleting waaA resulting in a 
lipidIVa instead of Kdo-lipidA anchor in the outer leaflet, reducing the toxicity tremendously.  
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5.1 Introduction 
Escherichia coli is a Gram-negative bacterium and its cell wall consists of a double membrane 
enclosing a peptidoglycan containing periplasmic space. The inner membrane (IM) or 
cytoplasmic membrane is a phospholipid bilayer whereas the outer membrane (OM) is 
asymmetrical. The OM is also a lipid bilayer, but its surface exposed outer leaflet is composed 
of lipopolysaccharides or LPS. This unique membrane structure protects Gram-negative 
bacteria against harsh environmental conditions. The LPS forms a barrier against numerous 
stress factors and because of its negative charge due to the presence of phosphate groups, it 
can interact with divalent cations regulating the rigidity and tightness of the outer membrane 
(153, 166).   
The hydrophobic anchor of LPS is a glucosamine-based phospholipid backbone called Kdo-
LipidA. The biogenesis of Kdo-LipidA involves nine enzymes and was first uncovered by 
Christian R.H. Raetz hence the Raetz pathway (See Figure 5-1). The first reaction is the 
acylation of UDP-GlcNAc by lpxA which is selective for a 14-carbon acyl chain, 
𝛽-hydroxymyristate. Yet, due to an unfavourable equilibrium the first committed step is 
conducted by lpxC, deacetylating the product. This function is highly conserved among diverse 
Gram-negative bacteria. Next a second hydroxymyristate is added by lpxD generating an 
activated diacylated glucosamine residue which is then cleaved at its pyrophosphate bond by 
lpxH to form Lipid X. Lipid X and its substrate are then subsequently condensed (lpxB) and 
phosphorylated (lpxK) to Lipid IVa, a phosphorylated tetraacylated disaccharide. To form Kdo-
LipidA, two Kdo (3-deoxy-D-manno-octulosonic acid) units are transferred by waaA to Lipid IVa 
(42, 167, 168).  
The last steps of the pathway involve the so called ‘late’ acyltransferases, which require the Kdo 
disaccharide to function. LpxL and lpxM add a lauroyl and myristoyl group respectively creating 
the characteristic hexaacylated lipopolysaccharide backbone structure of the outer leaflet of 
Escherichia coli. Under cold conditions, E. coli is able to add a palmitoleate fatty acid instead of 
laurate by activation of lpxP to adjust the membrane fluidity to cope with the cold environment 
(42, 167, 168). In contrast with the former genes of the pathway, lpxLMP are not essential for its 
viability, but deletion severely impairs growth. The secondary acyl chains are necessary to 
maintain the low degree of fluidity essential for the integrity and function of the outer membrane 
(169).  
Kdo-LipidA or endotoxin, as the name gives away, is also recognized by the mammalian innate 
immune system and is detectable at picomolar levels. When infected, the uncontrolled growth of 
Gram-negative bacteria can lead to the release of large amounts of LPS which triggers a severe 
sceptic shock, damaging small blood vessels with fatal consequences for the host (42). It is the 
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two phosphate groups and the addition of the late acyloxyacyl moieties that are needed to 
trigger the endotoxin response in human cells. Although the canonical structure is highly 
preserved in Gram-negative bacteria, the degree of acylation and phosphorylation can differ 
among species. Several pathogenic bacteria have LipidA modifications or are able to modulate 
their composition to escape the host’s immune response. For example, Yersinia pestis displays 
a tetraacylated LipidA outer membrane with a significant lower activity at 37°C than at lower 
temperatures (166).  
 
Figure 5-1: General overview of the synthesis and transport of lipopolysaccharides. Through the Raetz 
pathway of Kdo-LipidA biogenesis, UDP-GlcNAc is esterified and acylated to obtain the hexaacylated 
LipidA structure. By the core glycosyltransferases the Kdo disaccharide is subsequently extended with 
several sugar moieties. These events occur either in the cytosol or in the cytosolic leaflet of the inner 
membrane. Only until the sugar core is finished, the LPS is flipped at the expense of ATP by the 
membrane protein MsbA. Then the LPS follows the Lpt pathway to end up in the outer leaflet of the outer 
membrane. This figure was adapted from Henderson et al. (2016) (170).  
After completion of the Kdo-LipidA, it is extended with core oligosaccharides, arbitrarily divided 
in an inner and outer core of which the inner core is mostly conserved and exists typically of 
several heptopyranose residues. The structure of the outer core is much more diverse. In 
Escherichia coli for example 5 different core types are known. Most of these reactions occur at 
the cytosolic leaflet of the inner membrane and the accumulated LPS still has to move towards 
the outer membrane. For the latter, msbA plays a crucial role in achieving this transport. This 
ABC transporter conveys the hexaacylated LPS according to a ‘trap and flip’ mechanism in 
which MsbA is open when no nucleotides are bound permitting LPS to enter its cavity. 
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Subsequently MsbA closes around the LPS triggering a conformational change followed by ATP 
hydrolysis. This allows the LPS to flip and exit the protein at the periplasmic leaflet (171). Next 
the LPS follows the Lpt pathway, a seven protein complex towards the outer membrane (170, 
172).  
In contrast to the formation of Kdo-LipidA, the core oligosaccharides are readily deletable and it 
was found that the minimum structure for Gram-negative bacteria was Kdo-LipidA in which the 
Kdo disaccharide was key to its viability. It is the Kdo disaccharide that is required to allow the 
late acyltransferases to produce penta- and hexaacylated substrates which can be used by 
msbA which is in turn is an essential gene (168). However, mutants defective in Kdo 
biosynthesis were found to be viable due to certain so-called suppressor mutations. 
Overexpression of the secondary acyltransferases (lpxL and lxpM) increased the formation of 
penta- and hexaacylated Lipid IVa to allow growth, for LipidIVa otherwise is a poor substrate for 
MsbA (173) Overexpression of MsbA in itself can also act as a suppressor mutation (174).  
Using auxotrophic mutants for arabinose-5-phosphate, the building block for Kdo synthesis, 
Mamat and coworkers (2008) also found other suppressor mutations able to overcome Kdo 
essentiality. They found that a point mutation in the yhjD allele causing a substitution of an Arg 
to a Cys residue at position 134 was able to overcome the deletion of the otherwise essential 
Kdo transferase waaA in a wildtype E. coli strain (175). The exact function of YhjD is unknown, 
but it strongly interacts with the Lpt and MsbA membrane proteins playing a role in 
lipopolysaccharide transport (176). It was hypothesized that the modified YhjD protein is able to 
transport the Lipid IVa molecules across the inner membrane restoring the strain’s viability 
where MsbA alone was unable (175). To strengthen this hypothesis, mRNA levels of msbA 
were compared between the wildtype and the yhjD400 mutant strain and were found not to be 
significantly different. Moreover, they were able to delete the otherwise essential msbA gene in 
presence of the yhjD400 suppressor mutation. In addition to their work on the yhjD allele, 
suppressor mutations were also found inside msbA. Pro to Ser substitutions at position 18 or 50 
also confer viability in a waaA knock-out strain. It was suggested that these mutations relax the 
stringent specificity of msbA to handle the tetraacylated Lipid IVa as well (175).  
To create an expression host for recombinant protein devoid of the endotoxin LipidA as well as 
overacetylated Lipid IVa constituents, displaying only a tetraacylated Lipid IVa outer membrane, 
a BL21(DE3) variant named ClearColi was created. To achieve this pure Lipid IVa outer leaflet, 
all late acyltransferases (lpxL, lpxM, pagP, lpxP) and phosphoethanolamination (eptA) which 
are of major importance for the endotoxin immune response, were deleted in presence of the 
msbA148 suppressor mutation (175, 177). The ClearColi expression platform, commercially 
available through Lucigen Corporation (178), offers an interesting way of making protein 
therapeutics while minimizing the cost for endotoxin purification and elimination. However, it 
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must be noted that albeit the Lipid IVa acts antagonistically to human cells, other mammalian 
hosts may still develop an immune response due to species-specific Lipid IVa sensing.  
Despite the early view of Kdo-LipidA as an essential part of the membrane of Gram-negative 
bacteria, it is clear that the minimal LPS structure of Escherichia coli in particular, is highly 
dependent on the strain’s background (179). One can wonder what the actual minimal LPS 
structure is for viability and if LPS altogether is necessary? In nature, there are a few Gram-
negative bacteria living without LPS. The soil bacteria Sphingomonas paucimobilis (180) and 
Sorangium cellulosum (181) are known to have an unusual outer membrane lacking LPS 
molecules. Instead synthesized sphingolipids adopted the function of LPS and in turn also 
activate an immune response in humans. In contrast to these soil bacteria, a Neisseria 
meningitidis strain was created in 1998 which was defective in lpxA, the first step in LipidA 
formation, but viable and without detectable levels of endotoxin, as opposed to its parental 
species. To compensate for the LPS loss, a shift in both the inner and outer membrane to more 
saturated phospholipids was noticed. At first, it was thought that the 𝛼-2,8 polysialic acid 
capsule was essential to its viability (182), but was later disproved by creating a mutant 
defective in both lpxA as the capsular polysaccharide (183). To date, the actual ‘suppressor 
mutation’ is yet to be determined. Moreover, attempts to create similar mutations in the closely 
related Neisseria gonorrhoeae failed indicating a host specific trait. The same holds true for 
Moraxella catarrhalis (184), a mucosal pathogen, and Yersinia ruckeri (185), a fish pathogen, 
for which also endotoxin free mutants were created by deleting lpxA and lpxD respectively, but 
their compensation mechanisms remain unknown.  
Next to N. meningitidis, M. catarrhalis and Y. ruckeri, also a clinical case of an LPS deficient 
mutant was found in multidrug-resistant Acinetobacter baumannii strains. This opportunistic 
pathogen is responsible for a wide range of infections and is often found in intensive care 
settings. As a last resort treatment, polymyxin E or colistin, a polypeptide antibiotic produced by 
Bacillus polymyxa, is frequently used. However, also colistin resistant A. baumannii isolates 
were uncovered and some of these escape mutants showed a complete loss of LPS as a 
means to overcome colistin lethality (186, 187). The positively charged colistin normally causes 
membrane leakage due to the displacement of divalent cations bridging the LPS molecules. The 
inactivation of lipidA biosynthesis is a unique mechanism of colistin resistance not found in other 
isolates. Further research confirmed the nonessentiality of lipidA in the outer membrane of A. 
baumannii by complementation studies on lpxH and lpxK. It was found that these genes are 
essential for growth due to accumulation of otherwise toxic intermediates, but the essentiality 
was alleviated in the presence of lpxC inhibitors switching off lipidA biosynthesis (188, 189).  
Unlike N. meningitidis, M. catarrhalis and Y. ruckeri, the physiology of lipidA-deficient A. 
baumannii strains was studied in more detail. It was found for example that the Mla 
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phospholipid transport system was upregulated. The Mla transport system is responsible for the 
transport of phospholipids from the outer membrane to the inner membrane retaining the 
asymmetry of the lipid bilayer in Gram-negative bacteria. It was hypothesized that in the 
absence of LPS, the concentration of phospholipids in the outer membrane is increased and 
concomitant the level of transport by Mla. In addition, also the Lol pathway for lipoprotein 
transport and the pathway for poly-N-acetylglucosamine (PNAG) is upregulated (45). It is 
possible that the increase in PNAG biofilm and protein glycosylation may compensate for the 
absence of endotoxin in the outer membrane and as such create the necessary barrier against 
the environment. For a comparison between the LPS of the different species the reader is 
referred to recent excellent reviews (154, 190, 191).  
It is thus abundantly clear that the early view on LPS essentiality for Gram-negative bacteria is 
simply not correct. Whether LPS is essential will depend on the genera, the strain background 
and even the environmental conditions as LPS prevents the passage of toxic hydrophobic 
molecules. The first described LPS deficient mutants of Neisseria were created in a controlled, 
laboratory setting just like the M catarrhalis and Y. ruckeri variants. To what extent lpx mutants 
are also found in nature is currently unknown. The case of LPS deficient A. baumannii 
discovered in clinical isolates (187) and the more recently uncovered clinical isolate of LPS 
deficient N. meningitidis defective in LpxH (192) in contrast to the in vitro obtained lpxA mutants, 
show that their existence in nature is not insuperable. It also remains unclear if the LPS 
molecules as such are essential or is their elimination and the detrimental consequences on the 
outer membrane the reason of their essentiality. The loss of LPS will not only impact the outer 
membrane structure, also the distribution and function of membrane proteins will be altered as 
well. The way in which the strain will cope with the changed cell envelope will ultimately 
determine LPS essentiality.  
The newly gained insight on the biosynthesis and essentiality of lipidA structures in Gram-
negative bacteria give rise to new opportunities in therapeutics and vaccine development. LPS 
structures are powerful adjuvants, but their use is severely limited by its endotoxic activity. By 
altering the biosynthesis pathway creating other acylated or dephosphatated variants, the 
reactogenicity can be strongly attenuated while retaining vaccine efficacy. For example, 
monophospho-lipidA (MPLA), lacking one of the two phosphate groups is less toxic than the 
original structure. MPLA is synthesized in Salmonella strains as vaccine adjuvant to elicit 
moderate immune response (193). In addition, also lipidA deficient strains could be used to 
eliminate the cost of LPS detoxification which is otherwise necessary in e.g. the commercially 
available formulation of the meningococcal group B vaccine: Bexsero (170, 184, 194). 
The creation of LPS variant and deficient strains also opens a new window for industrial E. coli 
processes in feed, food and pharmaceutical productions as endotoxin levels need to be closely 
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monitored, assessed and mitigated. For example, in a high cell density biotechnological 
production process, endotoxin levels can rise to millions of EU/mL in the supernatant, causing 
potential harm to humans and other mammals. In comparison, LPS levels in our tab water only 
range from 1 to 20 EU/mL. Thus, to obtain a pure and safe product, these endotoxins must be 
removed. Detection of endotoxins is done using the LAL test, already approved by the FDA in 
1977 for testing drugs and is based on the amebocyte lysate of the horseshoe crab Limulus 
polyphemus (195). The blood lysate reacts with the endotoxin causing a gel-clotting reaction. 
Despite other more recently developed techniques, the LAL test remains the most sensitive 
(0.02 EU/mL) and economical test available. Removal of endotoxins is subsequently done using 
a wide range of techniques such as ultracentrifugation, two-phase extraction or affinity 
chromatography, but there is no universal removal technique, and all depends highly on the 
product type and application (43).  
In order to reduce the cost of downstream processing in respect to endotoxin removal and using 
the insight that LPS is no longer an essential part of Gram-negative bacteria, we investigated in 
Chapter 5 several routes to eliminate endotoxin formation inspired on the Neisseria and 
Acinetobacter mutants described above.  
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5.2 Material and methods 
5.2.1 Chemicals 
Tryptone and yeast extract were procured from Becton Dickinson. All other chemicals were 
purchased from Sigma-Aldrich, unless stated otherwise.  
5.2.2 Oligonucleotides and molecular reagents 
Oligonucleotides were purchased from Integrated DNA Technologies (Leuven, Belgium). 
Sequencing services were conducted by LGC genomics (Berlin, Germany). Deoxynucleotides, 
agarose and ethidium bromide were purchased from Thermo Fisher Scientific. QIAprep Spin 
Miniprep kit was used for plasmid isolation (QIAgen, USA). Analytik Jena kits were used for 
PCR purification (Jena, Germany). 
5.2.3 Strains 
E. coli K-12 MG1655 ΔthyA was used as a base strain for all future modifications. E. coli One 
Shot Top10 ElectrocompTM cells (Life Technologies) were solely used for cloning purposes. An 
overview of the strains used in this chapter is listed in Supplementary Table A.4-1. 
5.2.4 Media and culture conditions 
The culture medium lysogeny broth (LB) consisting of 1% tryptone, 0.5% yeast extract and 
0.5% sodium chloride was used throughout the work. Lysogeny broth agar (LBA) is similarly 
composed with the addition of 12 g/L agar. If required, media were supplemented with the 
antibiotics ampicillin (100 μg/mL), spectinomycin (100 µg/µL), kanamycin (50 μg/mL), 
chloramphenicol (34 μg/ mL) or tetracycline (10 µg/mL). 
5.2.5 Plasmids 
Plasmid pTKRED-msbA originates from pTKRED, which was a gift from Edward Cox & Thomas 
Kuhlman (Addgene plasmid # 41062) (38) in which the coding sequence of I-sceI is replaced 
with that of E. coli’s msbA. pCOLA-P14-Nm-msbA is made up of the ColA origin of replication, a 
kanamycin resistance marker, both originating from pCOLADuet™-1 (Novagen) and Nm-msbA, 
which was ordered with GeneArt Gene Synthesis (ThermoFisher Scientific, US) and is flanked 
with the P14 promoter (26) and the BioBricks terminator BBa_B0014. Plasmid pGEM-P14-
pgaABCD is made up similarly but the origin of replication and the ampicillin resistance cassette 
originates from pGEM-T (Promega). The pgaABCD operon with its natural terminator was 
amplified from the E. coli genome to which the P14 promoter (26) was added in the 
oligonucleotides. Plasmid pGEM-T-thyA was recreated according to Stringer et al. (2012) (93). 
All above mentioned plasmids were constructed using CPEC according to Tian & Quan (2009) 
(64). Plasmid pSC101-attPCC-P14-Nm-msbA-attPTT and plasmid pSC101-attPCC-P14-
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pgaABCD-attPTT on the other hand were made using Golden Gate according to Engler et al. 
(2009) (91) in which BsaI sites were added in the primers prior to amplification. The vector 
backbone originates from pDonor7 (See Chapter 2) while the insert sequences are derived 
from the respective plasmids mentioned above. Plasmid pSC101-attPCC-pYcaI-Nm-msbA-
attPTT is derived from pSC101-attPCC-P14-Nm-msbA-attPTT in which the P14 promoter was 
replaced by the endogenous promoter of the ycaI-msbA operon respectively.  
5.2.6 Thymidylate synthase A selection system for the creation of waaA mutants 
To create the waaA mutants in the thymine auxotroph base strain, the thyA cassette was 
amplified from pGEM-T-thyA with 50 bp homologous overhangs. The transformation protocol 
was followed according to Datsenko & Wanner (2000) (54). Cultures of the auxotroph base 
strain were always supplemented with 30 µg/mL thymidine to allow growth. After transformation, 
plating was done on LBA plates without thymidine to allow selection.  
5.2.7 SIRE protocol 
The SIRE knock-out and knock in protocol as described by Snoeck et al. (2018) (86) and which 
was extensively described in Chapter 2 was used to create all other modification in Chapter 5.  
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5.3 Results and discussion 
5.3.1 Hypothesis statement 
In order to alleviate endotoxin as an essential part of the outer membrane in Escherichia coli, 
we formulate 2 hypotheses based on Neisseria meningitidis and Acinetobacter baumannii 
isolates that were able to survive without LPS 
5.3.1.1 The Neisseria msbA compensation hypothesis 
LPS deficient mutants of Neisseria meningitidis were created defective in lpxA and even found 
in clinical isolates defective in lpxH, but the actual compensatory mechanism was not yet 
elucidated, nor was much research performed on the composition of the outer membrane. 
Moreover, no orthologues of yhjD were found in N. meningitidis, which is presumably 
responsible for the transport of LipidIVa in ClearColi. Therefore, we hypothesized that the inner 
membrane lipid flippase msbA of N. meningitidis must be more flexible than E. coli’s 
counterpart. Both genes only have a 32% identity and 52% similarity between them. If msbA of 
N. meningitidis (Hereafter Nm-msbA) can handle a wider variety of lipid structure, then it would 
explain why Neisseria mutants defective in lipidA biosynthesis are viable. To test this 
hypothesis, Nm-msbA will be introduced in E. coli after which the lipidA pathway will be 
eliminated step by step.  
5.3.1.2 The PNAG compensation hypothesis 
The case of LPS deficient Acinetobacter baumannii in contrast to N. meningitidis is well 
described in literature. After RNA-sequencing analysis, it was found that the genes coding for 
poly-N-acetylglucosamine (PNAG), a surface polysaccharide, were upregulated. According to 
this finding, it was thought that PNAG may act as a compensation mechanism restoring the 
barrier of the outer membrane. Therefore, we hypothesized that upregulating the expression of 
the natural PNAG biosynthesis coded by pgaABCD may act similarly in Escherichia coli. To this 
end, we incorporated extra copies of the pgaABCD cluster after which the lipidA pathway will be 
eliminated step by step. 
5.3.2 The Neisseria msbA compensation hypothesis 
5.3.2.1 Neisseria msbA codon harmonization 
In order to express heterologous genes in a host, codon optimization is often done to ensure 
high protein yield. Therefore every synonymous codon is replaced with the codon of the highest 
frequency of the coding genes of the native host. By using these common codons, the transcript 
is translated more quickly and with a higher fidelity (196). However by maximizing the 
translation speed, the chance of protein misfolding, often seen in expressing membrane 
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proteins, is much higher. This may result in insoluble aggregates called inclusion bodies, giving 
again a low yield. To overcome such problems codon harmonization is preferred for expressing 
msbA from Neisseria in E. coli. In codon harmonization the frequency of the synonymous codon 
of the heterologous gene is matched as much as possible to resemble the frequency in the 
native host. By keeping ‘rare’ codons, the translation speed slows down to accommodate proper 
folding.  
Nm-msbA was codon harmonized using Eugene (197) based on the relative synonymous codon 
usage (RSCU) minimizing mRNA secondary structures. The GC% content was set on 50% for 
the native gene had a slightly higher GC% content (57% instead of 50%) and 39 extra codons. 
The output was then evaluated using the %MinMax algorithm developed by Clarke IV et al. 
(2008) (196). Over a sliding window of 18 codons, this algorithm calculates in function of the 
arithmetic mean of all possible codon usage frequencies if the most common codons (maximum 
~ 100%) or the most ‘rare’ codons (minimum ~ -100%) were used. A value of 0% represents a 
codon usage equal to the mean of all possible codon choices for a given amino acid sequence. 
Results of the % MinMax are displayed in Figure 5-2. In the top half the codon usage of Nm-
msbA in the native host is compared with the codon usage of Escherichia coli, the expression 
host, and for multiple regions a clear difference is noted. In the bottom half a harmonized gene 
with E. coli’s codon usage is displayed which resembles that of the native gene indicating a well 
harmonized gene.  
To unequivocally determine the best design, the Codon Harmonization Index (CHI) is calculated 
(198). CHI is given by: 
 
𝐶𝐻𝐼 =
1
𝑁
 ∑ |𝑅𝐶𝐴𝑖 − 𝑅𝐶𝐴𝑖,𝑛𝑎𝑡𝑖𝑣𝑒|
𝑁
𝑖=1
 
(3) 
In which 𝑅𝐶𝐴𝑖 denotes the relative codon adaptiveness of the 𝑖th codon and 𝑅𝐶𝐴𝑖,𝑛𝑎𝑡𝑖𝑣𝑒 the 
relative adaptiveness of the 𝑖th native codon of a gene in the native host and 𝑁 the number of 
codons in a gene. The RCA is calculated as the ratio between the frequency of the 𝑖th codon 
and the most frequent codon used for that amino acid.   
The closer the CHI score to zero, the closer the codon landscape of the gene resembles the 
native one. The CHI score of the depicted harmonized gene in Figure 5-2, is 0.069.  
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Figure 5-2: The codon usage frequency calculated as a function of the arithmetic mean of the most 
common and the most rare codon frequencies is displayed in function of the amount of codons in a sliding 
window of 18. In the top figure, the codon usage of msbA of Neisseria meningitidis is displayed based on 
its native codon usage frequency table (dark blue) and that of E. coli (light blue). The bottom figure 
displays the harmonized msbA gene of N. meningitidis based on E. coli codon usage frequency table. 
Values are calculated according to Clarke IV et al. (2008) (196). 
5.3.2.2 LipidA elimination 
To replace Escherichia coli’s native msbA, an essential gene, by the one of N. meningitidis, 2 
plasmids were created. First, a variant of pTKRED (38) was created which harbors not only the 
𝜆-RED genes for homologous recombination and a temperature sensitive origin of replication, 
but also EC-msbA under an L-arabinose inducible promoter which replaced the original coding 
sequence of I-sceI. Second, an expression plasmid using the ColA origin of replication, resulting 
in a medium copy plasmid, was made. This plasmid contains the harmonized msbA gene from 
N. meningitidis under control of a strong constitutive promoter.  
By means of pTKRED-msbA, it was possible to delete the genomic msbA using a kanamycin 
cassette while expressing the plasmid copy of msbA when L-arabinose was supplied to the 
medium. Next the expression plasmid of Nm-msbA is introduced. Because of the compatible 
origins of replication and the different selection markers, both plasmids could be maintained. 
Finally, the obtained strain was cultured at 42°C without selective pressure towards pTKRED-
msbA, to eliminate the plasmid. Moreover, no induction to express msbA was applied. Normally 
this would result in cell death as the essential gene msbA is too low expressed or the plasmid 
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harboring the gene is eliminated. Yet viable colonies were found which only survived because of 
the overexpression of Nm-msbA. 
 
Figure 5-3: The plasmid map of pTKRED-msbA (left) and the plasmid map of pColA-P14-Nm-msbA (right).  
It is clear that the overexpression of Nm-msbA is able to complement an E. coli msbA mutant. 
The next step is to test whether this overexpression is also able to eliminate (parts of the) the 
lipidA pathway. Therefore, deletion of the waaA, the last step in the lipidA pathway was 
attempted. In this way not lipidA, but lipidIVa will be the major constituent of the outer 
membrane.  
To that end, the previous described strains were created in a thymine auxotroph base strain. 
When a thyA cassette, coding for the thymidylate synthase, is introduced successfully, the 
thymine auxotrophy of the base strain could be lifted. By replacing the waaA gene, which is 
normally essential, by the thyA cassette, viable colonies were obtained. This means that the 
overexpression of Nm-msbA is not only able to complement an msbA mutant but also a waaA 
mutant resulting in KDO elimination of the outer membrane.  
5.3.2.3 Lowering copy number 
The fact that overexpression of Nm-msbA overcomes a waaA mutant, is however in accordance 
with literature wherein overexpression of the native msbA was also found to act as a suppressor 
for waaA deletion (174). To test the hypothesis that Nm-msbA is more flexible than its native 
counterpart and allows waaA mutants to be viable, which is not directly linked with its 
overexpressing, new constructs were made with a lower copy number. In the first variant, the 
pSC101 ori, generating a copy number of ~5 (74) was used instead of the medium copy range 
of the ColA ori of ~20 (199). In the second variant, the strong P14 promoter was replaced by its 
native variant, which is located upstream of the ycaI gene, the first gene of the ycaI-msbA-lpxK-
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ycaQ operon, and a synthetic RBS calculated to have the same translation initiation rate as the 
native sequence (200, 201). 
Both plasmids were used in the same manner as described in Section 5.3.2.2 and transformed 
in the pTKRED-msbA harboring msbA mutant strain. After culturing at 42°C, without selective 
pressure towards pTKRED-msbA and without inducer, 2 observations could be made. The 
strain with the low copy variant and the P14 promoter was viable, but the strain with the native 
promoter had a completely different morphology. The obtained colonies were partly translucent 
and watery (See Figure 5-4). Reculturing them again in presence of the L-arabinose inducer to 
express msbA from pTKRED-msbA, reverted their phenotype back to normal, while reculturing 
without the inducer eventually caused cell death. The lower expression of Nm-msbA due to the 
lower copy number as well as the weaker promoter is thus insufficient to promote cell 
proliferation. However using the P14 promoter, altering the copy number did not affect the 
viability of the msbA mutant strain. Subsequently, the overexpression of Nm-msbA on the 
pSC101 ori was also tested and found sufficient to compensate a waaA deletion.  
   
Figure 5-4: Left: Zoomed-in photograph of the obtained colonies with the pYcaI promoter without L-
arabinose inducer for msbA. Edges of these colonies appear translucent. Reculturing them did not 
produce viable strains. Right: Zoomed-in photograph of a regular Escherichia coli phenotype for 
comparison.  
To even further lower the copy number, the Nm-msbA gene driven by the P14 promoter was 
also incorporated into the genome according to Snoeck et al. (2018) (86) (Chapter 2), but 
neither an msbA, waaA or an msbA waaA double mutant could be obtained. Instead a 
phenomenon of “double bands” is observed in which e.g. the wildtype band of waaA as well as 
its knock-out cassette is present. Streaking did not resolve this issue and neither did 
retransforming these cells with the plasmid harboring the overexpression cassette of Nm-msbA.  
From the above findings, we can state that overexpression Nm-msbA is a suppressor for waaA 
mutants. However it remains unclear whether this effect is attributed to N. meningitidis’ different 
protein version of msbA or to the overproduction of the flippase itself. As lowering the copy 
number and promoter strength failed to produce viable mutants, the latter assumption is 
favored. Nevertheless, in the double band strain, retransformation of the overexpression 
cassette should have created a pure waaA mutant, but did not.  
Chapter 5: Endotoxin elimination 
106 
5.3.3 The PNAG compensation hypothesis 
5.3.3.1 PNAG overexpression 
PNAG or poly-N-acetylglucosamine is a linear polymer of 𝛽-1,6-N-acetylglucosamine residues 
and is coded by the pgaABCD cluster in Escherichia coli. To overproduce PNAG as a potential 
suppressor for lipidA elimination, this cluster was cloned on a high copy plasmid (up to 500 
copies) due to the pUC origin of replication. In analogy with the previous created plasmids, the 
same strong P14 promoter was used together with the natural terminator of the cluster.  
 
Figure 5-5: Chemical structure of the polymer 𝛽-1,6-N-acetylglucosamine. 
The created plasmid pGEM-P14-pgaABCD was transformed in a thymine auxotroph wildtype 
strain where the waaA, a normally essential gene, was targeted for deletion. Surprisingly, viable 
colonies were obtained showing the complete knock-out of waaA. To make sure that the 
overexpression of pgaABCD is the actual suppressor mutation, known suppressor mutations 
used in the creation of ClearColi (175) (see Section 5.1) such as msbA52, msbA148 and 
yhjD400 were checked and were not present.  
To the best of our knowledge, this is the first time that a waaA mutant E. coli strain was 
obtained by means of PNAG overproduction as a suppressor mutation. Moreover, this finding 
also confirms to certain extent the compensation mechanism of Acinetobacter baumannii where 
PNAG upregulation was detected in an LPS deficient strain. Transferring these mechanisms to 
other hosts is thus a viable strategy to create new lipidA deficient strains.  
Next, the overexpression of pgaABCD was also tested on the genome instead on the pGEM 
plasmid. However, in this setting, the same phenomenon of “double bands” as described in 
Section 5.3.2.3 occurred. As previously encountered, streaking did not solve this problem but in 
contrast with Nm-msbA transforming these strains with the overexpression plasmid of PNAG did 
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result in pure waaA mutants. Apparently, overproduction of PNAG is key to create viable waaA 
mutants and a mere expression problem was found.  
 
5.3.3.2 Elimination of lipidA biosynthetic pathway.  
In order to further investigate the newly created strain in which overexpression of pgaABCD on 
a pGEM backbone was able to compensate a waaA modification which is otherwise essential, 
both downstream and upstream knockouts in the pathway of lipidA synthesis were attempted. 
Upstream knock-outs such as lpxB, lpxH and lpxC were however unsuccessful and yielded no 
colonies so the compensation mechanism of pgaABCD is thus not able to completely eliminate 
endotoxin in Escherichia coli. On the other hand upstream kdsD and gutQ as well as 
downstream lpxM and lpxL did yield successful knock-outs at first instance, but after closer 
examination the phenomenon of double bands as described earlier was encountered for the 
already deleted waaA gene in contrast with the above findings where the double bands were 
encountered for the targeted gene. Moreover after reculturing, the strains also appear to have 
lost the pGEM backbone, which is needed to compensate for the waaA deletion. Why these 
strains revert back or lose their compensation plasmid is at the moment unclear. New attempts 
should be made to anchor the compensation mechanism onto the genome to check whether the 
inability to create kdsD, gutQ, lpxLM mutants comes from an insufficient compensation 
mechanism or from engineering a knock-out. After all these latter genes have become 
redundant in a waaA mutant strain. Especially kdsD and gutQ which are involved in the 
synthesis of Kdo.  
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5.4 Conclusion and future perspective 
Endotoxin is the major constituent of the outer membrane of Gram-negative bacteria and 
induces an innate immune response in humans causing severe sepsis. That is why endotoxin 
levels after fermentation have to be closely monitored and removed to ensure a pure and safe 
product. Therefore creating a platform strain devoid of LPS would ensure less downstream 
processing steps and thus reduce costs. As the view of endotoxin being an essential part to the 
Gram-negative outer leaflet has begun to fade, new opportunities arise to create such platform 
strains. Several species such as A. baumannii and N. meningitidis were uncovered in nature as 
well as created in the laboratory without LPS. Inspired by these cases we tried to create an 
Escherichia coli strain devoid of endotoxin. 
By overexpressing Nm-msbA as well as the endogenous PNAG production, we were able to 
create waaA mutants, which is otherwise an essential gene. Consequently, the outer leaflet now 
consists of lipidIVa constituents instead of Kdo-LipidA, which already gives a significant reduced 
endotoxin response. However further attempts to delete parts of the upstream/downstream 
lipidA biosynthesis cluster did not result in viable colonies. To further elicit the compensation 
mechanisms necessary to delete endotoxin completely in Escherichia coli or in extension also 
to other organisms, it should be clear that a better understanding of the compensatory 
mechanisms in the naturally occurring species devoid of endotoxin is necessary and they must 
be studied in more detail. Indeed, to date little is known of why e. g. Neisseria meningitidis or 
Moraxella catharralis are able to survive without LPS. As A. baumannii and M. catharralis 
belong to the same family, one can wonder if there is somewhere a conserved mechanism to 
allow LPS-deficient strains rather than a host specific trait. Further research on this matter 
would certainly gain if all described cases would be studied and thoroughly compared to find 
common suppressor mutations which then could be transferred to other hosts  
Recently, Boll et al. (202) found that some A. baumannii strains were able to acquire colistin 
resistance through inactivation of the lipidA pathway while others could not. After extensive 
research it was found that the presence of the penicillin binding protein (PBP1A) coded by 
mrcA, a peptidoglycan assembly protein, was key to acquire the trait. For example, 
overexpressing mrcA in the ATCC 19606 isolate which is able to overcome LPS and has no 
copy of mrcA, impeded isolation of viable colonies after colistin exposure whereas the colistin 
sensitive ATCC 17978 isolate was able to develop colistin resistance through inactivation of the 
lipidA biosynthesis only after mrcA deletion. This finding links the lipidA biosynthesis with the 
highly conserved peptidoglycan synthesis and opens up new possibilities to transfer LPS-
deficiency to other organism.  
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Also the newly created waaA strains should be examined more thoroughly. Genomic and 
transcriptomic analysis for example could be used to check if no other compensatory 
mechanisms are at play. Certainly in light of the inability to perform downstream and upstream 
knockouts and the encountered phenomenon of double bands. This would be especially 
interesting for the genes kdsD and gutQ, which theoretically should have become redundant as 
they are responsible for synthesizing KDO, which is no longer attached in a waaA mutant. New 
attempts should also be made to move the compensation mechanism from plasmids onto to the 
chromosome to simplify further engineering efforts.  
Overall, small successes have been made to eliminate endotoxin in Escherichia coli by learning 
from other hosts and the prospects of such strains will hopefully facilitate and accelerate new 
biotechnological production processes in the future.  
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Abstract  
Fucosyllacto-N-neotetraose III is a pentasaccharide human milk oligosaccharide found to work 
specifically against norovirus, the main cause of gastro-enteritis in young children. Using 
transferases from Neisseria and Helicobacter, a heterologous pathway was built towards this 
HMO and subsequently implemented on the developed glycominimised platform strain as well 
as on its wildtype counterpart. Fermentation on a 5 L bioreactor scale resulted in a titer of 1 g/L 
FLNT III. Finally, by-products from both fermentations were analyzed and compared to validate 
the glycominimised platform strain.  
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6.1 Introduction 
Human milk oligosaccharides or HMOs, are naturally occurring carbohydrates found in mother’s 
milk not only from humans but also from marsupials and mammals in general (203, 204). These 
complex oligosaccharides together with lactose, a dimer of glucose and galactose almost 
exclusively found in mammals, comprise the carbohydrate fraction of mother’s milk (203). Their 
concentration can reach up to 25 g/L in the colostrum, the first milk that is produced a few days 
after parturition, and decreases slowly through transition to mature milk (205).  
HMOs are structurally very diverse and their composition varies between women and over the 
course of lactation (206–208). They are composed of five monosaccharides building blocks: 
glucose, galactose, N-acetylglucosamine (GlcNAc), fucose and sialic acid, with N-
acetylneuraminic acid (Neu5Ac) as the predominant form (See Figure 6-1). Furthermore, they 
can be divided in roughly two groups and lactose (Galβ1-4Glc) as core structure is always found 
at the reducing end. This base molecule is then either fucosylated, e.g. to form one of the most 
abundant HMOs found in mother’s milk, 2’-fucosyllactose (2’FL), or sialylated. Lactose can also 
be elongated either with lacto-N-biose (Galβ1-3GlcNAc) to form the type I chain or with 
N-acetyllactosamine (Galβ1-4GlcNAc) to form the type II chain. These molecules in turn can 
also be fucosylated or sialylated to create more complex structures. Branched structures are 
formed when elongation occurs in a β1-6 linkage instead of a β1-3 linkage between GlcNAc and 
lactose. Extension on this side chain occurs with N-acetyllactosamine while elongation with 
lacto-N-biose appears to terminate it.  
This wide variety in oligosaccharides is most complex in human milk, where 50% to 80% is 
fucosylated, and in those of other primates (209). Most other species however show very low 
levels of fucosylation (<1%) such as the milk of most farm animals (210, 211). Also the 
oligosaccharide concentration is often >100 fold lower and a smaller number of different 
oligosaccharides is found (205, 209–211). In Table 6-1 a comparison is made between human 
and bovine milk. 
The complex mixture of more than 100 different types of HMOs in human milk is related to the 
synthesis of the histo-blood group antigens (HBGAs) which include the ABH blood group 
system and the Lewis antigens (212). The ABH blood group antigens were named after their 
expression by red blood cells, but HBGAs are also present in epithelial cells and in most body 
fluids such as mother’s milk. HBGAs are synthesized from the type I or type II chain precursor 
and are 𝛼1,2-fucosylated dependent on the presence of the so called Secretor gene, FUT2, an 
𝛼1,2-fucosyltransferase. 𝛼1,2-fucosylation of the terminal Gal yields the H-type antigen 
characteristic for the O blood group type and can be further modified dependent on the 
presence of the A or B glycosyltransferase which adds a N-acetylgalactosamine or galactose 
Chapter 6: Evaluation of side product formation on the production of the HMO FLNT III 
116 
respectively giving the A, B or AB blood groups (212–214). 80% of the European and North-
American women possess this Secretor gene which is also responsible for the synthesis of 2’FL 
and FLNT I, the most abundant HMOs in milk of Secretor women (215). Non-secretor women 
on the other hand are characterized by the absence of all ABH antigens from mucus and 
secretions like saliva and mother’s milk, but they are still found on the erythrocytes. Only a 
mutation in the FUT1 allele, the only other 𝛼1,2-fucosyltransferase found in humans, will lead to 
the absence of ABH antigens on erythrocytes, causing the extremely rare Bombay blood group 
phenotype mostly encountered in India (216).  
 
Figure 6-1: Overview of the structural diversity of HMOs. Left is a list of the monosaccharides of which 
HMOs are constituted. Right a distinction is made between simple HMOs which are either sialylated or 
fucosylated on their lactose core and more complex HMOs. For example 2’-fucosyllactose is 𝛼1,2-
fucosylated at the galactose of the lactose core while 3-fucosyllactose is fucosylated at the glucose 
residue. The lactose core of complex HMOs is either elongated with lacto-N-biose or N-acetyllactosamine, 
which also provides a branching point. In turn these elongated and branched HMOs can be fucosylated 
and sialylated.  
Non-secretor women are thus unable to produce HMOs like 2’FL but are still able to synthesize 
fucosylated HMOs thanks to the Lewis gene or FUT3 which is responsible for the 𝛼1-3/4 
fucosylation creating the Lewis antigens as well as HMOs like 3’FL and FLNT II. So, dependent 
on the presence of the Secretor and/or the Lewis gene, different HMO profiles can be found 
(205). Women lacking both genes secrete milk with the least complex HMO composition in 
terms of fucosylation and also the total HMO concentration is lower (208). In contrast, variations 
in HMO sialylation are more subtle and a complete loss of sialylated HMOs has not yet been 
described (205).  
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Table 6-1: Overview of the concentration of the major macronutrients and HMOs in human and bovine 
milk. Table was adapted from Bode et al. (2012) (205).  
 Human Bovine 
Protein (g/L) 8 32 
Fat (g/L) 41 37 
Lactose (g/L) 70 48 
Oligosaccharides (g/L) 5-15 0.05 
Number of identified oligosaccharides > 100 40 
%fucosylated 50 - 80 1 
%sialylated 10 - 20 70 
 
The structural diversity of HMOs in human milk is the result of million years of Darwinian 
evolution. Because 99% of all ingested HMOs reach the intestinal tract being resistant to the 
low stomach pH as well as pancreatic and brush border enzymes (217), HMOs have a 
substantial influence in shaping a healthy infant gut microbiota by serving as prebiotics (218, 
219). The complex mixture of HMOs provides an advantage for certain Bifidobacteria, 
Bacteroides and Lactobacilli keeping harmful bacteria in check as they compete for limited 
nutrient supply and as a result, protecting the neonate from pathogenic infections (205). For 
example, Bifidobacterium infantis expresses a whole battery of hydrolytic enzymes and 
transporters that enables the bacteria to grow solely on HMOs, while other (sub)species cannot. 
In addition, they create an environment favoring other commensals such as L. reuteri which 
utilizes the HMO-derived monosaccharides and simpler oligosaccharides (220). In contrast, 
formula-fed babies showed a lower abundance in Bifidobacteria and Lactobacilli and a higher 
abundance in Clostridium and coliform bacteria (221).  
HMOs do not only serve as prebiotics, but they also have an antimicrobial effect. Pathogens like 
Helicobacter pylori or Campylobacter jejuni, employ lectins or glycan-binding proteins to adhere 
to the mucosal surfaces to colonize or to invade the host and cause disease (222). HMOs 
resemble the epithelial cell surface glycans and occupy these receptor sites acting as decoys. 
In this way pathogens are unable to bind and leave the intestinal tract without causing harm 
(205). It was found e.g. that infants whose mother’s milk contained high concentrations of 𝛼1,2-
fucosylated HMOs such as 2’FL and lacto-N-difucohexaose I (LNDFHI) had less incidences of 
C. jejuni-associated diarrhea than formula-fed babies (205, 223). The antiadhesive effect of 
HMOs is however not limited to bacteria, also norovirus and rotavirus (224) as well as 
Entamoeba histolytica, a protozoan parasite causing worldwide a 100,000 deaths annually 
(225), bind to the epithelial glycocalyx.  
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HMOs do not only interact with the gut microbiota, they also act as immune modulators, 
contributing to allergy prevention (226) and serve as nutrients for brain development. Sialylated 
HMOs in mother’s milk are a natural rich source of sialic acid, which is an essential component 
of brain gangliosides and polysialic acid chains that modify neural cell adhesion molecules (227, 
228). These HMOs and disialyllacto-N-tetraose (DSLNT) in particular also protect newborns 
against necrotizing enterocolitis (NEC), a fatal disorder mostly developed in preterm infants 
(229).  
It should be clear that many beneficial properties attributed to mother’s milk are a result of the 
presence of sialylated and fucosylated oligosaccharides. Many of these compounds however 
are unique to human milk and its structural diversity is so complex, that investigating all their 
potential benefits and possible applications is a major challenge. It is mainly their limited 
availability that hampers large-scale clinical intervention studies as purification from donor milk 
is costly and labour intensive (230). Even for studying supplementation in infant formula, which 
up until recently contained no HMOs, requires a substantial availability of different HMOs. In this 
respect, one should figure out which combination of HMOs and in what concentration they are 
most beneficial to be added to formula milk, for mimicking the entire human milk spectrum 
makes no economic sense. HMOs also have promising application in the development of new 
vaccines (224). Despite carbohydrates being poorly immunogenic, conjugation to protein 
scaffolds do offer a strong immune response (231). For example, the HMO fucosyllacto-N-
neotetraose (FLNT III) was found to inhibit norovirus (46), which is the main cause of gastro-
enteritis in young children (232). An additional advantage of HMO-conjugated vaccines is that 
many HMOs harbour multiple virus recognition sites. Moreover viral resistance is also unlikely 
since mutations to avoid HMO binding, will also result in low affinities to receptors on the target 
cells (224).  
Today the most promising way of synthesizing a wide variety of HMOs in sufficient quantities is 
via microbial metabolic engineering. In contrast to chemoenzymatic synthesis, there is no need 
to supplement expensive activated sugars necessary for the glycosyltransferases for they are 
inherently recycled in the natural metabolism of host strains such as Escherichia coli or 
Saccharomyces cerevisiae. For example, the synthesis of 2’-fucosyllactose has been 
extensively studied in both hosts reaching titers of 20 g/L. Key in this respect is the 𝛼1,2-
fucosyltransferase derived from H. pylori and coded by futC which transfers intracellular 
produced GDP-fucose to imported lactose (233–235). It is not surprising that 2’FL consequently 
was also the first HMO approved by the EU to be added to formula milk (236), which is now 
commercially available through Nestlé Evolia. Also other HMOs have been produced 
fermentatively (237–239). Using the same principles also lacto-N-neotetraose was produced in 
Escherichia coli using lgtAB from N. meningitidis coding for 𝛽1,3-N-
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acetylglucosaminyltransferase and 𝛽1,4-galactosyltransferase respectively adding GlcNAc and 
a galactose to imported lactose (240).  
However, despite these early successes, commercialization of these HMOs has only just begun 
with companies like Glycom (Denmark), Inbiose (Belgium) and Jennewein (Germany) producing 
their first HMOs for the infant formula market. In order to produce also more complex HMOs 
such as polyfucosylated and/or branched structures in sufficient quantities to lever 
pharmacological applications, some hurdles still have to be overcome. One of them, byproduct 
formation by the endogenous metabolism, is one issue already mentioned in Chapter 4. There 
we created an Escherichia coli base strain devoid of all nonessential glycosyltransferases 
potentially creating unwanted side products. In this chapter, we will validate this platform strain 
with the implementation of the biosynthetic route towards FLNT III, a fucosylated 
pentasaccharide HMO, with potential application in vaccine development against norovirus.  
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6.2 Material and methods 
6.2.1 Chemicals 
Tryptone and yeast extract were procured from Becton Dickinson while fucosyllacto-N-
neotetraose III analytical standard comes from Carbosynth. All other chemicals were purchased 
from Sigma-Aldrich, unless stated otherwise.  
6.2.2 Oligonucleotides and molecular reagents 
Oligonucleotides were purchased from Integrated DNA Technologies (Leuven, Belgium). 
Sequencing services were conducted by LGC genomics (Berlin, Germany). Deoxynucleotides, 
agarose and ethidium bromide were purchased from Thermo Fisher Scientific. QIAprep Spin 
Miniprep kit was used for plasmid isolation (QIAgen, USA). Analytik Jena kits were used for 
PCR purification (Jena, Germany). 
6.2.3 Strains 
Strain sNS4.29, the GM-strain (See Chapter 4) and the WT strain E. coli K-12 MG1655 
(sNS3.01) were used for all future modifications. E. coli One Shot Top10 ElectrocompTM cells 
(Life Technologies) were solely used for cloning purposes. An overview of the strains used in 
this chapter is listed in Supplementary Table A.5-1. 
6.2.4 Media and culture conditions 
The culture medium lysogeny broth (LB) consisting of 1% tryptone, 0.5% yeast extract and 
0.5% sodium chloride was used throughout the work. Lysogeny broth agar (LBA) is similarly 
composed with the addition of 12 g/L agar. If required, media were supplemented with the 
antibiotics ampicillin (100 μg/mL), spectinomycin (100 µg/µL), kanamycin (50 μg/mL), 
gentamycin (30 µg/mL), chloramphenicol (34 μg/ mL) or tetracycline (10 µg/mL). 
For production experiments a defined medium was used containing 2 g/L NH4Cl, 5 g/L 
(NH4)2SO4, 3 g/L KH2PO4, 7.3 g/L K2HPO4, 8.4 g/L MOPS, 0.5 g/L NaCl, 0.5 g/L MgSO4 ·7H2O, 
and 15.15 g/L glycerol, 1 ml/L trace element solution and 100 μL/L of a 0.967 g/L 
Na2MoO4·2H2O molybdate solution. The trace element solution contained 3.6 g/L FeCl2·4H2O, 5 
g/L CaCl2·2H2O, 1.3 g/L MnCl2·2H2O, 0.38 g/L CuCl2·2H2O, 0.5 g/L CoCl2·6H2O, 0.94 g/L 
ZnCl2, 0.0311 g/L H3BO4, 0.4 g/L Na2EDTA·2H2O, 1.01 g/L thiamine·HCl.  
For bioreactor experiments a variant of the above-mentioned medium was used. The batch 
medium contained 0.45 g/L (NH4)2SO4, 2.105 g/L KH2PO4, 1.68 g/L K2HPO4, 0.34 g/L NaCl, 
1 g/L citric acid monohydrate, 1 g/L MgSO4 ·7H2O, 50 g/L glycerol, 50 g/L lactose.H2O, 9 mL of 
the trace element solution and 0.9 mL of a 0.967 g/L Na2MoO4·2H2O molybdate solution. The 
fed-batch medium contained 1.9 g/L (NH4)2SO4, 3.05 g/L K2HPO4, 1.8 g/L (NH4)2HPO4, 4.5 g/L 
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NH4H2PO4, 1 g/L citric acid monohydrate, 1 g/L MgSO4 ·7H2O, 250 g/L glycerol, 50 g/L 
lactose.H2O, 53 mL of the trace element solution and 5 mL of a 0.967 g/L Na2MoO4·2H2O 
molybdate solution. 
6.2.5 Plasmids 
The donor plasmid pDonor15, is similarly composed as pDonor7 (See Chapter 2 and 
Supplementary Table A.1-3) except for the operon for GDP-fucose synthesis between the att 
sites. This operon was constructed with the endogenous genes cspBG and gmd/fcl and a 
synthetic RBS designed with the RBS calculator according to Salis et al. (2009) to mimic the 
original RBS strength (200). To drive expression promoter P14 (26) was used and BBa_B0014 
acts as the terminator (110). The plasmid was constructed using CPEC according to Tian & 
Quan (2009) (64). Plasmids pDonor16 and pDonor17 were a gift from Inbiose NV and hold the 
lgtB and lgtA genes from N. meningitidis respectively. Their expression is driven by the strong 
p5 promotor (28) and intermediate RBS GalE_BCD5 (28) and the intermediate J23104 
Anderson promotor and the strong LeuAB-BCD4 RBS (28) respectively. The production 
plasmids pProd1-12 are composed similarly and contain a medium copy ori CloDF13 and a 
spectinomycin cassette derived from DS-NMcas (241), which was a gift from George Church 
(Addgene plasmid # 48646). The 3-fucosyltransferases from Helicobacter pylori UA 948 (242), 
Bacteroides fragilis NCTC 9343 (3), Helicobacter hepaticus ATCC 51449 (243) were ordered 
codon harmonized from Twist Biosciences; the 3-fucosyltransferase from Helicobacter pylori 
ATCC 11639 was already available at the lab codon optimized. The fucosyltransferases are 
flanked with promoters either P14 (strong), P22 (medium) or P70 (weak) (26) combined with 
RBS either OmpC_BCD12 (strong), GalE_BCD12 (medium), GalE_HisHA (weak) (28), 
terminator rnpB_T1 (244) and attachment sites attPCC and attPTT. The above mentioned 
plasmids are constructed using Golden Gate according to Engler et al. (2009) (91) and all 
bacterial plasmids are listed in Supplementary Table A.5-2. 
6.2.6 SIRE protocol 
The SIRE knock-out and knock in protocol as described by Snoeck et al. (2018) (86) and which 
was extensively described in Chapter 2 was used to create all modification in Chapter 6.  
6.2.7 Production experiments 
Production trials were executed on deep-well plates (DWP) according to the Duetz system (245) 
with plate type CR1424 and sandwich cover CR1224 (Enzyscreen, The Netherlands). A culture 
volume of 2 mL of the defined medium was used and inoculated 1% from LB-precultures 
originating from cryovial. The DWPs were incubated at 37°C and 200 rpm. The production trials 
in Section 6.3.2 and 6.3.3 lasted 4 and 2 days after which an end-point sample was taken to 
measure OD600 and for LC-MS analysis.  
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6.2.8 Bioreactor experiments 
Fermentations were done in 5 L Biostat reactors (Sartorius Stedim Biotech, Germany). 
Temperature was kept at 37°C using the water jacket. pH was maintained at 7.0 using a 98% 
H2SO4 and 25% NH4OH solution. Aeration is kept at 1 L air/min and introduced in the reactor 
using a sparger after passing through a 0.2 µm PTFE filter (Sartorius Stedim Biotech Midisart 
2000, Germany). Off gas is cooled using an off-gas cooler, filtered and analyzed to detect the 
fraction CO2 and O2 respectively by infrared and paramagnetic detection (ABB Automation 
EL3020, Germany). Foaming is suppressed using anti-foam Struktol J637 (Schill und Seilacher, 
Germany). Temperature, pH, pO2, added volume acid and base, added volume of medium are 
continuously monitored using Sartorius MFCS software (Sartorius Stedim Biotech, Germany). 
The bioreactor containing 2 L physiological saline solution is subsequently sterilized by 
autoclaving for 1 hour at 121°C and 1 atm overpressure. Next the solution is replaced by adding 
the above-mentioned batch medium and inoculated through the available septum with 100 mL 
preculture (defined medium) using sterile syringes. Fed batch medium is added using a 
peristaltic pump when the glycerol was completely consumed at a constant volumetric feeding 
rate.  
6.2.9 Sample preparation and analytical analysis 
Samples from the DWP production experiments were heated for 15’ at 98°C and subsequently 
pelleted. The supernatant was filtered (0.2 µm) prior to analysis. Samples were analyzed with 
ThermoFisher’s Exactive Plus Orbitrap Mass Spectrometer UPLC-MS in negative mode. 
Samples from the bioreactor experiments were pelleted and filtered (0.2 µm) prior to analysis 
with the Waters Acquity H-class UPLC-ELSD system. Fed-batch samples were diluted 1:1 with 
200 g/L trichloro-acetic acid to precipitate proteins and cell debris and are subsequently pelleted 
and filtered (0.2 µm). The sugars are separated using the Waters Acquity BEH Amide Column 
(130Å, 1.7 µm, 2.1 mm x 100 mm) and an isocratic eluens (75% acetonitrile, 0.15% 
triethylamine) at 0.6 mL/min and 35°C. Fed-batch samples for organic acid analysis were 
diluted 1:1 with methanol to precipitate proteins and cell debris and are subsequently pelleted 
and filtered (0.2 µm). The organic acids were separated using the Phenomenex Rezex ROA-H+ 
column (8 µm 4.6 mm x 100 mm) and an isocratic eluens (10 mM H2SO4) at 0.1 mL/min and 
40°C and analyzed with the Waters Acquity H-class UPLC-UV system. 
6.2.10 Calculations of fermentation parameters 
6.2.10.1 OUR & CER 
The oxygen uptake rate (OUR) and the carbon dioxide evolution rate (CER) during fermentation 
is calculated from the aeration rate (L/min) and the O2 and CO2 fractions of the inlet and outlet 
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gas. Assuming that only three gasses are in the atmosphere: N2, O2 and CO2, then CER and 
OUR are calculated as:  
 
𝑂𝑈𝑅 =
𝐹𝑔
𝑉
∗ (𝐶𝑂2,𝑜𝑢𝑡 ∗
1 − 𝐶𝐶𝑂2,𝑖𝑛 − 𝐶𝑂2,𝑖𝑛
1 − 𝐶𝐶𝑂2,𝑜𝑢𝑡 − 𝐶𝑂2,𝑜𝑢𝑡
− 𝐶𝑂2,𝑖𝑛) 
(4) 
 𝐶𝐸𝑅 =
𝐹𝑔
𝑉
∗ (𝐶𝐶𝑂2,𝑜𝑢𝑡 ∗
1−𝐶𝐶𝑂2,𝑖𝑛−𝐶𝑂2,𝑖𝑛
1−𝐶𝐶𝑂2,𝑜𝑢𝑡−𝐶𝑂2,𝑜𝑢𝑡
− 𝐶𝐶𝑂2,𝑖𝑛)  
(5) 
where, 𝐹𝑔is the molar gas flow (mol/min), 𝑉, the volume (L) of the bioreactor and 𝐶𝑥 the mole 
fraction of gas 𝑥.  
6.2.10.2 Maximum specific growth rate 
During bacterial exponential growth, biomass concentration is expressed as: 
 𝑋(𝑡) = 𝑋(0) ∗ 𝑒𝜇𝑚𝑎𝑥𝑡 (6) 
with 𝑋(𝑖) the biomass concentration (g biomass/L) at time = 𝑖, 𝜇𝑚𝑎𝑥 the maximum growth rate 
(h-1) and 𝑡 the duration of the fermentation. Using 𝑂𝑈𝑅 or 𝐶𝐸𝑅 and the specific O2 consumption 
rate 𝑞𝑂2  or CO2 production rate 𝑞𝐶𝑂2 in which 𝑂𝑈𝑅 or 𝐶𝐸𝑅 are divided by the biomass 
concentration respectively, the maximum growth rate can be calculated as:  
 𝐶𝐸𝑅 = 𝑞𝐶𝑂2 ∗ 𝑋(0) ∗ 𝑒
𝜇𝑚𝑎𝑥𝑡 (7) 
6.2.10.3 Production rate and substrate uptake rate 
Consider 𝑃𝑖, the amount of product formed in g/L at time 𝑖, 𝑆𝑖, the amount of substrate used in 
g/L at time 𝑖, 𝑉𝑖, the volume at time 𝑖 (L) and 𝑡, the time in h, then the production rate 𝑞𝑃 and the 
substrate uptake rate  𝑞𝑆 respectively are calculated as:  
 
𝑞𝑃 =
𝑑𝑃
𝑑𝑡
=
𝑃2 ∗ 𝑉2 − 𝑃1 ∗ 𝑉1
𝑡2 − 𝑡1
 
(9) 
 
𝑞𝑆 =
𝑑𝑆
𝑑𝑡
=
𝑆2 ∗ 𝑉2 − 𝑆1 ∗ 𝑉1
𝑡2 − 𝑡1
 
(10) 
The specific production rate 𝑞𝑃,𝑋 and the specific substrate uptake rate 𝑞𝑆,𝑋 are calculated by 
dividing 𝑞𝑃 and 𝑞𝑆 respectively through 𝑋𝑖, the amount of biomass in g at time 𝑖.  
 
𝑞𝑃,𝑋 =
1
𝑋
𝑑𝑃
𝑑𝑡
=
𝑃2 ∗ 𝑉2 − 𝑃1 ∗ 𝑉1
𝑡2 − 𝑡1
∗
1
1
2 ∗
(𝑋1 ∗ 𝑉1 + 𝑋2 ∗ 𝑉2)
 
(10) 
 
𝑞𝑆,𝑋 =
1
𝑋
𝑑𝑆
𝑑𝑡
=
𝑆2 ∗ 𝑉2 − 𝑆1 ∗ 𝑉1
𝑡2 − 𝑡1
∗  
1
1
2 ∗
(𝑋1 ∗ 𝑉1 + 𝑋2 ∗ 𝑉2)
 
(11) 
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The volumetric production rate 𝑟𝑃 and the volumetric substrate uptake rate 𝑟𝑆 are calculated by 
dividing 𝑞𝑃 and 𝑞𝑆 respectively through 𝑉𝑖, the volume of the reactor at time 𝑖.  
 
𝑟𝑃 =
1
𝑉
𝑑𝑃
𝑑𝑡
=
𝑃2 ∗ 𝑉2 − 𝑃1 ∗ 𝑉1
𝑡2 − 𝑡1
∗
1
1
2 ∗
(𝑉1 + 𝑉2)
 
(12) 
 
𝑟𝑆 =
1
𝑉
𝑑𝑆
𝑑𝑡
=
𝑆2 ∗ 𝑉2 − 𝑆1 ∗ 𝑉1
𝑡2 − 𝑡1
∗
1
1
2 ∗
(𝑉1 + 𝑉2)
  
(13) 
6.2.10.4 Yield 
Consider 𝑃, the amount of product formed in mol/L and 𝑆, the amount of substrate used in 
mol/L, then the product yield 𝑌𝑃,𝑆 is calculated as: 
 
𝑌𝑃,𝑆 =
𝑃
𝑆
 
(14) 
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6.3 Results and discussion 
6.3.1 Background engineering 
In order to synthesize fucosyllacto-N-neotetraose III (FLNT III), the glycominimised strain 
sNS4.29 (See Chapter 4) must be further engineered. Also a wildtype K-12 MG1655 sNS3.01 
is engineered in parallel to compare the production profile of both backgrounds in function of 
side-product formation. Construction of these production strains focuses on three parts: 
1. Enhancing the availability of the activated donor sugars UDP-GlcNAc, UDP-galactose 
and GDP-fucose; 
2. Eliminating lactose degradation while maintaining lactose import; 
3. Introducing the pathway genes towards FLNT III. 
6.3.1.1 Overview of activated sugar synthesis from glycerol 
An overview of the pathway is given in Figure 6-2 starting from the carbon-source glycerol, an 
inexpensive by-product of the biodiesel production. Glycerol is dissimilated aerobically via glpK, 
which phosphorylated glycerol to glycerol-3-P (Gly-3-P) at the expense of ATP and glpD, which 
converts Gly-3-P into dihydroxyacetone (DHAP) using oxygen as the electron acceptor (246). 
DHAP together with its isomer glyceraldehyde-3-phosphate is converted by the fructose-
bisphosphate aldolase encoded by fbaAB, into fructose-1,6-bisphosphate entering the 
gluconeogenesis. Subsequently, fructose-1,6-bisphosphate is dephosphatated to yield fructose-
6-phosphate, an important intermediate for the synthesis of the necessary activated sugars.  
For the synthesis of UDP-GlcNAc, the first donor sugar being attached to lactose, fructose-6-P 
is first aminated to glucosamine-6-P, provided by L-glutamine. After conversion to glucosamine-
1-P, a bifunctional enzyme GlmU comes in play. GlmU contains two domains carrying out each 
reaction independently. The first reaction is the transfer of an acetyl group from acetyl-CoA to 
form GlcNAc-1-phosphate and the second is the transfer of an uridyl group to form the final 
product UDP-GlcNAc.  
UDP-galactose on the other hand is formed by an epimerization from UDP-glucose encoded by 
galE. The latter is also derived from fructose-6-phosphate with similar reaction steps as UDP-
GlcNAc. First fructose-6-P is isomerized to glucose-6-P and then converted to glucose-1-P, 
after which an uridylyltransferase finally creates UDP-glucose. Lastly, fructose-6-phosphate can 
also be isomerized to mannose-6-phosphate which is then metabolized to GDP-fucose over 
GDP-mannose by cpsBG, gmd and fcl.  
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Figure 6-2: Overview of the pathway towards fucosyllacto-N-neotetraose III from glycerol and lactose. The 
represented genes encode for: glpK, glycerol kinase; glpD, glycerol-3-P dehydrogenase; fbaAB, fructose-
bisphosphate aldolase; yggF, ybhA, glpX, fbp, fructose-1.6-bisphosphatase; glmS, L-glutamine-D-fructose-
6-P aminotransferase; nagB, glucosamine-6-P deaminase; glmM, phosphoglucosamine mutase; glum, 
GlcNAc-1-P uridyltransferase and glucosamine-1-P acetyltransferase; pgi, glucose-6-P isomerase; pgm, 
phosphoglucomutase; galU, UTP-glucose-1-P uridylyltransferase; gale, UDP-glucose epimerase; galT, 
galactose-1-P uridylyltransferase; ushA, UDP-sugar hydrolase; manA, mannose-6-P isomerase; cpsG, 
phosphomannomutase; cpsB, mannose-1-P guanylyltransferase; gmd, GDP-mannose 4,6-dehydratase; 
fcl, GDP-L-fucose synthase; lacZ, 𝛽-galactosidase; lacY, lactose permease; lgtA, 𝛽1,3-N-
acetylglucosaminyltransferase; lgtB, 𝛽1,4-galactosyltransferase; FT, a fucosyltransferase.  
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6.3.1.2 Enhancing the availability of the activated donor sugars 
In order to increase the pool of UDP-GlcNAc and UDP-galactose, three deletions were made in 
both backgrounds using SIRE (86) as described in Chapter 2. nagB is deleted to increase the 
UDP-GlcNAc pool (247) by eliminating the reconversion of glucosamine-6-P back to fructose-6-
P in a futile cycle with glmS. To improve UDP-galactose availability the reversible reaction from 
glucose-1-P and UDP-glucose to UDP-galactose and galactose-1-P coded by galT is also 
deleted (248). Finally, ushA is knocked out, which is known to hydrolyze UDP-glucose, the 
precursor of UDP-galactose (249, 250). UshA has promiscuous hydrolase activity towards other 
UDP-sugars as well and deletion thereof thus results in a general augmentation of the UDP-
sugar pool (251). Deletion of ushA has also another purpose as it also has a nucleotidase 
activity and it was found that its elimination improves NAD stability and cell growth (252).  
To increase the flux towards GDP-fucose and because the complete operon wcaAM including 
the genes cpsBG, gmd and fcl are deleted in the GM background, a synthetic operon consisting 
of those four genes was created and incorporated using SIRE (86) (See Chapter 2) on the 
intergenic region sibB_sibE (See Chapter 3), which is a high expression locus. The synthetic 
operon is driven by the strong constitutive P14 promoter (26) and has the natural two by two 
conformation of cpsBG and gmd/fcl, separated by a synthetic RBS designed with the Salis RBS 
calculator (200) to mimic the natural RBS strength.  
These activated sugars are also essential precursors of many cell wall components. UDP-
GlcNAc is used in the synthesis of peptidoglycan, lipopolysaccharides and the enterobacterial 
common antigen (ECA), while UDP-Gal and GDP-Fuc are incorporated in colonic acid and the 
lipid A core oligosaccharides. These sinks however are all eliminated in the GM-background 
(See Chapter 4) and should thus increase the availability of these donor sugars. 
6.3.1.3 Lactose import and pathway genes implementation 
For the activated donor sugars to be transferred to the substrate lactose, catabolism of lactose 
must be eliminated while maintaining the natural lactose import. Using the classical technique of 
homologous recombination according to Datsenko & Wanner (2000) (54), the complete operon 
lacZYA is first removed after which lacY under a constitutive promoter P22 (26) is reintroduced 
on the same locus.  
Finally, the codon harmonized versions of the glycosyltransferases lgtA and lgtB from 
N. meningitidis (240) are introduced using SIRE (86) (See Chapter 2). They code respectively 
for a 𝛽1,3-N-acetylglucosaminyltransferase adding GlcNAc to lactose, giving lacto-N-triose 
(LN3) and a 𝛽1,4-galactosyltransferase adding a galactose, giving lacto-N-neotetraose (LNnT). 
In order to create an expression cascade so that LN3 is readily converted into LNnT, a medium 
strength UTR is used to drive the expression of lgtA, while a strong UTR precedes lgtB. In 
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addition, lgtB is introduced on the intergenic locus atpI_gidB, which is a high expression location 
(See Chapter 3). lgtA on the other hand replaces adhE, which is located near the terminus 
being a lower expression region (See Chapter 3). The consequential deletion of the alcohol 
dehydrogenase has the additional benefit of producing less ethanol as a side-product (253). 
6.3.2 3-fucosyltransferase selection 
The last step of the pathway is the introduction of an 𝛼1,3-fucosyltransferase capable of adding 
an L-fucose to the GlcNAc of LNnT to yield FLNT III. To ensure production of the desired 
molecule four genes of different organisms were selected, which had proven activities on 
LacNAc (type II) to form the Lewis X antigen (𝛽-Gal-(1-4)-[𝛼-Fuc-(1,3)]-𝛽-GlcNAc). Two 3-
fucosyltransferases were chosen from Helicobacter pylori resp. NCTC 11639 and UA 948. Two 
others originate from Bacteroides fragilis NCTC 9343 and Helicobacter hepaticus ATCC 51449. 
The latter two in contrast to the H. pylori transferases are much shorter (See Table 6-2) and 
don’t have any heptamere repeats, which is essential for the enzyme’s activity of Hp’s 
fucosyltransferases (254). In Table 6-2 also the KM values are displayed for GDP-fucose 
indicating a 50-fold lower value for H. pylori’s fucosyltransferases in contrast to the others. 
Interestingly, the 3FT from H. hepaticus was also found not only to fucosylate LacNAc but also 
its sialylated variant, while the 3FT from H. pylori UA948 has activity towards type I 
(lacto-N-biose) as well as type II, albeit at 20-fold lower affinity.  
Table 6-2: List of the 3-fucosyltransferases chosen and their properties. 
Species Abbrev. Repeats Length (aa) KM (µM-1) Ref. 
Helicobacter pylori NCTC11639 Hp11639 10 478 44.7 (254) 
Bacteroides fragilis NCTC9343 Bf9343 None 331 1120 (3) 
Helicobacter hepaticus ATCC51449 Hh51449 None 320 2400 (243) 
Helicobacter pylori UA948 Hp948 8 467 56 (242) 
 
All genes were codon harmonized, except Hp11639 which was already available in the lab 
codon optimized. Using Golden-Gate assembly, each gene was preceded by a strong RBS and 
medium strength promoter to drive expression of the 3FTs on a medium copy plasmid. These 
production plasmids were then transformed in the engineered backgrounds of the GM- and WT 
strain (See 6.3.1).  
Subsequently, a small growth experiment was set up with no replicates to quickly screen these 
enzymes for their capability of producing FLNT III. In Figure 6-3 (left), the LC-MS result of the 
growth trial is displayed. The FLNT III concentration is determined according to an internal 
standard verbascose (a pentasaccharide consisting of 3 Gal, 1 Gluc and 1 Fruc residue) and 
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normalized for OD600. From the figure it is clear that each gene is capable of producing 
FLNT III in both backgrounds. Yet there are differences between the genes tested. The 3FT 
from B. fragilis for example has the lowest production in both backgrounds, while the 3FT from 
H. hepaticus has the highest. The production by H. pylori’s fucosyltransferases fall in-between.  
 
Figure 6-3: (Left) The production of FLNT III normalized over OD600 is displayed in function of the four 3-
fucosyltransferases used. The dark shaded blue represents the WT background, while the lighter variant 
represents the GM background. (Right) Here the peak area is displayed in function of the four 3FTs for the 
LNDFH side-product at m/z 998.36.  
From this experiment it is however not possible to choose the optimal candidate to continue 
with. In fact, only one expression level was tested, which may be optimal for one enzyme, but 
suboptimal for another. Also for the 3FTs of H. pylori, the full length enzymes were evaluated 
which includes the C-terminal amphipathic 𝛼-helices, and according to Ma et al. (2006) (254) 
had the highest specific enzyme activity, but a lower solubility and lower expression in their 
E. coli strains. Truncation of H. pylori’s 3FTs could therefore optimize production. Nevertheless, 
while screening the LC-MS data for the mass of lacto-N-difucohexaose (LNDFH) (m/z = 
998.36), a difucosylated LNnT molecule to which two fucose molecules were added, an 
interesting result was obtained. LNDFH was found in all strains, except for those harboring the 
3FT of H. hepaticus. This means that the other 3FTs have a promiscuous activity towards 
FLNT III. The most probable isomer formed is lacto-N-neodifucohexaose as depicted in Figure 
6-4 which has an extra fucose molecule on the glucose residue 𝛼1,3 bound, resembling 3’-
fucosyllactose. Other isomers with the type I backbone are impossible as only LNnT (type II) is 
formed. The only other available 3’-position is on the free galactose residue. However, no such 
molecules are found in mother’s milk and in the in vivo studies using LacNAc as a substrate, 
only Lex conformations were found. If lacto-N-neodifucohexaose was formed, one could suspect 
the formation of 3-fucosyllactose (3FL) as well. However, after screening for its mass (m/z = 
487.17) no 3FL was found. This would suggest that the enzymes are promiscuous towards 
FLNT III and not to lactose, or that the activity towards FLNT III is much higher so that no 3FL 
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was detected. Another possibility is that the little amount of 3FL formed fell below the detection 
limit.  
Based on the finding that the 3FT from H. hepaticus does not overfucosylate the intended 
product, which eventually means productivity loss and because the screening experiment 
indicated the highest production, this enzyme was chosen as the 3FT in the production strains.  
 
Figure 6-4: Schematic representation of lacto-N-neotetraose (LNnT), fucosyllacto-N-neotetraose III which 
is also known as lacto-N-fucopentaose III and lacto-N-neodifucohexaose (LNnDFH).  
6.3.3 3-fucosyltransferase expression optimization 
In 6.3.2 the 3-fucosyltransferase from H. hepaticus was selected to synthesize FLNT III in the 
WT- and GM-background. Because only one expression level was tested, new constructs were 
made to create an expression landscape with three promoters and three RBSs with variable 
strengths of Hh51449. This should allow to determine the expression hot spot before evaluation 
on a bio-reactor scale.  
In Figure 6-5 the result of the growth trial for both backgrounds for each promoter-RBS 
combination is shown. All WT-strains show production of FLNT III in contrast to the GM 
background, despite the use of the same production plasmid. Unexpectedly, the general 
production of the GM background is lower than the WT’s which contrasts with the preliminary 
screening in 6.3.2, where this effect was vice versa.   
When looking into more detail one can see a decreasing trend of FLNT III concentration with an 
increasing promoter strength for the weak RBS. For the GM background on the other hand only 
little production was noticed which is depicted for clarity but their signal was in fact too low for 
proper quantification. Looking at the strong RBS, the relation for the WT strains is the other way 
around. Here an increasing production is noticed when increasing the promoter strength. For 
the GM background on the other hand, the maximal production is noticed for the medium 
strength promoter. Increasing expression strength did not lead to more FLNT III. Moreover, no 
production was seen when lowering the expression strength.  
The results of the medium RBS strength are somewhat confusing. For the GM background no 
FLNT III at all was seen, while for the weak RBS there was already basal production. Also, for 
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the WT background little production is noticed for the weak and medium strength promoter, 
while relatively high concentration of FLNT III was seen for the other RBSs. The only well 
producing strain with a medium strength RBS is with a strong promoter in the WT background. 
When looking only at the strong promoter, an increasing trend is seen for the WT background 
when increasing the RBS strength.  
 
Figure 6-5: Expression landscape of the Hh51449 3-fucosyltransferase with 9 different promoter-RBS 
strength combinations. The dark blue bars represent the WT background, while the light blue bars 
represent the GM-background. Error bars are standard deviations of three replicates.  
Neglecting the results of the medium strength RBS, which appear to be inconsistent, it is clear 
that for the GM background the strong RBS is favoured over a weak RBS and that the 
production is maximized with a medium strength promoter. For the WT background, the best 
producers are either with a weak promoter and weak RBS or a stronger promoter with a strong 
RBS. Interestingly, the hot spot for expression of the 3FT differs for both backgrounds, although 
the same pathway genes and expression levels are maintained for the precursor LNnT. The 
only difference between both strains is the background as described in Chapter 4 in which all 
nonessential glycosyltransferases are eliminated. It should be noted that the WT background 
still harbours the original GDP-fucose operon, although the effect of this extra copy should be 
negligible as an optimized variant of this operon under a strong constitutive promoter is also 
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present. Nonetheless, the general pool of activated sugars should be higher in the GM 
background as all sinks towards unnecessary cell wall components are eliminated, yet this 
effect is not seen. Maybe the slower growth rate of the GM background (See section 4.3.2) may 
influence production. However, the measured end-point optical densities for the different strains 
are more or less the same. In fact the metabolism of both backgrounds should be compared to 
determine the difference in activated sugar pools and RNA-seq data could identify the 
differences in expression levels. It could for instance be possible that the used promoter-RBS 
combinations act differently in both backgrounds. Another possibility is that the plasmid copy 
number is influenced and not consistent over the different expression levels, explaining the 
inconsistencies. Though these experiments would explain the observed effects, they are out of 
scope of this Chapter.  
Finally, the medium strength promoter and strong RBS were chosen, which coincidently are the 
same used in Section 6.3.2, to continue the bio-reactor experiments with. The same 
combination is chosen for both background for the sake of comparison. This combination gives 
the highest production for the GM background and a fairly high production in the WT strain.  
6.3.4 Production of FLNT III on bioreactor scale 
To determine the differences in side-product formation in the production of the complex 
oligosaccharide FLNT III, both backgrounds were fermented on a 5L bioreactor scale in fed-
batch mode. The measured concentration of the final product as well as the intermediates LN3 
and LNnT and the optical density are displayed in Figure 6-6 while the OUR/CER profile is 
given in Figure 6-7. Productivities are summarized in Table 6-3. Fed batch conditions were 
started after approximately 30 h and the feed rate was kept constant, hence the OD600 plateau 
near the end of fermentation. Interestingly, in contrast to the wildtype and despite the same 
medium composition and fermenting conditions, the glycominimised background grew to a 
much higher OD. However, the increased amount of biomass did not result in increased titers 
and final concentrations are comparable as about 1 g/L FLNT III was produced in both 
backgrounds. Due to the higher biomass concentration near the end of the batch phase, the 
volumetric feed rate of the fed batch was higher for the GM background resulting in higher 
volumetric productivities, but lower specific productivities and the result is thus somehow 
biased. Why the glycominimised background grew to a higher OD600 remains unclear. Also 
differences in organic acids production are small (Figure 6-7) and do not explain the affected 
OD. Maybe the higher biomass concentration is due to the loss of all nonessential 
glycosyltransferases which code for many lipo- and polysaccharides and more energy is 
available to spend on biomass. The aimed result of higher production as the sinks of the 
activated donor sugars towards these cell wall products are eliminated, was also not achieved 
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which is in accordance with Section 6.3.3 and a better biomass/HMO-production equilibrium 
should be found. 
 
Figure 6-6: Production profile of LN3, LNnT and FLNT III (left axis) of both the wildtype and glycominimised 
background. The optical density is displayed on the right axis.  
Table 6-3: Summary of the growth rate, feeding rate, volumetric and specific productivities and yield of the 
fermentations displayed in Figure 6-6 
 µmax FB rate r,LN3 r,LNnT r,FLNT III q,LN3,X q,LNnT,X q,FLNTIII,X RQ YCO
2
,gly YFLNT III,gly 
 h-1 g/g/h mg/L/h mg/L/h mg/L/h mg/g/h mg/g/h mg/g/h mol/mol mol/mol mol/mol 
WT 0.222 0.22 23.12 75.27 9.93 1.21 3.95 0.52 1.253 2.395 1.49*10-5 
GM 0.232 0.17 38.32 88.78 9.44 1.48 3.43 0.36 1.314 2.495 1.20*10-5 
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Figure 6-7: Left: the OUR/CER profile of both backgrounds. Right: the succinate and acetate 
concentrations together with the OD600 displayed in function of time.  
Looking at LNnT and LN3 production, the ratio between both is constant around 3 for the WT 
background, while the same ratio keeps on rising from 1.2 to 3 in the GM background. Question 
remains here if the fermentation could have been prolonged if this ratio was maxed out or would 
still be rising. Nevertheless, during fed batch condition each mol of LN3 that was produced, was 
readily converted in LNnT for both backgrounds. It should be clear that the bottleneck of the 
pathway lies in the last step i.e. the conversion from LNnT into FLNT III. If all LN3 and LNnT 
would have been converted into FLNT III then 18 g/L would have been produced. It could be 
that the expression of the 3FT is sub-optimal and the expression landscape in 6.3.3 should be 
extended to find a better sweet spot, certainly for the GM-background were the hot spot seems 
narrow. On the other hand, redoing this experiment using a plasmid with a higher copy number 
could also suggest if the strains suffer from an expression problem or not.  
Another possibility is that the flux towards GDP-fucose is not high enough to convert all LNnT to 
FLNT III despite the overexpression of the GDP-fucose synthesis operon and the deletion of 
wcaJ as part of the wcaAM knock-out in the glycominimised strain. The latter gene is 
responsible for the addition of L-fucose moieties to colonic acid. Another way to enhance the 
GDP-fucose pool is to increase the level of NADPH which is a necessary cofactor in the last 
step towards GDP-fucose. Assuming the flux is high enough, then the transferase itself might 
not be able to handle the substrates fast enough. Indeed, in comparison with transferases from 
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Helicobacter pylori, the KM-value of the chosen 3FT is rather high. Redoing this fermentation 
with the other 3FTs would help to further elucidate the problem.  
As the goal of this chapter is not to maximize production and as optimization strategies will 
probably be background dependent, we will not further focus hereon. Instead as both 
backgrounds produced about 1 g/L FLNT III, the next paragraph will deal with the differences in 
side-product formation.  
6.3.5 Evaluation of side product formation 
After fermentation, the last fed-batch samples were analyzed using LC-MS to detect potential 
side-products. In Figure 6-8 both chromatograms for the WT- and GM-background are overlaid 
and in Table 6-4 a summary is given of the annotated peaks with their respective retention 
times and m/z-values. From the chromatogram the product, FLNT III (4), the intermediates LN3 
(2) and LNnT (3) and the substrate lactose (1) are clearly seen. Besides these, also other peaks 
occur. Strikingly, the chromatograms of both backgrounds are nearly the same and the side-
products are present in both strains. This means that they are the result of the heterologous 
pathway or originating from the essential endogenous glycosyltransferases. Side products due 
to the eliminated nonessential glycosyltransferases are thus not detected. Probably, the titer of 
the fermentation giving 1 g/L of the pentasaccharide FLNT III is too low to see detectable 
differences in both backgrounds. If for instance the side reactions of these transferases would 
convert only 0.1% of the product, then the total amount of side-product formed would be only 1 
mg/L, which is undetectable with the applied LC-MS.  
Nevertheless, six major peaks are found in the chromatogram which represent by-products 
most likely formed by the inserted heterologous pathway. First, the byproduct 
lacto-N-neodifucohexaose (F) is seen at retention time 22.6 min. This is in contrast with the 
earlier DWP-experiment were no LNnDFH was found with the 3FT of H. hepaticus (See 6.3.2). 
Probably, the side-activity causing LNnDFH is indeed much lower for this transferase, and with 
the small amounts of FLNT III produced in the DWP, LNnDFH was not detected. With the 
elevated titers of the fermentation on the other hand, LNnDFH will have risen above the 
detection limit.  
Peaks A and B have an m/z value of 503.2 corresponding with the mass of a trisaccharide of 
glucose/galactose isomers. Possibly, one of these peaks represent 4’-galactosyllactose in which 
an extra galactose molecule was added to lactose. Perhaps LgtB has a side activity toward the 
galactose residue of lactose causing not only LNnT but also 4’-galactosyllactose. Moreover, 
peak D with an m/z value of 665.2, suggests that the former compound is galactosylated once 
more as this mass corresponds with the mass of a tetrasaccharide of galactose/glucose 
isomers. In this respect peak E is also interesting as it has an m/Z value of 868.3 which 
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corresponds with the mass of a pentassachride composed of LNnT and a galactose isomer. It is 
possible that LgtB also galactosylates the galactose residue of LNnT giving this 
pentasaccharide. Another possibility is that LgtB does glycosylate a GlcNAc residue not from 
LNnT but from a GlcNAc-(1-,3)-Gal-(1,4)-Gal-(1,4)-Gluc, which gives a mass similar to LNnT 
being 706.2 and might explain peak C.  
 
Figure 6-8: Overlay of the chromatogram of the last sample of the fed-batch fermentation of the WT-
background (orange) and the GM-background (blue). Numbered peaks represent the substrate, 
intermediates and the final product while the letters represent side products.  
Table 6-4: Summary of the annotated peaks in Figure 6-8. The given molecules in italic are suggestions 
while the others are verified.  
Annotation Retention (min) m/z Molecule 
1 2.6 341.1 Lactose 
2 4.1 544.2 Lacto-N-triose 
3 7.7 706.2 Lacto-N-neotetraose 
4 13.2 852.3 Fucosyllacto-N-neotetraose III 
A 5.0 503.2 Gal-(1,4)-Lactose 
B 5.6 503.2 Gal-(1,4)-Lactose 
C 6.5 706.2 GlcNAc-(1-,3)-Gal-(1,4)-Lactose 
D 9.5 665.2 Gal-(1,4)-Gal-(1,4)-Lactose 
E 17.0 868.3 Gal-(1,4)-LNnT 
F 22.6 998.4 Lacto-N-neodifucohexaose 
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6.4 Conclusion and future perspectives 
In Chapter 6, we succeeded in synthesizing FLNT III, a fucosylated lacto-N-neotetraose with 
interesting pharmacological applications against norovirus, by implementing a 
3-fucosyltransferase of Helicobacter hepaticus. We have introduced this heterologous pathway 
not only on a WT-background but also on the developed GM-background from Chapter 4. 
There, a new background was created in which all nonessential glycosyltransferases were 
removed that are responsible for the many lipo- and exopolysaccharides of Escherichia coli but 
are in fact not necessary. On the contrary, these structures resemble the structure of many 
HMOs, so that side-product formation due to the inherent metabolism could be a potential 
problem. To validate the created platform, both backgrounds were fermented on a 5L bio-
reactor scale and samples were compared on production metrics and on side-product 
formation.  
Surprisingly, little differences were found amid these fermentations and the obtained byproducts 
are present in both backgrounds so that they are most likely the result of the inserted 
heterologous pathway. Production titers are thus too low to see an actual difference between 
byproducts from the endogenous metabolism of these two strains. Before this platform strain 
can be properly validated, the production towards FLNT III must be optimized. As the chosen 
fucosyltransferases does synthesize a difucosylated LNnT on a bioreactor in contrast to the 
initial finding, optimized variants of the H. pylori 3FTs should be explored for higher production. 
In addition, the flux towards GDP-fucose should be evaluated and if necessary, increased.  
Overall, the foundation is laid for the production of more complex HMOs in Escherichia coli. As 
the structures of these second generation of HMOs, which have applications outside the infant 
formula, become more and more complex, side products will become an issue. Then, the 
glycominimised strain, which eliminated side products from the endogenous metabolism might 
become important. But until then, the created platform strain should be validated first using for 
example FLNT III yet at much higher titers.  
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7.1 Escherichia coli as a model organism 
Escherichia coli is a key player in biotechnology and over the last 60 years it has become the 
prime prokaryotic genetic model. Due to its fast growth characteristics, easy cultivation and 
manipulation, it is an ideal host in laboratory settings. It is therefore not surprising that E. coli is 
the cornerstone of many important findings in molecular biology and cell physiology. In more 
than a dozen Nobel prizes, E. coli was used for groundbreaking research. For example, in 
untangling DNA replication (1959 – Ochoa & Kornberg), in cracking the genetic code (1968 – 
Holley, Khorana & Nirenberg), in creating the first genetically engineered DNA (1980 – Berg, 
Gilber & Sanger) and in unraveling the mechanisms of DNA repair (2015 – Lindahl, Modrich & 
Sancar). Because of these extensive fundamental studies, a massive collection of qualitative 
and quantitative data are nowadays available including transcriptomics, proteomics, 
metabolomics and fluxomics datasets. These have resulted in ready-to-use, freely available 
online tools and repositories such as EcoCyc (30), joining genomic and biochemical information, 
Regulon (27), promoter and terminator libraries and BioBricks (255), providing standardized 
genetic parts.  
Thanks to these fundamental studies and its gained status of model organism, E. coli is being 
used worldwide. In addition, a vast amount of engineering tools have been developed 
concurrently, mutually reinforcing each other making E. coli an ideal host for metabolic 
engineering. This is also highlighted by its many synthesized bioproducts described in literature 
such as alcohols (ethanol, (iso-)propanol, (iso-)butanol), organic acids (lactic acid, succinic 
acid), amino acids (threonine, valine, tyrosine) and many others (87). To develop such potent 
strains and to harness all available information, the endogenous host genes are precisely 
manipulated and heterologous genes or whole pathways are introduced on plasmid-based 
expression vectors. The latter is convenient from a cloning perspective, but when creating 
industrially relevant hosts, plasmids are less preferred. They require antibiotics supplemented to 
the medium increasing fermentation cost and in addition, they suffer from structural and 
segregational instability (35, 36) leading to batch-to-batch variations. Chromosomal integration 
of the biosynthetic pathway alleviates the need for expression plasmids, but then two questions 
arise: (1) How do you efficiently incorporate the pathway onto the genome and (2) where do you 
incorporate it? 
Most genome editing techniques rely on homologous recombination provided by the Red 
system from bacteriophage 𝜆 for high efficiency engineering in contrast to the endogenous 
homologous recombination system (52). Yet using the classical techniques of selecting and 
counterselecting with antibiotic and/or auxotrophic markers, 𝜆-Red mediated homologous 
recombination still suffers from very low efficiencies for inserts exceeding 2.5 kb (38). 
Combinations with CRISPR which uses homologous recombination to escape a lethal double 
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stranded break increasing the overall efficiency tremendously, offers only limited solace. 
Insertion of 10 kb, which is amply sufficient for biosynthetic pathways, was reported but also at 
low (~25%) efficiency (39). Therefore in Chapter 2 we have developed a new technique, SIRE 
(serine integrase recombinational engineering) to overcome these shortcomings. Using the 
serine integrase PhiC31, a bacteriophage derived recombinase that recognizes small 
attachment sites (att), we were able to introduce a 10 kb pathway with 100% efficiency and 
without the need for selection markers. By using landing pad strains, which already contain a 
cassette flanked with orthogonal att sites that only recombine with its pair and not with each 
other, and a corresponding donor vector containing the pathway of interest flanked with the 
orthogonal pairs, the serine integrase switches the flanked sequences obtaining the knock-in.  
An additional advantage of serine integrases over CRISPR techniques is the limited chance of 
off-target effects notoriously attributed to mismatching of the gRNA/Cas9 complex (256). 
However off-targets are possible with serine integrases as they may recognize pseudo-att sites 
(79). These are sequence-similar sites that are also recognized by PhiC31. Yet the recognition 
sites are much larger (~ 50 nt) (257) than the 20 nt protospacer needed for Cas9 (24, 37), so 
that the chance of off-targeting is several orders of magnitude lower. Moreover, to date no 
pseudosites were found in Escherichia coli and potential sites can always be deleted to obtain a 
pseudosite-free strain in contrast to gRNA mismatching.  
Just like the Cas9 enzyme, the PhiC31 serine integrase was also proven to be active in multiple 
hosts like Saccharomyces and Drosophila (258, 259). The developed methodology thus has the 
potential to be applied in other hosts as well. However, our attempts to recreate the same 
knock-in system in S. cerevisiae stumbled upon toxicity problems, whereas knock-outs were 
successfully created (86). Future attempt should aim to better control the PhiC31 expression in 
order to obtain viable yeast colonies and to expand the toolbox towards other hosts. Despite its 
current limited portability, the SIRE system developed for E. coli is fast, reliable, precise, and 
easy-to-use. Moreover, when SIRE could be combined with a MoClo design (76) for 
constructing donor vectors, a rapid design-build-test cycle directly on the genome could be 
established. This skips the optimizations done on expression vectors of which the results may 
be biased and sub-optimal when the pathway eventually has to be moved onto the 
chromosome.  
An other interesting property to further develop is the possibility to create a multiplex tool 
analogous to multiplex CRISPR set-ups (25, 260). There are six orthogonal att sites discovered 
(60) that do not interfere which each other and would thus allow simultaneous and consecutive 
integration of up to four donor clusters or genes.  
An inherent disadvantage of the system is the use of a landing pad, a cassette already present 
on the genome to be switched with the gene(s) of interest. Yet this does not necessarily have to 
Chapter 7: General discussion and outlook 
143 
be a hassle if for example a library of landing pad strains would become available. When these 
landing pads are combined with well-chosen and well-characterized locations, the researcher 
does not have to worry about the second question: “Where on the genome do you want to 
incorporate your pathway?” as these landing pad locations would then be predetermined. 
Hence the goal of Chapter 3: creating a library of landing pad locations extensively studied 
towards gene expression, environmental sensitivity and metabolic burden.  
To do so we have selected intergenic regions devoid of any regulatory elements spread over 
the different macrodomains and non-structured regions of E. coli to avoid interference with the 
endogenous metabolism, so that they can be used for multiple applications. On these locations, 
we subsequently inserted using the SIRE method an insulated GFP cassette to minimize 
interaction of the surrounding genes. Using our location set we have confirmed the long 
established ‘gene dosage’ effect where the expression near the start of replication oriC is higher 
than near the terminus dif. However, our expression range only exhibited a 2.2 fold range 
whereas others found higher differences, possibly due to the use of our stringent selection 
criteria and our insulated cassette. The genomic position can thus be used for pathway fine-
tuning, but to a much lesser extent than for example with promoter libraries.  
To make this location library broadly applicable, these locations were also tested on different 
media and despite that the same expression ranges were found, the absolute output differed 
with more than 50% demonstrating the importance of medium optimization. In addition, 
metabolic burden and environmental sensitivity were also tested and found that some locations 
are more susceptible to changes than others. From all the locations tested, intergenic region 
djlA_yabB is highly influenced and suffers greatly from metabolic burden. This finding thus 
indicates the importance of a well-characterized library of locations and that the position to 
insert a biosynthetic pathway does matter substantially.  
At this point only one expression level of the reporter gene was evaluated. To conclude on the 
generality of the observations, it would be interesting to evaluate different transcription and 
translation expression levels as well together with for example different reporter genes. 
Nevertheless combining the current landing pad strain library together with the SIRE 
methodology, a convenient workflow has been established of testing heterologous constructs 
directly onto the genome on predetermined and well-characterized locations. In this way by 
eliminating biased plasmid-based optimizations, expression vectors and the use of interfering, 
sensitive locations, we hope to reduce variability and to accelerate the development of new 
biotechnological processes. Finally, the developed toolbox and the gained knowledge from the 
location study will surely contribute to a better understanding of Escherichia coli as a model 
organism.  
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7.2 Escherichia coli as a platform organism for HMO production 
In E. coli many glycosyltransferases are responsible for the synthesis of the extracellular 
polysaccharide matrix including, poly-N-acetylglucosamine (146), colanic acid (147) and the 
enterobacterial common antigen (148). Their structures resemble those of interesting glycans 
such as human milk oligosaccharides, which are commercially produced by E. coli, and these 
glycosyltransferases may thus interfere with the intended product, intermediates or the used 
substrate causing unwanted side-reactions. Luckily, these sugar molecules are dispensable for 
the cell and their coding regions can be readily deleted. Moreover, it was found that removing 
nonessential genomic sequences may entail several advantages (133, 134). Hence in 
Chapter 4, we created an E. coli strain devoid of all nonessential glycosyltransferases to serve 
as platform organism for the synthesis of complex glycans. After studying the strain, we found 
that despite its severely altered cell wall, its growth characteristics and osmotic and antibiotic 
sensitivity were comparable to its wildtype counterpart, rendering it suitable as a base strain. In 
Chapter 6, we subsequently validated this glycominimised background for byproduct formation 
by synthesizing a complex HMO, FLNT III. Unfortunately, no differences in byproduct formation 
were detected compared to a wildtype background. Probably, the titers in these sub-optimized 
production strains were too low to detect side-products from the endogenous metabolism. 
On the other hand, some glycosyltransferases are also responsible for the synthesis of the 
lipopolysaccharide outer leaflet of the outer cell membrane, which includes the O-antigen and 
core oligosaccharides (149) on a Kdo-lipidA anchor. The latter is an essential part of the cell 
wall and is known as endotoxin. As the name suggests, endotoxins are recognized by the 
mammalian innate immune system and may trigger a severe sceptic shock with fatal 
consequences for the host (42). In a high cell density biotechnological production process, 
these endotoxins can rise to alarming levels, and must be monitored and eventually be removed 
through downstream processing.  
Deleting the latter glycosyltransferases is daunting given their essential nature, but would 
improve the platform strain created in Chapter 4 tremendously in a way that almost all 
glycosyltransferases would be deleted and in extension, be relieved from endotoxins reducing 
overall production process costs. Fortunately, the essential nature of endotoxins in Gram-
negative bacteria has been challenged recently as isolates of Acinetobacter sp. and 
Neisseria sp. have been uncovered devoid of LPS structures (179, 182, 187). These species 
have uniquely found a way to survive lpx mutations, but their compensation mechanisms to 
allow their viability are poorly understood. Therefore, in Chapter 5, we have postulated two 
hypotheses based on these two species to transfer their compensation mechanisms to 
Escherichia coli. This allowed us to create a waaA mutant, which is otherwise an essential 
gene, making it unable to transfer Kdo. Consequently its outer leaflet consists of lipid IVa 
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constituents instead of Kdo-LipidA, which already gives a significant reduced endotoxin 
response. However, further knock-outs upstream and downstream to completely eliminate lipidA 
synthesis were unsuccessful.  
Also, one of the compensation mechanisms used to create the waaA mutant was the 
overexpression of pgaABCD, which codes for poly-N-acetyl-glucosamine and thus includes a 
glycosyltransferase. In light of the envisaged platform strain, this compensation mechanism is 
not preferred. To further elicit (other) compensation mechanisms enabling complete elimination 
of endotoxin in Escherichia coli, a better understanding of the mechanisms in the naturally 
occurring species devoid of endotoxin is necessary. Moreover as several species that are able 
to survive without LPS belong to the same family, one can wonder if there is somewhere a 
conserved mechanism to allow LPS-deficient strains rather than a host specific trait. Further 
research on this matter would hopefully result in finding common suppressor mutations so that 
they can be transferred to other hosts. 
The only glycosyltransferases not considered in previous sections are those responsible for 
peptidoglycan, a cross-linked polymer composed of N-acetylglucosamine and N-acetylmuramic 
acid molecules trapped between the inner and outer membrane of Gram-negative bacteria. Just 
like endotoxins, peptidoglycan is essential and blocking its synthesis usually causes cell-death. 
However under osmoprotective conditions, pleomorphic cell-wall deficient cells, called L-forms, 
are created and may proliferate (261–263). As these L-forms not only lack peptidoglycan but 
also endotoxins, these cells might be interesting to be used as a platform and expression 
systems for protein production were developed in the late 90s (264, 265). However from a 
process engineering point of view, L-forms are not interesting as they require a strict medium 
composition and are sensitive to environmental influences, making scale-up impossible. 
Therefore, peptidoglycan glycosyltransferases were untouched to preserve the robustness from 
E. coli’s Gram-negative state. 
Finally, if endotoxin production in Escherichia coli could be eliminated, then the compensation 
mutations can be easily integrated in the glycominimised strain from Chapter 4. In addition 
when this would be combined with modifications increasing the activated sugar pool towards 
UDP-galactose, UDP-GlcNAc, GDP-fucose and CMP-sialic acid while also optimizing lactose 
import, then a true platform strain for HMO production will be created. 
7.3 Escherichia coli as a production host for HMOs 
Human milk oligosaccharides are the sugars naturally present in mother’s milk. More than 200 
different structures have been identified and all contribute to a healthy microbiome and general 
well-being of the neonate. They serve as prebiotics, pathogen decoys, brain development 
stimulants and immune modulators amongst others. Their function has been evolutionary 
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optimized for millions of years and HMOs or mother’s milk in general are considered the gold 
standard for every child. However, not every mother is able to breastfeed her child and 
therefore supplementing infant formula with these interesting sugars is of utmost importance.  
The most promising way of producing these 
HMOs, which are structurally so diverse, is by 
microbial fermentation because the cell 
factories recycle the expensive activated 
sugars needed by the glycosyltransferases 
responsible for them. Microbial synthesis of 
HMOs was already demonstrated in the early 
00s, but only recently gathered its momentum 
(See also Figure 7-1). The most commonly 
used production host is Escherichia coli (89, 
237, 240, 266), but other hosts such as 
Saccharomyces cerevisae (233) and Corynebacterium glutamicum (267) are emerging. Yet the 
titer of 2’-fucosyllactose in E. coli, the most abundant HMO, reaching up to 200 g/L, is 
unchallenged (268). Today, 2’-fucosyllactose is available in infant formula through Nestlé Evolia 
and other simple human milk oligosaccharides like 3-fucosyllactose, lacto-N-triose, lacto-N-
(neo)tetraose and 6’- and 3’-sialyllactose will become available soon (269).  
Beside supplements in infant formula, HMOs also have pharmacological applications and are 
promising candidates for the development of new vaccines. In this respect the pentasaccharide 
fucosyllacto-N-neotetraose III (FLNT III) is of particular interest as it was found to specifically 
work against norovirus, to which to date no vaccine is available. HMO-conjugated vaccines also 
have the benefit that HMOs often harbour multiple virus recognition sites and that viral 
resistance is unlikely since mutations to avoid HMO binding, will also result in low affinities to 
receptors on the target cells (224). 
Therefore in Chapter 6, we inserted the genes lgtA and lgtB from Neisseria meningitidis using 
the techniques developed in Chapter 2 and 3 on the chromosome of the base strain created in 
Chapter 4, to synthesize lacto-N-neotetraose. After screening for a suitable fucosyltransferase, 
we managed to produce FLNT III using a 3-FT from Helicobacter hepaticus. Finally, on a 
bioreactor scale a titer of 1 g/L and a productivity of 10 mg/L/h was obtained demonstrating the 
synthesis of complex HMOs.  
From the bioreactor it was clear that the main bottleneck lies in the conversion of LNnT to 
FLNT III. Either the flux towards GDP-fucose or the fucosyltransferases expression level were 
Figure 7-1: Number of journal articles and patent 
family applications per year containing “human milk 
oligosaccharide(s)” in any search field. Data 
obtained from lens.org.  
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too low or the enzyme’s activity was insufficient. Screening and/or optimizing other orthologues 
for a better conversion rate may increase production significantly. Then the challenge remains 
to balance the pathway in such a way that production of FLNT III is maximized and the 
concentration of intermediates LN3 and LNnT is minimized.  
As the simple, ‘first generation’ HMOs are gradually released on the market, the more complex 
HMOs will surely follow. From the food industry perspective, one can wonder if it is necessary to 
produce additional HMOs than the ones targeted now. The more HMOs supplemented to the 
infant formula, the more it will cost to produce it and to validate the mixtures in clinical trials. 
Moreover when both the fucosylated and unfucosylated neutral HMOs as well as the acidic 
sialylated HMOs are already covered, adding additional HMOs will probably lower the 
health benefit-to-cost ratio. Nevertheless being able to produce complex HMOs such as 
polyfucosylated, polysialylated and branched HMOs is interesting from a pharmacological 
perspective, as stated above. Overall, HMOs are booming business with their full potential yet 
to be exploited and until a better producing host is created, Escherichia coli will be the preferred 
production host.  
7.4 General conclusion 
With the expanding fields of synthetic biology, bioinformatics and industrial biotechnology, 
transition towards a sustainable bio-economy is almost within our grasp. As shown by the 
previous chapters, Escherichia coli, plays a central and essential part as a model organism and 
as a production host to attain this green deal. Every topic covered in this doctoral research, from 
eliminating interfering glycosylation reactions and endotoxin formation as bypassing the need 
for plasmids in strain development and the characterization of interesting chromosomal loci; all 
fit in an integrated process design strategy to accelerate the scale-up of new biotechnological 
production processes with the focus on human milk oligosaccharides.  
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A.1 Appendix Chapter 2 
Supplementary Table A.1-1: Comparison of different genome editing techniques. 1According to Datsenko 
& Wanner (2000); 2According to Li et al. (2015). 
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Supplementary Table A.1-2: Strains used in Chapter 2. 
sNS2.01 E. coli K-12 MG1655 ΔendA ΔrecA (DE3) 
sNS2.02 sNS2.01 mntH::LP2 
sNS2.03 sNS2.01 yahK_yahL::LP1 
sNS2.04 sNS2.01 dadX_cvrA::LP1 
sNS2.05 sNS2.01 yffL_yffM::LP1 
sNS2.06 sNS2.01 sibD_siBE::LP1 
sNS2.07 sNS2.01 yjhV_fecE::LP1 
sNS2.08 sNS2.01 yahK_yahL::LP2 
sNS2.09 sNS2.01 dadX_cvrA::LP2 
sNS2.10 sNS2.01 yffL_yffM::LP2 
sNS2.11 sNS2.01 sibD_siBE::LP2 
sNS2.12 sNS2.01 yjhV_fecE::LP2 
sNS2.13 sNS2.01 dadX_cvrA::LP3 yffL_yffM::LP2 
sNS2.14 sNS2.01 dadX_cvrA::LP3 sibD_siBE::LP2 
sNS2.15 sNS2.01 yffL_yffM::LP2 sibD_siBE::LP4 
sNS2.16 sNS2.01 dadX_cvrA::LP3 yffL_yffM::LP2 sibD_siBE::LP4 
 
Supplementary Table A.1-3: Plasmids created in Chapter 2.  
pDonor1 pColA-attPCC-proD-Dasher-bla-attPTT 
pDonor2 pColA-attPCC-bla-attPTT 
pDonor3 pColA-attPCC-lacI-vioAB-bla-attPTT 
pDonor4 pColA-attPCC-lacI-vioABE-bla-attPTT 
pDonor5 pColA-attPCC-lacI-vioABEC-bla-attPTT 
pDonor6 pColA-attPCC-lacI-vioABECD-attPTT 
pDonor7 pSC101-repA-attPCC-proD-Dasher-amp-attPTT 
pInt1 pSC101-repA-lacI-pLac-PhiC31 
pLP1 pJET-attBTT-chlR-attPTT 
pLP2 pJET-attBCC-chlR-attBTT 
pLP3 pJET-attBCC-gentamicin-attBTT 
pLP4 pJET-attBCC-tetracyclin-attBTT 
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Supplementary Table A.1-4: Annotated nucleotide sequence of pDonor1. Sequence of Dasher is not 
disclosed to comply with the terms and conditions of ATUM. 
Plasmid pDonor1 4297 bp DNA circular  
Features Qualifiers Location 
Misc. feature attPCC 21..70 
Promoter proD 91..234 
Coding Sequence Dasher 276..986 
Terminator rnpB_T1 991..1072 
Coding Sequence bla complement(1146..2006) 
Misc. feature attPCC 2188..2237 
Coding Sequence kanR complement(2530..3345) 
Origin of replication colA 3455..4090 
 
1 GACGGGCGCA AAGTATATTT GTAGTGCCCC AACTGGGGTA ACCTCCGAGT TCTCTCAGTT 
61 GGGGGCGTAG ATATTATTGT ACACCTACCG CACAGCTAAC ACCACGTCGT CCCTATCTGC 
121 TGCCCTAGGT CTATGAGTGG TTGCTGGATA ACTTTACGGG CATGCATAAG GCTCGTATAA 
181 TATATTCAGG GAGACCACAA CGGTTTCCCT CTACAAATAA TTTTGTTTAA CTTTGATCGC 
241 ATGGTTGCTA CTAGAGAAAG AGGAGAAATA CTAGAATG... 
983  ...TAAGCTG TCGGTCAGTT TCACCTGATT TACGTAAAAA 
1021 CCCGCTTCGG CGGGTTTTTG CTTTTGGAGG GGCAGAAAGA TGAATGACTG TCTACAAAGT 
1081 TATCAGCGGC GAAAGTATTC AATCTGTGCC AGTCTACATG AGACCGTGTA GGCTGGAGCT 
1141 GCTTCTTACC AATGCTTAAT CAGTGAGGCA CCTATCTCAG CGATCTGTCT ATTTCGTTCA 
1201 TCCATAGTTG CCTGACTCCC CGTCGTGTAG ATAACTACGA TACGGGAGGG CTTACCATCT 
1261 GGCCCCAGTG CTGCAATGAT ACCGCGAGAC CCACGCTCAC CGGCTCCAGA TTTATCAGCA 
1321 ATAAACCAGC CAGCCGGAAG GGCCGAGCGC AGAAGTGGTC CTGCAACTTT ATCCGCCTCC 
1381 ATCCAGTCTA TTAATTGTTG CCGGGAAGCT AGAGTAAGTA GTTCGCCAGT TAATAGTTTG 
1441 CGCAACGTTG TTGCCATTGC TACAGGCATC GTGGTGTCAC GCTCGTCGTT TGGTATGGCT 
1501 TCATTCAGCT CCGGTTCCCA ACGATCAAGG CGAGTTACAT GATCCCCCAT GTTGTGCAAA 
1561 AAAGCGGTTA GCTCCTTCGG TCCTCCGATC GTTGTCAGAA GTAAGTTGGC CGCAGTGTTA 
1621 TCACTCATGG TTATGGCAGC ACTGCATAAT TCTCTTACTG TCATGCCATC CGTAAGATGC 
1681 TTTTCTGTGA CTGGTGAGTA CTCAACCAAG TCATTCTGAG AATAGTGTAT GCGGCGACCG 
1741 AGTTGCTCTT GCCCGGCGTC AATACGGGAT AATACCGCGC CACATAGCAG AACTTTAAAA 
1801 GTGCTCATCA TTGGAAAACG TTCTTCGGGG CGAAAACTCT CAAGGATCTT ACCGCTGTTG 
1861 AGATCCAGTT CGATGTAACC CACTCGTGCA CCCAACTGAT CTTCAGCATC TTTTACTTTC 
1921 ACCAGCGTTT CTGGGTGAGC AAAAACAGGA AGGCAAAATG CCGCAAAAAA GGGAATAAGG 
1981 GCGACACGGA AATGTTGAAT ACTCATACTC TTCCTTTTTC AATATTATTG AAGCATTTAT 
2041 CAGGGTTATT GTCTCATGAG CGGATACATA TTTGAATGTA TTTAGAAAAA TAAACAAATA 
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2101 GGGGTTCCGC GCACATTTCC CCGAAAAGTG CCACCTGGGA ATAGGAACTA AGGAGGATAT 
2161 TCATATGGTC ACCAGCCAAC AATGTGCGTA GTGCCCCAAC TGGGGTAACC TTTGAGTTCT 
2221 CTCAGTTGGG GGCGTAGGGA TGGCGTTACA ACTTTCAATA ACCCCTTGGG GCCTCTAAAC 
2281 GGGTCTTGAG GGGTTTTTTG CTGAAACCTC AGGCATTTGA GAAGCACACG GTCACACTGC 
2341 TTCCGGTAGT CAATAAACCG GTAAACCAGC AATAGACATA AGCGGCTATT TAACGACCCT 
2401 GCCCTGAACC GACGACAAGC TGACGACCGG GTCTCCGCAA GTGGCACTTT TCGGGGAAAT 
2461 GTGCGCGGAA CCCCTATTTG TTTATTTTTC TAAATACATT CAAATATGTA TCCGCTCATG 
2521 AATTAATTCT TAGAAAAACT CATCGAGCAT CAAATGAAAC TGCAATTTAT TCATATCAGG 
2581 ATTATCAATA CCATATTTTT GAAAAAGCCG TTTCTGTAAT GAAGGAGAAA ACTCACCGAG 
2641 GCAGTTCCAT AGGATGGCAA GATCCTGGTA TCGGTCTGCG ATTCCGACTC GTCCAACATC 
2701 AATACAACCT ATTAATTTCC CCTCGTCAAA AATAAGGTTA TCAAGTGAGA AATCACCATG 
2761 AGTGACGACT GAATCCGGTG AGAATGGCAA AAGTTTATGC ATTTCTTTCC AGACTTGTTC 
2821 AACAGGCCAG CCATTACGCT CGTCATCAAA ATCACTCGCA TCAACCAAAC CGTTATTCAT 
2881 TCGTGATTGC GCCTGAGCGA GACGAAATAC GCGGTCGCTG TTAAAAGGAC AATTACAAAC 
2941 AGGAATCGAA TGCAACCGGC GCAGGAACAC TGCCAGCGCA TCAACAATAT TTTCACCTGA 
3001 ATCAGGATAT TCTTCTAATA CCTGGAATGC TGTTTTCCCG GGGATCGCAG TGGTGAGTAA 
3061 CCATGCATCA TCAGGAGTAC GGATAAAATG CTTGATGGTC GGAAGAGGCA TAAATTCCGT 
3121 CAGCCAGTTT AGTCTGACCA TCTCATCTGT AACATCATTG GCAACGCTAC CTTTGCCATG 
3181 TTTCAGAAAC AACTCTGGCG CATCGGGCTT CCCATACAAT CGATAGATTG TCGCACCTGA 
3241 TTGCCCGACA TTATCGCGAG CCCATTTATA CCCATATAAA TCAGCATCCA TGTTGGAATT 
3301 TAATCGCGGC CTAGAGCAAG ACGTTTCCCG TTGAATATGG CTCATACTCT TCCTTTTTCA 
3361 ATATTATTGA AGCATTTATC AGGGTTATTG TCTCATGAGC GGATACATAT TTGAATGTAT 
3421 TTAGAAAAAT AAACAAATAG GCATGCTAGC GCAGAAACGT CCTAGAAGAT GCCAGGAGGA 
3481 TACTTAGCAG AGAGACAATA AGGCCGGAGC GAAGCCGTTT TTCCATAGGC TCCGCCCCCC 
3541 TGACGAACAT CACGAAATCT GACGCTCAAA TCAGTGGTGG CGAAACCCGA CAGGACTATA 
3601 AAGATACCAG GCGTTTCCCC CTGATGGCTC CCTCTTGCGC TCTCCTGTTC CCGTCCTGCG 
3661 GCGTCCGTGT TGTGGTGGAG GCTTTACCCA AATCACCACG TCCCGTTCCG TGTAGACAGT 
3721 TCGCTCCAAG CTGGGCTGTG TGCAAGAACC CCCCGTTCAG CCCGACTGCT GCGCCTTATC 
3781 CGGTAACTAT CATCTTGAGT CCAACCCGGA AAGACACGAC AAAACGCCAC TGGCAGCAGC 
3841 CATTGGTAAC TGAGAATTAG TGGATTTAGA TATCGAGAGT CTTGAAGTGG TGGCCTAACA 
3901 GAGGCTACAC TGAAAGGACA GTATTTGGTA TCTGCGCTCC ACTAAAGCCA GTTACCAGGT 
3961 TAAGCAGTTC CCCAACTGAC TTAACCTTCG ATCAAACCGC CTCCCCAGGC GGTTTTTTCG 
4021 TTTACAGAGC AGGAGATTAC GACGATCGTA AAAGGATCTC AAGAAGATCC TTTACGGATT 
4081 CCCGACACCA TCACTCTAGA TTTCAGTGCA ATTTATCTCT TCAAATGTAG CACCTGAAGT 
4141 CAGCCCCATA CGATATAAGT TGTAATTCTC ATGTTAGTCA TGCCCCGCGC CCACCGGAAG 
4201 GAGCTGACTG GGTTGAAGGC TCTCAAGGGC ATCGGTCGAG ATCCCGGTGC CTAATGAGTG 
4261 AGCTAACTTA CATTAATTGC GTTGCGCACA CCGACTA 
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Supplementary Table A.1-5: Annotated nucleotide sequence of pLP2. 
Plasmid pLP2 4026 bp DNA circular  
Features Qualifiers Location 
Misc. feature ‘Eco47IR complement(16..371) 
Misc. feature attBCC 392..444 
Coding Sequence chlR complement(488..1128) 
Misc. feature attBTT 1351..1403 
Misc. feature Eco47IR’ complement(1424..1805) 
Promoter pLac complement(1821..1944) 
Origin of replication pMB1 ori 2200..2814 
Coding Sequence bla complement(2974..3834) 
 
1 GCCCCTGCAG CCGAATTATA TTATTTTTGC CAAATAATTT TTAACAAAAG CTCTGAAGTC 
61 TTCTTCATTT AAATTCTTAG ATGATACTTC ATCTGGAAAA TTGTCCCAAT TAGTAGCATC 
121 ACGCTGTGAG TAAGTTCTAA ACCATTTTTT TATTGTTGTA TTATCTCTAA TCTTACTACT 
181 CGATGAGTTT TCGGTATTAT CTCTATTTTT AACTTGGAGC AGGTTCCATT CATTGTTTTT 
241 TTCATCATAG TGAATAAAAT CAACTGCTTT AACACTTGTG CCTGAACACC ATATCCATCC 
301 GGCGTAATAC GACTCACTAT AGGGAGAGCG GCCGCCAGAT CTTCCGGATG GCTCGAGTTT 
361 TTCAGCAAGA TGGAAGACTT AACACGATAG GCCGCGGTGC GGGTGCCAGG GCGTGCCCCC 
421 GGGCTCCCCG GGCGCGTACT CCACAGCTTG TAATCAGACT CGTTCGCCTT ACGCCCCGCC 
481 CTGCCACTCA TCGCAGTACT GTTGTAATTC ATTAAGCATT CTGCCGACAT GGAAGCCATC 
541 ACAAACGGCA TGATGAACCT GAATCGCCAG CGGCATCAGC ACCTTGTCGC CTTGCGTATA 
601 ATATTTGCCC ATGGTGAAAA CGGGGGCGAA GAAGTTGTCC ATATTGGCCA CGTTTAAATC 
661 AAAACTGGTG AAACTCACCC AGGGATTGGC TGAGACGAAA AACATATTCT CAATAAACCC 
721 TTTAGGGAAA TAGGCCAGGT TTTCACCGTA ACACGCCACA TCTTGCGAAT ATATGTGTAG 
781 AAACTGCCGG AAATCGTCGT GGTATTCACT CCAGAGCGAT GAAAACGTTT CAGTTTGCTC 
841 ATGGAAAACG GTGTAACAAG GGTGAACACT ATCCCATATC ACCAGCTCAC CGTCTTTCAT 
901 TGCCATACGT AATTCCGGAT GAGCATTCAT CAGGCGGGCA AGAATGTGAA TAAAGGCCGG 
961 ATAAAACTTG TGCTTATTTT TCTTTACGGT CTTTAAAAAG GCCGTAATAT CCAGCTGAAC 
1021 GGTCTGGTTA TAGGTACATT GAGCAACTGA CTGAAATGCC TCAAAATGTT CTTTACGATG 
1081 CCATTGGGAT ATATCAACGG TGGTATATCC AGTGATTTTT TTCTCCATTT TAGCTTCCTT 
1141 AGCTCCTGAA AATCTCGACA ACTCAAAAAA TACGCCCGGT AGTGATCTTA TTTCATTATG 
1201 GTGAAAGTTG GAACCTCTTA CGTGCCGATC AACGTCTCAT TTTCGCCAAA AGTTGGCCCA 
1261 GGGCTTCCCG GTATCAACAG GGACACCAGG ATTTATTTAT TCTGCGAAGT GATCTTCCGT 
1321 CACAGGTAGG AGCATACGCT GTTCGATTTA CCGCGGTGCG GGTGCCAGGG CGTGCCCTTG 
1381 GGCTCCCCGG GCGCGTACTC CACCCTAGCA AGTTCATGAT TGTATCTTTC TAGAAGATCT 
1441 CCTACAATAT TCTCAGCTGC CATGGAAAAT CGATGTTCTT CTTTTATTCT CTCAAGATTT 
1501 TCAGGCTGTA TATTAAAACT TATATTAAGA ACTATGCTAA CCACCTCATC AGGAACCGTT 
1561 GTAGGTGGCG TGGGTTTTCT TGGCAATCGA CTCTCATGAA AACTACGAGC TAAATATTCA 
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1621 ATATGTTCCT CTTGACCAAC TTTATTCTGC ATTTTTTTTG AACGAGGTTT AGAGCAAGCT 
1681 TCAGGAAACT GAGACAGGAA TTTTATTAAA AATTTAAATT TTGAAGAAAG TTCAGGGTTA 
1741 ATAGCATCCA TTTTTTGCTT TGCAAGTTCC TCAGCATTCT TAACAAAAGA CGTCTCTTTT 
1801 GACATGTTTA AAGTTTAAAC CTCCTGTGTG AAATTATTAT CCGCTCATAA TTCCACACAT 
1861 TATACGAGCC GGAAGCATAA AGTGTAAAGC CTGGGGTGCC TAATGAGTGA GCTAACTCAC 
1921 ATTAATTGCG TTGCGCTCAC TGCCAATTGC TTTCCAGTCG GGAAACCTGT CGTGCCAGCT 
1981 GCATTAATGA ATCGGCCAAC GCGCGGGGAG AGGCGGTTTG CGTATTGGGC GCTCTTCCGC 
2041 TTCCTCGCTC ACTGACTCGC TGCGCTCGGT CGTTCGGCTG CGGCGAGCGG TATCAGCTCA 
2101 CTCAAAGGCG GTAATACGGT TATCCACAGA ATCAGGGGAT AACGCAGGAA AGAACATGTG 
2161 AGCAAAAGGC CAGCAAAAGG CCAGGAACCG TAAAAAGGCC GCGTTGCTGG CGTTTTTCCA 
2221 TAGGCTCCGC CCCCCTGACG AGCATCACAA AAATCGACGC TCAAGTCAGA GGTGGCGAAA 
2281 CCCGACAGGA CTATAAAGAT ACCAGGCGTT TCCCCCTGGA AGCTCCCTCG TGCGCTCTCC 
2341 TGTTCCGACC CTGCCGCTTA CCGGATACCT GTCCGCCTTT CTCCCTTCGG GAAGCGTGGC 
2401 GCTTTCTCAT AGCTCACGCT GTAGGTATCT CAGTTCGGTG TAGGTCGTTC GCTCCAAGCT 
2461 GGGCTGTGTG CACGAACCCC CCGTTCAGCC CGACCGCTGC GCCTTATCCG GTAACTATCG 
2521 TCTTGAGTCC AACCCGGTAA GACACGACTT ATCGCCACTG GCAGCAGCCA CTGGTAACAG 
2581 GATTAGCAGA GCGAGGTATG TAGGCGGTGC TACAGAGTTC TTGAAGTGGT GGCCTAACTA 
2641 CGGCTACACT AGAAGGACAG TATTTGGTAT CTGCGCTCTG CTGAAGCCAG TTACCTTCGG 
2701 AAAAAGAGTT GGTAGCTCTT GATCCGGCAA ACAAACCACC GCTGGTAGCG GTGGTTTTTT 
2761 TGTTTGCAAG CAGCAGATTA CGCGCAGAAA AAAAGGATCT CAAGAAGATC CTTTGATCTT 
2821 TTCTACGGGG TCTGACGCTC AGTGGAACGA AAACTCACGT TAAGGGATTT TGGTCATGAG 
2881 ATTATCAAAA AGGATCTTCA CCTAGATCCT TTTAAATTAA AAATGAAGTT TTAAATCAAT 
2941 CTAAAGTATA TATGAGTAAA CTTGGTCTGA CAGTTACCAA TGCTTAATCA GTGAGGCACC 
3001 TATCTCAGCG ATCTGTCTAT TTCGTTCATC CATAGTTGCC TGACTCCCCG TCGTGTAGAT 
3061 AACTACGATA CGGGAGGGCT TACCATCTGG CCCCAGTGCT GCAATGATAC CGCGAGACCC 
3121 ACGCTCACCG GCTCCAGATT TATCAGCAAT AAACCAGCCA GCCGGAAGGG CCGAGCGCAG 
3181 AAGTGGTCCT GCAACTTTAT CCGCCTCCAT CCAGTCTATT AATTGTTGCC GGGAAGCTAG 
3241 AGTAAGTAGT TCGCCAGTTA ATAGTTTGCG CAACGTTGTT GCCATTGCTA CAGGCATCGT 
3301 GGTGTCACGC TCGTCGTTTG GTATGGCTTC ATTCAGCTCC GGTTCCCAAC GATCAAGGCG 
3361 AGTTACATGA TCCCCCATGT TGTGCAAAAA AGCGGTTAGC TCCTTCGGTC CTCCGATCGT 
3421 TGTCAGAAGT AAGTTGGCCG CAGTGTTATC ACTCATGGTT ATGGCAGCAC TGCATAATTC 
3481 TCTTACTGTC ATGCCATCCG TAAGATGCTT TTCTGTGACT GGTGAGTACT CAACCAAGTC 
3541 ATTCTGAGAA TAGTGTATGC GGCGACCGAG TTGCTCTTGC CCGGCGTCAA TACGGGATAA 
3601 TACCGCGCCA CATAGCAGAA CTTTAAAAGT GCTCATCATT GGAAAACGTT CTTCGGGGCG 
3661 AAAACTCTCA AGGATCTTAC CGCTGTTGAG ATCCAGTTCG ATGTAACCCA CTCGTGCACC 
3721 CAACTGATCT TCAGCATCTT TTACTTTCAC CAGCGTTTCT GGGTGAGCAA AAACAGGAAG 
3781 GCAAAATGCC GCAAAAAAGG GAATAAGGGC GACACGGAAA TGTTGAATAC TCATACTCTT 
3841 CCTTTTTCAA TATTATTGAA GCATTTATCA GGGTTATTGT CTCATGAGCG GATACATATT 
3901 TGAATGTATT TAGAAAAATA AACAAATAGG GGTTCCGCGC ACATTTCCCC GAAAAGTGCC 
3961 ACCTGACGTC TAAGAAACCA TTATTATCAT GACATTAACC TATAAAAATA GGCGTATCAC 
4021 GAGGCC 
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Supplementary Table A.1-6: Annotated nucleotide sequence of pInt1. 
Plasmid pInt1 7083 bp DNA circular  
Features Qualifiers Location 
Coding Sequence aadA 585..1376 
Origin of replication pSC101 2321..2543 
Coding Sequence repA101 2591..3541 
Promoter pLacI 3759..3836 
Coding Sequence  lacI 3837..4919 
Promoter pLac 4968..4998 
Coding Sequence  PhiC31 integrase 5042..6883 
Misc. feature 6xHis 6890..6907 
Terminator T7 terminator 6918..7046 
 
1 GCATGCCCGT TCCATACAGA AGCTGGGCGA ACAAACGATG CTCGCCTTCC AGAAAACCGA 
61 GGATGCGAAC CACTTCATCC GGGGTCAGCA CCACCGGCAA GCGCCGCGAC GGCCGAGGTC 
121 TTCCGATCTC CTGAAGCCAG GGCAGATCCG TGCACAGCAC CTTGCCGTAG AAGAACAGCA 
181 AGGCCGCCAA TGCCTGACGA TGCGTGGAGA CCGAAACCTT GCGCTCGTTC GCCAGCCAGG 
241 ACAGAAATGC CTCGACTTCG CTGCTGCCCA AGGTTGCCGG GTGACGCACA CCGTGGAAAC 
301 GGATGAAGGC ACGAACCCAG TGGACATAAG CCTGTTCGGT TCGTAAGCTG TAATGCAAGT 
361 AGCGTATGCG CTCACGCAAC TGGTCCAGAA CCTTGACCGA ACGCAGCGGT GGTAACGGCG 
421 CAGTGGCGGT TTTCATGGCT TGTTATGACT GTTTTTTTGG GGTACAGTCT ATGCCTCGGG 
481 CATCCAAGCA GCAAGCGCGT TACGCCGTGG GTCGATGTTT GATGTTATGG AGCAGCAACG 
541 ATGTTACGCA GCAGGGCAGT CGCCCTAAAA CAAAGTTAAA CATCATGAGG GAAGCGGTGA 
601 TCGCCGAAGT ATCGACTCAA CTATCAGAGG TAGTTGGCGT CATCGAGCGC CATCTCGAAC 
661 CGACGTTGCT GGCCGTACAT TTGTACGGCT CCGCAGTGGA TGGCGGCCTG AAGCCACACA 
721 GTGATATTGA TTTGCTGGTT ACGGTGACCG TAAGGCTTGA TGAAACAACG CGGCGAGCTT 
781 TGATCAACGA CCTTTTGGAA ACTTCGGCTT CCCCTGGAGA GAGCGAGATT CTCCGCGCTG 
841 TAGAAGTCAC CATTGTTGTG CACGACGACA TCATTCCGTG GCGTTATCCA GCTAAGCGCG 
901 AACTGCAATT TGGAGAATGG CAGCGCAATG ACATTCTTGC AGGTATCTTC GAGCCAGCCA 
961 CGATCGACAT TGATCTGGCT ATCTTGCTGA CAAAAGCAAG AGAACATAGC GTTGCCTTGG 
1021 TAGGTCCAGC GGCGGAGGAA CTCTTTGATC CGGTTCCTGA ACAGGATCTA TTTGAGGCGC 
1081 TAAATGAAAC CTTAACGCTA TGGAACTCGC CGCCCGACTG GGCTGGCGAT GAGCGAAATG 
1141 TAGTGCTTAC GTTGTCCCGC ATTTGGTACA GCGCAGTAAC CGGCAAAATC GCGCCGAAGG 
1201 ATGTCGCTGC CGACTGGGCA ATGGAGCGCC TGCCGGCCCA GTATCAGCCC GTCATACTTG 
1261 AAGCTAGACA GGCTTATCTT GGACAAGAAG AAGATCGCTT GGCCTCGCGC GCAGATCAGT 
1321 TGGAAGAATT TGTCCACTAC GTGAAAGGCG AGATCACCAA GGTAGTCGGC AAATAATGTC 
1381 TAACAATTCG TTCAAGCCGA CGCCGCTTCG CGGCGCGGCT TAACTCAAGC GTTAGATGCA 
1441 CTAAGCACAT AATTGCTCAC AGCCAAACTA TCAGGTCAAG TCTGCTTTTA TTATTTTTAA 
1501 GCGTGCATAA TAAGCCCTAC ACAAATTGGG AGATATATCA TGAAAGGCTG GCTTTTTCTT 
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1561 GTTATCGCAA TAGTTGGCGA AGTAATCGCA ACATCCGCAT TAAAATCTAG CGAGGGCTTT 
1621 ACTAAGCTCC TGCAGAGATC TGAATTCCCT AGAGAGACGA AAGTGATTGC GCCTACCCGG 
1681 ATATTATCGT GAGGATGCGC TGTCAGACCA AGTTTACTCA TATATACTTT AGATTGATTT 
1741 AAAACTTCAT TTTTAATTTA AAAGGATCTA GGTGAAGATC CTTTTTGATA ATCTCATGAC 
1801 CAAAATCCCT TAACGTGAGT TTTCGTTCCA CTGAGCGTCA GACCCCGTTG ATGATACCGC 
1861 TGCCTTACTG GGTGCATTAG CCAGTCTGAA TGACCTGTCA CGGGATAATC CGAAGTGGTC 
1921 AGACTGGAAA ATCAGAGGGC AGGAACTGCT GAACAGCAAA AAGTCAGATA GCACCACATA 
1981 GCAGACCCGC CATAAAACGC CCTGAGAAGC CCGTGACGGG CTTTTCTTGT ATTATGGGTA 
2041 GTTTCCTTGC ATGAATCCAT AAAAGGCGCC TGTAGTGCCA TTTACCCCCA TTCACTGCCA 
2101 GAGCCGTGAG CGCAGCGAAC TGAATGTCAC GAAAAAGACA GCGACTCAGG TGCCTGATGG 
2161 TCGGAGACAA AAGGAATATT CAGCGATTTG CCCGATTGCG GCCGCAACCG AGCTTGCGAG 
2221 GGTGCTACTT AAGCCTTTAG GGTTTTAAGG TCTGTTTTGT AGAGGAGCAA ACAGCGTTTG 
2281 CGACATCCTT TTGTAATACT GCGGAACTGA CTAAAGTAGT GAGTTATACA CAGGGCTGGG 
2341 ATCTATTCTT TTTATCTTTT TTTATTCTTT CTTTATTCTA TAAATTATAA CCACTTGAAT 
2401 ATAAACAAAA AAAACACACA AAGGTCTAGC GGAATTTACA GAGGGTCTAG CAGAATTTAC 
2461 AAGTTTTCCA GCAAAGGTCT AGCAGAATTT ACAGATACCC ACAACTCAAA GGAAAAGGAC 
2521 TAGTAATTAT CATTGACTAG CCCATCTCAA TTGGTATAGT GATTAAAATC ACCTAGACCA 
2581 ATTGAGATGT ATGTCTGAAT TAGTTGTTTT CAAAGCAAAT GAACTAGCGA TTAGTCGCTA 
2641 TGACTTAACG GAGCATGAAA CCAAGCTAAT TTTATGCTGT GTGGCACTAC TCAACCCCAC 
2701 GATTGAAAAC CCTACAAGGA AAGAACGGAC GGTATCGTTC ACTTATAACC AATACGCTCA 
2761 GATGATGAAC ATCAGTAGGG AAAATGCTTA TGGTGTATTA GCTAAAGCAA CCAGAGAGCT 
2821 GATGACGAGA ACTGTGGAAA TCAGGAATCC TTTGGTTAAA GGCTTTGAGA TTTTCCAGTG 
2881 GACAAACTAT GCCAAGTTCT CAAGCGAAAA ATTAGAATTA GTTTTTAGTG AAGAGATATT 
2941 GCCTTATCTT TTCCAGTTAA AAAAATTCAT AAAATATAAT CTGGAACATG TTAAGTCTTT 
3001 TGAAAACAAA TACTCTATGA GGATTTATGA GTGGTTATTA AAAGAACTAA CACAAAAGAA 
3061 AACTCACAAG GCAAATATAG AGATTAGCCT TGATGAATTT AAGTTCATGT TAATGCTTGA 
3121 AAATAACTAC CATGAGTTTA AAAGGCTTAA CCAATGGGTT TTGAAACCAA TAAGTAAAGA 
3181 TTTAAACACT TACAGCAATA TGAAATTGGT GGTTGATAAG CGAGGCCGCC CGACTGATAC 
3241 GTTGATTTTC CAAGTTGAAC TAGATAGACA AATGGATCTC GTAACCGAAC TTGAGAACAA 
3301 CCAGATAAAA ATGAATGGTG ACAAAATACC AACAACCATT ACATCAGATT CCTACCTACG 
3361 TAACGGACTA AGAAAAACAC TACACGATGC TTTAACTGCA AAAATTCAGC TCACCAGTTT 
3421 TGAGGCAAAA TTTTTGAGTG ACATGCAAAG TAAGTATGAT CTCAATGGTT CGTTCTCATG 
3481 GCTCACGCAA AAACAACGAA CCACACTAGA GAACATACTG GCTAAATACG GAAGGATCTG 
3541 AGGTTCTTAT GGCTCTTGTA TCTATCAGTG AAGCATCAAG ACTAACAAAC AAAAGTAGAA 
3601 CAACTGTTCA CCGTTACATA TCAAAGGGAA AACTGTCCAT ACCCATGGAT TCTTCGTCTG 
3661 TTTCTACTGG TATTGGCACA AACCTGATTC CAATTTGAGC AAGGCTATGT GCCATCTCGA 
3721 TACCGGCGTA GAGGATCGAG ATCTCGATCC CGCGAAATGA CACCATCGAA TGGCGCAAAA 
3781 CCTTTCGCGG TATGGCATGA TAGCGCCCGG AAGAGAGTCA ATTCAGGGTG GTGAATGTGA 
3841 AACCAGTAAC GTTATACGAT GTCGCAGAGT ATGCCGGTGT CTCTTATCAG ACCGTTTCCC 
3901 GCGTGGTGAA CCAGGCCAGC CACGTTTCTG CGAAAACGCG GGAAAAAGTG GAAGCGGCGA 
3961 TGGCGGAGCT GAATTACATT CCCAACCGCG TGGCACAACA ACTGGCGGGC AAACAGTCGT 
4021 TGCTGATTGG CGTTGCCACC TCCAGTCTGG CCCTGCACGC GCCGTCGCAA ATTGTCGCGG 
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4081 CGATTAAATC TCGCGCCGAT CAACTGGGTG CCAGCGTGGT GGTGTCGATG GTAGAACGAA 
4141 GCGGCGTCGA AGCCTGTAAA GCGGCGGTGC ACAATCTTCT CGCGCAACGC GTCAGTGGGC 
4201 TGATCATTAA CTATCCGCTG GATGACCAGG ATGCCATTGC TGTGGAAGCT GCCTGCACTA 
4261 ATGTTCCGGC GTTATTTCTT GATGTCTCTG ACCAGACACC CATCAACAGT ATTATTTTCT 
4321 CCCATGAAGA CGGTACGCGA CTGGGCGTGG AGCATCTGGT CGCATTGGGT CACCAGCAAA 
4381 TCGCGCTGTT AGCGGGCCCA TTAAGTTCTG TCTCGGCGCG TCTGCGTCTG GCTGGCTGGC 
4441 ATAAATATCT CACTCGCAAT CAAATTCAGC CGATAGCGGA ACGGGAAGGC GACTGGAGTG 
4501 CCATGTCCGG TTTTCAACAA ACCATGCAAA TGCTGAATGA GGGCATCGTT CCCACTGCGA 
4561 TGCTGGTTGC CAACGATCAG ATGGCGCTGG GCGCAATGCG CGCCATTACC GAGTCCGGGC 
4621 TGCGCGTTGG TGCGGATATC TCGGTAGTGG GATACGACGA TACCGAAGAC AGCTCATGTT 
4681 ATATCCCGCC GTTAACCACC ATCAAACAGG ATTTTCGCCT GCTGGGGCAA ACCAGCGTGG 
4741 ACCGCTTGCT GCAACTCTCT CAGGGCCAGG CGGTGAAGGG CAATCAGCTG TTGCCCGTCT 
4801 CACTGGTGAA AAGAAAAACC ACCCTGGCGC CCAATACGCA AACCGCCTCT CCCCGCGCGT 
4861 TGGCCGATTC ATTAATGCAG CTGGCACGAC AGGTTTCCCG ACTGGAAAGC GGGCAGTGAG 
4921 CGCAACGCAA TTAATGTGAG TTAGCTCACT CATTAGGCAC CCCAGGCTTT ACACTTTATG 
4981 CTTCCGGCTC GTATGTTGTG TGGAATTGTG AGCGGATAAC AATTTCACAC AGGAAACAGC 
5041 TATGACACAA GGGGTTGTGA CCGGGGTGGA CACGTACGCG GGTGCTTACG ACCGTCAGTC 
5101 GCGCGAGCGC GAGAATTCGA GCGCAGCAAG CCCAGCGACA CAGCGTAGCG CCAACGAAGA 
5161 CAAGGCGGCC GACCTTCAGC GCGAAGTCGA GCGCGACGGG GGCCGGTTCA GGTTCGTCGG 
5221 GCATTTCAGC GAAGCGCCGG GCACGTCGGC GTTCGGGACG GCGGAGCGCC CGGAGTTCGA 
5281 ACGCATCCTG AACGAATGCC GCGCCGGGCG GCTCAACATG ATCATTGTCT ATGACGTGTC 
5341 GCGCTTCTCG CGCCTGAAGG TCATGGACGC GATTCCGATT GTCTCGGAAT TGCTCGCCCT 
5401 GGGCGTGACG ATTGTTTCCA CTCAGGAAGG CGTCTTCCGG CAGGGAAACG TCATGGACCT 
5461 GATTCACCTG ATTATGCGGC TCGACGCGTC GCACAAAGAA TCTTCGCTGA AGTCGGCGAA 
5521 GATTCTCGAC ACGAAGAACC TTCAGCGCGA ATTGGGCGGG TACGTCGGCG GGAAGGCGCC 
5581 TTACGGCTTC GAGCTTGTTT CGGAGACGAA GGAGATCACG CGCAACGGCC GAATGGTCAA 
5641 TGTCGTCATC AACAAGCTTG CGCACTCGAC CACTCCCCTT ACCGGACCCT TCGAGTTCGA 
5701 GCCCGACGTA ATCCGGTGGT GGTGGCGTGA GATCAAGACG CACAAACACC TTCCCTTCAA 
5761 GCCGGGCAGT CAAGCCGCCA TTCACCCGGG CAGCATCACG GGGCTTTGTA AGCGCATGGA 
5821 CGCTGACGCC GTGCCGACCC GGGGCGAGAC GATTGGGAAG AAGACCGCTT CAAGCGCCTG 
5881 GGACCCGGCA ACCGTTATGC GAATCCTTCG GGACCCGCGT ATTGCGGGCT TCGCCGCTGA 
5941 GGTGATCTAC AAGAAGAAGC CGGACGGCAC GCCGACCACG AAGATTGAGG GTTACCGCAT 
6001 TCAGCGCGAC CCGATCACGC TCCGGCCGGT CGAGCTTGAT TGCGGACCGA TCATCGAGCC 
6061 CGCTGAGTGG TATGAGCTTC AGGCGTGGTT GGACGGCAGG GGGCGCGGCA AGGGGCTTTC 
6121 CCGGGGGCAA GCCATTCTGT CCGCCATGGA CAAGCTGTAC TGCGAGTGTG GCGCCGTCAT 
6181 GACTTCGAAG CGCGGGGAAG AATCGATCAA GGACTCTTAC CGCTGCCGTC GCCGGAAGGT 
6241 GGTCGACCCG TCCGCACCTG GGCAGCACGA AGGCACGTGC AACGTCAGCA TGGCGGCACT 
6301 CGACAAGTTC GTTGCGGAAC GCATCTTCAA CAAGATCAGG CACGCCGAAG GCGACGAAGA 
6361 GACGTTGGCG CTTCTGTGGG AAGCCGCCCG ACGCTTCGGC AAGCTCACTG AGGCGCCTGA 
6421 GAAGAGCGGC GAACGGGCGA ACCTTGTTGC GGAGCGCGCC GACGCCCTGA ACGCCCTTGA 
6481 AGAGCTGTAC GAAGACCGCG CGGCAGGCGC GTACGACGGA CCCGTTGGCA GGAAGCACTT 
6541 CCGGAAGCAA CAGGCAGCGC TGACGCTCCG GCAGCAAGGG GCGGAAGAGC GGCTTGCCGA 
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6601 ACTTGAAGCC GCCGAAGCCC CGAAGCTTCC CCTTGACCAA TGGTTCCCCG AAGACGCCGA 
6661 CGCTGACCCG ACCGGCCCTA AGTCGTGGTG GGGGCGCGCG TCAGTAGACG ACAAGCGCGT 
6721 GTTCGTCGGG CTCTTCGTAG ACAAGATCGT TGTCACGAAG TCGACTACGG GCAGGGGGCA 
6781 GGGAACGCCC ATCGAGAAGC GCGCTTCGAT CACGTGGGCG AAGCCGCCGA CCGACGACGA 
6841 CGAAGACGAC GCCCAGGACG GCACGGAAGA CGTAGCGGCG TAGCTCGAGC ACCACCACCA 
6901 CCACCACTGA GATCCGGCTG CTAACAAAGC CCGAAAGGAA GCTGAGTTGG CTGCTGCCAC 
6961 CGCTGAGCAA TAACTAGCAT AACCCCTTGG GGCCTCTAAA CGGGTCTTGA GGGGTTTTTT 
7021 GCTGAAAGGA GGAACTATAT CCGGATTGGC GAATGGGACG CGCCCTGTAG CGGCGCATTA 
7081 AGC 
 
Supplementary Table A.1-7: Nucleotide sequence for attB and attP sites. The TT-core dinucleotide is 
highlighted in red. The TT-, CT-, GT-, CA-, CC- and TC-cores are orthogonal and will only recombine with 
each other in a specific orientation. 
attBTT CCGCGGTGCGGGTGCCAGGGCGTGCCCTTGGGCTCCCCGGGCGCGTACTCCAC 
attPTT GTAGTGCCCCAACTGGGGTAACCTTTGAGTTCTCTCAGTTGGGGGCGTAG 
 
 
Supplementary Figure A.1-1: Growth curve of the Dasher knock-in strains compared to the wild type. Error 
bars display standard deviations of three replicates. 
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Supplementary Figure A.1-2: Fluorescence corrected for optical density measured at 600 nm in arbitrary 
units (a.u.) in function of time for the Dasher knock-in strains compared to the wild type. Error bars display 
standard deviations of three replicates. 
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A.2 Appendix Chapter 3 
 
Supplementary Figure A.2-1: Comparison of fluorescent proteins Dasher, mCherry, and mKate2 on nine 
locations spread over the genome of E. coli. Fluorescence output is corrected for OD600 measurements 
and wildtype fluorescence. Error bars represent the standard deviation of six replicates. Experiment 
conducted in defined glucose medium. 
Appendices 
163 
 
Supplementary Figure A.2-2: Fluorescence of the Dasher reporter cassette integrated on the 49 intergenic 
locations spread over the genome of E. coli, corrected for wildtype fluorescence and OD600 (A.U.) and 
measured at the start of the stationary phase. Error bars represent the standard deviation of at least four 
replicates. Experiment conducted in defined glucose medium.  
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Supplementary Figure A.2-3: From top to bottom: overview of the growth rate and saturation OD of all 49 
intergenic locations and subsequently the change in growth rate and saturation OD when the orientation is 
inverted, novobiocin is added or burden is induced for the 26 selected locations. Error bars represent the 
standard deviation of at least 3 replicates. Experiments conducted in defined glucose medium. 
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Supplementary Figure A.2-4: Overview of the fluorescence of the reporter cassette inserted on the 26 
chosen intergenic locations, corrected for wildtype fluorescence and OD600 (A.U.), in function of the net 
distance from oriC for the four media tested. Error bars represent the standard deviation of three 
replicates. 
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Supplementary Figure A.2-5: The coefficient of variation of the fluorescence measured with flow cytometry 
for the 26 selected locations with (blue) and without (grey) induced burden. Error bars represent the 
standard deviation of three replicates. 
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Supplementary Figure A.2-6: Scatter plot showing the correlation between net distance from oriC and the 
ratio of Dasher fluorescence with and without induction of the VioB-mCherry burden plasmid only for the 
significantly affected locations. The linear regression line is shown in blue and has an R2 of 0.579. The 
regression is significant (95%) with an F-statistic of 17.90 and a p-value of 0.00098 (see Supplementary 
Table 12). Error bars represent the standard deviation of three replicates. Experiment conducted in defined 
glucose medium. 
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Supplementary Table A.2-1: Strains used in Chapter 3.  
sNS3.01 E. coli K-12 MG1655 
sNS3.02 sNS3.01 djlA_yabP::attLCC-proD-Bba_B0034-Dasher-rnpB_T1-attRTT 
sNS3.03 sNS3.01 ylcI_nohD::attLCC-proD-Bba_B0034-Dasher-rnpB_T1-attRTT 
sNS3.04 sNS3.01 tyrV_tyrT::attLCC-proD-Bba_B0034-Dasher-rnpB_T1-attRTT 
sNS3.05 sNS3.01 ypjC_ileY::attLCC-proD-Bba_B0034-Dasher-rnpB_T1-attRTT 
sNS3.06 sNS3.01 yhiM_yhiN::attLCC-proD-Bba_B0034-Dasher-rnpB_T1-attRTT 
sNS3.07 sNS3.01 thrW_ykfN::attLCC-proD-Bba_B0034-Dasher-rnpB_T1-attRTT 
sNS3.08 sNS3.01 entF_fepE::attLCC-proD-Bba_B0034-Dasher-rnpB_T1-attRTT 
sNS3.09 sNS3.01 ydaG_racR::attLCC-proD-Bba_B0034-Dasher-rnpB_T1-attRTT 
sNS3.10 sNS3.01 ileY_ygaQ::attLCC-proD-Bba_B0034-Dasher-rnpB_T1-attRTT 
sNS3.11 sNS3.01 dinD_yicG::attLCC-proD-Bba_B0034-Dasher-rnpB_T1-attRTT 
sNS3.12 sNS3.01 ykfA_perR::attLCC-proD-Bba_B0034-Dasher-rnpB_T1-attRTT 
sNS3.13 sNS3.01 ybfK_kdpE::attLCC-proD-Bba_B0034-Dasher-rnpB_T1-attRTT 
sNS3.14 sNS3.01 cspF_quuQ::attLCC-proD-Bba_B0034-Dasher-rnpB_T1-attRTT 
sNS3.15 sNS3.01 yqaB_argQ::attLCC-proD-Bba_B0034-Dasher-rnpB_T1-attRTT 
sNS3.16 sNS3.01 frvA_rhaM::attLCC-proD-Bba_B0034-Dasher-rnpB_T1-attRTT 
sNS3.17 sNS3.01 insN_eyeA::attLCC-proD-Bba_B0034-Dasher-rnpB_T1-attRTT 
sNS3.18 sNS3.01 ybfC_ybfQ::attLCC-proD-Bba_B0034-Dasher-rnpB_T1-attRTT 
sNS3.19 sNS3.01 rseX_yedS::attLCC-proD-Bba_B0034-Dasher-rnpB_T1-attRTT 
sNS3.20 sNS3.01 ygcE_queE::attLCC-proD-Bba_B0034-Dasher-rnpB_T1-attRTT 
sNS3.21 sNS3.01 frwA_frwC::attLCC-proD-Bba_B0034-Dasher-rnpB_T1-attRTT 
sNS3.22 sNS3.01 ykgA_ykgQ::attLCC-proD-Bba_B0034-Dasher-rnpB_T1-attRTT 
sNS3.23 sNS3.01 ybiJ_ybiI::attLCC-proD-Bba_B0034-Dasher-rnpB_T1-attRTT 
sNS3.24 sNS3.01 yeeJ_yeeL::attLCC-proD-Bba_B0034-Dasher-rnpB_T1-attRTT 
sNS3.25 sNS3.01 ygeF_ygeG::attLCC-proD-Bba_B0034-Dasher-rnpB_T1-attRTT 
sNS3.26 sNS3.01 malM_yjbI::attLCC-proD-Bba_B0034-Dasher-rnpB_T1-attRTT 
sNS3.27 sNS3.01 ykgH_betA::attLCC-proD-Bba_B0034-Dasher-rnpB_T1-attRTT 
sNS3.28 sNS3.01 ymgF_ycgH::attLCC-proD-Bba_B0034-Dasher-rnpB_T1-attRTT 
sNS3.29 sNS3.01 udk_yegE::attLCC-proD-Bba_B0034-Dasher-rnpB_T1-attRTT 
sNS3.30 sNS3.01 ygeK_ygeN::attLCC-proD-Bba_B0034-Dasher-rnpB_T1-attRTT 
sNS3.31 sNS3.01 yjcS_alsK::attLCC-proD-Bba_B0034-Dasher-rnpB_T1-attRTT 
sNS3.32 sNS3.01 yahK_yahL::attLCC-proD-Bba_B0034-Dasher-rnpB_T1-attRTT 
sNS3.33 sNS3.01 dadX_cvrA::attLCC-proD-Bba_B0034-Dasher-rnpB_T1-attRTT 
sNS3.34 sNS3.01 yffL_yffM::attLCC-proD-Bba_B0034-Dasher-rnpB_T1-attRTT 
sNS3.35 sNS3.01 sibD_sibE::attLCC-proD-Bba_B0034-Dasher-rnpB_T1-attRTT 
sNS3.36 sNS3.01 yjhV_fecE::attLCC-proD-Bba_B0034-Dasher-rnpB_T1-attRTT 
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sNS3.37 sNS3.01 yfjQ_yfjR::attLCC-proD-Bba_B0034-Dasher-rnpB_T1-attRTT 
sNS3.38 sNS3.01 glpD_yzgL::attLCC-proD-Bba_B0034-Dasher-rnpB_T1-attRTT 
sNS3.39 sNS3.01 yjiP_yjiR::attLCC-proD-Bba_B0034-Dasher-rnpB_T1-attRTT 
sNS3.40 sNS3.01 lacZ_lacI::attLCC-proD-Bba_B0034-Dasher-rnpB_T1-attRTT 
sNS3.41 sNS3.01 ycbW_ycbX::attLCC-proD-Bba_B0034-Dasher-rnpB_T1-attRTT 
sNS3.42 sNS3.01 nupG_speC::attLCC-proD-Bba_B0034-Dasher-rnpB_T1-attRTT 
sNS3.43 sNS3.01 aslB_aslA::attLCC-proD-Bba_B0034-Dasher-rnpB_T1-attRTT 
sNS3.44 sNS3.01 atpI_gidB::attLCC-proD-Bba_B0034-Dasher-rnpB_T1-attRTT 
sNS3.45 sNS3.01 yieN_trkD::attLCC-proD-Bba_B0034-Dasher-rnpB_T1-attRTT 
sNS3.46 sNS3.01 ybbD_ylbI::attLCC-proD-Bba_B0034-Dasher-rnpB_T1-attRTT 
sNS3.47 sNS3.01 essQ_cspB::attLCC-proD-Bba_B0034-Dasher-rnpB_T1-attRTT 
sNS3.48 sNS3.01 nth_ydgR::attLCC-proD-Bba_B0034-Dasher-rnpB_T1-attRTT 
sNS3.49 sNS3.01 fucl_fucK::attLCC-proD-Bba_B0034-Dasher-rnpB_T1-attRTT 
sNS3.50 sNS3.01 xylB_xylA::attLCC-proD-Bba_B0034-Dasher-rnpB_T1-attRTT 
sNS3.51 sNS3.01 dadX_cvrA::attLCC-proD-Bba_B0034-mCherry-rnpB_T1-attRTT 
sNS3.52 sNS3.01 sibD_sibE::attLCC-proD-Bba_B0034-mCherry-rnpB_T1-attRTT 
sNS3.53 sNS3.01 entF_fepE::attLCC-proD-Bba_B0034-mCherry-rnpB_T1-attRTT 
sNS3.54 sNS3.01 ydaG_racR::attLCC-proD-Bba_B0034-mCherry-rnpB_T1-attRTT 
sNS3.55 sNS3.01 ykgH_betA::attLCC-proD-Bba_B0034-mCherry-rnpB_T1-attRTT 
sNS3.56 sNS3.01 ygeK_ygeN::attLCC-proD-Bba_B0034-mCherry-rnpB_T1-attRTT 
sNS3.57 sNS3.01 yjcS_alsK::attLCC-proD-Bba_B0034-mCherry-rnpB_T1-attRTT 
sNS3.58 sNS3.01 essQ_cspB::attLCC-proD-Bba_B0034-mCherry-rnpB_T1-attRTT 
sNS3.59 sNS3.01 nth_ydgR::attLCC-proD-Bba_B0034-mCherry-rnpB_T1-attRTT 
sNS3.60 sNS3.01 dadX_cvrA::attLCC-proD-Bba_B0034-mKate2-rnpB_T1-attRTT 
sNS3.61 sNS3.01 sibD_sibE::attLCC-proD-Bba_B0034-mKate2-rnpB_T1-attRTT 
sNS3.62 sNS3.01 entF_fepE::attLCC-proD-Bba_B0034-mKate2-rnpB_T1-attRTT 
sNS3.63 sNS3.01 ydaG_racR::attLCC-proD-Bba_B0034-mKate2-rnpB_T1-attRTT 
sNS3.64 sNS3.01 ykgH_betA::attLCC-proD-Bba_B0034-mKate2-rnpB_T1-attRTT 
sNS3.65 sNS3.01 ygeK_ygeN::attLCC-proD-Bba_B0034-mKate2-rnpB_T1-attRTT 
sNS3.66 sNS3.01 yjcS_alsK::attLCC-proD-Bba_B0034-mKate2-rnpB_T1-attRTT 
sNS3.67 sNS3.01 essQ_cspB::attLCC-proD-Bba_B0034-mKate2-rnpB_T1-attRTT 
sNS3.68 sNS3.01 nth_ydgR::attLCC-proD-Bba_B0034-mKate2-rnpB_T1-attRTT 
sNS3.69 sNS3.01 djlA_yabP::attRTT-proD-Bba_B0034-Dasher-rnpB_T1-attLCC (inverted) 
sNS3.70 sNS3.01 tyrV_tyrT::attRTT-proD-Bba_B0034-Dasher-rnpB_T1-attLCC (inverted) 
sNS3.71 sNS3.01 ypjC_ileY::attRTT-proD-Bba_B0034-Dasher-rnpB_T1-attLCC (inverted) 
sNS3.72 sNS3.01 yhiM_yhiN::attRTT-proD-Bba_B0034-Dasher-rnpB_T1-attLCC (inverted) 
sNS3.73 sNS3.01 thrW_ykfN::attRTT-proD-Bba_B0034-Dasher-rnpB_T1-attLCC (inverted) 
sNS3.74 sNS3.01 ileY_ygaQ::attRTT-proD-Bba_B0034-Dasher-rnpB_T1-attLCC (inverted) 
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sNS3.75 sNS3.01 ybfK_kdpE::attRTT-proD-Bba_B0034-Dasher-rnpB_T1-attLCC (inverted) 
sNS3.76 sNS3.01 cspF_quuQ::attRTT-proD-Bba_B0034-Dasher-rnpB_T1-attLCC (inverted) 
sNS3.77 sNS3.01 yqaB_argQ::attRTT-proD-Bba_B0034-Dasher-rnpB_T1-attLCC (inverted) 
sNS3.78 sNS3.01 frvA_rhaM::attRTT-proD-Bba_B0034-Dasher-rnpB_T1-attLCC (inverted) 
sNS3.79 sNS3.01 ybfC_ybfQ::attRTT-proD-Bba_B0034-Dasher-rnpB_T1-attLCC (inverted) 
sNS3.80 sNS3.01 rseX_yedS::attRTT-proD-Bba_B0034-Dasher-rnpB_T1-attLCC (inverted) 
sNS3.81 sNS3.01 ygcE_queE::attRTT-proD-Bba_B0034-Dasher-rnpB_T1-attLCC (inverted) 
sNS3.82 sNS3.01 frwA_frwC::attRTT-proD-Bba_B0034-Dasher-rnpB_T1-attLCC (inverted) 
sNS3.83 sNS3.01 ykgA_ykgQ::attRTT-proD-Bba_B0034-Dasher-rnpB_T1-attLCC (inverted) 
sNS3.84 sNS3.01 ybiJ_ybiI::attRTT-proD-Bba_B0034-Dasher-rnpB_T1-attLCC (inverted) 
sNS3.85 sNS3.01 yeeJ_yeeL::attRTT-proD-Bba_B0034-Dasher-rnpB_T1-attLCC (inverted) 
sNS3.86 sNS3.01 malM_yjbI::attRTT-proD-Bba_B0034-Dasher-rnpB_T1-attLCC (inverted) 
sNS3.87 sNS3.01 ykgH_betA::attRTT-proD-Bba_B0034-Dasher-rnpB_T1-attLCC (inverted) 
sNS3.88 sNS3.01 ymgF_ycgH::attRTT-proD-Bba_B0034-Dasher-rnpB_T1-attLCC (inverted) 
sNS3.89 sNS3.01 udk_yegE::attRTT-proD-Bba_B0034-Dasher-rnpB_T1-attLCC (inverted) 
sNS3.90 sNS3.01 dadX_cvrA::attRTT-proD-Bba_B0034-Dasher-rnpB_T1-attLCC (inverted) 
sNS3.91 sNS3.01 yffL_yffM::attRTT-proD-Bba_B0034-Dasher-rnpB_T1-attLCC (inverted) 
sNS3.92 sNS3.01 sibD_sibE::attRTT-proD-Bba_B0034-Dasher-rnpB_T1-attLCC (inverted) 
sNS3.93 sNS3.01 glpD_yzgL::attRTT-proD-Bba_B0034-Dasher-rnpB_T1-attLCC (inverted) 
sNS3.94 sNS3.01 yjiP_yjiR::attRTT-proD-Bba_B0034-Dasher-rnpB_T1-attLCC (inverted) 
 
Supplementary Table A.2-2: Plasmids created in Chapter 3.  
pLP5 pSC101-repA-attPTT-TetA-attPCC-Tn5 
pDonor8 pSC101-repA-attBCC-proD-Bba_B0034-Dasher-rnpB_T1-attBTT-neo 
pDonor9 pSC101-repA-attBCC-proD-Bba_B0034-mCherry-rnpB_T1-attBTT-neo 
pDonor10 pSC101-repA-attBCC-proD-Bba_B0034-mKate2-rnpB_T1-attBTT-neo 
pDonor11 pSC101-repA-attBTT-proD-Bba_B0034-Dasher-rnpB_T1-attBCC-neo (inverted) 
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Supplementary Table A.2-3: Annotated nucleotide sequence of landing pad plasmid pLP5 (5250 bp DNA 
circular). 
Plasmid pLP5 5250 bp DNA circular  
Features Qualifiers Location 
Coding Sequence repA 37..987 
Origin of replication pSC101 1035..1257 
Misc. feature attPTT 1796..1845 
Coding Sequence neo 1968..3173 
Misc. feature attP_CC 3366..3415 
Coding Sequence Tn5 3843..4637 
 
1 GATGCTTCAC TGATAGATAC AAGAGCCATA AGAACCTCAG ATCCTTCCGT ATTTAGCCAG 
61 TATGTTCTCT AGTGTGGTTC GTTGTTTTTG CGTGAGCCAT GAGAACGAAC CATTGAGATC 
121 ATACTTACTT TGCATGTCAC TCAAAAATTT TGCCTCAAAA CTGGTGAGCT GAATTTTTGC 
181 AGTTAAAGCA TCGTGTAGTG TTTTTCTTAG TCCGTTATGT AGGTAGGAAT CTGATGTAAT 
241 GGTTGTTGGT ATTTTGTCAC CATTCATTTT TATCTGGTTG TTCTCAAGTT CGGTTACGAG 
301 ATCCATTTGT CTATCTAGTT CAACTTGGAA AATCAACGTA TCAGTCGGGC GGCCTCGCTT 
361 ATCAACCACC AATTTCATAT TGCTGTAAGT GTTTAAATCT TTACTTATTG GTTTCAAAAC 
421 CCATTGGTTA AGCCTTTTAA ACTCATGGTA GTTATTTTCA AGCATTAACA TGAACTTAAA 
481 TTCATCAAGG CTAATCTCTA TATTTGCCTT GTGAGTTTTC TTTTGTGTTA GTTCTTTTAA 
541 TAACCACTCA TAAATCCTCA TAGAGTATTT GTTTTCAAAA GACTTAACAT GTTCCAGATT 
601 ATATTTTATG AATTTTTTTA ACTGGAAAAG ATAAGGCAAT ATCTCTTCAC TAAAAACTAA 
661 TTCTAATTTT TCGCTTGAGA ACTTGGCATA GTTTGTCCAC TGGAAAATCT CAAAGCCTTT 
721 AACCAAAGGA TTCCTGATTT CCACAGTTCT CGTCATCAGC TCTCTGGTTG CTTTAGCTAA 
781 TACACCATAA GCATTTTCCC TACTGATGTT CATCATCTGA GCGTATTGGT TATAAGTGAA 
841 CGATACCGTC CGTTCTTTCC TTGTAGGGTT TTCAATCGTG GGGTTGAGTA GTGCCACACA 
901 GCATAAAATT AGCTTGGTTT CATGCTCCGT TAAGTCATAG CGACTAATCG CTAGTTCATT 
961 TGCTTTGAAA ACAACTAATT CAGACATACA TCTCAATTGG TCTAGGTGAT TTTAATCACT 
1021 ATACCAATTG AGATGGGCTA GTCAATGATA ATTACTAGTC CTTTTCCTTT GAGTTGTGGG 
1081 TATCTGTAAA TTCTGCTAGA CCTTTGCTGG AAAACTTGTA AATTCTGCTA GACCCTCTGT 
1141 AAATTCCGCT AGACCTTTGT GTGTTTTTTT TGTTTATATT CAAGTGGTTA TAATTTATAG 
1201 AATAAAGAAA GAATAAAAAA AGATAAAAAG AATAGATCCC AGCCCTGTGT ATAACTCACT 
1261 ACTTTAGTCA GTTCCGCAGT ATTACAAAAG GATGTCGCAA ACGCTGTTTG CTCCTCTACA 
1321 AAACAGACCT TAAAACCCTA AAGGCTTAAG TAGCACCCTC GCAAGCTCGG GCAAATCGCT 
1381 GAATATTCCT TTTGTCTCCG ACCATCAGGC ACCTGAGTCG CTGTCTTTTT CGTGACATTC 
1441 AGTTCGCTGC GCTCACGGCT CTGGCAGTGA ATGGGGGTAA ATGGCACTAC AGGCGCCTTT 
1501 TATGGATTCA TGCAAGGAAA CTACCCATAA TACAAGAAAA GCCCGTCACG GGCTTCTCAG 
1561 GGCGTTTTAT GGCGGGTCTG CTATGTGGTG CTATCTGACT TTTTGCTGTT CAGCAGTTCC 
1621 TGCCCTCTGA TTTTCCAGTC TGACCACTTC GGATTATCCC GTGACAGGTC ATTCAGACTG 
1681 GCTAATGCAC CCAGTAAGGC AGCGGTATCA TCAACAGGCT TACCCGTCTT ACTGTCGGGA 
1741 ATTCGCGTTG GCCGATTCAT TAATGCAGCT GGCACGACAG GTTTCCCGAC TGGAAGTAGT 
1801 GCCCCAACTG GGGTAACCTT TGAGTTCTCT CAGTTGGGGG CGTAGTTGAT CTTTTCTACG 
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1861 GGCAGGACGG TGATAGGGAT AACAGGGTAA TGTACCATTT ACGTTGACAC CACCTTTCGC 
1921 GTATGGCGTG ATAGCGCCCG GAAGAGAGTC AATTCAGGGT GGTGAATATG AATAGTTCGA 
1981 CAAAGATCGC ATTGGTAATT ACGTTGCTCG ATGCCATGGG GATTGGCCTT ATCATGCCAG 
2041 TCTTGCCAAC GTTATTACGT GAATTTATTG CTTCGGAAGA TATCGCTAAC CACTTTGGCG 
2101 TATTGCTTGC ACTTTATGCG TTAATGCAGG TTATCTTTGC TCCTTGGCTT GGAAAAATGT 
2161 CTGACCGATT TGGTCGGCGC CCAGTGCTGT TGTTGTCATT AATAGGCGCA TCGCTGGATT 
2221 ACTTATTGCT GGCTTTTTCA AGTGCGCTTT GGATGCTGTA TTTAGGCCGT TTGCTTTCAG 
2281 GGATCACAGG AGCTACTGGG GCTGTCGCGG CATCGGTCAT TGCCGATACC ACCTCAGCTT 
2341 CTCAACGCGT GAAGTGGTTC GGTTGGTTAG GGGCAAGTTT TGGGCTTGGT TTAATAGCGG 
2401 GGCCTATTAT TGGTGGTTTT GCAGGAGAGA TTTCACCGCA TAGTCCCTTT TTTATCGCTG 
2461 CGTTGCTAAA TATTGTCACT TTCCTTGTGG TTATGTTTTG GTTCCGTGAA ACCAAAAATA 
2521 CACGTGATAA TACAGATACC GAAGTAGGGG TTGAGACGCA ATCAAATTCG GTGTACATCA 
2581 CTTTATTTAA AACGATGCCC ATTTTGTTGA TTATTTATTT TTCAGCGCAA TTGATAGGCC 
2641 AAATTCCCGC AACGGTGTGG GTGCTATTTA CCGAAAATCG TTTTGGATGG AATAGCATGA 
2701 TGGTTGGCTT TTCATTAGCG GGTCTTGGTC TTTTACACTC AGTATTCCAA GCCTTTGTGG 
2761 CAGGAAGAAT AGCCACTAAA TGGGGCGAAA AAACGGCAGT ACTGCTCGAA TTTATTGCAG 
2821 ATAGTAGTGC ATTTGCCTTT TTAGCGTTTA TATCTGAAGG TTGGTTAGTT TTCCCTGTTT 
2881 TAATTTTATT GGCTGGTGGT GGGATCGCTT TACCTGCATT ACAGGGAGTG ATGTCTATCC 
2941 AAACAAAGAG TCATCAGCAA GGTGCTTTAC AGGGATTATT GGTGAGCCTT ACCAATGCAA 
3001 CCGGTGTTAT TGGCCCATTA CTGTTTGCTG TTATTTATAA TCATTCACTA CCAATTTGGG 
3061 ATGGCTGGAT TTGGATTATT GGTTTAGCGT TTTACTGTAT TATTATCCTG CTATCAATGA 
3121 CCTTCATGTT GACCCCTCAA GCTCAGGGGA GTAAACAGGA GACAAGTGCT TAGTAGGGAT 
3181 AACAGGGTAA TGATGGCGCC TCATCCCTGA AGCCAAGGCA TCAAATAAAA CGAAAGGCTC 
3241 AGTCGAAAGA CTGGGCCTTT CGTTTTATCT GTTGTTTGTC GGTGAACGCT CTCCTGAGTA 
3301 GGACAAATCC GCCGCCCTAG ACCTAGGGGA TATATTCCGC TAAATCACTA GTGCGGCCGC 
3361 CTGCAGTAGT GCCCCAACTG GGGTAACCTC CGAGTTCTCT CAGTTGGGGG CGTAGGTGTA 
3421 GGCTGGAGCT GCTTCGAAGT TCCTATACTT TCTAGAGAAT AGGAACTTCG GAATAGGAAC 
3481 TTCAAGATCC CCCACGCTGC CGCAAGCACT CAGGGCGCAA GGGCTGCTAA AGGAAGCGGA 
3541 ACACGTAGAA AGCCAGTCCG CAGAAACGGT GCTGACCCCG GATGAATGTC AGCTACTGGG 
3601 CTATCTGGAC AAGGGAAAAC GCAAGCGCAA AGAGAAAGCA GGTAGCTTGC AGTGGGCTTA 
3661 CATGGCGATA GCTAGACTGG GCGGTTTTAT GGACAGCAAG CGAACCGGAA TTGCCAGCTG 
3721 GGGCGCCCTC TGGTAAGGTT GGGAAGCCCT GCAAAGTAAA CTGGATGGCT TTCTTGCCGC 
3781 CAAGGATCTG ATGGCGCAGG GGATCAAGAT CTGATCAAGA GACAGGATGA GGATCGTTTC 
3841 GCATGATTGA ACAAGATGGA TTGCACGCAG GTTCTCCGGC CGCTTGGGTG GAGAGGCTAT 
3901 TCGGCTATGA CTGGGCACAA CAGACAATCG GCTGCTCTGA TGCCGCCGTG TTCCGGCTGT 
3961 CAGCGCAGGG GCGCCCGGTT CTTTTTGTCA AGACCGACCT GTCCGGTGCC CTGAATGAAC 
4021 TGCAGGACGA GGCAGCGCGG CTATCGTGGC TGGCCACGAC GGGCGTTCCT TGCGCAGCTG 
4081 TGCTCGACGT TGTCACTGAA GCGGGAAGGG ACTGGCTGCT ATTGGGCGAA GTGCCGGGGC 
4141 AGGATCTCCT GTCATCTCAC CTTGCTCCTG CCGAGAAAGT ATCCATCATG GCTGATGCAA 
4201 TGCGGCGGCT GCATACGCTT GATCCGGCTA CCTGCCCATT CGACCACCAA GCGAAACATC 
4261 GCATCGAGCG AGCACGTACT CGGATGGAAG CCGGTCTTGT CGATCAGGAT GATCTGGACG 
4321 AAGAGCATCA GGGGCTCGCG CCAGCCGAAC TGTTCGCCAG GCTCAAGGCG CGCATGCCCG 
4381 ACGGCGAGGA TCTCGTCGTG ACCCATGGCG ATGCCTGCTT GCCGAATATC ATGGTGGAAA 
4441 ATGGCCGCTT TTCTGGATTC ATCGACTGTG GCCGGCTGGG TGTGGCGGAC CGCTATCAGG 
4501 ACATAGCGTT GGCTACCCGT GATATTGCTG AAGAGCTTGG CGGCGAATGG GCTGACCGCT 
4561 TCCTCGTGCT TTACGGTATC GCCGCTCCCG ATTCGCAGCG CATCGCCTTC TATCGCCTTC 
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4621 TTGACGAGTT CTTCTGAGCG GGACTCTGGG GTTCGAAATG ACCGACCAAG CGACGCCCAA 
4681 CCTGCCATCA CGAGATTTCG ATTCCACCGC CGCCTTCTAT GAAAGGTTGG GCTTCGGAAT 
4741 CGTTTTCCGG GACGCCGGCT GGATGATCCT CCAGCGCGGG GATCTCATGC TGGAGTTCTT 
4801 CGCCCACCCC AGCTTCAAAA GCGCTCTGAA GTTCCTATAC TTTCTAGAGA ATAGGAACTT 
4861 CGGAATAGGA ACTAAGGAGG ATATTCATAT GCATGACCAA AATCCCTTAA CGTGAGTTTT 
4921 CGTTCCACTG AGCGTCAGAC TTCGATAAGC AGCATCGCCT GTTTCAGGCT GTCTATGTGT 
4981 GACTGTTGAG CTGTAACAAG TTGTCTCAGG TGTTCAATTT CATGTTCTAG TTGCTTTGTT 
5041 TTACTGGTTT CACCTGTTCT ATTAGGTGTT ACATGCTGTT CATCTGTTAC ATTGTCGATC 
5101 TGTTCATGGT GAACAGCTTT GAATGCACCA AAAACTCGTA AAAGCTCTGA TGTATCTATC 
5161 TTTTTTACAC CGTTTTCATC TGTGCATATG GACAGTTTTC CCTTTGATAT GTAACGGTGA 
5221 ACAGTTGTTC TACTTTTGTT TGTTAGTCTT 
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Supplementary Table A.2-4: Annotated nucleotide sequence of donor plasmid pDonor8 (4428 bp DNA 
circular). The sequence of Dasher is not disclosed to comply with the terms and conditions of ATUM. 
Sequences of pDonor9 and pDonor10 are identical to pDasher, with exception of the coding sequence of 
mCherry (109) and mKate2 (108) respectively. The sequence of pDonor11 is identical to pDonor8, except 
for the part from 4349 bp to 1069 bp which is reversed. 
Plasmid pDonor8 4428 bp DNA circular  
Features Qualifiers Location 
Promotor proD 5..148 
Ribosome binding site Bba_B0034 171..182 
Coding Sequence Dasher 190..900 
Terminator rnpB_T1 905..986 
Misc. feature SpacerRightA 991..1050 
Misc. feature attBTT Complement(1103..1155) 
Coding Sequence repA 1398..2348 
Origin of replication pSC101 2396..2618 
Coding Sequence neo Complement(3223..4017) 
Misc. feature attBCC Complement(4331..4279) 
Misc. feature SpacerLeftA 4369..4428 
 
1 CCCTCACAGC TAACACCACG TCGTCCCTAT CTGCTGCCCT AGGTCTATGA GTGGTTGCTG 
61 GATAACTTTA CGGGCATGCA TAAGGCTCGT ATAATATATT CAGGGAGACC ACAACGGTTT 
121 CCCTCTACAA ATAATTTTGT TTAACTTTGA TCGCATGGTT GCTACTAGAG AAAGAGGAGA 
181 AATACTAGAA TG…TAA 
901 GCTGTCGGTC AGTTTCACCT GATTTACGTA AAAACCCGCT TCGGCGGGTT TTTGCTTTTG 
961 GAGGGGCAGA AAGATGAATG ACTGTCTACA AAGTTATCAG CGGCGAAAGT ATTCAATCTG 
1021 TGCCAGTCGT AGTTTATTTA CACGGAGAAA CCCTTGAGAC GCCGAGTCGG GAAACCTGTC 
1081 GTGGTAAGGC GCGCCATTTA AAGTGGAGTA CGCGCCCGGG GAGCCCAAGG GCACGCCCTG 
1141 GCACCCGCAC CGCGGGAAGC AGCTCCAGCC TACACAATCG CACATGTGAG CATGGCGTTA 
1201 CATTGTCGAT CTGTTCATGG TGAACAGCTT TGAATGCACC AAAAACTCGT AAAAGCTCTG 
1261 ATGTATCTAT CTTTTTTACA CCGTTTTCAT CTGTGCATAT GGACAGTTTT CCCTTTGATA 
1321 TGTAACGGTG AACAGTTGTT CTACTTTTGT TTGTTAGTCT TGATGCTTCA CTGATAGATA 
1381 CAAGAGCCAT AAGAACCTCA GATCCTTCCG TATTTAGCCA GTATGTTCTC TAGTGTGGTT 
1441 CGTTGTTTTT GCGTGAGCCA TGAGAACGAA CCATTGAGAT CATACTTACT TTGCATGTCA 
1501 CTCAAAAATT TTGCCTCAAA ACTGGTGAGC TGAATTTTTG CAGTTAAAGC ATCGTGTAGT 
1561 GTTTTTCTTA GTCCGTTATG TAGGTAGGAA TCTGATGTAA TGGTTGTTGG TATTTTGTCA 
1621 CCATTCATTT TTATCTGGTT GTTCTCAAGT TCGGTTACGA GATCCATTTG TCTATCTAGT 
1681 TCAACTTGGA AAATCAACGT ATCAGTCGGG CGGCCTCGCT TATCAACCAC CAATTTCATA 
1741 TTGCTGTAAG TGTTTAAATC TTTACTTATT GGTTTCAAAA CCCATTGGTT AAGCCTTTTA 
1801 AACTCATGGT AGTTATTTTC AAGCATTAAC ATGAACTTAA ATTCATCAAG GCTAATCTCT 
1861 ATATTTGCCT TGTGAGTTTT CTTTTGTGTT AGTTCTTTTA ATAACCACTC ATAAATCCTC 
1921 ATAGAGTATT TGTTTTCAAA AGACTTAACA TGTTCCAGAT TATATTTTAT GAATTTTTTT 
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1981 AACTGGAAAA GATAAGGCAA TATCTCTTCA CTAAAAACTA ATTCTAATTT TTCGCTTGAG 
2041 AACTTGGCAT AGTTTGTCCA CTGGAAAATC TCAAAGCCTT TAACCAAAGG ATTCCTGATT 
2101 TCCACAGTTC TCGTCATCAG CTCTCTGGTT GCTTTAGCTA ATACACCATA AGCATTTTCC 
2161 CTACTGATGT TCATCATCTG AGCGTATTGG TTATAAGTGA ACGATACCGT CCGTTCTTTC 
2221 CTTGTAGGGT TTTCAATCGT GGGGTTGAGT AGTGCCACAC AGCATAAAAT TAGCTTGGTT 
2281 TCATGCTCCG TTAAGTCATA GCGACTAATC GCTAGTTCAT TTGCTTTGAA AACAACTAAT 
2341 TCAGACATAC ATCTCAATTG GTCTAGGTGA TTTTAATCAC TATACCAATT GAGATGGGCT 
2401 AGTCAATGAT AATTACTAGT CCTTTTCCTT TGAGTTGTGG GTATCTGTAA ATTCTGCTAG 
2461 ACCTTTGCTG GAAAACTTGT AAATTCTGCT AGACCCTCTG TAAATTCCGC TAGACCTTTG 
2521 TGTGTTTTTT TTGTTTATAT TCAAGTGGTT ATAATTTATA GAATAAAGAA AGAATAAAAA 
2581 AAGATAAAAA GAATAGATCC CAGCCCTGTG TATAACTCAC TACTTTAGTC AGTTCCGCAG 
2641 TATTACAAAA GGATGTCGCA AACGCTGTTT GCTCCTCTAC AAAACAGACC TTAAAACCCT 
2701 AAAGGCTTAA GTAGCACCCT CGCAAGCTCG GGCAAATCGC TGAATATTCC TTTTGTCTCC 
2761 GACCATCAGG CACCTGAGTC GCTGTCTTTT TCGTGACATT CAGTTCGCTG CGCTCACGGC 
2821 TCTGGCAGTG AATGGGGGTA AATGGCACTA CAGGCGCCTT TTATGGATTC ATGCAAGGAA 
2881 ACTACCCATA ATACAAGAAA AGCCCGTCAC GGGCTTCTCA GGGCGTTTTA TGGCGGGTCT 
2941 GCTATGTGGT GCTATCTGAC TTTTTGCTGT TCAGCAGTTC CTGCCCTCTG ATTTTCCAGT 
3001 CTGACCACTT CGGATTATCC CGTGACAGGT CATTCAGACT GGCTAATGCA CCCAGTAAGG 
3061 CAGCGGTATC ATCAACAGGC TTACCCGTCT TACGCTGAAC TCACGTTAAG GGATTTTGGT 
3121 CATGAGATTA TCAAAAAGGA TCTTCACCTA GATCCTTTTA AATTAAAAAT GAAGTTTTAA 
3181 ATCAATCTAA AGTATATATG AGTAAACTTG GTCTGACAGT TATTAGAAAA ATTCATCCAG 
3241 CAGACGATAA AACGCAATAC GCTGGCTATC CGGTGCCGCA ATGCCATACA GCACCAGAAA 
3301 ACGATCCGCC CATTCGCCGC CCAGTTCTTC CGCAATATCA CGGGTGGCCA GCGCAATATC 
3361 CTGATAACGA TCCGCCACGC CCAGACGGCC GCAATCAATA AAGCCGCTAA AACGGCCATT 
3421 TTCCACCATA ATGTTCGGCA GGCACGCATC ACCATGGGTC ACCACCAGAT CTTCGCCATC 
3481 CGGCATGCTC GCTTTCAGAC GCGCAAACAG CTCTGCCGGT GCCAGGCCCT GATGTTCTTC 
3541 ATCCAGATCA TCCTGATCCA CCAGGCCCGC TTCCATACGG GTACGCGCAC GTTCAATACG 
3601 ATGTTTCGCC TGATGATCAA ACGGACAGGT CGCCGGGTCC AGGGTATGCA GACGACGCAT 
3661 GGCATCCGCC ATAATGCTCA CTTTTTCTGC CGGCGCCAGA TGGCTAGACA GCAGATCCTG 
3721 ACCCGGCACT TCGCCCAGCA GCAGCCAATC ACGGCCCGCT TCGGTCACCA CATCCAGCAC 
3781 CGCCGCACAC GGAACACCGG TGGTGGCCAG CCAGCTCAGA CGCGCCGCTT CATCCTGCAG 
3841 CTCGTTCAGC GCACCGCTCA GATCGGTTTT CACAAACAGC ACCGGACGAC CCTGCGCGCT 
3901 CAGACGAAAC ACCGCCGCAT CAGAGCAGCC AATGGTCTGC TGCGCCCAAT CATAGCCAAA 
3961 CAGACGTTCC ACCCACGCTG CCGGGCTACC CGCATGCAGG CCATCCTGTT CAATCATACT 
4021 CTTCCTTTTT CAATATTATT GAAGCATTTA TCAGGGTTAT TGTCTCATGA GCGGATACAT 
4081 ATTTGAATGT ATTTAGAAAA ATAAACAAAT AGGGGTTCCG CGCACATTTC CCCGAAAAGT 
4141 GCCACCTAAA TTGTAAGCGT TAATATTTTG TTAAAATTCG CGTTAAATTT TTGTTAAATC 
4201 AGCTCATTTT TTAACCAATA GGCCGAAATC GGCAATTAAA TCAATCTAAA GTATATATGA 
4261 GTAAACTTGG TCTGACAGGT GGAGTACGCG CCCGGGGAGC CCGGGGGCAC GCCCTGGCAC 
4321 CCGCACCGCG GGCGCCTACC TGTGACGGAC GTCCCCTCGT CTCACAATTT GAAAAGTATC 
4381 TCGTGCCAAT AAGTCTATCA CACTGACAAT CCGTTGAGGT CTGAGTTA  
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Supplementary Table A.2-5: Genomic homologies used to integrate the landing pad on the genome. 
Location Homology 1 (5'-3') Homology 2 (5'-3') 
djlA_yabP 
CTCAATGCACGGTTTACGGGAGGGGTTCT
GTAGGTTTTATCGCGTTGACC 
AGACGTAAAAATATAATTCCGCTCGTCGTA
AAGCTCTCAACCTTAAGCAG 
ylcI_nohD 
TAGATGATAATTATTATCATTTTGTGGGTCC
TTTCCGGCGATCCGACAGG 
CCGGAAAATTTTCATAAATAGCGAAAACCC
GCGAGGTCGCCGCCCCGTAA 
tyrV_tyrT 
TTCGTCGCTTCGCTCCTCACCCTTCGGGCC
GTTGCCTGTGGCAACGTTCT 
CGGGGAAGGGTGAGAACCTTCGACTAAGG
TTCGATTCGAGCGAAAGCGAG 
ypjC_ileY 
AGTAGTAGATGTTTAAGGCGTGGCAGAGA
CATTTCATCCTTACTCTACGG 
TCGCTCACTGATGATAAGTGAGTACCACAA
CCAATGTATGTAGAACAATG 
yhiM_yhiN 
CAGCAAAGTTACTGTTTTTTTCAACCTGTTC
ATATTTCATAAAGATCTGG 
CATGCTTAATATAAGGTGGATGGAAAGGTG
ATTGAAAACTCACTCAGTGG 
thrW_ykfN 
TCTTAATGTAACAGCTGGTGTAAGTAAATTC
TATCAACGAAGATCAATCT 
AAGGATGTATAGTGAGCGAAGCCCTATCAG
GCCTTTTTGGTCAGTAGATA 
entF_fepE 
TTGATTTATAGGTTTGATGAATATTTCTCTT
AAATAGAGTGAATGTTGCA 
AGTTGGTGATAATTATCCGAAGCTGAAGTT
TGTAAATTCCTTCCACTGAA 
ydaG_racR 
ACCACTGCCTGGTAACTCGAAGTATTGCCC
GGCGTTCTGTGGGGCGGGGT 
AGCCTATTGACAATCAATTAGGCATTACCT
ATAGTTCCAGCATACCACCC 
ileY_ygaQ 
GTATCTAATAATATAACTTTATTACATTAGC
TGAAGAGTTTTCGCATCAT 
ATTGCTATACGAAGTTTATTTTTATGGAGTG
AAAAGTAACAGATATCATA 
dinD_yicG 
TTTTCCCCCTCAGTTTTAACCTATTTTTTCTT
ATGCATTTTCTCAGACAA 
GTTATGTGAAATCGCTATTTTCTGTAGCAG
AGATGCATTCTTCTGACTTC 
ykfA_perR 
AGGCAGCTGCGCGACTGCTGGCTCAGGCA
ATGAATGAGTTATAATAGCAG 
AAGGTGTATCACGGCGGCTCATACTCTCAA
TAAATCCCTGTTAGTAAATG 
ybfK_kdpE 
CAATAAAAAATGATCAATCTTAATTTATTTAA
TGATGAGCTTTTTACTCA 
TTTTTATCTTAAACAACACACAAAAATAACA
ATTCAATATTTTATATTAC 
cspF_quuQ 
GTTTAGGGACATTGTACTGGAAGAAAACAT
TTTAAACATCAGGCAAATAA 
CTCATCCCGGGACTCATGTCTGTTAACTTA
TTATTTAGCTGGTGACTTGG 
yqaB_argQ 
TGGATAAAGGAGTTATTTAGAAATGAGATA
TTTTTGAAGGAAATTTTTTG 
CCCGAAGGGCGAACGTCAGTGAGTCATCC
TCCCGGATGCACCATCTTCTC 
frvA_rhaM 
TGAAAGGTCAGATTTGCGGAGTAATGCACA
TAATGGTTATTTAAATAAAC 
ATTGTGAGTAAATCACAAAAATAATGAATAA
CCCATTAATGATTCATGTG 
insN_eyeA 
TGCCCGCAGGGTGATGTAACCCGCTGACA
ACGGGGATTGAGGCGAGATCA 
CATGTTCTTCAACCTTTCAGTACTTAACCTT
GAGGATCATCTCGGCTTAG 
ybfC_ybfQ 
TTTATTTTGCGTTCCATTTGCAGGGAAAGAT
CACGTAACGCTACTTTTTT 
CAATAAGTAGTATCTCAATTGTTGAACTTAA
AATTCGAATTATTTAGTAC 
rseX_yedS 
ATTTTCATGAATATTTATATTTAGAATTCATA
ATTATGAATTATATTAAA 
GATTACATGTAACAAATGTATTTAAAAGATA
TCAAAATGTTTCTAATCTA 
ygcE_queE 
GGTGGTTTATCCCCGCTGGCGCGGGGAAC
TCGACAGAACGGCCTCAGTAG 
GAAAACAGGTGTTCCCCGCGCCAGCGGGG
ATAAACCGGAGCCTGACGAGA 
frwA_frwC 
CAATTTGCGACGCGTCTCACAAGACGCTGT
TTTGCGGCATGCTTCCGGTT 
ACTTTTGTAATATCAGTACAAAAATGCGATC
CGCCTCATAACTTGCGATA 
ykgA_ykgQ 
CCGAAAATAGAGAGGTTTCAGTCCTACATT
ATTAATGAATTTTTTGCATA 
GTCTACGTTAAAACGTAACCTCAAAGTAGT
ATGTGGATTTTGATATCACT 
ybiJ_ybiI 
AAATCGAAGAGAATTGACCGCCTTGTTCAA
ATAAATTGATTGATATCTAA 
CGGTATAAAACAAGTTCATAAGTACAACAA
ATAAATGGTTTATCAGTAGG 
yeeJ_yeeL 
CACAGAAAATGAATAAATAAAAATGCGGCA
CCGCCAGAATCGCGTTCGAT 
AAACCAGCCTTTAGATCAAAGCAGTACTCA
CCGAAAATGATCATAGTCAC 
ygeF_ygeG 
GATGTTATTAGTTTGTAGTGAACAGTACTTT
TACCAATAATGAAAAATAT 
TATATTTATCTTTTTTAAATTATGAGTTTTAA
GCTTGCATTGCTTATGGT 
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malM_yjbI 
TCCTTCCTGGGATATGAGCGATTTTTTATA
GTAACTCACTTCTTCTTCAC 
GCGAAAGGAAAAGAATCTCTGATAAGGCAT
TGAGATAATGGATATTCTTA 
ykgH_betA 
AGGAATGTTCGGGTTAAATATCAGCAAAAA
GCCCGCATCATGAATACTGG 
GGGGGACCGAATCCTTATATAAACACTGAG
GTAACTCTCATGCTTCATAT 
ymgF_ycgH 
GCAACTATTAACAATTTTGATGTCGAAGAG
TTATTTGTTAAACAAAATCG 
GCATTATCATTTTTCACCTTATTTTCATGAC
ATTGATCACTTTGAGGTGA 
udk_yegE 
CGCGCTCAGAGTTAATTGTTGACAAAGAAT
TCCCGGGGGCAAATTACGTT 
ATAATTTGCGCAACTGCGTTTAACATTTTTT
ACCTTACATAAAACTGATC 
ygeK_ygeN 
ATTATAAGCAAAATCCAAAGAATACATTGAT
GAAATAATAATGAAATATA 
GATTTTTTAATGCCTGTGGTATTTTTTTACG
CAAAAATTTTATTTTTAAT 
yjcS_alsK 
TTGCGACTTTAATAAGTGGAAGTGTGAGCG
GAACGCGCCATTTTATTAGG 
ATTTTCTGCAATGATAGTTTTACTGTAATTT
TCCCTCTTCAGCACAAATG 
yahK_yahL 
CGAAATAATATCAAAGTAGCAGTAAAACCT
ATAACGTAAATTTAAATTGT 
TCGCTCATAACTAACGTGTGAAGTATTGTG
TACTGGAGGGCGTTAATTTA 
dadX_cvrA 
AACCTGAACTCACCGCACAGGCGTTCTACA
TAAAACGCTTACGCTTCATT 
GCTCCATCAAGGGTAAAGCGTGATTTATCT
GAAGTCGAGTTCGAGTCAAC 
yffL_yffM 
TTTTTAGCCTCCCGGTCGGTCATAGAGAGT
CGCCTAGAGTTAAACAGAAG 
AGCATGGTTAATGCTCGCAACCAGCCGAC
CTATCAGGCGGCGAAATAATT 
sibD_sibE 
AAAAGCCGGGGATTTTTTATATCTGCGTTC
CGCTAAAAGGTGCAAATGCT 
AGGCAATTTTGCCTTCCCCGAGCGGTCAC
GCAAAACGCTGCAACGTCCTG 
yjhV_fecE 
CCTGAAATCTAAACTTAGTCATGTCACGTTT
TTGGGTTTCTAAAATTTTA 
GCTTAACGGACATTTCTGTATAACCCTTAC
GGCAACGAAAAACGCGAAGT 
yfjQ_yfjR 
TCGTGTGCCTCAATCCCCCGGTTATAGCTT
TTAACCCCCGTTACATCTGG 
GGCGGACAGGGTATGGACAACGCAGAAAC
TATTTTTTATTTCTGCAAAAG 
glpD_yzgL 
AGGCCTACGTGGTTTATGCAATATATTGAA
TTTGCATGGTCTTGTAGGCC 
TTGACAAAGTGCGCTTTGTTCATGCCGGAT
GCGACGTGAACGTCTTATCT 
yjiP_yjiR 
TATTGAACTTTAAAGATTTTTGTAGACCTGG
TCAGGCGTTCACATGGCAT 
ATCGCCACGTTCCAGCCTGAATTAAGCAAA
GTACGCTTTGTTCATGCCGG 
lacZ_lacI 
CCGAGTTAACGCCATCAAAAATAATTCGCG
TCTGGCCTTCCTGTAGCCAG 
CATTAATGCAGCTGGCACGACAGGTTTCCC
GACTGGAAAGCGGGCAGTGA 
ycbW_ycbX 
TGAAACCGCAGGTTAATGTTGACAGCTTCA
GCCTCGAACAGGCAGTCTAA 
TTCTTTGCTGTAGCTGTGTACCGAAGACTG
CACTTAAGTTGGCGCGTTAG 
nupG_speC 
ATAAACACGTTCGTGTCCCGACAGGCACAC
AGACGGTTAGCCACTAATTA 
GTAAGAATAAAAAAAACGGGTCACCTTCTG
GCGACCCGTTTTTCTTTGCG 
aslB_aslA 
TGTAGGCTGGATAAGATGCGTCAGCATCG
CATCCGGCAAAGGCAGATCTC 
AATATCCACCACGCGCGCAGATTAAATCTG
ACTAAGCCGGCGCTATCGCT 
atpI_gidB 
CAAAAAGCGGTCAAATTATACGGTGCGCCC
CCGTGATTTCAAACAATAAG 
ATAACGTGGCTTTTTTTGGTAAGCAGAAAA
TAAGTCATTAGTGAAAATAT 
yieN_trkD 
TGGCGTCCTTTCGTCAAAAGTTCTGCGTAA
ATTGCGAGTATAGACGTTTC 
GTATGCACGATTAACGGCAAAATCGTACTC
CTAAATGCGGCCACATTAAC 
ybbD_ylbI 
CTGAGAAAAGACATGTCGGCTATTGTGTAA
AGCCATATAGCTCAGACGAT 
TTCTATGTAAACTCTCTGACTGTTCATTTTA
TTTGTTGTTTCAGGGTCGG 
essQ_cspB 
ATGGTGCAATATGTTTGAAAAGATCGGAGT
CTACGGGGTAGTTTTGACAG 
GATAATTACGGCGTGATTTTGAGTTTTTAC
GTTCTGACATAGGCTTTTCC 
nth_ydgR 
TTAACGTCAATGATGCCATTGCTTAGCGTT
ATCATCAGGTAATCCGTTTG 
GATAGTCCAGTTTCTGAAAAATAGCCAGTG
TAATGTTTTGTAGGTCAATA 
fucl_fucK 
TTACTCCCTGATGTGATGCCCGGTCGCTCC
GGCTACCGGGCCTGAACAAG 
GCTCCTGCAATATAGCCGGATAACATTGCT
TATCCGGCTAACCACTCTTG 
xylB_xylA 
TATCCCGATATACATATCGATCGTTCCTTAA
AAAAATGCCCGGTATCGCT 
TGTTCGACAAATAACGGCTAACTGTGCAGT
CCGTTGGCCCGGTTATCGGT 
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Supplementary Table A.2-6: Detailed information on the 49 genomic locations and their position on the 
E. coli genome. The 26 locations in grey shade are discussed more in detail in this article. All locations 
meet the premised criteria, more specifically are intergenic regions larger than 200 bp, contain no 
promoters (27, 119), no terminators (27, 29) and no other (potential) regulatory sequences or sRNAs 
(118), except when stated otherwise in the last column. Macrodomains according to Espeli et al. (121). 
Location Orientation 
Macro- 
domain  
heEPODs 
(100) 
tsEPODs 
(100) 
Deviation from criteria 
aslB_aslA Convergent ORI no overlap no overlap 
<200 bp, terminator according 
to WebGeSTer (29) but not to 
RegulonDB (27) 
atpI_gidB Codirectional- ORI right overlap no overlap promoter (27, 119) 
cspF_quuQ Convergent TER internal no overlap  
dadX_cvrA Convergent TER no overlap no overlap  
dinD_yicG Codirectional+ ORI no overlap no overlap  
djlA_yabP Codirectional+ R-NS no overlap no overlap  
entF_fepE Codirectional+ Right no overlap no overlap  
essQ_cspB Codirectional- TER left overlap no overlap 
Terminator (29), potential 
regulatory sequences (118) 
frvA_rhaM Codirectional- ORI no overlap no overlap  
frwA_frwC Divergent ORI no overlap no overlap  
fucl_fucK Codirectional+ L-NS no overlap no overlap <200 bp 
glpD_yzgL Convergent L-NS internal no overlap  
ileY_ygaQ Divergent LEFT no overlap internal  
insN_eyeA Codirectional+ R-NS no overlap no overlap  
lacZ_lacI Codirectional- R-NS no overlap no overlap 
<200 bp, promoter (27, 119) 
and terminator according to 
WebGeSTer (29) but not to 
RegulonDB (27) 
malM_yjbI Codirectional+ ORI no overlap internal  
nth_ydgR Codirectional+ TER no overlap no overlap 
promotor according to 
RegulonDB (27) but not to 
PromEC (119) 
nupG_speC Convergent L-NS no overlap no overlap 
<200 bp, terminator according 
to WebGeSTer (29) but not to 
RegulonDB (27) 
rseX_yedS Codirectional+ TER no overlap no overlap  
sibD_sibE Codirectional- L-NS no overlap no overlap  
thrW_ykfN Convergent R-NS no overlap no overlap  
tyrV_tyrT Codirectional- TER internal no overlap  
udk_yegE Divergent LEFT no overlap no overlap  
xylB_xylA Codirectional- L-NS no overlap no overlap 
<200 bp, terminator according 
to WebGeSTer (29) but not to 
RegulonDB (27) 
yahK_yahL Codirectional+ R-NS no overlap internal  
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ybbD_ylbI Codirectional+ R-NS no overlap right overlap  
ybfC_ybfQ Codirectional+ Right no overlap internal  
ybfK_kdpE Convergent Right no overlap no overlap  
ybiJ_ybiI Codirectional- Right no overlap no overlap  
ycbW_ycbX Convergent Right no overlap no overlap <200 bp 
ydaG_racR Codirectional- TER no overlap no overlap  
yeeJ_yeeL Convergent LEFT no overlap no overlap  
yffL_yffM Codirectional+ LEFT no overlap no overlap  
yfjQ_yfjR Codirectional+ LEFT no overlap no overlap  
ygcE_queE Convergent L-NS no overlap no overlap  
ygeF_ygeG Codirectional+ L-NS no overlap internal  
ygeK_ygeN Codirectional- L-NS no overlap internal  
yhiM_yhiN Convergent L-NS no overlap internal  
yieN_trkD Divergent ORI no overlap no overlap 
promoter according to 
RegulonDB (27) but not to 
PromEC (119) 
yjcS_alsK Codirectional- ORI no overlap internal  
yjhV_fecE Convergent ORI no overlap no overlap  
yjiP_yjiR Convergent ORI no overlap no overlap  
ykfA_perR Codirectional- R-NS no overlap no overlap  
ykgA_ykgQ Divergent R-NS no overlap internal  
ykgH_betA Codirectional- R-NS no overlap internal  
ylcI_nohD Divergent R-NS no overlap no overlap  
ymgF_ycgH Codirectional+ TER no overlap internal  
ypjC_ileY Codirectional- LEFT no overlap internal  
yqaB_argQ Codirectional- LEFT internal no overlap  
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Supplementary Table A.2-7: Time until fluorescent signal and maturation time of the different fluorescent 
proteins. mCherry and mKate data is based on literature, the other data was determined in house on 
plasmid level. 
 Time until fluorescent signal Maturation time Source 
CindyLou CFP ~40 min ~2.5 h In house 
Comet GFP ~1 h ~3.5 h In house 
Cratchit YFP ~50 min ~4 h In house 
Dasher GFP ~40 min ~5 min In house 
eBFP2 ~4.5 h ~11.5 h In house 
Frosty CFP ~1 h ~4.5 h In house 
Holly GFP ~30 min ~5 min In house 
Ivy GFP ~3.5 h ~9.5 h In house 
Kringle YFP ~1 h ~4 h In house 
Marley YFP ~1 h ~5.5 h In house 
mCherry RFP - 40 min (108) 
mKate2 RFP - <20 min (108) 
Rudolph RFP ~3.5 h ~8.5 h In house 
Tannen RFP ~4 h ~9 h In house 
Twinkle CFP ~50 min ~4 h In house 
Yeti YFP ~50 min ~5 h In house 
yPET YFP ~2.5 h ~1.5 h In house 
Yukon OFP ~4.5 h ~10 h In house 
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Supplementary Table A.2-8: Statistical output for the linear regression model of the natural logarithm of the 
fluorescence of the Dasher reporter cassette (y) in function of the net distance from oriC (x) according  to 
𝑦 = 𝐴𝑒𝑘𝑥 ⇔ 𝑙𝑛(𝑦) = 𝑙𝑛(𝐴) + 𝑘 ∗ 𝑙𝑛 (𝑥). Analysis performed with the package StatsModel for Python. 
OLS Regression Results                             
Dep. Variable: Dasher corr. OD and WT R-squared: 0.717 
Model: OLS Adj. R-squared: 0.698 
Method: Least Squares F-statistic: 37.97 
No. Observations: 49 Prob (F-statistic): 2.18e-14 
Df Residuals: 45 Log-Likelihood: 37.826 
Df Model: 3 AIC: -67.65 
Covariance Type: nonrobust BIC: -60.09 
 coef std err t P>|t| [0.025 0.975] 
ln(A)          8.7178 0.035 247.32 0.000 8.647 8.789 
C(Category)[T.heEPODs] 0.0115 0.053 0.219 0.828 -0.095 0.118 
C(Category)[T.tsEPODs] -0.1552 0.039 -4.00 0.000 -0.233 -0.077 
x -0.6046 0.060 -10.08 0.000 -0.725 -0.484 
Omnibus: 14.897 Durbin-Watson: 2.081 
Prob(Omnibus): 0.001 Jarque-Bera (JB): 16.348 
Skew: -1.317 Prob(JB): 0.000282 
Kurtosis: 4.032 Cond. No. 4.67 
 
Supplementary Table A.2-9: Statistical output for the linear regression model of the fluorescence of the 
Dasher reporter cassette in the inverted orientation in function of the fluorescence of the cassette in 
normal orientation. Analysis performed with the package StatsModel for Python. 
OLS Regression Results 
Dep. Variable: Dasher corr. OD and WT RV R-squared: 0.830 
Model: OLS Adj. R-squared: 0.823 
Method: Least Squares F-statistic: 116.9 
No. Observations: 26 Prob (F-statistic): 1.05e-10 
Df Residuals: 24 Log-Likelihood: -188.52 
Df Model: 1 AIC: 381.0 
Covariance Type: nonrobust BIC: 383.6 
 coef std err t P>|t| [0.025 0.975] 
const 63.5841 422.398 0.151 0.882 -808.202 935.370 
Dasher corr. OD and WT 0.9812 0.091 10.810 0.000 0.794 1.169 
Omnibus: 0.603 Durbin-Watson: 2.219 
Prob(Omnibus): 0.740 Jarque-Bera (JB): 0.561 
Skew: -0.317 Prob(JB): 0.755 
Kurtosis: 2.658 Cond. No. 2.82e+04 
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Supplementary Table A.2-10: Statistical output for the paired one-sided t-test for the 26 locations to check 
if the green fluorescence output is significantly diminished on imposing burden by pLys-M1. Analysis 
performed with the package SciPy for Python. 
Location p-value Rejecting null hypothesis 
dadX_cvrA 0.076 False 
rseX_yedS 0.005 True 
djlA_yabP 0.006 True 
tyrV_tyrT 0.011 True 
ypjC_ileY 0.078 False 
yhiM_yhiN 0.011 True 
thrW_ykfN 0.141 False 
ileY_ygaQ 0.461 False 
ybfK_kdpE 0.018 True 
cspF_quuQ 0.058 False 
yqaB_argQ 0.009 True 
frvA_rhaM 0.012 True 
frwA_frwC 0.012 True 
ykgA_ykgQ 0.060 False 
ybiJ_ybiI 0.030 True 
yeeJ_yeeL 0.040 False 
malM_yjbI 0.003 True 
ykgH_betA 0.058 False 
udk_yegE 0.007 True 
yffL_yffM 0.016 True 
sibD_sibE 0.024 True 
glpD_yzgL 0.007 True 
yjiP_yjiR 0.084 False 
ybfC_ybfQ 0.357 False 
ygcE_queE 0.016 True 
ymgF_ycgH 0.223 False 
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Supplementary Table A.2-11: Statistical output for the ANOVA analysis with Tukey correction for 
determining significant differences between strains influenced by burden. Values indicated with an * show 
that the mean difference is significant at the 5% level. Analysis performed with SPSS software. 
Location I Location J Mean Diff.  Std. Error p-value 95% Confidence Interval 
     
Lower 
Bound 
Upper 
Bound 
djlA_yabP frwA_frwC -0.0937 0.02628 0.066 -0.1906 0.0031 
 
glpD_yzgL -.1178* 0.02628 0.007 -0.2147 -0.021 
 
malM_yjbI -.1307* 0.02628 0.002 -0.2276 -0.0339 
 
sibD_sibE -.1346* 0.02628 0.001 -0.2314 -0.0377 
 
frvA_rhaM -.1380* 0.02628 0.001 -0.2349 -0.0412 
 
yhiM_yhiN -.1401* 0.02628 0.001 -0.2369 -0.0432 
 
yqaB_argQ -.1650* 0.02628 0 -0.2619 -0.0682 
 
yffL_yffM -.1876* 0.02628 0 -0.2845 -0.0908 
 
ygcE_queE -.1905* 0.02628 0 -0.2874 -0.0937 
 
ybiJ_ybiI -.2054* 0.02628 0 -0.3023 -0.1086 
 
ybfK_kdpE -.2222* 0.02628 0 -0.3191 -0.1254 
 
rseX_yedS -.2295* 0.02628 0 -0.3264 -0.1327 
 
udk_yegE -.2334* 0.02628 0 -0.3303 -0.1366 
 
tyrV_tyrT -.2633* 0.02628 0 -0.3601 -0.1664 
frwA_frwC djlA_yabP 0.0937 0.02628 0.066 -0.0031 0.1906 
 
glpD_yzgL -0.0241 0.02628 1 -0.121 0.0727 
 
malM_yjbI -0.037 0.02628 0.98 -0.1338 0.0598 
 
sibD_sibE -0.0409 0.02628 0.956 -0.1377 0.056 
 
frvA_rhaM -0.0443 0.02628 0.922 -0.1411 0.0526 
 
yhiM_yhiN -0.0463 0.02628 0.895 -0.1432 0.0505 
 
yqaB_argQ -0.0713 0.02628 0.344 -0.1681 0.0256 
 
yffL_yffM -0.0939 0.02628 0.065 -0.1907 0.003 
 
ygcE_queE -0.0968 0.02628 0.05 -0.1936 0.0001 
 
ybiJ_ybiI -.1117* 0.02628 0.013 -0.2086 -0.0149 
 
ybfK_kdpE -.1285* 0.02628 0.002 -0.2253 -0.0316 
 
rseX_yedS -.1358* 0.02628 0.001 -0.2327 -0.039 
 
udk_yegE -.1397* 0.02628 0.001 -0.2366 -0.0429 
 
tyrV_tyrT -.1696* 0.02628 0 -0.2664 -0.0727 
glpD_yzgL djlA_yabP .1178* 0.02628 0.007 0.021 0.2147 
 
frwA_frwC 0.0241 0.02628 1 -0.0727 0.121 
 
malM_yjbI -0.0129 0.02628 1 -0.1097 0.084 
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sibD_sibE -0.0167 0.02628 1 -0.1136 0.0801 
 
frvA_rhaM -0.0202 0.02628 1 -0.117 0.0767 
 
yhiM_yhiN -0.0222 0.02628 1 -0.1191 0.0746 
 
yqaB_argQ -0.0472 0.02628 0.882 -0.144 0.0497 
 
yffL_yffM -0.0698 0.02628 0.376 -0.1666 0.0271 
 
ygcE_queE -0.0727 0.02628 0.317 -0.1695 0.0242 
 
ybiJ_ybiI -0.0876 0.02628 0.109 -0.1844 0.0093 
 
ybfK_kdpE -.1044* 0.02628 0.025 -0.2012 -0.0075 
 
rseX_yedS -.1117* 0.02628 0.013 -0.2085 -0.0148 
 
udk_yegE -.1156* 0.02628 0.009 -0.2125 -0.0188 
 
tyrV_tyrT -.1454* 0.02628 0 -0.2423 -0.0486 
malM_yjbI djlA_yabP .1307* 0.02628 0.002 0.0339 0.2276 
 
frwA_frwC 0.037 0.02628 0.98 -0.0598 0.1338 
 
glpD_yzgL 0.0129 0.02628 1 -0.084 0.1097 
 
sibD_sibE -0.0039 0.02628 1 -0.1007 0.093 
 
frvA_rhaM -0.0073 0.02628 1 -0.1041 0.0896 
 
yhiM_yhiN -0.0093 0.02628 1 -0.1062 0.0875 
 
yqaB_argQ -0.0343 0.02628 0.99 -0.1311 0.0626 
 
yffL_yffM -0.0569 0.02628 0.685 -0.1537 0.04 
 
ygcE_queE -0.0598 0.02628 0.615 -0.1566 0.0371 
 
ybiJ_ybiI -0.0747 0.02628 0.278 -0.1716 0.0221 
 
ybfK_kdpE -0.0915 0.02628 0.079 -0.1883 0.0054 
 
rseX_yedS -.0988* 0.02628 0.042 -0.1957 -0.002 
 
udk_yegE -.1027* 0.02628 0.03 -0.1996 -0.0059 
 
tyrV_tyrT -.1326* 0.02628 0.002 -0.2294 -0.0357 
sibD_sibE djlA_yabP .1346* 0.02628 0.001 0.0377 0.2314 
 
frwA_frwC 0.0409 0.02628 0.956 -0.056 0.1377 
 
glpD_yzgL 0.0167 0.02628 1 -0.0801 0.1136 
 
malM_yjbI 0.0039 0.02628 1 -0.093 0.1007 
 
frvA_rhaM -0.0034 0.02628 1 -0.1003 0.0934 
 
yhiM_yhiN -0.0055 0.02628 1 -0.1023 0.0914 
 
yqaB_argQ -0.0304 0.02628 0.997 -0.1273 0.0664 
 
yffL_yffM -0.053 0.02628 0.773 -0.1499 0.0438 
 
ygcE_queE -0.0559 0.02628 0.708 -0.1528 0.0409 
 
ybiJ_ybiI -0.0709 0.02628 0.353 -0.1677 0.026 
 
ybfK_kdpE -0.0876 0.02628 0.109 -0.1845 0.0092 
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rseX_yedS -0.095 0.02628 0.059 -0.1918 0.0019 
 
udk_yegE -.0989* 0.02628 0.042 -0.1957 -0.002 
 
tyrV_tyrT -.1287* 0.02628 0.002 -0.2256 -0.0319 
frvA_rhaM djlA_yabP .1380* 0.02628 0.001 0.0412 0.2349 
 
frwA_frwC 0.0443 0.02628 0.922 -0.0526 0.1411 
 
glpD_yzgL 0.0202 0.02628 1 -0.0767 0.117 
 
malM_yjbI 0.0073 0.02628 1 -0.0896 0.1041 
 
sibD_sibE 0.0034 0.02628 1 -0.0934 0.1003 
 
yhiM_yhiN -0.0021 0.02628 1 -0.0989 0.0948 
 
yqaB_argQ -0.027 0.02628 0.999 -0.1239 0.0698 
 
yffL_yffM -0.0496 0.02628 0.841 -0.1465 0.0472 
 
ygcE_queE -0.0525 0.02628 0.785 -0.1493 0.0444 
 
ybiJ_ybiI -0.0674 0.02628 0.429 -0.1643 0.0294 
 
ybfK_kdpE -0.0842 0.02628 0.142 -0.181 0.0127 
 
rseX_yedS -0.0915 0.02628 0.079 -0.1884 0.0053 
 
udk_yegE -0.0954 0.02628 0.057 -0.1923 0.0014 
 
tyrV_tyrT -.1253* 0.02628 0.003 -0.2221 -0.0284 
yhiM_yhiN djlA_yabP .1401* 0.02628 0.001 0.0432 0.2369 
 
frwA_frwC 0.0463 0.02628 0.895 -0.0505 0.1432 
 
glpD_yzgL 0.0222 0.02628 1 -0.0746 0.1191 
 
malM_yjbI 0.0093 0.02628 1 -0.0875 0.1062 
 
sibD_sibE 0.0055 0.02628 1 -0.0914 0.1023 
 
frvA_rhaM 0.0021 0.02628 1 -0.0948 0.0989 
 
yqaB_argQ -0.025 0.02628 1 -0.1218 0.0719 
 
yffL_yffM -0.0476 0.02628 0.876 -0.1444 0.0493 
 
ygcE_queE -0.0504 0.02628 0.826 -0.1473 0.0464 
 
ybiJ_ybiI -0.0654 0.02628 0.477 -0.1622 0.0315 
 
ybfK_kdpE -0.0821 0.02628 0.166 -0.179 0.0147 
 
rseX_yedS -0.0895 0.02628 0.094 -0.1863 0.0074 
 
udk_yegE -0.0934 0.02628 0.067 -0.1902 0.0035 
 
tyrV_tyrT -.1232* 0.02628 0.004 -0.2201 -0.0264 
yqaB_argQ djlA_yabP .1650* 0.02628 0 0.0682 0.2619 
 
frwA_frwC 0.0713 0.02628 0.344 -0.0256 0.1681 
 
glpD_yzgL 0.0472 0.02628 0.882 -0.0497 0.144 
 
malM_yjbI 0.0343 0.02628 0.99 -0.0626 0.1311 
 
sibD_sibE 0.0304 0.02628 0.997 -0.0664 0.1273 
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frvA_rhaM 0.027 0.02628 0.999 -0.0698 0.1239 
 
yhiM_yhiN 0.025 0.02628 1 -0.0719 0.1218 
 
yffL_yffM -0.0226 0.02628 1 -0.1195 0.0742 
 
ygcE_queE -0.0255 0.02628 0.999 -0.1223 0.0714 
 
ybiJ_ybiI -0.0404 0.02628 0.96 -0.1373 0.0564 
 
ybfK_kdpE -0.0572 0.02628 0.678 -0.154 0.0397 
 
rseX_yedS -0.0645 0.02628 0.498 -0.1614 0.0323 
 
udk_yegE -0.0684 0.02628 0.406 -0.1653 0.0284 
 
tyrV_tyrT -.0983* 0.02628 0.044 -0.1951 -0.0014 
yffL_yffM djlA_yabP .1876* 0.02628 0 0.0908 0.2845 
 
frwA_frwC 0.0939 0.02628 0.065 -0.003 0.1907 
 
glpD_yzgL 0.0698 0.02628 0.376 -0.0271 0.1666 
 
malM_yjbI 0.0569 0.02628 0.685 -0.04 0.1537 
 
sibD_sibE 0.053 0.02628 0.773 -0.0438 0.1499 
 
frvA_rhaM 0.0496 0.02628 0.841 -0.0472 0.1465 
 
yhiM_yhiN 0.0476 0.02628 0.876 -0.0493 0.1444 
 
yqaB_argQ 0.0226 0.02628 1 -0.0742 0.1195 
 
ygcE_queE -0.0029 0.02628 1 -0.0997 0.094 
 
ybiJ_ybiI -0.0178 0.02628 1 -0.1147 0.079 
 
ybfK_kdpE -0.0346 0.02628 0.989 -0.1314 0.0623 
 
rseX_yedS -0.0419 0.02628 0.947 -0.1388 0.0549 
 
udk_yegE -0.0458 0.02628 0.902 -0.1427 0.051 
 
tyrV_tyrT -0.0757 0.02628 0.261 -0.1725 0.0212 
ygcE_queE djlA_yabP .1905* 0.02628 0 0.0937 0.2874 
 
frwA_frwC 0.0968 0.02628 0.05 -0.0001 0.1936 
 
glpD_yzgL 0.0727 0.02628 0.317 -0.0242 0.1695 
 
malM_yjbI 0.0598 0.02628 0.615 -0.0371 0.1566 
 
sibD_sibE 0.0559 0.02628 0.708 -0.0409 0.1528 
 
frvA_rhaM 0.0525 0.02628 0.785 -0.0444 0.1493 
 
yhiM_yhiN 0.0504 0.02628 0.826 -0.0464 0.1473 
 
yqaB_argQ 0.0255 0.02628 0.999 -0.0714 0.1223 
 
yffL_yffM 0.0029 0.02628 1 -0.094 0.0997 
 
ybiJ_ybiI -0.0149 0.02628 1 -0.1118 0.0819 
 
ybfK_kdpE -0.0317 0.02628 0.995 -0.1286 0.0651 
 
rseX_yedS -0.039 0.02628 0.969 -0.1359 0.0578 
 
udk_yegE -0.0429 0.02628 0.937 -0.1398 0.0539 
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tyrV_tyrT -0.0728 0.02628 0.314 -0.1696 0.0241 
ybiJ_ybiI djlA_yabP .2054* 0.02628 0 0.1086 0.3023 
 
frwA_frwC .1117* 0.02628 0.013 0.0149 0.2086 
 
glpD_yzgL 0.0876 0.02628 0.109 -0.0093 0.1844 
 
malM_yjbI 0.0747 0.02628 0.278 -0.0221 0.1716 
 
sibD_sibE 0.0709 0.02628 0.353 -0.026 0.1677 
 
frvA_rhaM 0.0674 0.02628 0.429 -0.0294 0.1643 
 
yhiM_yhiN 0.0654 0.02628 0.477 -0.0315 0.1622 
 
yqaB_argQ 0.0404 0.02628 0.96 -0.0564 0.1373 
 
yffL_yffM 0.0178 0.02628 1 -0.079 0.1147 
 
ygcE_queE 0.0149 0.02628 1 -0.0819 0.1118 
 
ybfK_kdpE -0.0168 0.02628 1 -0.1136 0.0801 
 
rseX_yedS -0.0241 0.02628 1 -0.121 0.0727 
 
udk_yegE -0.028 0.02628 0.999 -0.1249 0.0688 
 
tyrV_tyrT -0.0579 0.02628 0.662 -0.1547 0.039 
ybfK_kdpE djlA_yabP .2222* 0.02628 0 0.1254 0.3191 
 
frwA_frwC .1285* 0.02628 0.002 0.0316 0.2253 
 
glpD_yzgL .1044* 0.02628 0.025 0.0075 0.2012 
 
malM_yjbI 0.0915 0.02628 0.079 -0.0054 0.1883 
 
sibD_sibE 0.0876 0.02628 0.109 -0.0092 0.1845 
 
frvA_rhaM 0.0842 0.02628 0.142 -0.0127 0.181 
 
yhiM_yhiN 0.0821 0.02628 0.166 -0.0147 0.179 
 
yqaB_argQ 0.0572 0.02628 0.678 -0.0397 0.154 
 
yffL_yffM 0.0346 0.02628 0.989 -0.0623 0.1314 
 
ygcE_queE 0.0317 0.02628 0.995 -0.0651 0.1286 
 
ybiJ_ybiI 0.0168 0.02628 1 -0.0801 0.1136 
 
rseX_yedS -0.0073 0.02628 1 -0.1042 0.0895 
 
udk_yegE -0.0112 0.02628 1 -0.1081 0.0856 
 
tyrV_tyrT -0.0411 0.02628 0.954 -0.1379 0.0558 
rseX_yedS djlA_yabP .2295* 0.02628 0 0.1327 0.3264 
 
frwA_frwC .1358* 0.02628 0.001 0.039 0.2327 
 
glpD_yzgL .1117* 0.02628 0.013 0.0148 0.2085 
 
malM_yjbI .0988* 0.02628 0.042 0.002 0.1957 
 
sibD_sibE 0.095 0.02628 0.059 -0.0019 0.1918 
 
frvA_rhaM 0.0915 0.02628 0.079 -0.0053 0.1884 
 
yhiM_yhiN 0.0895 0.02628 0.094 -0.0074 0.1863 
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yqaB_argQ 0.0645 0.02628 0.498 -0.0323 0.1614 
 
yffL_yffM 0.0419 0.02628 0.947 -0.0549 0.1388 
 
ygcE_queE 0.039 0.02628 0.969 -0.0578 0.1359 
 
ybiJ_ybiI 0.0241 0.02628 1 -0.0727 0.121 
 
ybfK_kdpE 0.0073 0.02628 1 -0.0895 0.1042 
 
udk_yegE -0.0039 0.02628 1 -0.1008 0.0929 
 
tyrV_tyrT -0.0338 0.02628 0.991 -0.1306 0.0631 
udk_yegE djlA_yabP .2334* 0.02628 0 0.1366 0.3303 
 
frwA_frwC .1397* 0.02628 0.001 0.0429 0.2366 
 
glpD_yzgL .1156* 0.02628 0.009 0.0188 0.2125 
 
malM_yjbI .1027* 0.02628 0.03 0.0059 0.1996 
 
sibD_sibE .0989* 0.02628 0.042 0.002 0.1957 
 
frvA_rhaM 0.0954 0.02628 0.057 -0.0014 0.1923 
 
yhiM_yhiN 0.0934 0.02628 0.067 -0.0035 0.1902 
 
yqaB_argQ 0.0684 0.02628 0.406 -0.0284 0.1653 
 
yffL_yffM 0.0458 0.02628 0.902 -0.051 0.1427 
 
ygcE_queE 0.0429 0.02628 0.937 -0.0539 0.1398 
 
ybiJ_ybiI 0.028 0.02628 0.999 -0.0688 0.1249 
 
ybfK_kdpE 0.0112 0.02628 1 -0.0856 0.1081 
 
rseX_yedS 0.0039 0.02628 1 -0.0929 0.1008 
 
tyrV_tyrT -0.0298 0.02628 0.997 -0.1267 0.067 
tyrV_tyrT djlA_yabP .2633* 0.02628 0 0.1664 0.3601 
 
frwA_frwC .1696* 0.02628 0 0.0727 0.2664 
 
glpD_yzgL .1454* 0.02628 0 0.0486 0.2423 
 
malM_yjbI .1326* 0.02628 0.002 0.0357 0.2294 
 
sibD_sibE .1287* 0.02628 0.002 0.0319 0.2256 
 
frvA_rhaM .1253* 0.02628 0.003 0.0284 0.2221 
 
yhiM_yhiN .1232* 0.02628 0.004 0.0264 0.2201 
 
yqaB_argQ .0983* 0.02628 0.044 0.0014 0.1951 
 
yffL_yffM 0.0757 0.02628 0.261 -0.0212 0.1725 
 
ygcE_queE 0.0728 0.02628 0.314 -0.0241 0.1696 
 
ybiJ_ybiI 0.0579 0.02628 0.662 -0.039 0.1547 
 
ybfK_kdpE 0.0411 0.02628 0.954 -0.0558 0.1379 
 
rseX_yedS 0.0338 0.02628 0.991 -0.0631 0.1306 
 
udk_yegE 0.0298 0.02628 0.997 -0.067 0.1267 
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Supplementary Table A.2-12: Statistical output for the linear regression model of the net distance from 
oriC in function of the ratio of fluorescence output when burden is imposed. Analysis performed with the 
package StatsModel for Python. 
OLS Regression Results 
Dep. Variable: Ratio Dasher fluo. R-squared: 0.579 
Model: OLS Adj. R-squared: 0.547 
Method: Least Squares F-statistic: 17.90 
No. Observations: 15 Prob (F-statistic): 0.00098 
Df Residuals: 13 Log-Likelihood: 26.312 
Df Model: 1 AIC: -48.62 
Covariance Type: nonrobust BIC: -47.21 
 coef std err t P>|t| [0.025 0.975] 
const 0.7979 0.022 36.346 0.000 0.750 0.845 
Dasher fluo. -7.867e-05 1.86e-05 -4.231 0.001 -3.85e-05 0.000 
Omnibus: 30.371 Durbin-Watson: 2.090 
Prob(Omnibus): 0.000 Jarque-Bera (JB): 47.385 
Skew: -2.673 Prob(JB): 5.14e-11 
Kurtosis: 9.873 Cond. No. 2.23e+03 
 
Supplementary Table A.2-13: Statistical output for the ANOVA analysis with Tukey correction for 
determining significant differences between VioB-mCherry fluorescence. Values indicated with an * show 
that the mean difference is significant at the 5% level. Analysis performed with SPSS software. 
Location Location Mean Diff Std Error p-value 95% Confidence Interval 
     
Lower Bound 
Upper 
Bound 
cspF_quuQ dadX_cvrA 144.3333 290.50684 1.000 -983.8838 1272.5505 
djlA_yabP 2279.0000* 290.50684 0.000 1150.7828 3407.2172 
frvA_rhaM 186.0000 290.50684 1.000 -942.2172 1314.2172 
frwA_frwC 181.3333 290.50684 1.000 -946.8838 1309.5505 
glpD_yzgL 257.0000 290.50684 1.000 -871.2172 1385.2172 
ileY_ygaQ 495.6667 290.50684 0.991 -632.5505 1623.8838 
malM_yjbI -13.0000 290.50684 1.000 -1141.2172 1115.2172 
rseX_yedS 207.0000 290.50684 1.000 -921.2172 1335.2172 
sibD_sibE 221.6667 290.50684 1.000 -906.5505 1349.8838 
thrW_ykfN -8.0000 290.50684 1.000 -1136.2172 1120.2172 
tyrV_tyrT 278.0000 290.50684 1.000 -850.2172 1406.2172 
udk_yegE 50.3333 290.50684 1.000 -1077.8838 1178.5505 
Appendices 
190 
ybfC_ybfQ 424.6667 290.50684 0.999 -703.5505 1552.8838 
ybfK_kdpE 142.0000 290.50684 1.000 -986.2172 1270.2172 
ybiJ_ybiI 254.0000 290.50684 1.000 -874.2172 1382.2172 
yeeJ_yeeL 26.3333 290.50684 1.000 -1101.8838 1154.5505 
yffL_yffM -40.6667 290.50684 1.000 -1168.8838 1087.5505 
ygcE_queE -243.6667 290.50684 1.000 -1371.8838 884.5505 
yhiM_yhiN 268.6667 290.50684 1.000 -859.5505 1396.8838 
yjiP_yjiR 682.6667 290.50684 0.800 -445.5505 1810.8838 
ykgA_ykgQ 178.3333 290.50684 1.000 -949.8838 1306.5505 
ykgH_betA -346.0000 290.50684 1.000 -1474.2172 782.2172 
ymgF_ycgH 305.0000 290.50684 1.000 -823.2172 1433.2172 
ypjC_ileY 264.0000 290.50684 1.000 -864.2172 1392.2172 
yqaB_argQ 70.6667 290.50684 1.000 -1057.5505 1198.8838 
dadX_cvrA cspF_quuQ -144.3333 290.50684 1.000 -1272.5505 983.8838 
djlA_yabP 2134.6667* 290.50684 0.000 1006.4495 3262.8838 
frvA_rhaM 41.6667 290.50684 1.000 -1086.5505 1169.8838 
frwA_frwC 37.0000 290.50684 1.000 -1091.2172 1165.2172 
glpD_yzgL 112.6667 290.50684 1.000 -1015.5505 1240.8838 
ileY_ygaQ 351.3333 290.50684 1.000 -776.8838 1479.5505 
malM_yjbI -157.3333 290.50684 1.000 -1285.5505 970.8838 
rseX_yedS 62.6667 290.50684 1.000 -1065.5505 1190.8838 
sibD_sibE 77.3333 290.50684 1.000 -1050.8838 1205.5505 
thrW_ykfN -152.3333 290.50684 1.000 -1280.5505 975.8838 
tyrV_tyrT 133.6667 290.50684 1.000 -994.5505 1261.8838 
udk_yegE -94.0000 290.50684 1.000 -1222.2172 1034.2172 
ybfC_ybfQ 280.3333 290.50684 1.000 -847.8838 1408.5505 
ybfK_kdpE -2.3333 290.50684 1.000 -1130.5505 1125.8838 
ybiJ_ybiI 109.6667 290.50684 1.000 -1018.5505 1237.8838 
yeeJ_yeeL -118.0000 290.50684 1.000 -1246.2172 1010.2172 
yffL_yffM -185.0000 290.50684 1.000 -1313.2172 943.2172 
ygcE_queE -388.0000 290.50684 1.000 -1516.2172 740.2172 
yhiM_yhiN 124.3333 290.50684 1.000 -1003.8838 1252.5505 
yjiP_yjiR 538.3333 290.50684 0.976 -589.8838 1666.5505 
ykgA_ykgQ 34.0000 290.50684 1.000 -1094.2172 1162.2172 
ykgH_betA -490.3333 290.50684 0.992 -1618.5505 637.8838 
ymgF_ycgH 160.6667 290.50684 1.000 -967.5505 1288.8838 
Appendices 
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ypjC_ileY 119.6667 290.50684 1.000 -1008.5505 1247.8838 
yqaB_argQ -73.6667 290.50684 1.000 -1201.8838 1054.5505 
djlA_yabP cspF_quuQ -2279.000* 290.50684 0.000 -3407.2172 -1150.782 
dadX_cvrA -2134.666* 290.50684 0.000 -3262.8838 -1006.449 
frvA_rhaM -2093.000* 290.50684 0.000 -3221.2172 -964.7828 
frwA_frwC -2097.666* 290.50684 0.000 -3225.8838 -969.4495 
glpD_yzgL -2022.000* 290.50684 0.000 -3150.2172 -893.7828 
ileY_ygaQ -1783.333* 290.50684 0.000 -2911.5505 -655.1162 
malM_yjbI -2292.000* 290.50684 0.000 -3420.2172 -1163.782 
rseX_yedS -2072.000* 290.50684 0.000 -3200.2172 -943.7828 
sibD_sibE -2057.333* 290.50684 0.000 -3185.5505 -929.1162 
thrW_ykfN -2287.000* 290.50684 0.000 -3415.2172 -1158.782 
tyrV_tyrT -2001.000* 290.50684 0.000 -3129.2172 -872.7828 
udk_yegE -2228.666* 290.50684 0.000 -3356.8838 -1100.449 
ybfC_ybfQ -1854.333* 290.50684 0.000 -2982.5505 -726.1162 
ybfK_kdpE -2137.000* 290.50684 0.000 -3265.2172 -1008.782 
ybiJ_ybiI -2025.000* 290.50684 0.000 -3153.2172 -896.7828 
yeeJ_yeeL -2252.666* 290.50684 0.000 -3380.8838 -1124.449 
yffL_yffM -2319.666* 290.50684 0.000 -3447.8838 -1191.449 
ygcE_queE -2522.666* 290.50684 0.000 -3650.8838 -1394.449 
yhiM_yhiN -2010.333* 290.50684 0.000 -3138.5505 -882.1162 
yjiP_yjiR -1596.333* 290.50684 0.000 -2724.5505 -468.1162 
ykgA_ykgQ -2100.666* 290.50684 0.000 -3228.8838 -972.4495 
ykgH_betA -2625.000* 290.50684 0.000 -3753.2172 -1496.782 
ymgF_ycgH -1974.000* 290.50684 0.000 -3102.2172 -845.7828 
ypjC_ileY -2015.000* 290.50684 0.000 -3143.2172 -886.7828 
yqaB_argQ -2208.333* 290.50684 0.000 -3336.5505 -1080.116 
frvA_rhaM cspF_quuQ -186.0000 290.50684 1.000 -1314.2172 942.2172 
dadX_cvrA -41.6667 290.50684 1.000 -1169.8838 1086.5505 
djlA_yabP 2093.0000* 290.50684 0.000 964.7828 3221.2172 
frwA_frwC -4.6667 290.50684 1.000 -1132.8838 1123.5505 
glpD_yzgL 71.0000 290.50684 1.000 -1057.2172 1199.2172 
ileY_ygaQ 309.6667 290.50684 1.000 -818.5505 1437.8838 
malM_yjbI -199.0000 290.50684 1.000 -1327.2172 929.2172 
rseX_yedS 21.0000 290.50684 1.000 -1107.2172 1149.2172 
sibD_sibE 35.6667 290.50684 1.000 -1092.5505 1163.8838 
Appendices 
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thrW_ykfN -194.0000 290.50684 1.000 -1322.2172 934.2172 
tyrV_tyrT 92.0000 290.50684 1.000 -1036.2172 1220.2172 
udk_yegE -135.6667 290.50684 1.000 -1263.8838 992.5505 
ybfC_ybfQ 238.6667 290.50684 1.000 -889.5505 1366.8838 
ybfK_kdpE -44.0000 290.50684 1.000 -1172.2172 1084.2172 
ybiJ_ybiI 68.0000 290.50684 1.000 -1060.2172 1196.2172 
yeeJ_yeeL -159.6667 290.50684 1.000 -1287.8838 968.5505 
yffL_yffM -226.6667 290.50684 1.000 -1354.8838 901.5505 
ygcE_queE -429.6667 290.50684 0.999 -1557.8838 698.5505 
yhiM_yhiN 82.6667 290.50684 1.000 -1045.5505 1210.8838 
yjiP_yjiR 496.6667 290.50684 0.990 -631.5505 1624.8838 
ykgA_ykgQ -7.6667 290.50684 1.000 -1135.8838 1120.5505 
ykgH_betA -532.0000 290.50684 0.979 -1660.2172 596.2172 
ymgF_ycgH 119.0000 290.50684 1.000 -1009.2172 1247.2172 
ypjC_ileY 78.0000 290.50684 1.000 -1050.2172 1206.2172 
yqaB_argQ -115.3333 290.50684 1.000 -1243.5505 1012.8838 
frwA_frwC cspF_quuQ -181.3333 290.50684 1.000 -1309.5505 946.8838 
dadX_cvrA -37.0000 290.50684 1.000 -1165.2172 1091.2172 
djlA_yabP 2097.6667* 290.50684 0.000 969.4495 3225.8838 
frvA_rhaM 4.6667 290.50684 1.000 -1123.5505 1132.8838 
glpD_yzgL 75.6667 290.50684 1.000 -1052.5505 1203.8838 
ileY_ygaQ 314.3333 290.50684 1.000 -813.8838 1442.5505 
malM_yjbI -194.3333 290.50684 1.000 -1322.5505 933.8838 
rseX_yedS 25.6667 290.50684 1.000 -1102.5505 1153.8838 
sibD_sibE 40.3333 290.50684 1.000 -1087.8838 1168.5505 
thrW_ykfN -189.3333 290.50684 1.000 -1317.5505 938.8838 
tyrV_tyrT 96.6667 290.50684 1.000 -1031.5505 1224.8838 
udk_yegE -131.0000 290.50684 1.000 -1259.2172 997.2172 
ybfC_ybfQ 243.3333 290.50684 1.000 -884.8838 1371.5505 
ybfK_kdpE -39.3333 290.50684 1.000 -1167.5505 1088.8838 
ybiJ_ybiI 72.6667 290.50684 1.000 -1055.5505 1200.8838 
yeeJ_yeeL -155.0000 290.50684 1.000 -1283.2172 973.2172 
yffL_yffM -222.0000 290.50684 1.000 -1350.2172 906.2172 
ygcE_queE -425.0000 290.50684 0.999 -1553.2172 703.2172 
yhiM_yhiN 87.3333 290.50684 1.000 -1040.8838 1215.5505 
yjiP_yjiR 501.3333 290.50684 0.989 -626.8838 1629.5505 
Appendices 
193 
ykgA_ykgQ -3.0000 290.50684 1.000 -1131.2172 1125.2172 
ykgH_betA -527.3333 290.50684 0.981 -1655.5505 600.8838 
ymgF_ycgH 123.6667 290.50684 1.000 -1004.5505 1251.8838 
ypjC_ileY 82.6667 290.50684 1.000 -1045.5505 1210.8838 
yqaB_argQ -110.6667 290.50684 1.000 -1238.8838 1017.5505 
glpD_yzgL cspF_quuQ -257.0000 290.50684 1.000 -1385.2172 871.2172 
dadX_cvrA -112.6667 290.50684 1.000 -1240.8838 1015.5505 
djlA_yabP 2022.0000* 290.50684 0.000 893.7828 3150.2172 
frvA_rhaM -71.0000 290.50684 1.000 -1199.2172 1057.2172 
frwA_frwC -75.6667 290.50684 1.000 -1203.8838 1052.5505 
ileY_ygaQ 238.6667 290.50684 1.000 -889.5505 1366.8838 
malM_yjbI -270.0000 290.50684 1.000 -1398.2172 858.2172 
rseX_yedS -50.0000 290.50684 1.000 -1178.2172 1078.2172 
sibD_sibE -35.3333 290.50684 1.000 -1163.5505 1092.8838 
thrW_ykfN -265.0000 290.50684 1.000 -1393.2172 863.2172 
tyrV_tyrT 21.0000 290.50684 1.000 -1107.2172 1149.2172 
udk_yegE -206.6667 290.50684 1.000 -1334.8838 921.5505 
ybfC_ybfQ 167.6667 290.50684 1.000 -960.5505 1295.8838 
ybfK_kdpE -115.0000 290.50684 1.000 -1243.2172 1013.2172 
ybiJ_ybiI -3.0000 290.50684 1.000 -1131.2172 1125.2172 
yeeJ_yeeL -230.6667 290.50684 1.000 -1358.8838 897.5505 
yffL_yffM -297.6667 290.50684 1.000 -1425.8838 830.5505 
ygcE_queE -500.6667 290.50684 0.989 -1628.8838 627.5505 
yhiM_yhiN 11.6667 290.50684 1.000 -1116.5505 1139.8838 
yjiP_yjiR 425.6667 290.50684 0.999 -702.5505 1553.8838 
ykgA_ykgQ -78.6667 290.50684 1.000 -1206.8838 1049.5505 
ykgH_betA -603.0000 290.50684 0.924 -1731.2172 525.2172 
ymgF_ycgH 48.0000 290.50684 1.000 -1080.2172 1176.2172 
ypjC_ileY 7.0000 290.50684 1.000 -1121.2172 1135.2172 
yqaB_argQ -186.3333 290.50684 1.000 -1314.5505 941.8838 
ileY_ygaQ cspF_quuQ -495.6667 290.50684 0.991 -1623.8838 632.5505 
dadX_cvrA -351.3333 290.50684 1.000 -1479.5505 776.8838 
djlA_yabP 1783.3333* 290.50684 0.000 655.1162 2911.5505 
frvA_rhaM -309.6667 290.50684 1.000 -1437.8838 818.5505 
frwA_frwC -314.3333 290.50684 1.000 -1442.5505 813.8838 
glpD_yzgL -238.6667 290.50684 1.000 -1366.8838 889.5505 
Appendices 
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malM_yjbI -508.6667 290.50684 0.987 -1636.8838 619.5505 
rseX_yedS -288.6667 290.50684 1.000 -1416.8838 839.5505 
sibD_sibE -274.0000 290.50684 1.000 -1402.2172 854.2172 
thrW_ykfN -503.6667 290.50684 0.989 -1631.8838 624.5505 
tyrV_tyrT -217.6667 290.50684 1.000 -1345.8838 910.5505 
udk_yegE -445.3333 290.50684 0.998 -1573.5505 682.8838 
ybfC_ybfQ -71.0000 290.50684 1.000 -1199.2172 1057.2172 
ybfK_kdpE -353.6667 290.50684 1.000 -1481.8838 774.5505 
ybiJ_ybiI -241.6667 290.50684 1.000 -1369.8838 886.5505 
yeeJ_yeeL -469.3333 290.50684 0.995 -1597.5505 658.8838 
yffL_yffM -536.3333 290.50684 0.976 -1664.5505 591.8838 
ygcE_queE -739.3333 290.50684 0.675 -1867.5505 388.8838 
yhiM_yhiN -227.0000 290.50684 1.000 -1355.2172 901.2172 
yjiP_yjiR 187.0000 290.50684 1.000 -941.2172 1315.2172 
ykgA_ykgQ -317.3333 290.50684 1.000 -1445.5505 810.8838 
ykgH_betA -841.6667 290.50684 0.427 -1969.8838 286.5505 
ymgF_ycgH -190.6667 290.50684 1.000 -1318.8838 937.5505 
ypjC_ileY -231.6667 290.50684 1.000 -1359.8838 896.5505 
yqaB_argQ -425.0000 290.50684 0.999 -1553.2172 703.2172 
malM_yjbI cspF_quuQ 13.0000 290.50684 1.000 -1115.2172 1141.2172 
dadX_cvrA 157.3333 290.50684 1.000 -970.8838 1285.5505 
djlA_yabP 2292.0000* 290.50684 0.000 1163.7828 3420.2172 
frvA_rhaM 199.0000 290.50684 1.000 -929.2172 1327.2172 
frwA_frwC 194.3333 290.50684 1.000 -933.8838 1322.5505 
glpD_yzgL 270.0000 290.50684 1.000 -858.2172 1398.2172 
ileY_ygaQ 508.6667 290.50684 0.987 -619.5505 1636.8838 
rseX_yedS 220.0000 290.50684 1.000 -908.2172 1348.2172 
sibD_sibE 234.6667 290.50684 1.000 -893.5505 1362.8838 
thrW_ykfN 5.0000 290.50684 1.000 -1123.2172 1133.2172 
tyrV_tyrT 291.0000 290.50684 1.000 -837.2172 1419.2172 
udk_yegE 63.3333 290.50684 1.000 -1064.8838 1191.5505 
ybfC_ybfQ 437.6667 290.50684 0.998 -690.5505 1565.8838 
ybfK_kdpE 155.0000 290.50684 1.000 -973.2172 1283.2172 
ybiJ_ybiI 267.0000 290.50684 1.000 -861.2172 1395.2172 
yeeJ_yeeL 39.3333 290.50684 1.000 -1088.8838 1167.5505 
yffL_yffM -27.6667 290.50684 1.000 -1155.8838 1100.5505 
Appendices 
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ygcE_queE -230.6667 290.50684 1.000 -1358.8838 897.5505 
yhiM_yhiN 281.6667 290.50684 1.000 -846.5505 1409.8838 
yjiP_yjiR 695.6667 290.50684 0.773 -432.5505 1823.8838 
ykgA_ykgQ 191.3333 290.50684 1.000 -936.8838 1319.5505 
ykgH_betA -333.0000 290.50684 1.000 -1461.2172 795.2172 
ymgF_ycgH 318.0000 290.50684 1.000 -810.2172 1446.2172 
ypjC_ileY 277.0000 290.50684 1.000 -851.2172 1405.2172 
yqaB_argQ 83.6667 290.50684 1.000 -1044.5505 1211.8838 
rseX_yedS cspF_quuQ -207.0000 290.50684 1.000 -1335.2172 921.2172 
dadX_cvrA -62.6667 290.50684 1.000 -1190.8838 1065.5505 
djlA_yabP 2072.0000* 290.50684 0.000 943.7828 3200.2172 
frvA_rhaM -21.0000 290.50684 1.000 -1149.2172 1107.2172 
frwA_frwC -25.6667 290.50684 1.000 -1153.8838 1102.5505 
glpD_yzgL 50.0000 290.50684 1.000 -1078.2172 1178.2172 
ileY_ygaQ 288.6667 290.50684 1.000 -839.5505 1416.8838 
malM_yjbI -220.0000 290.50684 1.000 -1348.2172 908.2172 
sibD_sibE 14.6667 290.50684 1.000 -1113.5505 1142.8838 
thrW_ykfN -215.0000 290.50684 1.000 -1343.2172 913.2172 
tyrV_tyrT 71.0000 290.50684 1.000 -1057.2172 1199.2172 
udk_yegE -156.6667 290.50684 1.000 -1284.8838 971.5505 
ybfC_ybfQ 217.6667 290.50684 1.000 -910.5505 1345.8838 
ybfK_kdpE -65.0000 290.50684 1.000 -1193.2172 1063.2172 
ybiJ_ybiI 47.0000 290.50684 1.000 -1081.2172 1175.2172 
yeeJ_yeeL -180.6667 290.50684 1.000 -1308.8838 947.5505 
yffL_yffM -247.6667 290.50684 1.000 -1375.8838 880.5505 
ygcE_queE -450.6667 290.50684 0.997 -1578.8838 677.5505 
yhiM_yhiN 61.6667 290.50684 1.000 -1066.5505 1189.8838 
yjiP_yjiR 475.6667 290.50684 0.994 -652.5505 1603.8838 
ykgA_ykgQ -28.6667 290.50684 1.000 -1156.8838 1099.5505 
ykgH_betA -553.0000 290.50684 0.967 -1681.2172 575.2172 
ymgF_ycgH 98.0000 290.50684 1.000 -1030.2172 1226.2172 
ypjC_ileY 57.0000 290.50684 1.000 -1071.2172 1185.2172 
yqaB_argQ -136.3333 290.50684 1.000 -1264.5505 991.8838 
sibD_sibE cspF_quuQ -221.6667 290.50684 1.000 -1349.8838 906.5505 
dadX_cvrA -77.3333 290.50684 1.000 -1205.5505 1050.8838 
djlA_yabP 2057.3333* 290.50684 0.000 929.1162 3185.5505 
Appendices 
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frvA_rhaM -35.6667 290.50684 1.000 -1163.8838 1092.5505 
frwA_frwC -40.3333 290.50684 1.000 -1168.5505 1087.8838 
glpD_yzgL 35.3333 290.50684 1.000 -1092.8838 1163.5505 
ileY_ygaQ 274.0000 290.50684 1.000 -854.2172 1402.2172 
malM_yjbI -234.6667 290.50684 1.000 -1362.8838 893.5505 
rseX_yedS -14.6667 290.50684 1.000 -1142.8838 1113.5505 
thrW_ykfN -229.6667 290.50684 1.000 -1357.8838 898.5505 
tyrV_tyrT 56.3333 290.50684 1.000 -1071.8838 1184.5505 
udk_yegE -171.3333 290.50684 1.000 -1299.5505 956.8838 
ybfC_ybfQ 203.0000 290.50684 1.000 -925.2172 1331.2172 
ybfK_kdpE -79.6667 290.50684 1.000 -1207.8838 1048.5505 
ybiJ_ybiI 32.3333 290.50684 1.000 -1095.8838 1160.5505 
yeeJ_yeeL -195.3333 290.50684 1.000 -1323.5505 932.8838 
yffL_yffM -262.3333 290.50684 1.000 -1390.5505 865.8838 
ygcE_queE -465.3333 290.50684 0.996 -1593.5505 662.8838 
yhiM_yhiN 47.0000 290.50684 1.000 -1081.2172 1175.2172 
yjiP_yjiR 461.0000 290.50684 0.996 -667.2172 1589.2172 
ykgA_ykgQ -43.3333 290.50684 1.000 -1171.5505 1084.8838 
ykgH_betA -567.6667 290.50684 0.957 -1695.8838 560.5505 
ymgF_ycgH 83.3333 290.50684 1.000 -1044.8838 1211.5505 
ypjC_ileY 42.3333 290.50684 1.000 -1085.8838 1170.5505 
yqaB_argQ -151.0000 290.50684 1.000 -1279.2172 977.2172 
thrW_ykfN cspF_quuQ 8.0000 290.50684 1.000 -1120.2172 1136.2172 
dadX_cvrA 152.3333 290.50684 1.000 -975.8838 1280.5505 
djlA_yabP 2287.0000* 290.50684 0.000 1158.7828 3415.2172 
frvA_rhaM 194.0000 290.50684 1.000 -934.2172 1322.2172 
frwA_frwC 189.3333 290.50684 1.000 -938.8838 1317.5505 
glpD_yzgL 265.0000 290.50684 1.000 -863.2172 1393.2172 
ileY_ygaQ 503.6667 290.50684 0.989 -624.5505 1631.8838 
malM_yjbI -5.0000 290.50684 1.000 -1133.2172 1123.2172 
rseX_yedS 215.0000 290.50684 1.000 -913.2172 1343.2172 
sibD_sibE 229.6667 290.50684 1.000 -898.5505 1357.8838 
tyrV_tyrT 286.0000 290.50684 1.000 -842.2172 1414.2172 
udk_yegE 58.3333 290.50684 1.000 -1069.8838 1186.5505 
ybfC_ybfQ 432.6667 290.50684 0.998 -695.5505 1560.8838 
ybfK_kdpE 150.0000 290.50684 1.000 -978.2172 1278.2172 
Appendices 
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ybiJ_ybiI 262.0000 290.50684 1.000 -866.2172 1390.2172 
yeeJ_yeeL 34.3333 290.50684 1.000 -1093.8838 1162.5505 
yffL_yffM -32.6667 290.50684 1.000 -1160.8838 1095.5505 
ygcE_queE -235.6667 290.50684 1.000 -1363.8838 892.5505 
yhiM_yhiN 276.6667 290.50684 1.000 -851.5505 1404.8838 
yjiP_yjiR 690.6667 290.50684 0.783 -437.5505 1818.8838 
ykgA_ykgQ 186.3333 290.50684 1.000 -941.8838 1314.5505 
ykgH_betA -338.0000 290.50684 1.000 -1466.2172 790.2172 
ymgF_ycgH 313.0000 290.50684 1.000 -815.2172 1441.2172 
ypjC_ileY 272.0000 290.50684 1.000 -856.2172 1400.2172 
yqaB_argQ 78.6667 290.50684 1.000 -1049.5505 1206.8838 
tyrV_tyrT cspF_quuQ -278.0000 290.50684 1.000 -1406.2172 850.2172 
dadX_cvrA -133.6667 290.50684 1.000 -1261.8838 994.5505 
djlA_yabP 2001.0000* 290.50684 0.000 872.7828 3129.2172 
frvA_rhaM -92.0000 290.50684 1.000 -1220.2172 1036.2172 
frwA_frwC -96.6667 290.50684 1.000 -1224.8838 1031.5505 
glpD_yzgL -21.0000 290.50684 1.000 -1149.2172 1107.2172 
ileY_ygaQ 217.6667 290.50684 1.000 -910.5505 1345.8838 
malM_yjbI -291.0000 290.50684 1.000 -1419.2172 837.2172 
rseX_yedS -71.0000 290.50684 1.000 -1199.2172 1057.2172 
sibD_sibE -56.3333 290.50684 1.000 -1184.5505 1071.8838 
thrW_ykfN -286.0000 290.50684 1.000 -1414.2172 842.2172 
udk_yegE -227.6667 290.50684 1.000 -1355.8838 900.5505 
ybfC_ybfQ 146.6667 290.50684 1.000 -981.5505 1274.8838 
ybfK_kdpE -136.0000 290.50684 1.000 -1264.2172 992.2172 
ybiJ_ybiI -24.0000 290.50684 1.000 -1152.2172 1104.2172 
yeeJ_yeeL -251.6667 290.50684 1.000 -1379.8838 876.5505 
yffL_yffM -318.6667 290.50684 1.000 -1446.8838 809.5505 
ygcE_queE -521.6667 290.50684 0.983 -1649.8838 606.5505 
yhiM_yhiN -9.3333 290.50684 1.000 -1137.5505 1118.8838 
yjiP_yjiR 404.6667 290.50684 0.999 -723.5505 1532.8838 
ykgA_ykgQ -99.6667 290.50684 1.000 -1227.8838 1028.5505 
ykgH_betA -624.0000 290.50684 0.898 -1752.2172 504.2172 
ymgF_ycgH 27.0000 290.50684 1.000 -1101.2172 1155.2172 
ypjC_ileY -14.0000 290.50684 1.000 -1142.2172 1114.2172 
yqaB_argQ -207.3333 290.50684 1.000 -1335.5505 920.8838 
Appendices 
198 
udk_yegE cspF_quuQ -50.3333 290.50684 1.000 -1178.5505 1077.8838 
dadX_cvrA 94.0000 290.50684 1.000 -1034.2172 1222.2172 
djlA_yabP 2228.6667* 290.50684 0.000 1100.4495 3356.8838 
frvA_rhaM 135.6667 290.50684 1.000 -992.5505 1263.8838 
frwA_frwC 131.0000 290.50684 1.000 -997.2172 1259.2172 
glpD_yzgL 206.6667 290.50684 1.000 -921.5505 1334.8838 
ileY_ygaQ 445.3333 290.50684 0.998 -682.8838 1573.5505 
malM_yjbI -63.3333 290.50684 1.000 -1191.5505 1064.8838 
rseX_yedS 156.6667 290.50684 1.000 -971.5505 1284.8838 
sibD_sibE 171.3333 290.50684 1.000 -956.8838 1299.5505 
thrW_ykfN -58.3333 290.50684 1.000 -1186.5505 1069.8838 
tyrV_tyrT 227.6667 290.50684 1.000 -900.5505 1355.8838 
ybfC_ybfQ 374.3333 290.50684 1.000 -753.8838 1502.5505 
ybfK_kdpE 91.6667 290.50684 1.000 -1036.5505 1219.8838 
ybiJ_ybiI 203.6667 290.50684 1.000 -924.5505 1331.8838 
yeeJ_yeeL -24.0000 290.50684 1.000 -1152.2172 1104.2172 
yffL_yffM -91.0000 290.50684 1.000 -1219.2172 1037.2172 
ygcE_queE -294.0000 290.50684 1.000 -1422.2172 834.2172 
yhiM_yhiN 218.3333 290.50684 1.000 -909.8838 1346.5505 
yjiP_yjiR 632.3333 290.50684 0.887 -495.8838 1760.5505 
ykgA_ykgQ 128.0000 290.50684 1.000 -1000.2172 1256.2172 
ykgH_betA -396.3333 290.50684 1.000 -1524.5505 731.8838 
ymgF_ycgH 254.6667 290.50684 1.000 -873.5505 1382.8838 
ypjC_ileY 213.6667 290.50684 1.000 -914.5505 1341.8838 
yqaB_argQ 20.3333 290.50684 1.000 -1107.8838 1148.5505 
ybfC_ybfQ cspF_quuQ -424.6667 290.50684 0.999 -1552.8838 703.5505 
dadX_cvrA -280.3333 290.50684 1.000 -1408.5505 847.8838 
djlA_yabP 1854.3333* 290.50684 0.000 726.1162 2982.5505 
frvA_rhaM -238.6667 290.50684 1.000 -1366.8838 889.5505 
frwA_frwC -243.3333 290.50684 1.000 -1371.5505 884.8838 
glpD_yzgL -167.6667 290.50684 1.000 -1295.8838 960.5505 
ileY_ygaQ 71.0000 290.50684 1.000 -1057.2172 1199.2172 
malM_yjbI -437.6667 290.50684 0.998 -1565.8838 690.5505 
rseX_yedS -217.6667 290.50684 1.000 -1345.8838 910.5505 
sibD_sibE -203.0000 290.50684 1.000 -1331.2172 925.2172 
thrW_ykfN -432.6667 290.50684 0.998 -1560.8838 695.5505 
Appendices 
199 
tyrV_tyrT -146.6667 290.50684 1.000 -1274.8838 981.5505 
udk_yegE -374.3333 290.50684 1.000 -1502.5505 753.8838 
ybfK_kdpE -282.6667 290.50684 1.000 -1410.8838 845.5505 
ybiJ_ybiI -170.6667 290.50684 1.000 -1298.8838 957.5505 
yeeJ_yeeL -398.3333 290.50684 1.000 -1526.5505 729.8838 
yffL_yffM -465.3333 290.50684 0.996 -1593.5505 662.8838 
ygcE_queE -668.3333 290.50684 0.827 -1796.5505 459.8838 
yhiM_yhiN -156.0000 290.50684 1.000 -1284.2172 972.2172 
yjiP_yjiR 258.0000 290.50684 1.000 -870.2172 1386.2172 
ykgA_ykgQ -246.3333 290.50684 1.000 -1374.5505 881.8838 
ykgH_betA -770.6667 290.50684 0.599 -1898.8838 357.5505 
ymgF_ycgH -119.6667 290.50684 1.000 -1247.8838 1008.5505 
ypjC_ileY -160.6667 290.50684 1.000 -1288.8838 967.5505 
yqaB_argQ -354.0000 290.50684 1.000 -1482.2172 774.2172 
ybfK_kdpE cspF_quuQ -142.0000 290.50684 1.000 -1270.2172 986.2172 
dadX_cvrA 2.3333 290.50684 1.000 -1125.8838 1130.5505 
djlA_yabP 2137.0000* 290.50684 0.000 1008.7828 3265.2172 
frvA_rhaM 44.0000 290.50684 1.000 -1084.2172 1172.2172 
frwA_frwC 39.3333 290.50684 1.000 -1088.8838 1167.5505 
glpD_yzgL 115.0000 290.50684 1.000 -1013.2172 1243.2172 
ileY_ygaQ 353.6667 290.50684 1.000 -774.5505 1481.8838 
malM_yjbI -155.0000 290.50684 1.000 -1283.2172 973.2172 
rseX_yedS 65.0000 290.50684 1.000 -1063.2172 1193.2172 
sibD_sibE 79.6667 290.50684 1.000 -1048.5505 1207.8838 
thrW_ykfN -150.0000 290.50684 1.000 -1278.2172 978.2172 
tyrV_tyrT 136.0000 290.50684 1.000 -992.2172 1264.2172 
udk_yegE -91.6667 290.50684 1.000 -1219.8838 1036.5505 
ybfC_ybfQ 282.6667 290.50684 1.000 -845.5505 1410.8838 
ybiJ_ybiI 112.0000 290.50684 1.000 -1016.2172 1240.2172 
yeeJ_yeeL -115.6667 290.50684 1.000 -1243.8838 1012.5505 
yffL_yffM -182.6667 290.50684 1.000 -1310.8838 945.5505 
ygcE_queE -385.6667 290.50684 1.000 -1513.8838 742.5505 
yhiM_yhiN 126.6667 290.50684 1.000 -1001.5505 1254.8838 
yjiP_yjiR 540.6667 290.50684 0.974 -587.5505 1668.8838 
ykgA_ykgQ 36.3333 290.50684 1.000 -1091.8838 1164.5505 
ykgH_betA -488.0000 290.50684 0.992 -1616.2172 640.2172 
Appendices 
200 
ymgF_ycgH 163.0000 290.50684 1.000 -965.2172 1291.2172 
ypjC_ileY 122.0000 290.50684 1.000 -1006.2172 1250.2172 
yqaB_argQ -71.3333 290.50684 1.000 -1199.5505 1056.8838 
ybiJ_ybiI cspF_quuQ -254.0000 290.50684 1.000 -1382.2172 874.2172 
dadX_cvrA -109.6667 290.50684 1.000 -1237.8838 1018.5505 
djlA_yabP 2025.0000* 290.50684 0.000 896.7828 3153.2172 
frvA_rhaM -68.0000 290.50684 1.000 -1196.2172 1060.2172 
frwA_frwC -72.6667 290.50684 1.000 -1200.8838 1055.5505 
glpD_yzgL 3.0000 290.50684 1.000 -1125.2172 1131.2172 
ileY_ygaQ 241.6667 290.50684 1.000 -886.5505 1369.8838 
malM_yjbI -267.0000 290.50684 1.000 -1395.2172 861.2172 
rseX_yedS -47.0000 290.50684 1.000 -1175.2172 1081.2172 
sibD_sibE -32.3333 290.50684 1.000 -1160.5505 1095.8838 
thrW_ykfN -262.0000 290.50684 1.000 -1390.2172 866.2172 
tyrV_tyrT 24.0000 290.50684 1.000 -1104.2172 1152.2172 
udk_yegE -203.6667 290.50684 1.000 -1331.8838 924.5505 
ybfC_ybfQ 170.6667 290.50684 1.000 -957.5505 1298.8838 
ybfK_kdpE -112.0000 290.50684 1.000 -1240.2172 1016.2172 
yeeJ_yeeL -227.6667 290.50684 1.000 -1355.8838 900.5505 
yffL_yffM -294.6667 290.50684 1.000 -1422.8838 833.5505 
ygcE_queE -497.6667 290.50684 0.990 -1625.8838 630.5505 
yhiM_yhiN 14.6667 290.50684 1.000 -1113.5505 1142.8838 
yjiP_yjiR 428.6667 290.50684 0.999 -699.5505 1556.8838 
ykgA_ykgQ -75.6667 290.50684 1.000 -1203.8838 1052.5505 
ykgH_betA -600.0000 290.50684 0.928 -1728.2172 528.2172 
ymgF_ycgH 51.0000 290.50684 1.000 -1077.2172 1179.2172 
ypjC_ileY 10.0000 290.50684 1.000 -1118.2172 1138.2172 
yqaB_argQ -183.3333 290.50684 1.000 -1311.5505 944.8838 
yeeJ_yeeL cspF_quuQ -26.3333 290.50684 1.000 -1154.5505 1101.8838 
dadX_cvrA 118.0000 290.50684 1.000 -1010.2172 1246.2172 
djlA_yabP 2252.6667* 290.50684 0.000 1124.4495 3380.8838 
frvA_rhaM 159.6667 290.50684 1.000 -968.5505 1287.8838 
frwA_frwC 155.0000 290.50684 1.000 -973.2172 1283.2172 
glpD_yzgL 230.6667 290.50684 1.000 -897.5505 1358.8838 
ileY_ygaQ 469.3333 290.50684 0.995 -658.8838 1597.5505 
malM_yjbI -39.3333 290.50684 1.000 -1167.5505 1088.8838 
Appendices 
201 
rseX_yedS 180.6667 290.50684 1.000 -947.5505 1308.8838 
sibD_sibE 195.3333 290.50684 1.000 -932.8838 1323.5505 
thrW_ykfN -34.3333 290.50684 1.000 -1162.5505 1093.8838 
tyrV_tyrT 251.6667 290.50684 1.000 -876.5505 1379.8838 
udk_yegE 24.0000 290.50684 1.000 -1104.2172 1152.2172 
ybfC_ybfQ 398.3333 290.50684 1.000 -729.8838 1526.5505 
ybfK_kdpE 115.6667 290.50684 1.000 -1012.5505 1243.8838 
ybiJ_ybiI 227.6667 290.50684 1.000 -900.5505 1355.8838 
yffL_yffM -67.0000 290.50684 1.000 -1195.2172 1061.2172 
ygcE_queE -270.0000 290.50684 1.000 -1398.2172 858.2172 
yhiM_yhiN 242.3333 290.50684 1.000 -885.8838 1370.5505 
yjiP_yjiR 656.3333 290.50684 0.848 -471.8838 1784.5505 
ykgA_ykgQ 152.0000 290.50684 1.000 -976.2172 1280.2172 
ykgH_betA -372.3333 290.50684 1.000 -1500.5505 755.8838 
ymgF_ycgH 278.6667 290.50684 1.000 -849.5505 1406.8838 
ypjC_ileY 237.6667 290.50684 1.000 -890.5505 1365.8838 
yqaB_argQ 44.3333 290.50684 1.000 -1083.8838 1172.5505 
yffL_yffM cspF_quuQ 40.6667 290.50684 1.000 -1087.5505 1168.8838 
dadX_cvrA 185.0000 290.50684 1.000 -943.2172 1313.2172 
djlA_yabP 2319.6667* 290.50684 0.000 1191.4495 3447.8838 
frvA_rhaM 226.6667 290.50684 1.000 -901.5505 1354.8838 
frwA_frwC 222.0000 290.50684 1.000 -906.2172 1350.2172 
glpD_yzgL 297.6667 290.50684 1.000 -830.5505 1425.8838 
ileY_ygaQ 536.3333 290.50684 0.976 -591.8838 1664.5505 
malM_yjbI 27.6667 290.50684 1.000 -1100.5505 1155.8838 
rseX_yedS 247.6667 290.50684 1.000 -880.5505 1375.8838 
sibD_sibE 262.3333 290.50684 1.000 -865.8838 1390.5505 
thrW_ykfN 32.6667 290.50684 1.000 -1095.5505 1160.8838 
tyrV_tyrT 318.6667 290.50684 1.000 -809.5505 1446.8838 
udk_yegE 91.0000 290.50684 1.000 -1037.2172 1219.2172 
ybfC_ybfQ 465.3333 290.50684 0.996 -662.8838 1593.5505 
ybfK_kdpE 182.6667 290.50684 1.000 -945.5505 1310.8838 
ybiJ_ybiI 294.6667 290.50684 1.000 -833.5505 1422.8838 
yeeJ_yeeL 67.0000 290.50684 1.000 -1061.2172 1195.2172 
ygcE_queE -203.0000 290.50684 1.000 -1331.2172 925.2172 
yhiM_yhiN 309.3333 290.50684 1.000 -818.8838 1437.5505 
Appendices 
202 
yjiP_yjiR 723.3333 290.50684 0.712 -404.8838 1851.5505 
ykgA_ykgQ 219.0000 290.50684 1.000 -909.2172 1347.2172 
ykgH_betA -305.3333 290.50684 1.000 -1433.5505 822.8838 
ymgF_ycgH 345.6667 290.50684 1.000 -782.5505 1473.8838 
ypjC_ileY 304.6667 290.50684 1.000 -823.5505 1432.8838 
yqaB_argQ 111.3333 290.50684 1.000 -1016.8838 1239.5505 
ygcE_queE cspF_quuQ 243.6667 290.50684 1.000 -884.5505 1371.8838 
dadX_cvrA 388.0000 290.50684 1.000 -740.2172 1516.2172 
djlA_yabP 2522.6667* 290.50684 0.000 1394.4495 3650.8838 
frvA_rhaM 429.6667 290.50684 0.999 -698.5505 1557.8838 
frwA_frwC 425.0000 290.50684 0.999 -703.2172 1553.2172 
glpD_yzgL 500.6667 290.50684 0.989 -627.5505 1628.8838 
ileY_ygaQ 739.3333 290.50684 0.675 -388.8838 1867.5505 
malM_yjbI 230.6667 290.50684 1.000 -897.5505 1358.8838 
rseX_yedS 450.6667 290.50684 0.997 -677.5505 1578.8838 
sibD_sibE 465.3333 290.50684 0.996 -662.8838 1593.5505 
thrW_ykfN 235.6667 290.50684 1.000 -892.5505 1363.8838 
tyrV_tyrT 521.6667 290.50684 0.983 -606.5505 1649.8838 
udk_yegE 294.0000 290.50684 1.000 -834.2172 1422.2172 
ybfC_ybfQ 668.3333 290.50684 0.827 -459.8838 1796.5505 
ybfK_kdpE 385.6667 290.50684 1.000 -742.5505 1513.8838 
ybiJ_ybiI 497.6667 290.50684 0.990 -630.5505 1625.8838 
yeeJ_yeeL 270.0000 290.50684 1.000 -858.2172 1398.2172 
yffL_yffM 203.0000 290.50684 1.000 -925.2172 1331.2172 
yhiM_yhiN 512.3333 290.50684 0.986 -615.8838 1640.5505 
yjiP_yjiR 926.3333 290.50684 0.255 -201.8838 2054.5505 
ykgA_ykgQ 422.0000 290.50684 0.999 -706.2172 1550.2172 
ykgH_betA -102.3333 290.50684 1.000 -1230.5505 1025.8838 
ymgF_ycgH 548.6667 290.50684 0.970 -579.5505 1676.8838 
ypjC_ileY 507.6667 290.50684 0.987 -620.5505 1635.8838 
yqaB_argQ 314.3333 290.50684 1.000 -813.8838 1442.5505 
yhiM_yhiN cspF_quuQ -268.6667 290.50684 1.000 -1396.8838 859.5505 
dadX_cvrA -124.3333 290.50684 1.000 -1252.5505 1003.8838 
djlA_yabP 2010.3333* 290.50684 0.000 882.1162 3138.5505 
frvA_rhaM -82.6667 290.50684 1.000 -1210.8838 1045.5505 
frwA_frwC -87.3333 290.50684 1.000 -1215.5505 1040.8838 
Appendices 
203 
glpD_yzgL -11.6667 290.50684 1.000 -1139.8838 1116.5505 
ileY_ygaQ 227.0000 290.50684 1.000 -901.2172 1355.2172 
malM_yjbI -281.6667 290.50684 1.000 -1409.8838 846.5505 
rseX_yedS -61.6667 290.50684 1.000 -1189.8838 1066.5505 
sibD_sibE -47.0000 290.50684 1.000 -1175.2172 1081.2172 
thrW_ykfN -276.6667 290.50684 1.000 -1404.8838 851.5505 
tyrV_tyrT 9.3333 290.50684 1.000 -1118.8838 1137.5505 
udk_yegE -218.3333 290.50684 1.000 -1346.5505 909.8838 
ybfC_ybfQ 156.0000 290.50684 1.000 -972.2172 1284.2172 
ybfK_kdpE -126.6667 290.50684 1.000 -1254.8838 1001.5505 
ybiJ_ybiI -14.6667 290.50684 1.000 -1142.8838 1113.5505 
yeeJ_yeeL -242.3333 290.50684 1.000 -1370.5505 885.8838 
yffL_yffM -309.3333 290.50684 1.000 -1437.5505 818.8838 
ygcE_queE -512.3333 290.50684 0.986 -1640.5505 615.8838 
yjiP_yjiR 414.0000 290.50684 0.999 -714.2172 1542.2172 
ykgA_ykgQ -90.3333 290.50684 1.000 -1218.5505 1037.8838 
ykgH_betA -614.6667 290.50684 0.910 -1742.8838 513.5505 
ymgF_ycgH 36.3333 290.50684 1.000 -1091.8838 1164.5505 
ypjC_ileY -4.6667 290.50684 1.000 -1132.8838 1123.5505 
yqaB_argQ -198.0000 290.50684 1.000 -1326.2172 930.2172 
yjiP_yjiR cspF_quuQ -682.6667 290.50684 0.800 -1810.8838 445.5505 
dadX_cvrA -538.3333 290.50684 0.976 -1666.5505 589.8838 
djlA_yabP 1596.3333* 290.50684 0.000 468.1162 2724.5505 
frvA_rhaM -496.6667 290.50684 0.990 -1624.8838 631.5505 
frwA_frwC -501.3333 290.50684 0.989 -1629.5505 626.8838 
glpD_yzgL -425.6667 290.50684 0.999 -1553.8838 702.5505 
ileY_ygaQ -187.0000 290.50684 1.000 -1315.2172 941.2172 
malM_yjbI -695.6667 290.50684 0.773 -1823.8838 432.5505 
rseX_yedS -475.6667 290.50684 0.994 -1603.8838 652.5505 
sibD_sibE -461.0000 290.50684 0.996 -1589.2172 667.2172 
thrW_ykfN -690.6667 290.50684 0.783 -1818.8838 437.5505 
tyrV_tyrT -404.6667 290.50684 0.999 -1532.8838 723.5505 
udk_yegE -632.3333 290.50684 0.887 -1760.5505 495.8838 
ybfC_ybfQ -258.0000 290.50684 1.000 -1386.2172 870.2172 
ybfK_kdpE -540.6667 290.50684 0.974 -1668.8838 587.5505 
ybiJ_ybiI -428.6667 290.50684 0.999 -1556.8838 699.5505 
Appendices 
204 
yeeJ_yeeL -656.3333 290.50684 0.848 -1784.5505 471.8838 
yffL_yffM -723.3333 290.50684 0.712 -1851.5505 404.8838 
ygcE_queE -926.3333 290.50684 0.255 -2054.5505 201.8838 
yhiM_yhiN -414.0000 290.50684 0.999 -1542.2172 714.2172 
ykgA_ykgQ -504.3333 290.50684 0.988 -1632.5505 623.8838 
ykgH_betA -1028.6667 290.50684 0.119 -2156.8838 99.5505 
ymgF_ycgH -377.6667 290.50684 1.000 -1505.8838 750.5505 
ypjC_ileY -418.6667 290.50684 0.999 -1546.8838 709.5505 
yqaB_argQ -612.0000 290.50684 0.914 -1740.2172 516.2172 
ykgA_ykgQ cspF_quuQ -178.3333 290.50684 1.000 -1306.5505 949.8838 
dadX_cvrA -34.0000 290.50684 1.000 -1162.2172 1094.2172 
djlA_yabP 2100.6667* 290.50684 0.000 972.4495 3228.8838 
frvA_rhaM 7.6667 290.50684 1.000 -1120.5505 1135.8838 
frwA_frwC 3.0000 290.50684 1.000 -1125.2172 1131.2172 
glpD_yzgL 78.6667 290.50684 1.000 -1049.5505 1206.8838 
ileY_ygaQ 317.3333 290.50684 1.000 -810.8838 1445.5505 
malM_yjbI -191.3333 290.50684 1.000 -1319.5505 936.8838 
rseX_yedS 28.6667 290.50684 1.000 -1099.5505 1156.8838 
sibD_sibE 43.3333 290.50684 1.000 -1084.8838 1171.5505 
thrW_ykfN -186.3333 290.50684 1.000 -1314.5505 941.8838 
tyrV_tyrT 99.6667 290.50684 1.000 -1028.5505 1227.8838 
udk_yegE -128.0000 290.50684 1.000 -1256.2172 1000.2172 
ybfC_ybfQ 246.3333 290.50684 1.000 -881.8838 1374.5505 
ybfK_kdpE -36.3333 290.50684 1.000 -1164.5505 1091.8838 
ybiJ_ybiI 75.6667 290.50684 1.000 -1052.5505 1203.8838 
yeeJ_yeeL -152.0000 290.50684 1.000 -1280.2172 976.2172 
yffL_yffM -219.0000 290.50684 1.000 -1347.2172 909.2172 
ygcE_queE -422.0000 290.50684 0.999 -1550.2172 706.2172 
yhiM_yhiN 90.3333 290.50684 1.000 -1037.8838 1218.5505 
yjiP_yjiR 504.3333 290.50684 0.988 -623.8838 1632.5505 
ykgH_betA -524.3333 290.50684 0.982 -1652.5505 603.8838 
ymgF_ycgH 126.6667 290.50684 1.000 -1001.5505 1254.8838 
ypjC_ileY 85.6667 290.50684 1.000 -1042.5505 1213.8838 
yqaB_argQ -107.6667 290.50684 1.000 -1235.8838 1020.5505 
ykgH_betA cspF_quuQ 346.0000 290.50684 1.000 -782.2172 1474.2172 
dadX_cvrA 490.3333 290.50684 0.992 -637.8838 1618.5505 
Appendices 
205 
djlA_yabP 2625.0000* 290.50684 0.000 1496.7828 3753.2172 
frvA_rhaM 532.0000 290.50684 0.979 -596.2172 1660.2172 
frwA_frwC 527.3333 290.50684 0.981 -600.8838 1655.5505 
glpD_yzgL 603.0000 290.50684 0.924 -525.2172 1731.2172 
ileY_ygaQ 841.6667 290.50684 0.427 -286.5505 1969.8838 
malM_yjbI 333.0000 290.50684 1.000 -795.2172 1461.2172 
rseX_yedS 553.0000 290.50684 0.967 -575.2172 1681.2172 
sibD_sibE 567.6667 290.50684 0.957 -560.5505 1695.8838 
thrW_ykfN 338.0000 290.50684 1.000 -790.2172 1466.2172 
tyrV_tyrT 624.0000 290.50684 0.898 -504.2172 1752.2172 
udk_yegE 396.3333 290.50684 1.000 -731.8838 1524.5505 
ybfC_ybfQ 770.6667 290.50684 0.599 -357.5505 1898.8838 
ybfK_kdpE 488.0000 290.50684 0.992 -640.2172 1616.2172 
ybiJ_ybiI 600.0000 290.50684 0.928 -528.2172 1728.2172 
yeeJ_yeeL 372.3333 290.50684 1.000 -755.8838 1500.5505 
yffL_yffM 305.3333 290.50684 1.000 -822.8838 1433.5505 
ygcE_queE 102.3333 290.50684 1.000 -1025.8838 1230.5505 
yhiM_yhiN 614.6667 290.50684 0.910 -513.5505 1742.8838 
yjiP_yjiR 1028.6667 290.50684 0.119 -99.5505 2156.8838 
ykgA_ykgQ 524.3333 290.50684 0.982 -603.8838 1652.5505 
ymgF_ycgH 651.0000 290.50684 0.857 -477.2172 1779.2172 
ypjC_ileY 610.0000 290.50684 0.916 -518.2172 1738.2172 
yqaB_argQ 416.6667 290.50684 0.999 -711.5505 1544.8838 
ymgF_ycgH cspF_quuQ -305.0000 290.50684 1.000 -1433.2172 823.2172 
dadX_cvrA -160.6667 290.50684 1.000 -1288.8838 967.5505 
djlA_yabP 1974.0000* 290.50684 0.000 845.7828 3102.2172 
frvA_rhaM -119.0000 290.50684 1.000 -1247.2172 1009.2172 
frwA_frwC -123.6667 290.50684 1.000 -1251.8838 1004.5505 
glpD_yzgL -48.0000 290.50684 1.000 -1176.2172 1080.2172 
ileY_ygaQ 190.6667 290.50684 1.000 -937.5505 1318.8838 
malM_yjbI -318.0000 290.50684 1.000 -1446.2172 810.2172 
rseX_yedS -98.0000 290.50684 1.000 -1226.2172 1030.2172 
sibD_sibE -83.3333 290.50684 1.000 -1211.5505 1044.8838 
thrW_ykfN -313.0000 290.50684 1.000 -1441.2172 815.2172 
tyrV_tyrT -27.0000 290.50684 1.000 -1155.2172 1101.2172 
udk_yegE -254.6667 290.50684 1.000 -1382.8838 873.5505 
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ybfC_ybfQ 119.6667 290.50684 1.000 -1008.5505 1247.8838 
ybfK_kdpE -163.0000 290.50684 1.000 -1291.2172 965.2172 
ybiJ_ybiI -51.0000 290.50684 1.000 -1179.2172 1077.2172 
yeeJ_yeeL -278.6667 290.50684 1.000 -1406.8838 849.5505 
yffL_yffM -345.6667 290.50684 1.000 -1473.8838 782.5505 
ygcE_queE -548.6667 290.50684 0.970 -1676.8838 579.5505 
yhiM_yhiN -36.3333 290.50684 1.000 -1164.5505 1091.8838 
yjiP_yjiR 377.6667 290.50684 1.000 -750.5505 1505.8838 
ykgA_ykgQ -126.6667 290.50684 1.000 -1254.8838 1001.5505 
ykgH_betA -651.0000 290.50684 0.857 -1779.2172 477.2172 
ypjC_ileY -41.0000 290.50684 1.000 -1169.2172 1087.2172 
yqaB_argQ -234.3333 290.50684 1.000 -1362.5505 893.8838 
ypjC_ileY cspF_quuQ -264.0000 290.50684 1.000 -1392.2172 864.2172 
dadX_cvrA -119.6667 290.50684 1.000 -1247.8838 1008.5505 
djlA_yabP 2015.0000* 290.50684 0.000 886.7828 3143.2172 
frvA_rhaM -78.0000 290.50684 1.000 -1206.2172 1050.2172 
frwA_frwC -82.6667 290.50684 1.000 -1210.8838 1045.5505 
glpD_yzgL -7.0000 290.50684 1.000 -1135.2172 1121.2172 
ileY_ygaQ 231.6667 290.50684 1.000 -896.5505 1359.8838 
malM_yjbI -277.0000 290.50684 1.000 -1405.2172 851.2172 
rseX_yedS -57.0000 290.50684 1.000 -1185.2172 1071.2172 
sibD_sibE -42.3333 290.50684 1.000 -1170.5505 1085.8838 
thrW_ykfN -272.0000 290.50684 1.000 -1400.2172 856.2172 
tyrV_tyrT 14.0000 290.50684 1.000 -1114.2172 1142.2172 
udk_yegE -213.6667 290.50684 1.000 -1341.8838 914.5505 
ybfC_ybfQ 160.6667 290.50684 1.000 -967.5505 1288.8838 
ybfK_kdpE -122.0000 290.50684 1.000 -1250.2172 1006.2172 
ybiJ_ybiI -10.0000 290.50684 1.000 -1138.2172 1118.2172 
yeeJ_yeeL -237.6667 290.50684 1.000 -1365.8838 890.5505 
yffL_yffM -304.6667 290.50684 1.000 -1432.8838 823.5505 
ygcE_queE -507.6667 290.50684 0.987 -1635.8838 620.5505 
yhiM_yhiN 4.6667 290.50684 1.000 -1123.5505 1132.8838 
yjiP_yjiR 418.6667 290.50684 0.999 -709.5505 1546.8838 
ykgA_ykgQ -85.6667 290.50684 1.000 -1213.8838 1042.5505 
ykgH_betA -610.0000 290.50684 0.916 -1738.2172 518.2172 
ymgF_ycgH 41.0000 290.50684 1.000 -1087.2172 1169.2172 
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yqaB_argQ -193.3333 290.50684 1.000 -1321.5505 934.8838 
yqaB_argQ cspF_quuQ -70.6667 290.50684 1.000 -1198.8838 1057.5505 
dadX_cvrA 73.6667 290.50684 1.000 -1054.5505 1201.8838 
djlA_yabP 2208.3333* 290.50684 0.000 1080.1162 3336.5505 
frvA_rhaM 115.3333 290.50684 1.000 -1012.8838 1243.5505 
frwA_frwC 110.6667 290.50684 1.000 -1017.5505 1238.8838 
glpD_yzgL 186.3333 290.50684 1.000 -941.8838 1314.5505 
ileY_ygaQ 425.0000 290.50684 0.999 -703.2172 1553.2172 
malM_yjbI -83.6667 290.50684 1.000 -1211.8838 1044.5505 
rseX_yedS 136.3333 290.50684 1.000 -991.8838 1264.5505 
sibD_sibE 151.0000 290.50684 1.000 -977.2172 1279.2172 
thrW_ykfN -78.6667 290.50684 1.000 -1206.8838 1049.5505 
tyrV_tyrT 207.3333 290.50684 1.000 -920.8838 1335.5505 
udk_yegE -20.3333 290.50684 1.000 -1148.5505 1107.8838 
ybfC_ybfQ 354.0000 290.50684 1.000 -774.2172 1482.2172 
ybfK_kdpE 71.3333 290.50684 1.000 -1056.8838 1199.5505 
ybiJ_ybiI 183.3333 290.50684 1.000 -944.8838 1311.5505 
yeeJ_yeeL -44.3333 290.50684 1.000 -1172.5505 1083.8838 
yffL_yffM -111.3333 290.50684 1.000 -1239.5505 1016.8838 
ygcE_queE -314.3333 290.50684 1.000 -1442.5505 813.8838 
yhiM_yhiN 198.0000 290.50684 1.000 -930.2172 1326.2172 
yjiP_yjiR 612.0000 290.50684 0.914 -516.2172 1740.2172 
ykgA_ykgQ 107.6667 290.50684 1.000 -1020.5505 1235.8838 
ykgH_betA -416.6667 290.50684 0.999 -1544.8838 711.5505 
ymgF_ycgH 234.3333 290.50684 1.000 -893.8838 1362.5505 
ypjC_ileY 193.3333 290.50684 1.000 -934.8838 1321.5505 
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Supplementary Script A.2-1: Python script used to select the intergenic regions.   
### Import 
import numpy as np 
import pandas as pd 
import xlrd 
import xlsxwriter 
import string 
import math 
from urllib.request import urlopen 
 
 
### Functions 
def overlap(start1, stop1, start2, stop2): 
    if start2 < start1 and stop2 < start1: 
        return False 
    elif start2 > stop1 and stop2 > stop1: 
        return False 
    else: 
        return True 
 
 
def start_in_IGR(start1, start_IGR, stop_IGR): 
    if start1 >= start_IGR and start1 <= stop_IGR: 
        return True 
    else: 
        return False 
 
 
def find_neighbours(value, df, num): 
    exactmatch = df[df[num] == value] 
    if exactmatch.empty == False: 
        return exactmatch.index[0] 
    elif value <= df[num][0]: 
        lowerneighbour_ind = 0 
        return lowerneighbour_ind 
    elif value >= int(df[num][-1:]): 
        upperneighbour_ind = len(df[num]) - 1 
        return upperneighbour_ind 
    else: 
        lowerneighbour_ind = df[df[num] < value][num].idxmax() 
        return lowerneighbour_ind 
 
 
def deletion_overlap(df, IGR): 
    for i in range(len(df)): 
        a = int(find_neighbours(df['Start'][i], IGR, 'Start')) 
        if overlap(IGR['Start'].iloc[a], IGR['Stop'].iloc[a], 
df['Start'][i], df['Stop'][i]) == True: 
            IGR = IGR.drop(a).reset_index().drop(columns=['index']) 
        else: 
            pass 
    return IGR 
 
 
def deletion_intern(df, IGR): 
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    for i in range(len(df)): 
 
        a = int(find_neighbours(df['Start'][i], IGR, 'Start')) 
 
        if start_in_IGR(df['Start'][i], IGR['Start'].iloc[a], 
IGR['Stop'].iloc[a]) == True: 
            IGR = IGR.drop(a).reset_index().drop(columns=['index']) 
 
        else: 
            pass 
    return IGR 
 
 
### Request Terminator db from Regulon 
link = 
"http://regulondb.ccg.unam.mx/menu/download/datasets/files/TerminatorS
et.txt" 
f = urlopen(link) 
myfile = f.readlines() 
name = [] 
start = [] 
stop = [] 
for line in myfile: 
    linestring = line.decode("utf-8") 
    if linestring[0] == "#": 
        pass 
    else: 
        linestring = linestring.split('\t') 
        name.append(linestring[0]) 
        start.append(int(linestring[1])) 
        stop.append(int(linestring[2])) 
terminators = pd.DataFrame(list(zip(name, start, stop)), 
columns=["name", "Start", "Stop"]) 
 
### Request Promoter db from Regulon 
link = 
"http://regulondb.ccg.unam.mx/menu/download/datasets/files/PromoterSet
.txt" 
f = urlopen(link) 
myfile = f.readlines() 
name = [] 
start = [] 
for line in myfile: 
    linestring = line.decode("utf-8") 
    if linestring[0] == "#": 
        pass 
    else: 
        linestring = linestring.split('\t') 
        name.append(linestring[1]) 
        start.append(int(linestring[3])) 
promoters = pd.DataFrame(list(zip(name, start)), columns=["name", 
"Start"]) 
 
### Parsing excel database 
xl = pd.ExcelFile("DataFile" + ".xlsx") 
IGR = xl.parse("IGR")  # Downloaded from ecogene.org and corrected for 
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U00096.3 coordinate system 
heEPODS = xl.parse("heEPODS")  # According to Vora et al. (2009) 
corrected for U00096.3 coordinate system 
tsEPODS = xl.parse("tsEPODS")  # According to Vora et al. (2009) 
corrected for U00096.3 coordinate system 
regulatory = xl.parse( 
    "Putative regulatory leader seq")  # According to Raghavan et al. 
(2011) corrected for U00096.3 coordinate system 
sRNA = xl.parse("sRNA")  # According to Raghavan et al. (2011) 
corrected for U00096.3 coordinate system 
transcripts = xl.parse( 
    "IG with transcript")  # According to Raghavan et al. (2011) 
corrected for U00096.3 coordinate system 
prom1 = xl.parse("PromEC promoter db")  # According to hershberg et 
al. (2001) corrected for U00096.3 coordinate system 
term1 = xl.parse( 
    "Predicted term from Webgester")  # According to Mitra et al. 
(2011) corrected for U00096.3 coordinate system 
term2 = terminators.sort_values(by=['Start']) 
prom2 = promoters.sort_values(by=['Start']) 
 
### 200 bp cutoff 
IGR['Length'] = IGR["Stop"] - IGR['Start'] + 1 
IGR = IGR[IGR.Length > 
200].dropna().reset_index().drop(columns=['index']) 
 
IGR = deletion_overlap(regulatory, IGR) 
IGR = deletion_overlap(sRNA, IGR) 
IGR = deletion_overlap(transcripts, IGR) 
IGR = deletion_intern(term1, IGR) 
IGR = deletion_intern(prom1, IGR) 
IGR = deletion_intern(prom2, IGR) 
IGR = deletion_overlap(term2, IGR) 
 
writer = pd.ExcelWriter("IGR" + '.xlsx', engine='xlsxwriter') 
IGR.to_excel(writer, sheet_name='Blad1') 
writer.save() 
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A.3 Appendix Chapter 4 
Supplementary Table A.3-1: Strains created in Chapter 4 
sNS4.01 sNS3.01 ∆mdoGH::attL 
sNS4.02 sNS3.01 ∆pgaABCD::attL 
sNS4.03 sNS3.01 ∆arnBF::attL 
sNS4.04 sNS3.01 ∆wceG-rfe::attL 
sNS4.05 sNS3.01 ∆wcaAM::attL 
sNS4.06 sNS3.01 ∆glgBP::attL 
sNS4.07 sNS3.01 ∆yibD::attL 
sNS4.08 sNS3.01 ∆malPQ::attL 
sNS4.09 sNS3.01 ∆bscQC::attL 
sNS4.10 sNS3.01 ∆ycjM::attL 
sNS4.11 sNS3.01 ∆yaiP::attL 
sNS4.12 sNS3.01 ∆wbbIK::attL 
sNS4.13 sNS3.01 ∆otsAB::attL 
sNS4.14 sNS3.01 ∆yfdH::attL 
sNS4.15 sNS3.01 ∆waaDQ::attL 
sNS4.16 sNS4.01 ∆arnBF::attL 
sNS4.17 sNS4.16 ∆wceG-rfe::attL 
sNS4.18 sNS4.16 ∆bscQC::attL 
sNS4.19 sNS4.18 ∆wceG-rfe::attL 
sNS4.20 sNS4.19 ∆wcaAM::attL 
sNS4.21 sNS4.20 ∆yibD::attL 
sNS4.22 sNS4.21 ∆pgaABCD::attL ∆malPQ::attL 
sNS4.23 sNS4.22 ∆otsAB::attL 
sNS4.24 sNS4.23 ∆wbbIK::attL 
sNS4.25 sNS4.23 ∆ycjM::attL 
sNS4.26 sNS4.24 ∆glgBP::attL ∆ycjM::attL 
sNS4.27 sNS4.26 ∆yaiP::attL 
sNS4.28 sNS4.27 ∆yfdH::attL 
sNS4.29 sNS4.28 ∆waaDQ::attL 
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Supplementary Table A.3-2: Plasmids created in Chapter 4.  
pLP6 pJET-attBTT-kanR-attPTT 
 
A.4 Appendix Chapter 5 
Supplementary Table A.4-1: Strains created in Chapter 5 
sNS5.01 E. coli K-12 MG1655 ∆thyA::sl 
sNS5.02 sNS5.01 + pTKRED-msbA 
sNS5.03 sNS5.02 ∆msbA::attBCA-kan-attPCA 
sNS5.04 sNS5.02 ∆msbA::attL 
sNS5.05 sNS5.01 ∆msbA::attL + pColA-P14-Nm-msbA 
sNS5.06 sNS5.05 ∆waaA::thyA 
sNS5.07 sNS5.01 ∆msbA::attL + pSC101-attPCC-P14-Nm-msbA-attPTT 
sNS5.08 sNS5.07 ∆waaA::thyA 
sNS5.09 sNS5.01 ∆sibD_siBE::attL_P14-Nm-msbA-attR 
sNS5.10 sNS5.01 + pGEM-P14-pga ∆waaA::thyA 
sNS5.11 sNS5.01 ∆sibD_siBE::attL_P14-pga-attR 
 
Supplementary Table A.4-2: Plasmids created in Chapter 5.  
pThyA pGEM-T-thyA 
pMsbA pTKRED-msbA 
pNm-msbA pCOLA-P14-Nm-msbA-kan 
pPga pGEM-p14-pga 
pDonor12 pSC101-kan-attPCC-P14-Nm-msbA-attPTT 
pDonor13 pSC101-kan-attPCC-pYcaI-Nm-msbA-attPTT 
pDonor14 pSC101-kan-attPCC-P14-pgaABCD-attPTT 
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Supplementary Table A.4-3: Annotated nucleotide sequence of pNm-msbA. 
Plasmids pNm-msbA 4142 bp DNA circular  
Features Qualifiers Location 
Coding Sequence Nm-msbA Complement (34..1899 
Promoter P14 Complement (1900..2030) 
Origin of replication cola Complement (2238..2873) 
Coding Sequence kanR 2983..3798 
Terminator BBa_B0014 Complement(4071..23) 
 
1 CACCCGAAGG TGAGCCAGTG TGATGAGGCC CAGTTATGCC GTCCGCACCG CCGCGTCTTT 
61 GTTTGAAATA TTGCGTAACA TCGTATAATA CCCGTTCTGG CTCATCAGCT GTTCATGTGT 
121 GCCCTGTTCA ATAATTTTGC CATCATCCAT AACAATAATG CGATCCGCTC CTTCAATGGT 
181 GGTCAGGCGA TGCGCCACAA TAATGCCGGT GCGGTTTTCC ATCAGGCGTT CTAAGGCTTG 
241 CTGCACTAAG CGTTCGCTTT CGTTATCTAA TGCGCTGGTC GCTTCATCTA ATAAGAGTAT 
301 CGGGGCATCT TTTAAGATCG CGCGCGCGAT CGCCACGCGC TGCCGTTGTC CGCCGCTTAA 
361 GTTGCTGCCG TTACTTCCAA TTGGTTGATG CAGTCCTAAC GGGCTGCTAT CGATCAGGCT 
421 CTGCAGGTTC GCGGTCTGTA ACGCAAACAG CACTTCCGCT TCGCCGGCAT CTGGCCGGCT 
481 ATATCTCACG TTTTCGAACA GGGTATCATC GAACAGAAAT ACATCCTGGC TCACTAACGC 
541 AAACTGCGCG CGCAGGCAAT CTAATTTAAT ATCCGCAATA TCAATCCCAT CTATGCAAAT 
601 GTTGCCCGCT GACGGTTCCA CGAAGCGTGG CAGCAGGTTC ACCACGGTGC TTTTGCCGCT 
661 GCCGCTCCGT CCCACCAGCG CCACGCGTTC GCCCTGTCTA ATATCTAAGT TAAAGTTATC 
721 TAACGCTTTA ATGCCATCTG ACCGATATTC CACGTCCACG TTGCGAAAGC TAATGCGTCC 
781 TTCCACCCGT TGCGGTGCTA ACGTGCCCTT ATCTTGTTCT GGCGGGGTAT CTAAGAATGC 
841 ACATACCCCA TCCGCCGCTA AAAACATCGT TTGCATTGGA ATGCTAATGT TCGCGAGGCT 
901 TTTAATTGGC GCATACATCT GCAGCATGGC CACAATAAAT GCCATGAATT CGCCAATGGT 
961 GGTATAGCCG TTCTGGCTCT GCCACAGCGC AATAAAAATC ACCACCGCTA ACGCAATACT 
1021 CGCAATCAGT TCGCTAAACG GGCTGTGTGC GGCCGTTGCT TGCGTAATTT TTTTGCTTAA 
1081 GCGCACAATG GTGCGGTTCA CGGCATCAAA CCGGTTTGCG GCTTGGGCTT GTCCGTTAAA 
1141 CAGCTTCACC ACGCGATGTC CTTGGTGGGT TTCCGCGATA ACGTTGTTCA TCGTGCCTAT 
1201 GCTTTTCTGA CTATCGCTGA TCACATGTTT CAGCCGATCG CGATAATAGC GACTTAACAG 
1261 GCTTAACAGT GGAAACATCA GCACCACAAT TAAGCTTAAT TGCCAGTTTA AATAGAGCAG 
1321 CACAATGGTC AGGCCGGTAA CAATCATCGT ATCGCGCGTT AACACGGTAA AAATATCGCT 
1381 CGCGTTGCTC ACACTTTGTT CGGTCAGGTT TAACATATTC ATCAGTACGG TGCCGCTCGG 
1441 CGTTTCTTGG TGATAGCGGC TGCTGAGGGT CAGCATTTTC GCGAACATGT CTTTGCGAAT 
1501 TTTGCTAATG GTCATAACGC TCACCCATGT CATCAGGTAG GTGCTGGTGA AGCGGCAAAT 
1561 GCCCCGAATC ACCACTAAAA TAATTAAAAA TAACGGCACG GTCCAAATTT TGTTTTCCGT 
1621 TCCCCAAACC ATGTAGGTGA ATTGTTCGCG CCAGTTCTGC AGGGTGCTGA TAATGCCCGC 
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1681 CGCCGCTGAC AGCTCTGGCG GGGCCGCAGG TGCGCTGAAG CCATGGTTGA TCAGTGGCGC 
1741 AATAAACGCC GCGAGATAGC TTTCGGTCGC CGCAACGCCA AAGATCGCGA TCAGCGCCGC 
1801 AACAATGCGA ATTTTATATG GGCGCACATA GGCCATCAGG CGCATGAAGC TGCGGGCATC 
1861 TTCTTTTTTG AACAGTCCAA ATGTCAGTTT TTCTATCATC TTTGTTTCCT CCGAATTCGA 
1921 GGTCGACGGA TCCCAAGCTT CTTCTAGAGC GGCCGCCATG GAAATTTCCC TATTATACCA 
1981 TATGCCGGCC AAGATGTCAA GAAACTTATA GAATGAAGGC GGCCGCCCGG TAGTCGGTGT 
2041 GCGCAACGCA ATTAATGTAA GTTAGCTCAC TCATTAGGCA CCGGGATCTC GACCGATGCC 
2101 CTTGAGAGCC TTCAACCCAG TCAGCTCCTT CCGGTGGGCG CGGGGCATGA CTAACATGAG 
2161 AATTACAACT TATATCGTAT GGGGCTGACT TCAGGTGCTA CATTTGAAGA GATAAATTGC 
2221 ACTGAAATCT AGAGTGATGG TGTCGGGAAT CCGTAAAGGA TCTTCTTGAG ATCCTTTTAC 
2281 GATCGTCGTA ATCTCCTGCT CTGTAAACGA AAAAACCGCC TGGGGAGGCG GTTTGATCGA 
2341 AGGTTAAGTC AGTTGGGGAA CTGCTTAACC TGGTAACTGG CTTTAGTGGA GCGCAGATAC 
2401 CAAATACTGT CCTTTCAGTG TAGCCTCTGT TAGGCCACCA CTTCAAGACT CTCGATATCT 
2461 AAATCCACTA ATTCTCAGTT ACCAATGGCT GCTGCCAGTG GCGTTTTGTC GTGTCTTTCC 
2521 GGGTTGGACT CAAGATGATA GTTACCGGAT AAGGCGCAGC AGTCGGGCTG AACGGGGGGT 
2581 TCTTGCACAC AGCCCAGCTT GGAGCGAACT GTCTACACGG AACGGGACGT GGTGATTTGG 
2641 GTAAAGCCTC CACCACAACA CGGACGCCGC AGGACGGGAA CAGGAGAGCG CAAGAGGGAG 
2701 CCATCAGGGG GAAACGCCTG GTATCTTTAT AGTCCTGTCG GGTTTCGCCA CCACTGATTT 
2761 GAGCGTCAGA TTTCGTGATG TTCGTCAGGG GGGCGGAGCC TATGGAAAAA CGGCTTCGCT 
2821 CCGGCCTTAT TGTCTCTCTG CTAAGTATCC TCCTGGCATC TTCTAGGACG TTTCTGCGCT 
2881 AGCATGCCTA TTTGTTTATT TTTCTAAATA CATTCAAATA TGTATCCGCT CATGAGACAA 
2941 TAACCCTGAT AAATGCTTCA ATAATATTGA AAAAGGAAGA GTATGAGCCA TATTCAACGG 
3001 GAAACGTCTT GCTCTAGGCC GCGATTAAAT TCCAACATGG ATGCTGATTT ATATGGGTAT 
3061 AAATGGGCTC GCGATAATGT CGGGCAATCA GGTGCGACAA TCTATCGATT GTATGGGAAG 
3121 CCCGATGCGC CAGAGTTGTT TCTGAAACAT GGCAAAGGTA GCGTTGCCAA TGATGTTACA 
3181 GATGAGATGG TCAGACTAAA CTGGCTGACG GAATTTATGC CTCTTCCGAC CATCAAGCAT 
3241 TTTATCCGTA CTCCTGATGA TGCATGGTTA CTCACCACTG CGATCCCCGG GAAAACAGCA 
3301 TTCCAGGTAT TAGAAGAATA TCCTGATTCA GGTGAAAATA TTGTTGATGC GCTGGCAGTG 
3361 TTCCTGCGCC GGTTGCATTC GATTCCTGTT TGTAATTGTC CTTTTAACAG CGACCGCGTA 
3421 TTTCGTCTCG CTCAGGCGCA ATCACGAATG AATAACGGTT TGGTTGATGC GAGTGATTTT 
3481 GATGACGAGC GTAATGGCTG GCCTGTTGAA CAAGTCTGGA AAGAAATGCA TAAACTTTTG 
3541 CCATTCTCAC CGGATTCAGT CGTCACTCAT GGTGATTTCT CACTTGATAA CCTTATTTTT 
3601 GACGAGGGGA AATTAATAGG TTGTATTGAT GTTGGACGAG TCGGAATCGC AGACCGATAC 
3661 CAGGATCTTG CCATCCTATG GAACTGCCTC GGTGAGTTTT CTCCTTCATT ACAGAAACGG 
3721 CTTTTTCAAA AATATGGTAT TGATAATCCT GATATGAATA AATTGCAGTT TCATTTGATG 
3781 CTCGATGAGT TTTTCTAAGA ATTAATTCAT GAGCGGATAC ATATTTGAAT GTATTTAGAA 
3841 AAATAAACAA ATAGGGGTTC CGCGCACATT TCCCCGAAAA GTGCCACTTG CGGAGACCCG 
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3901 GTCGTCAGCT TGTCGTCGGT TCAGGGCAGG GTCGTTAAAT AGCCGCTTAT GTCTATTGCT 
3961 GGTTTACCGG TTTATTGACT ACCGGAAGCA GTGTGACCGT GTGCTTCTCA AATGCCTGAG 
4021 GTTTCAGCAA AAAACCCCTC AAGACCCGTT TAGAGGCCCC AAGGGGTTAT AAATAATAAA 
4081 AAAGCCGGAT TAATAATCTG GCTTTTTATA TTCTCTCTCT AGTATATAAA CGCAGAAAGG 
4141 CC 
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A.5 Appendix Chapter 6 
Supplementary Table A.5-1: Strains created in Chapter 6. 
sNS6.01 sNS4.29  ∆lacZYA::p22-lacY 
sNS6.02 sNS3.01 ∆lacZYA::p22-lacY 
sNS6.03 sNS6.01 ∆ushA::attL 
sNS6.04 sNS6.02 ∆ushA::attL 
sNS6.05 sNS6.03  ∆galT::attL 
sNS6.06 sNS6.04  ∆galT::attL 
sNS6.07 sNS6.05 ∆nagB::attL 
sNS6.08 sNS6.06 ∆nagB::attL 
sNS6.09 sNS6.07 ∆atpi_gidB::lgtB 
sNS6.10 sNS6.08 ∆atpi_gidB::lgtB 
sNS6.11 sNS6.09 ∆adhE::lgtA 
sNS6.12 sNS6.10 ∆adhE::lgtA 
sNS6.13 sNS6.11  ∆sibD_siBE::attBCC-P14-gmd-fcl-cpsBG-BBa_B0014 
sNS6.14 sNS6.12  ∆sibD_siBE::attBCC-P14-gmd-fcl-cpsBG-BBa_B0014 
 
Supplementary Table A.5-2: Plasmids created in Chapter 6. 
pDonor15 pSC101-attPCC-P14-cpsBG-gmd-fcl-BBa_B0014-attPTT 
pDonor16 pSC101-attBTT-P5-OmpC_BCD12-NM-lgtB-attBCC 
pDonor17 pSC101-attBTT-J23104-GalE_BCD5-NM-lgtA-attBCC 
pProd1 pCLoDF13_attPCC_P22_UTR_OmpC_BCD12_Hp11639_3FT_rnpB_T1_attPTT 
pProd2 pCLoDF13_attPCC_P22_UTR_OmpC_BCD12_Bf9343_3FT_rnpB_T1_attPTT 
pProd3 pCLoDF13_attPCC_P22_UTR_OmpC_BCD12_Hp948_3FT_rnpB_T1_attPTT 
pProd4 pCLoDF13_attPCC_P14_UTR_GalE_BCD12_Hh_3FT_rnpB_T1_attPTT 
pProd5 pCLoDF13_attPCC_P14_UTR_GalE_HisHA_Hh_3FT_rnpB_T1_attPTT 
pProd6 pCLoDF13_attPCC_P14_UTR_OmpC_BCD12_Hh_3FT_rnpB_T1_attPTT 
pProd7 pCLoDF13_attPCC_P22_UTR_GalE_BCD12_Hh_3FT_rnpB_T1_attPTT 
pProd8 pCLoDF13_attPCC_P22_UTR_GalE_HisHA_Hh_3FT_rnpB_T1_attPTT 
pProd9 pCLoDF13_attPCC_P22_UTR_OmpC_BCD12_Hh_3FT_rnpB_T1_attPTT 
pProd10 pCLoDF13_attPCC_P70_UTR_GalE_BCD12_Hh_3FT_rnpB_T1_attPTT 
pProd11 pCLoDF13_attPCC_P70_UTR_GalE_HisHA_Hh_3FT_rnpB_T1_attPTT 
pProd12 pCLoDF13_attPCC_P70_UTR_OmpC_BCD12_Hh_3FT_rnpB_T1_attPTT 
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Since the industrial revolution, the concentration of CO2 in air has risen with more than 50% to 
>400 ppm, a level that was never reached in the past millions of years. This augmentation is the 
result of the use of fossil fuels and is the main cause of global warming. Under a no-policy-
change assumption the global temperature will rise with more than 2°C near the end of the 
century with devastating consequences as a result: sea level rise, biodiversity decline, extreme 
weather, droughts … 
To tackle these consequences, a switch towards a circular biobased economy is urgent so that 
current society becomes independent of fossil fuels. By using renewable resources, a CO2-
neutral economy can be built. One of the most important fields to make this transition is 
industrial biotechnology, which makes use of renewable resources and converts these into 
‘green’ fuels or other added-value products using enzymes or micro-organisms. 
Before industrial biotechnology can replace or complement the current petrochemical industry, 
more research is needed to develop new production processes, to make renewable resources 
more available to enzymes and micro-organisms and to create efficient microbial cell factories. 
For the latter, Escherichia coli is an important example. Due to its fast growth characteristics, 
the decades of fundamental and applied research and its capacity to easily express 
heterologous genes, makes from E. coli an ideal production host for the synthesis of non-natural 
products like therapeutic proteins, diols such as 1,3-propanediol and sugars such as human 
milk oligosaccharides, to which many of the beneficial properties of mother’s milk are attributed 
to.  
To further establish E. coli as an efficient production host, a new toolbox was developed in this 
dissertation that allows easy integration of heterologous pathways directly onto the genome. In 
this way the use of plasmids are avoided which may be affected by instability, cause additional 
variation and metabolic burden. Moreover, a study was performed to find out interesting 
locations on the genome to introduce biosynthetic pathways and links gene expression with a 
particular position. In addition, it was found that some positions are more susceptible to 
metabolic burden than others and the position of a biosynthetic pathway is thus crucial in the 
development of new production strains.  
Next the acquired knowledge was used to develop new production hosts for the synthesis of a 
complex human milk oligosaccharide: fucosyllacto-N-neotetraose III, a pentasaccharide that 
was found to work specifically against norovirus. Because a vaccine against norovirus is yet to 
be found, the production of FLNT III may be an important milestone in the development of a 
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working vaccine. After fermentation on a 5L bioreactor scale, a titer of 1 g/L or a productivity of 
10 mg/L/h was attained. Fermentations were not only done using a wildtype background but 
also using a for human milk oligosaccharides developed platform that was created to eliminate 
interfering endogenous glycosylation reactions that may cause unwanted byproducts. For that 
purpose, all nonessential glycosyltransferases were deleted in a wildtype strain. Unfortunately, 
after analyzing these fermentation samples, little differences were noticed with regard to side 
product formation. Probably the achieved titers were too low in these sub-optimal production 
hosts to see a notable difference. 
Finally, also endotoxin elimination in E. coli was pursued having a double purpose. On the one 
hand, deletion of endotoxin formation would be a process optimization alleviating the need to 
remove these from the end product as they are harmful and potentially life-threatening. On the 
other hand, elimination of endotoxins would allow to delete essential glycosyltransferases 
responsible for these endotoxins and would complement the already created platform. To be 
able to eliminate these essential genes, compensation mechanisms of Acinetobacter 
baumannii’s and Neisseria meningitidis’ endotoxin-free mutants were transferred to E. coli.  
In conclusion, the use of Escherichia coli as a production host is still a competitive strategy as 
indicated by the booming business of HMOs. Moreover, all studied topics from eliminating 
interfering glycosylation reactions and endotoxin formation as bypassing the need for plasmids 
in strain development and the characterization of interesting chromosomal loci; all fit in an 
integrated process design strategy to accelerate the scale-up of new biotechnological 
production processes with the focus on human milk oligosaccharides. 
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Samenvatting 
Sinds de industriële revolutie is de concentratie aan CO2 in de lucht met meer dan de helft 
toegenomen tot >400 ppm, een in miljoenen jaren nooit eerder gezien niveau. De stijging is het 
gevolg van het gebruik van fossiele brandstoffen en is de oorzaak van klimaatopwarming. Met 
een ongewijzigd beleid zal de globale temperatuur tegen het eind van de eeuw met meer dan 
2°C zijn toegenomen, wat desastreuze gevolgen kan hebben zoals stijging van de zeespiegel, 
afname van biodiversiteit, extreme hitte en droogtes, enz.  
Om deze gevolgen tegen te gaan is er nood aan een circulaire biogebaseerde economie, 
waarbij de mens onafhankelijk wordt van fossiele brandstoffen. Door gebruik te maken van 
hernieuwbare grondstoffen, kan zo’n CO2-neutrale economie opgebouwd worden. Één van de 
belangrijkste sectoren om deze doelstellingen te halen is industriële biotechnologie, die gebruik 
maakt van hernieuwbare bronnen en deze via enzymen of micro-organismen omzet tot groene 
brandstoffen en tal van andere hoogwaardige producten.  
Vooraleer industriële biotechnologie de klassieke petrochemische industrie kan vervangen en/of 
aanvullen is er nog veel onderzoek nodig naar nieuwe productieprocessen, naar het 
beschikbaar maken van deze groene grondstoffen voor enzymes en micro-organismen en naar 
het creëren van efficiënte microbiële fabriekjes. Voor dat laatste is Escherichia coli een 
belangrijk productieorganisme. Door zijn snelle groeikarakteristieken, de vele tientallen jaren 
aan fundamentele kennis en zijn capaciteit om eenvoudig heterologe genen tot expressie te 
brengen, is E. coli een ideale gastheer voor de vorming van niet-natuurlijke producten zoals 
therapeutische proteïnen, diolen zoals 1,3-propaandiol en suikers zoals humane melk 
oligosachariden, aan de welke de goede eigenschappen van moedermelk onder andere worden 
toegeschreven.  
Om E. coli verder te bewerkstelligen als een efficiënt productieorganisme werd in deze thesis 
een nieuwe toolbox ontwikkeld die het toelaat om op een eenvoudige manier heterologe 
pathways rechtstreeks in te brengen op het genoom. Op die manier worden plasmides 
vermeden die anders mogelijks zorgen voor instabiliteit, meer variatie en metabolische last. 
Bovendien hebben we ook gekeken naar waar het interessant is om toekomstige pathways in te 
brengen. Hiervoor werd een locatiestudie uitgevoerd die de link legt tussen positie en 
genexpressie en vonden we dat sommige posities meer of minder afhankelijk zijn van 
metabolische last. De positie van een gen is dus een cruciaal gegeven in het ontwikkelen van 
productiestammen. 
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Vervolgens werd deze opgebouwde kennis gebruikt om productiestammen te ontwikkelen voor 
complexe humane melksuikers zoals fucosyllacto-N-neotetraose III, een pentasacharide dat 
specifiek werkt tegen norovirus. Aangezien hiertegen nog geen vaccin ontwikkeld werd, kan de 
vorming van FLNT III een belangrijk hulpmiddel zijn voor de zoektocht naar een werkend 
vaccin. Na fermentatie op een 5L bioreactor schaal, werd dan een titer van 1 g/L of een 
productiviteit van 10 mg/L/h gehaald. Dit werd niet enkel gedaan gebruik makend van een 
wildtype achtergrond maar ook op een speciaal voor humane melksuikers ontwikkeld platform 
dat er voor moet zorgen dat interfererende endogene glycosylatie mechanismen, die mogelijks 
zorgen voor ongewenste bijproducten, uitgeschakeld zijn. Daartoe werden alle niet-essentiële 
glycosyltransferases verwijderd. Jammer genoeg werd na de fermentaties met beide 
achtergronden, weinig verschil opgemerkt in bijproduct vorming. Waarschijnlijk is de behaalde 
titer te laag in deze suboptimale productiestammen om op kleine schaal een wezenlijk verschil 
te zien.  
Als laatste werd ook getracht om endotoxine vorming in E. coli tegen te gaan en dit had een 
dubbele doelstelling. Enerzijds zou het verwijderen van endotoxines een welgekomen 
procesoptimalisatie zijn, aangezien deze moleculen schadelijk zijn en uit het gevormde product 
moeten verwijderd worden; Anderzijds zou het opheffen van de endotoxine vorming ook 
betekenen dat essentiële glycosyltransferases verantwoordelijk voor die endotoxines ook 
geëlimineerd kunnen worden, om het hierboven beschreven platform te vervolledigen. Om deze 
essentiële genen te verwijderen werd gekeken om compensatiemechanismen van reeds 
gekende endotoxine-vrije mutanten zoals beschreven voor Acinetobacter baumannii en 
Neisseria meningtidis, over te dragen.  
Kortom, het gebruik van Escherichia coli als productie-organisme is nog steeds een 
aangewezen strategie. Bovendien kaderen alle aangehaalde onderwerpen van het verwijderen 
van interfererende glycosylaties, het elimineren van endotoxine alsook het omzeilen van het 
gebruik van plasmides in stamontwikkeling als het karakteriseren van interessante 
chromosomale locaties in een geïntegreerde procesontwikkelingsstrategie om de opschaling 
van bv. humane melksuikers zo vlot mogelijk te laten gebeuren.  
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